



The University of Texas at Austin
Dell Medical School

1501 Red River Street, MC: Z0100 • Austin, TX 78712 • T: 512-495-5555

To: Janet M. Dukerich, Ph.D.
Professor and Senior Vice Provost for Faculty Affairs
Office of Executive Vice President and Provost

From: Clay Johnston, MD, PhD
Vice President and Dean
Dell Medical School

Date: July 11, 2018

Re: UTS 144 Request – Charles Nemeroff, M.D., Ph.D

The University of Texas at Dell Medical School is requesting to offer Charles Nemeroff, MD, PhD an appointment at the rank of Professor with tenure in the Department of Psychiatry. Dr. Nemeroff will direct the Institute for Early Life Adversity within Dell Medical School in collaboration with the Mulva Clinics for Neuroscience to establish a world-class research institute that translates neuroscience advances and understandings of the impact of early life adversity to clinical studies of potential interventions.

Dr. Nemeroff will report to the Associate Vice President for Regional Mental Health and Department Chair of Psychiatry, Dr. Stephen M. Strakowski, for his effort in establishing the research institute, sustaining the institute long-term, and for his clinical time establishing a comprehensive diagnostic and treatment evaluation program. Dr. Nemeroff will report to myself, as the Vice President for Medical Affairs and Dean of Dell Medical School, for his work in assisting in the development and implementation of research strategy and cross-university research projects as a senior advisor for research strategy.

It is difficult to overstate Dr. Nemeroff's tremendous contributions to his field. Dr. Nemeroff's curriculum vitae provides detail on his extraordinary level of productivity and national/international reputation within the field. I have highlighted a few important points below.

Dr. Nemeroff began his career at the University of North Carolina at Chapel Hill, where he earned a doctoral degree in neurobiology in 1976 and a medical degree in 1981. After completing a research fellowship in neurology, Dr. Nemeroff went on to residency training in psychiatry at the University of North Carolina and completed a subsequent residency at Duke University. Dr. Nemeroff earned his board certification in psychiatry and neurology in 1986. He joined the faculty at Duke University as an assistant professor in 1983, where he served as a senior fellow in the Center for Aging and Human Development and Director of the Laboratory of Psychoneuroendocrinology. In 1988, Dr. Nemeroff became chief of the Division of Biological Psychiatry in the Department of Psychiatry at Duke University. He achieved the rank of Professor in 1991. From 1991-2008, Dr. Nemeroff served as the Renunette W. Harris Professor and Chairman in the Department of Psychiatry and Behavioral Sciences at Emory University. In 2009, Dr. Nemeroff became the Leonard M. Miller Professor, with Tenure, and Chairman of the Department of

Psychiatry and Behavioral Sciences at the University of Miami, in which role he continues to serve today. From 2011-2016, Dr. Nemeroff was Director for the Center on Aging at the University of Miami, and he is currently the Center's clinical director. In his current role as department chair, Dr. Nemeroff also serves as Chief of Psychiatry for Jackson Health Systems and Chief of Psychiatry for University of Miami Hospital.

Dr. Nemeroff's productivity in publication is unmatched. He has published extensively in the highest quality journals in science and medicine, including *New England Journal of Medicine*, *JAMA*, *Science*, *Nature*, *Nature Neuroscience*, and *Nature Communications*, as well as the highest-ranked specialty journals in psychiatry and neuroscience, including *Neuron*, *JAMA Psychiatry*, the *American Journal of Psychiatry*, *Biological Psychiatry*, *Translational Psychiatry* and *Molecular Psychiatry*. Dr. Nemeroff's h-Index of 140 puts him among the most frequently cited clinical neuroscientists and psychiatric researchers in the world.

Dr. Nemeroff has maintained nearly continuous extramural funding from the National Institutes of Health. He has been the principal investigator of two Conte Center Grants (perhaps the most prestigious awards possible from the NIMH), two U19 center grants on drug development, and a CIDAR center grant on Prediction of Antidepressant Response. He was recently awarded another grant in collaboration with UT Senior Scientist, Frances Champagne, of the Department of Psychology. Most recently, he is a Co-PI of a \$3.8M NIH grant looking at stem cell therapy to treat alcoholism-depression comorbidities, and he is expecting a notice of award on an NIH R01 from examining Post Traumatic Stress Disorder (PTSD) through post-mortem brain multi-omics.

Dr. Nemeroff has a long and distinguished career of mentorship. He leads the APA Research Colloquium for Young Investigators, and he founded the ADAA Career Development Leadership Program. He has mentored several major figures in the field, including Kerry Ressler, M.D., PhD. at Harvard University and Elisabeth Binder, M.D., PhD., of the Max Plank Institute in Munich. His mentees have launched highly successful independent research careers around the world, as evidenced by the number of first author lists on which Dr. Nemeroff served as senior scientist. Dr. Nemeroff established a strong record of attracting and mentoring outstanding faculty recruits, building grant and research portfolios, and developing outstanding training programs. Dr. Nemeroff was recently awarded the American College of Neuropsychopharmacology (ACNP) Julius Axelrod Mentorship Award, one of the field's highest acknowledgements for the development of young scientists.

Dr. Nemeroff is also an excellent clinician. His patients are referred to him from all over the world to seek his guidance for hard-to-treat and treatment resistant illnesses, particularly mood and anxiety disorders.

The Dell Medical School is very fortunate to have this unique opportunity to bring such a world-renowned scientist, clinician, mentor, and administrator to UT Austin. As part of this recruitment, we are requesting to offer Dr. Nemeroff a total eligible compensation package of \$500,000 annual salary at 100%. The total annual compensation is comprised of a base compensation rate of \$300,000 as a Professor of Psychiatry, an administrative stipend of \$150,000 annually while serving as Director of the Early Life Adversity Research Institute, and an annual incentive payment of \$50,000 to be paid annually that is guaranteed for the first two fiscal years, through August 21, 2020. The first year will be pro-rated based on hire date. In subsequent years, incentive payments will be based on achieving pre-defined, mutually agreed-upon performance goals developed by Drs. Nemeroff and Strakowski, consistent with the faculty compensation plan. Should Dr. Nemeroff no longer serve in his administrative capacities, he will be compensated at his base compensation (for

100% effort) for his role as a faculty member and will work with the Chair of Psychiatry on productivity expectations in this role.

The Dell Medical School seeks to pay within the 50th to 75th percentiles of the American Association of Medical Colleges (AAMC) reported compensation, reserving the upper end of the range for competitive recruits such as Dr. Nemeroff. For the expectations that we have set forth for Dr. Nemeroff in establishing and leading a world-class Institute for Early Life Adversity, we have chosen to utilize a Chair benchmark for Dr. Nemeroff's leadership role given that similar compensable factors of leadership and scope are utilized in those positions. The AAMC 75th percentile for Psychiatry Chair positions is \$522,000 which places our total compensation request of \$500,000 within our standard compensation methodology. Additionally, should Dr. Nemeroff no longer serve in his leadership role, the \$300,000 base salary for Dr. Nemeroff falls at the AAMC 75th percentile for Professor of Psychiatry; the 75th percentile for a Professor of Psychiatry is currently \$305,000. Due to his leadership ability and caliber of work as a luminary in his field, I respectfully seek your support and presentation of this request to the Executive Vice Chancellor for approval. Please do not hesitate to let me know if you have any questions.



The University of Texas at Austin
Dell Medical School

1501 Red River Street, MC: Z0100 • Austin, TX 78712 • T: 512-495-5555

CONFIDENTIAL

"Term Sheet" for Charles Nemeroff, MD, PhD

June 15, 2018

This term sheet is the basis for discussion between The University of Texas at Austin and Dr. Charles Nemeroff to appoint him as a faculty member in the Dell Medical School and to have him set up a world-class research institute into the study of the neurobiological, psychological and social impact of early life adversity. This term sheet does not represent a commitment or obligation by Dr. Nemeroff or by The University of Texas at Austin. It is expected these terms will be put into a formal offer letter from The University of Texas at Austin upon conferral of tenure and in accordance with the UT System Rule 144 process and procedures.

Appointment and Reporting

Full time (100%) 12-month administrative appointment as Director of the Early-Life Adversity Research Institute studying the impact of early life adversity initially based in the Department of Psychiatry, but expected to extend across The University of Texas at Austin (UTA) campus. Dr. Nemeroff will hold a concurrent 12-month faculty appointment at The University of Texas at Austin Dell Medical School in the Department of Psychiatry and the Mulva Clinic for Neurosciences. Dr. Stephen Strakowski, Department Chair, has recommended an initial rank of Professor of Psychiatry with tenure. Final assignment of academic rank is determined upon review and approval by the Dell Medical School Appointment, Promotion and Tenure committee and the University Provost and will be defined in the formal offer letter upon receipt of three letters of reference from external reviewers. Dr. Nemeroff's curriculum vitae will be submitted for pre-review to the Provost's Office to ensure appropriateness of appointment of rank and tenure. Dr. Nemeroff is expected to provide letters of academic review from internal and external sources who will offer detailed assessments, evaluating him for this tenured position.

Dr. Nemeroff will be appointed to the Medical Service Research and Development Plan (MSRDP), Dell Medical School's faculty practice plan. Please see [MSRDP bylaws](#) for more information.

The following expectations are outlined for Dr. Nemeroff's responsibilities and time allocation in his first three years. Effort allocations may evolve over time. Specific assignments will be made at the Department Chair's and Dean's discretion.

Research and Institute Leadership: 60%

- Establish a world-class research institute that translates neuroscience advances and understandings of the impact of early life (including in-utero) adversity to clinical studies of potential interventions. Recruit at least 4 to 6 world-class faculty to the institute that may include individuals with primary appointments in the main campus upon agreement and approval with other college deans. Work closely with the Dell Medical School Development team to raise at least a \$5 million endowment to help support and sustain the institute long-term; included are plans to establish at least one endowed chair. Develop clinical interventions through the Mulva Clinics as well as other UTHA clinics.

Dean's Office: 10%

- Assist Dean Johnston in the development and implementation of research strategy and cross-university research projects as a senior advisor for research strategy.

Clinical Time: 20%

- Establish a Comprehensive Diagnostic and Treatment Evaluation Program at the Dell Medical School (similar to what was done at U. Miami) and continue to provide national consultation services, both directly and with other expert providers at UT Health Austin.
- Provide other clinical care as agreed upon with the Department Chair.

Faculty Time: 10%

- Provide committee service within the Department of Psychiatry and Dell Medical School, medical student and resident teaching, and other university service.

Dr. Nemeroff will report to Dr. Clay Johnston, Vice President for Medical Affairs and Dean of Dell Medical School, for his work in the Dean's office and to Dr. Stephen M. Strakowski, Associate Vice President for Regional Mental Health and Department Chair of Psychiatry, for his remaining effort. He will collaborate with the Director and Executive Board of the Mulva Neuroscience Clinics as well as other College Deans in his efforts to establish the Early-life Adversity Research Institute.

Salary and Other Commitments

Dr. Nemeroff will be eligible for a total annual compensation of \$500,000, consisting of a guaranteed 12-month academic rate of \$300,000, an annual \$150,000 administrative stipend while serving as Director of the Early-life Adversity Research Institute, and an annual incentive payment of \$50,000 to be paid annually that is guaranteed for the first two fiscal years, through August 31, 2020. The first year will be pro-rated based on hire date. In subsequent years, incentive payments will be based on achieving pre-defined, mutually agreed-upon performance goals developed by Drs. Nemeroff and Strakowski, consistent with the faculty compensation plan. Should Dr. Nemeroff no longer serve in his administrative capacities as Director, he will be eligible for his base salary of \$300,000 (for 100% effort), commensurate with other senior, distinguished faculty and will work with the Chair of Psychiatry on productivity expectations in this role. Merit increases of salary are subject to the faculty compensation plan, performance and the annual policy on salary increases issued by the University President.

Dell Medical School will provide up to \$5 million in start-up funds to launch the Institute to be used for up to four years. These funds will be used to fund his annual compensation, administrative support, start-up and salary packages for faculty recruited into the Department of Psychiatry, and start-up contributions to faculty jointly hired with the main campus. If Dr. Nemeroff is successful in securing STARS and GURI (NAM matching) funds, his start-up funds may be increased to \$6 million.

The Department will provide an office workspace with computers and supplies separate from these designated start-up funds, as well as research space for clinical studies. We estimate that initial space requirements to establish the Institute in the HDB will include 5-6 faculty offices, laboratory bench space for 2-3 research scientists, with more space available as the program grows, and practice space for Dr. Nemeroff and any clinic recruits to see patients.

Salary support beyond the startup phase will be provided upon conferral of tenure; the Department will provide \$80,000 annual salary support for the rank of Professor with tenure. After five years, Dr. Nemeroff will be expected to maintain sufficient funding for the remaining portion of his salary through a combination of administrative stipends, clinical activities, sponsored research projects, and other support from outside sources.

As a faculty member of Dell Medical School, Dr. Nemeroff will be provided \$3,500 annually for continuing professional development as part of the Dell Medical School Professional Education Fund. These funds can be used to cover conference attendance and travel, professional society memberships, journal subscriptions, and other related items. All certification and licensure required for the practice of medicine will be supported financially by the Department, which is not drawn from professional development funding.

Dr. Nemeroff will be entitled to all employee benefits authorized by the state legislature. As a new employee, he will have 31 calendar days from the initial date of his appointment to enroll for insurance coverage.

Outside activity income will be required to be disclosed, and if applicable, approved in advance. In most cases, Dell Medical School will require that income-generating activities with third parties be contracted through Dell Medical School. Income for certain professional activities must be assigned to the faculty practice plan. These policies are currently under development, but we anticipate that outside income equal to or below 20% of base compensation will likely not be considered a conflict of commitment, but income beyond this will trigger additional approval requirements. Dr. Nemeroff will be expected to follow any other Dell Medical School and University of Texas at Austin policies for managing all outside activity relationships and payments that are not met by this expectation.

Relocation and Transition

It is expected that Dr. Nemeroff's appointment would begin on or around October 1, 2018. Relocation expenses not to exceed \$35,000 will be reimbursed by the Chair's Office. Employer-provided payments for moving expenses and relocation are considered taxable to the employee. Expenses for moving household goods and personal effects may be paid as an out-of-pocket reimbursement or directly to the moving company. Please present receipts to the Chair's office for reimbursement.

Other Requirements

All UT appointments are subject to criminal background check and confirmation of degrees and licenses. Three (3) reference letters will be required to finalize the offer letter; please submit to Cathy Stacy at cathy.stacy@austin.utexas.edu (to be sent by the referee).

No later than the date of hire, Dr. Nemeroff will be required to complete an Agreement of Participation which assigns a member provider's professional income to the MSRDP. (See §3.1 of the bylaws for information on membership.)



Stephen M. Strakowski, MD
Associate Vice President, Regional Mental Health
Chair, Department of Psychiatry
Dell Medical School



Charles Nemeroff, MD, PhD

6/23/18

Date

June 7, 2018

Charles B. Nemeroff, M.D., Ph.D.

Leonard M. Miller Professor and Chairman
Department of Psychiatry and Behavioral Sciences
Professor of Biochemistry and Molecular Biology
Clinical Director, Center on Aging
University of Miami Miller School of Medicine
Miami, Florida 33136

Curriculum Vitae

Charles B. Nemeroff, M.D., Ph.D.

Leonard M. Miller Professor and Chairman
Department of Psychiatry and Behavioral Sciences
Director, Center on Aging
University of Miami Miller School of Medicine
Miami, Florida 33136

Curriculum Vitae


Index

ABSTRACTS	124
BOOKS	115
BOOK REVIEWS, LETTERS TO THE EDITOR, AUDIO TAPES, OTHER PUBLICATIONS.....	117
RECENT GRANT SUPPORT	18
DUKE UNIVERSITY COMMITTEES	27
EDITORIAL BOARDS	23
EDUCATION	3
EMORY UNIVERSITY COMMITTEES	28
HONORS AND AWARDS	5
INVITED PRESENTATIONS	187
PERSONAL INFORMATION	3
PROFESSIONAL EXPERIENCE	3
PROFESSIONAL SOCIETIES	30
RESEARCH REPORTS AND REVIEWS.....	31
SUPERVISION OF PHD STUDENTS	27
SUPERVISION OF POST-DOCTORAL FELLOWS	27
UNIVERSITY OF MIAMI COMMITTEES	29

PERSONAL INFORMATION

NAME: **Charles Barnet Nemeroff**

PLACE OF BIRTH: Bronx, New York



EDUCATION

George Washington High School, New York, New York; *Academic Diploma*, June 1966

City College of New York, New York, New York; *Bachelor of Science (Biology)*, June 1970

Northeastern University, Boston, Massachusetts; *Master of Science (Biology)*, September 1973

University of North Carolina, Chapel Hill, North Carolina; *Doctor of Philosophy (Major: Neurobiology; Minor: Biochemistry)*, August 1976

University of North Carolina, School of Medicine, Chapel Hill, North Carolina; *Doctor of Medicine*, May 1981

Resident in Psychiatry, North Carolina Memorial Hospital, University of North Carolina, School of Medicine, Chapel Hill, North Carolina, 1981 - 1983

Resident in Psychiatry, Duke University Medical Center, Durham, North Carolina, December 1983 – 1985

Doctorate Honoris Causa, Maimonides University, Buenos Aires, Argentina, March 2015

PROFESSIONAL EXPERIENCE

Research Assistant, Department of Ichthyology, American Museum of Natural History, New York, New York, 1968 - 1971

Research Assistant, Neurochemistry Laboratory, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, 1971 - 1972

Research Associate, Department of Surgery, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts, 1972 - 1973

Teaching Assistant in Biology, Northeastern University, Boston, Massachusetts, 1972 - 1973

Post-doctoral Fellowship (National Institute of Neurologic, Communicative Disorders and Stroke), Biological Sciences Research Center, University of North Carolina, School of Medicine, Chapel Hill, North Carolina, 1976 - 1977

Research Fellow, Biological Sciences Research Center, University of North Carolina, School of Medicine, 1977 - 1983

Clinical Instructor in Psychiatry, University of North Carolina, School of Medicine, February - December 1983

Assistant Professor, Department of Pharmacology, Duke University Medical Center, Durham, North Carolina, December 1983 - June 1986

Senior Fellow, Center for Aging and Human Development, Duke University Medical Center, Durham, North Carolina, December 1983 - 1991

Director, Laboratory of Psychoneuroendocrinology, Department of Psychiatry, Duke University Medical Center, Durham, North Carolina, December 1983 - 1991

Associate Professor, Department of Psychiatry, Duke University Medical Center, Durham, North Carolina, 1985 - 1989

Associate Professor, Department of Pharmacology, Duke University Medical Center, Durham, North Carolina, 1986 - 1989

Faculty Member, Toxicology Training Program, Duke University Medical Center, Durham, North Carolina, 1986 - 1991

Chief, Division of Biological Psychiatry, Department of Psychiatry, Duke University Medical Center, 1988 - 1991

Professor, Department of Psychiatry, Duke University Medical Center, Durham, North Carolina, 1989 - 1991

Professor, Department of Pharmacology, Duke University Medical Center, Durham, North Carolina, 1989 - 1991

Reunette W. Harris Professor, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1991 - 2009

Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, 1991 - 2008

Faculty member, Graduate Program in Neuroscience and Molecular Pharmacology and Toxicology, Emory University School of Medicine, 1991 - 2009

Associate, Winship Cancer Center, Emory University School of Medicine, 1993 - 2009

Leonard M. Miller Professor with Tenure and Chairman, Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, Florida, 2009 - Present

Interim Director, Center on Aging, University of Miami Miller School of Medicine, Miami, Florida, 2010

Director, Center on Aging, University of Miami Miller School of Medicine, Miami, Florida, 2011 – 2016

Clinical Director, Center on Aging, University of Miami Miller School of Medicine, Miami, Florida, 2011 - present

Chief of Psychiatry, Jackson Health Systems, Miami, Florida, 2009 - Present

Chief of Psychiatry, University of Miami Hospital, Miami, Florida, 2010 - Present

Associate Director, MD, PhD Program, University of Miami, 2014 - 2016

Member, Sylvester Cancer Center, University of Miami Miller School of Medicine 2012 - Present

Member, Graduate Program in Neuroscience, University of Miami 2014 - Present

Professor, Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine 2016 - Present

HONORS AND AWARDS

American Board of Psychiatry and Neurology

- Diplomat in Psychiatry - 1987 Certificate # 28952
- Added Qualification in Geriatric Psychiatry, 1991; recertified, 2000, 2010
- Examiner, Part II, 1991 - 2002; senior examiner, 1992 - 2002
- Part I Committee, 1993 - 1995

American College of Neuropsychopharmacology

- Mead Johnson Travel Award, 1982
- Program and Scientific Communications Committee, 1987-1989, 2003 - 2005
- Daniel H. Efron Award, 1987
- Honoric Awards Committee, 1991
- Ethics Committee, Member 1990 - 1992; Chairman 1991 - 1992
- Council Member, 1993 - 1995, 1997 - 1999
- President, 1996 - 1997
- Credentials Committee, 2000 - 2002
- Medicine Development Task Force, 2003
- Editor-in-Chief, Neuropsychopharmacology, 2001 - 2006
- History Committee, 2006 - 2009
- Liaison Committee, 2013 - Present; vice-chairman, 2016 - Present
- Membership Committee, 2016 - Present
- Julius Axelrod Mentorship Award, 2016

American College of Psychiatrists

- Laughlin Fellow, 1985
- Committee on Contributions, 1989 - 1992; Chair, 1991, 1992, 1995 - Present
- Chair, Committee on Education, 1993 - 1995, Member 2010
- Chair, Nominating Committee, 2000 - 2001
- Board of Regents, 1994 - 1996
- Award for Research in Mood Disorders, 1998
- Second Vice President, 1998
- Bowis Award, 1999

- First Vice President, 1999
- President-elect, 2000
- President, 2001-2002
- Stanley Dean Award for Research in Schizophrenia, 2004
- Chair, Program Committee, 2005, 2006, 2007, 2008, 2010
- Chair, Committee on the Award for Research in Mood Disorders, 2009 - 2018
- Committee on the Dean Award, 2018 - 2021

American Foundation for Suicide Prevention

- Scientific Council, 1992 - Present
- Board of Directors, 1999 - Present
- Research Award, 2001
- Vice President, 2006
- Chair, Scientific Council 2007 - 2008
- President, 2009
- President, Southeast Florida chapter, 2011 - 2013

American Psychiatric Association

- Kempf Fund Award for Research Development in Psychobiological Psychiatry, 1989
- Samuel G. Hibbs Award, 1991
- Chair, Young Faculty, Fellowship and Kempf Awards Committee, 1994 - 2002
- Council on Research, 1992 - 1997; 2006 - 2007; 2013 - 2017; 2017 - 2020; Chairman 1994 - 1995
- Award for Research in Psychiatry, 1996
- Corresponding Committee on Research on Psychiatric Treatments, Council on Research, Member, 1997 - 2003; Vice Chair, 1997- 2000; Chair, 1999 - 2003; Consultant, 2003 - 2011
- Committee for Award for Research, Council on Internal Organization, 1998 - 1999
- Chair, Task Force on Biomarkers and Novel Treatment, Council of Research, 2014 - Present
- Distinguished Psychiatrist Lecture - Annual Meeting, 1999, 2003
- American Psychiatric Institute for Research and Education, Board of Directors, 1999 - 2007
- Committee, APA Award for Research, 1999 - 2008; Chair 2000 - 2002
- Distinguished Fellow, 2003
- Distinguished Life Fellow, 2014
- Member, Young Faculty Awards Committee, 2003 - 2010
- Research Mentorship Award, 2006
- Corresponding Committee on Research Training, Member 2006 - 2009, Chair 2006 - 2009
- Vestermark Award, 2006
- Judson Marmor Award, 2008
- Council on Geriatric Psychiatry, 2012
- Chair, Research Colloquium for Junior Investigators, 2014 - Present
- Mental Health and Faith Community Partnership, Steering Committee, 2014

American Society for Neurochemistry

- Jordi Folch-Pi Award, 1987
- Committee for Travel for Young Investigators, 1987 - 1991

Anxiety and Depression Association of America (formerly Anxiety Disorders Association of America)

- Board of Directors, 2012 - 2015, 2015 - 2018, 2019 - 2022
- Scientific Advisory Board, 1999 - Present; co-Chair 2000 - 2002, Chair 2002 - 2003
- Program Chair, 2001
- Career Development Travel Award Committee, 2005

- Trainee Travel Award Committee, 2005
- Junior Faculty Research Grant Committee, 2005 - 2007
- Chair, Career Development Leadership Program, 2014 - 2017

Brain Canada Multi-Investigator Research Initiative

- Grant Review Committee, 2012, 2014

Collegium Internationale Neuropsychopharmacologicum

- Member, 1990
- Program Committee, XVIII Congress, 1992
- Nominating Committee, 1992 - 1996
- Chair, Membership Committee, 1996 - 1998

Canadian Foundation for Innovation

- Leading Edge/New Initiatives Fund Multidisciplinary Assessment Committee, 2009

Depression and Bipolar Support Alliance (DBSA), previously the National Depressive and Manic Depressive Disorders Association

- Scientific Advisory Board, Member, 1993 - Present; Executive Committee, 2002 - 2004; Vice Chairman, 1995 - 1998; Chairman, 1998 - 2001
- Gerald L. Klerman Lifetime Research Award, 1996
- Member, Board of Directors, 1998 - 2001

Department of Defense/American Institute of Biological Sciences,

- Chairman, Grant Review Committee on Suicide Prevention, 2009
- Member, Grant Review Committee on Post-Traumatic Stress Disorder, 2011

George West Mental Health Foundation

- Advisory Board 1993 - 1995
- Board of Directors 1995 - 2009
- Nominating Committee, 2008 - 2009
- Chair, National Advisory Board, 2006 - Present

Georgia Psychiatric Physicians Association

- Psychiatrist of the Year, 2006
- Awards Committee, 2000 - 2009

International Society for CNS Clinical Trials and Methodology

- Task Force on Suicide Assessment and Clinical Trial Design, 2015

International Society of Psychoneuroendocrinology

- Curt P. Richter Award, 1985
- Scientific Program Committee, 1991, 1995 - 1999
- President-Elect, 1990 - 1993
- President, 1993 - 1996
- Past-President, 1996 - 1999
- Executive Committee, 1990 - 1999; 2000 - 2002
- Awards Committee, 2004, 2015
- Nominating Committee, 2006 - 2008, 2013 - 2014
- Lifetime Achievement Award, 2015

- Curt P. Richter Award Committee, 2015
- Program Chair, 2016 Annual Meeting, 2016

Institute of Medicine of the National Academy of Sciences (National Academy of Medicine)

- Member, 2002
- Planning Committee, Neuroscience Special Interest Group, 2010 - 2012

International Academy of Behavioral Medicine Counseling and Psychotherapy

- Advisory Council, 2010

Max Planck Institute for Psychiatry, Munich, Federal Republic of Germany

- External Advisory Board, 1990 - 2001
- Nominating Committee, Kraepelin Medal, 1997
- Visiting Professor, 2013

The National Aeronautics and Space Administration (NASA) Biomedical Research Council, 2000 - 2002

National Alliance for the Mentally Ill (NAMI)

- Ad Hoc Scientific Advisory Group, 1990 - Present
- Exemplary Psychiatrist Award, 1997
- Scientific Council, 2002 - Present

NAMI Georgia

- Sponsorship Committee, 1998 - 2009
- Board of Directors, 1998 - 2009

National Alliance for Research on Schizophrenia and Depression (NARSAD), now Brain and Behavior Research Foundation (BBRF)

- Scientific Council, 1996 - Present
- Established Investigator Award, 1996, 2003
- Selo Prize for Research in Mood Disorders, 1997

National Institutes of Health

- Member, Neurobehavioral Research Subcommittee of the Neurosciences Research Review Committee, July 1983 - June 1987
- Member, Biological Psychopathology Study Section, 1990 - 1993
- Member, National Advisory Council, October 1, 1998 - September 30, 2002
- Member, Review Group, Interventions Committee for Adult Mood and Anxiety Disorders (ITAV), July 1, 2006 – June 30, 2010
- Member, Review Group, Loan Repayment Program, 2006
- Ad Hoc Member, Review Group, Neurotechnology, June 2010
- Member, Special Emphasis Panel, National Institute of Occupational Safety and Health, 2014
- Member, Special Emphasis Panel, ZRGI BBBP-Y (02) Neuroscience of Stress, Sleep and Psychopathology, 2015
- Member, Special Emphasis Panel, ZDAI-JXR-D (13), National Institute of Drug Abuse, Smoking Cessation Interventions for People with Schizophrenia, 2015, 2016
- Pennsylvania State University NICHD Transnational Center for Child Maltreatment Studies (TCCMS) External Advisory Board, 2017 - Present

NeuroMAP CoBRE project at LIBR
- External Advisory Board, 2017 - Present

North Carolina Psychiatric Association
- Committee on Research, 1988 - 1991
- Program Committee, 1990
- V. Sagar Sethi, M.D. Mental Health Research Award, 2013

Pennsylvania Department of Health and the Oak Ridge Associated Universities
- Pennsylvania Final Performance Review, 2013, 2015

Rivermend Health LLC
- Scientific Advisory Board, 2014

SAVE (Suicide Awareness Voices of Education)
- Board of Reference 2010 - Present

Society of Biological Psychiatry
- A.E. Bennett Neuropsychiatric Research Foundation Award in Basic Science 1979
- Program Committee, 1988, 1990, 1993, 1994, 1998, 2005 – 2007, 2015-2017
- A. E. Bennett Award Committee, 1990 - 1992, 2003 - 2006
- Gold Medal Award, 1996
- Resource Development Committee, 1997 - 1999
- Chair, Membership Committee, 1999 - 2001
- International Committee, 2008 - Present
- Contributions Committee, 2008 - 2010
- Chair's Choice Travel Fellowship Award Committee, 2013 - 2015

University of North Carolina
- First Prize (The Michiko Kuno Award) Research Presentations, 1978, 1979; Special Recognition, Student Research Day, 1980
- Third Prize, Student Research Paper Competition, 1978
- The Deborah Cushing Leary Award, First Prize, Student Research Paper Competition, 1979
- The Merck Award for Academic Excellence, 1981
- AOA Lecture, 1998
- Distinguished Alumni Award, School of Medicine, 1999
- George Ham Society Award, 2000
- University Alumni Award, 2006

Patient-Centered Outcomes Research Institute (PCORI)
- Grant Reviewer Panel, 2012

World Federation of the Societies of Biological Psychiatry
- Research Prize, 1991

World Psychiatric Association
- Co-chair, Operational Committee on Education, 2011 - 2014
- Education Committee, 1993 - Present
- Task Force on Affective Disorders, 2001
- Task Force on Bipolar Affective Disorders, 2005 - 2009
- Task Force on the Heart and Brain, 2006 - 2009

Review of Departments of Psychiatry

- University of Minnesota, School of Medicine, 1995
- Brown University, 2002
- Robert Wood Johnson College of Medicine and Dentistry, 2003
- University of North Carolina, School of Medicine, 2005
- University of Texas- Houston, 2007
- University of South Florida-Tampa (Neurology and Psychiatry Curriculum), 2011

State of Georgia

- Governor's Mental Health Service Delivery Commission, 2007 - 2008
- Chair, Subcommittee on State Hospitals

Veterans Administration

- Mental Health and Behavioral Sciences Review Committee, Spring 2017

Predoctoral Fellowship, the Schizophrenia Research Foundation, Society of the Scottish Rite, Lexington, Massachusetts, 1975 - 1976

Postdoctoral Fellowship, National Institute of Neurologic, Communicative Disorders and Stroke, 1977

Third Prize, Student Competition, Research Presentations, Society of Experimental Biology and Medicine, Southeastern Section, Duke University School of Medicine, Durham, North Carolina, October 1975

Visiting Professor, Department of Physiology, The Catholic University Medical School, Santiago, Chile, July - August 1978

Second Prize, Roche Laboratories Award in Neuroscience, 1979 National Student Research Forum, Galveston, Texas

Honorable Mention, Mead Johnson Excellence in Research Award, 1979 National Student Research Forum, Galveston, Texas

Co-Principal Investigator, North Carolina Alcoholism Research Authority Grant # 7908, \$23,500, 1980; Grant # 8010, \$27,400, 1981

Nominating Committee, American Pain Society, 1982 - 1983

Member, Scientific Council - Argentine Association of Psychoneuroendocrinology, 1982 - 2000

Nanaline H. Duke Scholarship, 1985 - 1987, \$90,000

American Geriatrics Society, New Investigator Award, 1985

American Men and Women of Science, 1986 - Present

Visiting Faculty Program, Mead-Johnson Company, Evansville, IN, 1987 - 1991

Anna Monika Foundation Award for Research in Depression - Second Prize, 1987

Member, Florida Society of Clinical Oncology, 2016 - Present

Men of Achievement, 1988 - Present

Personalities of the Americas, 1988 - Present

Judith Silver Memorial Young Scientist Award, The National Alliance for the Mentally Ill, 1988

VA Schizophrenia Center Research Review Committee, 1988 - 1989

Scientific Advisory Board, National Center for Post-Traumatic Stress Disorder, 1989 - Present

Consultant, Information Systems and Network Corporation, 1989

Beverly Professor of Psychiatry, University of Toronto, Clarke Institute of Psychiatry, 1990 - 1991

Consultant, Serono Laboratories, Norwell, Massachusetts, 1989 - 1990

Men and Women of Distinction, 1990 - Present

Roy R. Grinker, Sr. Visiting Professor, Department of Psychiatry, University of Illinois and Michael Reese Hospital, 1991

Distinguished Physicians of America, 1991 - Present

Psychoneuroimmunology Advisory Board, Starbright Foundation, Los Angeles, California, 1992 - Present

Program Committee, Society for Neuroscience, 1992 - 1995

Scientific Program Committee, 1st International Congress on Hormones, Brain and Neuropsychopharmacology, 1992 - 1993; 2nd International congress, 1999 - 2000

Research Advisory Board - National Medical Enterprises, Inc., 1993 - 1994

Program Committee, Winter Conference on *Brain Research*, 1993

Edward J. Sachar Award for Research in Biological Psychiatry, Columbia University College of Physicians and Surgeons, 1993

Edward A. Strecker Award, Institute of Pennsylvania Hospital, 1993

Veterans Affairs Subcommittee, American Association of Chairmen of Departments of Psychiatry, 1992 - 1995

Eleventh Annual Feldman Lecture, Biology, Diagnosis and Treatment of Depression, Edmonton, Alberta, Canada, October 22, 1993

Consultant, ALZA Corporation, San Francisco, California, 1994 - 1996

Second Annual David Lester Memorial Lecture in Drug and Alcohol Abuse, Rutgers University, New Brunswick, New Jersey, 1994

Southern Association for Research in Psychiatry (SARP)

- Council, 1994 - 1995

- President, 1996

Best Doctors in America, 1994 - Present

Best Doctors in America, Southeast Region, 1996 - 1997

Best Doctors in Atlanta, Atlanta Magazine, 1997 - 2008

Reunette W. Harris Professor of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1994 - 2009

Maudsley Bequest Lecture, Royal College of Psychiatrists, 1994

Scientific Advisory Council, Center for Psychobiology and Psychosomatics, University of Trier, Trier, Federal Republic of Germany, 1994 - 1998

External Scientific Advisory Board, NIH Center Grants

- University of California, San Diego, 1994 - 1999
- Yale University, Chair of Committee, 1997- 2000
- Stanford University, 2000 - 2008
- UCLA, Center for Neurovisceral Sciences & Women's Health, External Advisory Board, 2003 - 2007
- Laureate Institute, Tulsa, Oklahoma. The Center for Neuroscience-based Mental Health Assessment and Prediction (1P20GM121312), Chair of Committee 2018 - Present

Board of Directors, Research Foundation for Mental Hygiene, Albany, New York, 1994 - 2002

Advisory Board, Treatment and Research Advancements Association for Personality Disorder, 1996 - 1998

American Men and Women in Science, 1997 - Present

Northeastern University 1995 Outstanding Alumni Award in Health Sciences

America Health Magazine, Best Psychiatrists in America, 1996 - Present

Academic Advisory Board, Pfizer Visiting Professorship Program in Psychiatry, Pfizer, Inc., 1997 - 1999

Honorary Member, Colegio Argentino De Neuropsicofarmacología, 1997

Alpha Omega Alpha, Honor Medical Society, 1998 - Present

The 26th Annual Herbert S. Ripley Lecture, Department of Psychiatry and Behavioral Sciences, The University of Washington, Seattle, Washington, May 6, 1998

The Julius Axelrod Lecture in Neuroscience, The City College of New York, New York, New York, December 2, 1998

The 1999 Myself Lecture, Harvard Medical School Department of Psychiatry, Boston, Massachusetts, April 14, 1999

The Fleur Strand Research Award Lecture in Neuropeptides, International Neuropeptide Society, Key West, Florida, June 29, 1999

American Association of Chairs of Departments of Psychiatry
- Advocacy Committee, 2000 - 2004

Institute for the Study of Aging
- Scientific Advisory Board, 2000 - 2002

William C. Menninger Award, American College of Physicians, 2000

Scientific Committee, XI World Congress of Psychiatry, 1999

International Scientific Committee of the Association Argentina of Psychopathology and Neuroscience (AAPN), 2010

The Carter Center of Emory University, Board of Trustees, 2000 - 2002

Medical Advisory Board, InforMed Psychiatry, 2000 - 2006

Distinguished Leadership Award, Huntington's Disease Society of America, 2001

Patricia R. Barchas Award, American Psychosomatic Society, 2001

Scientific Council, Hathaway Children's Clinical Research Institute, 2001 - 2004

Burlingame Prize, The Institute of Living, 2002

Best Doctors in Atlanta, Consumer Reports, 2002

Most Cited Authors in Psychiatry, "Citation Classico", 2002

Hamilton Ford Lecture, Titus Harris Society, Galveston Texas, April 26, 2002

Usdin Award Lecture, "Stress and its impact on Brain Development", West Coast College of Biological Psychiatry, Santa Monica, California, April 19, 2002

NIH Grand Rounds, "Contemporary Clinical Medicine - Great Teachers", 2003

APA Medical Science Section Committee Representative, American Association for the Advancement of Science (AAAS), 2003 - Present

Pine Woods Retreat, Advisory Board, 2003 - Present

Fellow, The Council for Scientific Medicine and Mental Health, 2003 - Present

Scientific Board of Directors, Heinz C. Prechter Fund for Manic Depression, 2003 - 2004

Neuroscience Education Institute Lifetime Achievement Award, 2004

Frank O. Shobe Lecture, Washington University School of Medicine, 2004

Advisory Board, Conference on Innovations in Trauma Research Methods (CITRM), 2004

Irene and Eric Simon *Brain Research Foundation*, Honorary Board of Directors, 2004

National Psychiatry Training Council Task Force, Research Literacy Committee, 2004 - 2006

National Foundation for Mental Health (NFMH), Board of Directors, 2005 - Present

Atlanta Foundation of Psychoanalysis, Board of Advisors, 2006 - 2009

America's Top Psychiatrists, 2007, 2008, 2010, 2011

5th Annual Chair Summit, Master Class for Neuroscience Professional Development, Chair of the Year, 2012

8th Annual Jack Hanni Memorial Lecture, Adventist Midwest Health, "The Neurobiology of Child Abuse: Treatment Implications", Oakbrook, IL, 2007

American Association of Chairs of Psychiatry/Janssen Visiting Professorship, Department of Psychiatry, Dartmouth School of Medicine, Hanover, NH. June 10 - 12, 2007

College of Mathematics, Natural Sciences and Technology (CMNST) Guest Speaker – Dean's Distinguished Lecturer Series, Delaware State University, Dover, Delaware, February 28, 2012

Mental Health Service Delivery Commission Member, Appointed by Speaker of the House of Representatives for the State of Georgia, 2007 - 2009

Pfizer Visiting Professor, Department of Psychiatry, Ohio State University School of Medicine, Columbus, Ohio, October 25-28, 2010

International Union of Biochemistry and Molecular Biology, Gold Medal Award, 2014

Top 400 Most Cited Biomedical Researchers, 1996 -2011 (Eur J. Clin Invest. 43:1339-1396, 2013)

Who's Who in America, 1996 - Present

Who's Who in North America, 1996

Who's Who in Medicine and Healthcare, 1995 - Present

Who's Who in the South and Southwest, 1979 - Present

Who's Who in Frontier Science and Technology, 1982 - Present

Who's Who in the Behavioral Sciences, 1982, 1983

Who's Who of Emerging Leaders in America, 1986 - Present

Who's Who among Human Services Professionals, 1990 - Present

Who's Who in American Education, 1991 - Present

Who's Who in Science and Engineering, 1992 - Present

Who's Who in the World, 1993 - Present

The International Who's Who in Medicine, 1994 - Present

Who's Who in Sciences Higher Education (WWSHE), 2004 - Present

Who's Who in American Education, 2007 - Present

Who's Who Among Executives and Professionals, 2008 - 2010 "Honors Edition"

Pharmaceutical and Clinical Research Company Scientific Advisory Boards

Abbott Laboratories

Consultant, Abbott Laboratories, Diagnostics Division, Abbott Park, IL, 1986 - 1992

Research and Education Advisory Board for Psychiatry

- Member, 1990 - 2006
- Executive Board, 1991 - 1993, 2003 - 2006
- Antidepressant Advisory Board, 1991 - 1992

ACADIA Pharmaceuticals Clinical Advisory Board

- Member, 2000 - 2006

Allergan

- Consultant, 2012

AstraZeneca Pharmaceuticals

- Psychiatry Advisory Board, 1997 - 2001
- Chairman, 1999 - 2002
- Neuroscience Scientific Advisory Board, 1999 - 2009

Bristol-Myers-Squibb

- Antipsychotic Advisory Board, 2003 - 2006
- Antidepressant Advisory Board, 2003 - 2006
- EMSAM Advisory Board - Chairman, 2005 - 2006

CeNeRx

- Chairman, Scientific Advisory Board, 2007 - 2012

Clintara/Bracket

- Chairman, Scientific Advisory Board, 2014 - Present

Cephalon Pharmaceuticals

- Scientific Advisory Board, 2002

Comprehensive Neuroscience, Inc.

- Scientific Advisory Board, 1999 - 2004

Corcept

- Scientific Advisory Board, 2001 - 2006

Cyberonics

- Scientific Advisory Board, 2002 - 2006
- Chair, Mechanism of Action Board, 2003 - 2006

Cypress Biosciences, Inc.

- Board of Directors, 2001 - 2004
- Consultant, 2004 - 2006

Eli Lilly and Company

- Psychiatry Advisory Board, 1990 - 2000
- Bipolar Advisory Board, 1998 - 1999
- Consultant, 2002 - 2003
- Global Neuroscience Advisory Board, 2005 - 2006

Forest Laboratories

- Citalopram Clinical Advisory Board, 1997 - 2002
- Psychiatry Scientific Advisory Board, Chairman, 1999 - 2008

Fortress Biotech

- Consultant, 2015

GlaxoSmithKline Advisory Board of Psychiatrists

- Chairman, 1991 - 2004

Janssen Pharmaceuticals

- Mood Disorders Advisory Board, Member and Chairman, 1998 - 2004
- Topiramate Advisory Board, Member and Chairman, 1999 - 2001
- Antipsychotic Advisory Board, Member, 1999 - 2005
- Johnson & Johnson Scientific Advisory Board, 2007- 2008

Lundbeck

- Consultant, 2006

Magstim

- Consultant, 2016

Merck Sharp & Dohme Research Laboratories

- Consultant, Neuroscience Research Center, 1994
- Mood Disorders Advisory Board, 1999 - 2003

Merck-MedCo Mental Health Advisory Board

- Member, 1996 - 1998

Mitsubishi Pharma

- Consultant, 2013 - Present

Mt. Cook Pharma

- Board of Directors, 2007 - 2010

Neurocrine Biosciences

- Scientific Advisory Board, 1994 - 2004

Neuronetics

- Scientific Advisory Board, 2006

Novadel Pharma

- Board of Directors, 2003 - 2011
- Chair, Scientific Advisory Committee
- Member, Compensation Committee
- Member, Nominating Committee
- Member, Audit Committee

Novartis Pharmaceutical Company

- Bipolar Advisory Board Chairman, 2001 - 2003
- Pediatric Bipolar Advisory Board, 2002 - 2003
- Antidepressant Advisory Board, 2006

Organon Pharmaceuticals Psychiatry Advisory Board

- Member, 1997 - 2004

Otsuka Psychiatry Advisory Board

- Chairman, 2003 - 2006

PharmaNeuroboost

- Chair, Scientific Advisory Board, 2006 - 2012

Pfizer Pharmaceuticals

- Clinical Neuroscience Advisory Board, 2004 - 2006
- Chair, Antipsychotic Advisory Board, 2004 - 2006

Prismic Pharmaceuticals

- Consultant, 2014 - Present

Quintiles Scientific Advisory Board, 2004 - 2008

Roche Laboratories, a Division of Hoffman-LaRoche, Inc.

- Mania Advisory Board, 1993
- Pharmacogenomics Advisory Board, 2006

Sanofi/Synthelabo

- Psychiatry Advisory Board, 2002 - 2005

SciRex

- Scientific Advisory Board, 1999 - 2003

Shire Pharmaceuticals

- Consultant, 2011

SK Pharma

- Consultant, 2011 - 2012

Solvay Pharmaceuticals Psychiatry Advisory Board

- Member, 1991 - 1999
- Chairman, 1991 - 1999
- Antipsychotic Advisory Board, 2005 - 2006

Somerset Pharmaceuticals Psychiatry Advisory Board
- Chair, 2000 - 2004

Taisho Pharmaceutical Inc.
- Consultant, 2013 - Present

Takeda Pharmaceuticals
- Consultant, 2011 - 2015

Vela Pharmaceuticals
- Scientific Advisory Board, 2001 - 2002

Wyeth-Ayerst Psychiatric Advisory Board
- Chairman and Member, 1995 - 2002

Xhale
- Consultant, 2010 - Present
- Chair, Scientific Advisory Board, 2012 - Present

RECENT GRANT SUPPORT

. I. Federal Funding

Co-Principal Investigator, National Institute on Alcohol Abuse and Alcoholism/National Institutes of Health Grant 1R01AA024933 Stem Cell Therapy, Inflammation and Treatment Response in Alcoholism-Depression Co-morbidity, 9/1/2017 – 6/30/2022, \$3,824,185.

Co-Investigator, National Institute on Drug Abuse/National Institutes of Health Grant 1R01DA034589 (Predictive Biomarkers of CVD Risk in Diverse HIV-1+ Cocaine Abusers), Mahendra Kumar, Ph.D., Principal Investigator, 9/15/2014 – 8/31/2019, \$2,900,000.

Principal Investigator, National Institute of Mental Health Grant 1R01MH094759 (Prospective Determination of Risk Factors for PTSD), 5/17/2012 - 4/30/2017, \$1,808,691.

Co-Investigator, National Institutes of Health Grant 7R01MH078775-04 (Validation of Measures of Real-World Outcome), Philip Harvey, Ph.D., Principal Investigator, 7/28/10 – 6/30/12, \$688,500.

Co-Investigator, National Institutes of Health Grant 1R01DA031201 (HIV-1 Infection in Methamphetamine Abusers: Endocrine Outcomes), Mahendra Kumar, Ph.D., Principal Investigator, 4/1/11 – 1/31/16, \$3,087,798.

Principal Investigator, National Institute of Mental Health Grant P50 MH-077083 (Predictors of Antidepressant Treatment Response: The Emory CIDAR), 4/11/2006 – 11/30/2008 as PI, funded through 3/31/2011, \$10,327,500.

Principal Investigator, National Institute of Mental Health Grant U19 MH069056 (The Emory GSK-NIMH Collaborative Antidepressant Drug Discovery Initiative), 7/1/03 - 6/30/08, \$4,900,000, 9/1/08 – 11/30/2008 as PI, funded through 8/31/13, \$11,133,680.

Principal Investigator, National Institute of Mental Health Grant MH- 58922 (Sylvio O. Conte Center for the Neuroscience of Mental Disorders), 9/1/99 - 8/31/04, \$13,079,284; 9/1/04 - 8/31/09, \$11,787,322.

Principal Investigator, National Institute of Mental Health Grant MH-39415 (Neurotensin, an Endogenous Neuroleptic-like Peptide), 12/1/83 - 11/30/86, \$386,000; 12/1/86 - 11/30/90, \$694,495; MERIT award to extend funding until 11/30/94, \$850,000; 8/1/95 - 6/30/2000, \$803,577; 8/1/00 - 7/31/05, \$1,125,000, 6/30/06 – 11/30/2008 as PI, funded through 7/31/2011, \$2,257,545.

Principal Investigator, National Institute of Mental Health Grant MH-40524 (Neuropeptide and Cholinergic Function in Alzheimer's Disease); 7/1/85 - 6/30/87, \$317,951; 7/1/87 - 6/30/90, \$480,000; 4/1/91 - 3/31/94, \$958,795; 2/1/96 - 1/31/99, \$636,719.

Principal Investigator, National Institute of Mental Health Grant MH-42088 (The Psychobiology of Corticotrophin-releasing Factor); 1/1/87 - 12/31/88, \$189,882; 7/1/89 - 6/30/92, \$476,015; 1/1/93 - 12/31/97, \$800,000; 1/1/98 - 12/31/2000, \$399,093; 2/1/01 - 1/31/05, \$1,000,000, 7/1/06 - 3/31/2011, \$2,754,000.

Principal Investigator, National Institute of Drug Abuse Grant DA-09492 (The Neurochemical Pathology of Human Cocaine Abuse); 7/1/95 - 5/31/98, \$556,477.

Principal Investigator, National Institute of Mental Health Grant, MH-46791. Pancreatic Cancer, Depression and Immune Function), 9/30/91 - 8/30/96, \$634,550.

Principal Investigator, The Emory Research Infrastructure Support Program, National Institute of Mental Health Grant MH-51761, 8/1/94 - 7/31/99, \$1,676,680 (includes supplement of \$300,000 and indirect costs).

Principal Investigator, National Institute of Mental Health Grant MH-90001 (Comparative Effectiveness of Antipsychotic Medications - CATIE Project), 12/1/00 - 11/29/02, \$342,611; 11/30/02 - 9/30/07, \$383,750.

II. Foundations

Principal Investigator, Stanley Foundation Fund for Medical Student Research in Psychiatry, Duke University Medical Center, 1989 - 1992, \$45,000; Emory University School of Medicine, 1992 - 2004, \$180,000.

Principal Investigator, American Suicide Foundation Institutional Grant, 1996 - 1997, \$50,000; 1998 - 1999, \$60,000.

Principal Investigator, American Foundation for Suicide Prevention (The College Screening Project: A Program to Identify and Help Students with Significant Psychological Problems), 4/16/2002 - 12/31/04, Total direct costs \$200,000.

Principal Investigator, MacArthur Foundation Depression Network. Project on Neuroendocrine Effects of Early Separation, 1990 - 1991, \$45,000; 1992 - 1993, \$34,500.

Established Investigator Award, National Alliance for Research in Schizophrenia and Depression (NARSAD), "Mechanisms of Increased Risk of Depressed Patients to Cardiovascular Disease", 1996, \$100,000.

Established Investigator Award, National Alliance for Research in Schizophrenia and Depression (NARSAD), "Comparison of Serotonin Transporter Binding by Functional Brain Imaging versus Transfected Cell Assay", 5/1/03 - 5/30/06, direct costs \$100,000.

Distinguished Investigator Award, American Foundation for Suicide prevention (AFSP), "Investigation for Serotonin Transporter Binding Alterations in Violent and Non-Violent Suicide Attempters Using SPECT with [¹²³I] ZIENT", 7/1/02 - 6/30/06, direct costs \$100,000.

Co-Principal Investigator, Stanley Medical Research Institute, Mesenchymal Stem Cell Therapy for Treatment-Resistant Bipolar Depression, 2016-2018, \$650,000.

III. Pharmaceutical Grants

Principal Investigator, DuPont Pharmaceuticals, The effect of DUP-996 in Alzheimer's Disease, 1990 - 1992, \$240,000; 1992 - 1993, \$121,305.

Principal Investigator, Immunology Research Institute, Johnson & Johnson, Basic and Clinical Studies of Thymopoietin, 1991 - 1994, \$51,000.

Principal Investigator, Eli Lilly Company, Amesergide versus placebo versus fluoxetine in Major Depression, 1992 - 1993, \$251,650.

Principal Investigator, Solvay Pharmaceuticals, A Comparison of fluvoxamine and fluoxetine in Major Depression, 1992 - 1993, \$87,360.

Principal Investigator, SmithKline Beecham, A double-blind randomized trial of paroxetine versus placebo in patients with depression accompanied by anxiety, 1992 - 1993, \$75,600.

Principal Investigator, SmithKline Beecham, Paroxetine versus clomipramine and placebo in the treatment of obsessive-compulsive disorder, 1992 - 1993, \$253,700; extension of the comparative study, \$100,680.

Principal Investigator, SmithKline Beecham, A double blind place-controlled multicenter study of fixed doses of paroxetine in the treatment of panic disorder, 1993 - 1994, \$76,440; continuation study, \$60,840.

Principal Investigator, Eli Lilly Company, Olanzapine (LY170053) vs. placebo and haloperidol in the treatment of schizophrenia, 1991 - 1994, \$318,500.

Principal Investigator, Pfizer Pharmaceuticals, "Study evaluating three doses of oral CP 88059-1 in the acute exacerbations of schizophrenia and schizoaffective disorder". 1992 - 1993, \$316,632.

Principal Investigator, SmithKline Beecham, Studies of fixed doses of paroxetine in treatment of panic disorder, 1992 - 1994, \$76,440, extension \$60,840.

Principal Investigator, Boots Pharmaceuticals, "Zotepine in acute schizophrenia", 1993 - 1995, \$104,160.

Principal Investigator, Pharmaco-LSR, "Olanzapine vs. haloperidol in the treatment of schizophrenia and other psychotic disorders", 1993 - 1994, \$346,080.

Principal Investigator, ICON-Abbott laboratories, "A double-blind placebo controlled, haloperidol-referenced study for the safety and efficacy of sertindole in schizophrenic patients", 1993 - 1994, \$120,000.

Principal Investigator, Solvay Pharmaceuticals, A double-blind comparison of fluvoxamine and sertraline in major depression, 1994 - 1995, \$88,440.

Principal Investigator, SmithKline Beecham, Paroxetine in the treatment of bipolar depression, 1994 - 1995, \$96,192.

Principal Investigator, SmithKline Beecham, A paroxetine, desipramine and placebo comparison of depressed breast cancer patients, 1994 - 1997, \$130,000.

Principal Investigator, Hoechst-Roussel Pharmaceuticals, A study of the efficacy of HP873 administered to schizophrenic patients, 1994 - 1995, \$150,000.

Principal Investigator, Forest Laboratories, Inc., "Clinical evaluation of extended release oral physostigmine in the treatment of patients with dementia of the Alzheimer's type, 1994 - 1995, \$240,000.

Principal Investigator, The Upjohn Company, A pilot trial of pramipexole in the treatment of Tardive Dyskinesia, 1994 - 1995, \$50,000.

Principal Investigator, Pfizer Pharmaceuticals, A fifty-two week, open label, randomized study evaluating the safety and efficacy of ziprasidone (CP-88,059-1) (40-80 MG BID) and risperidone (3-5 MG BID) in the maintenance treatment of outpatients with schizophrenia or schizoaffective disorder, 1994 - 1995, \$175,000.

Principal Investigator, Zeneca Pharmaceuticals, "A multicenter, open-label trial evaluating the safety and tolerability of Seroquel in treatment of elderly subjects with selected idiopathic and organic psychoses", 1995 - 1997, \$67,000.

Principal Investigator, Janssen Pharmaceuticals, "Comparison of Risperidone and Haloperidol for Prevention of Relapse in Schizophrenia and Schizoaffective Disorders", 6/1/96 - 5/31/97, \$126,000.

Principal Investigator, Wyeth-Ayerst Pharmaceuticals, "Double-Blind, Placebo-Controlled Study of Venlafaxine-ER and Venlafaxine-OROS", 7/1/96 - 3/31/97, \$150,540.

Principal Investigator, Eli Lilly & Company, "Study of Olanzapine in Schizophrenic Patients Discontinuing Clozaril", 6/1/96 - 5/31/97, \$93,820.

Principal Investigator, Wyeth-Ayerst Pharmaceuticals, "Double-Blind, Placebo-Controlled Study of Venlafaxine-ER and Fluoxetine in Inpatients with Major Depression and Melancholia", 6/1/96 - 12/31/97, \$270,160.

Principal Investigator, Wyeth-Ayerst Pharmaceuticals, "Double-Blind, Placebo-Controlled Study of Venlafaxine-ER and Fluoxetine in Outpatients with Major Depression", 7/1/96 - 12/31/97, \$158,040.

Principal Investigator, Eli Lilly & company, "Olanzapine versus placebo in the treatment of mania associated with bipolar I disorder", 1996 - 1998, \$310,720.

Principal Investigator, SmithKline Beecham, A 38-week, two phase, multicenter study to investigate the safety and effectiveness of paroxetine (10-60 mg/day) in the treatment of children and adolescent outpatients with obsessive-compulsive disorder, 1996 - 1999, \$48,703.

Principal Investigator, Boots Pharmaceuticals, "Study of zotepine 75, 150 and 300 mg daily doses in schizophrenia", 1993 - 1997 \$45,297.

Principal Investigator, Bristol-Myers Squibb Company, "An *in vitro* study of the receptor binding profile of nefazodone and its metabolites on various neurotransmitter receptors", 1995 - 1997, \$116,064.

Principal Investigator, Zeneca Pharmaceuticals, "A multicenter, open, randomized comparison of ICI204,636 (Seroquel) and usual care on health outcomes in subjects with schizophrenia and schizoaffective disorders", 1995 - 1998, \$116,064.

Principal Investigator, Eli Lilly Company, "The effects of olanzapine on neurotensin in the rat brain", 1994 - 1998, \$137,000.

Principal Investigator, Eli Lilly Company, "The acute and long-term efficacy of olanzapine in first-episode psychotic disorders" a randomized double-blind comparison with haloperidol", 1997 - 2001, \$2,395,366.

Principal Investigator, Abbott Laboratories, "The efficacy and safety of rapid loading Depakote in the treatment of acutely manic patients with bipolar disorder", 1997 - 1998, \$62,100.

Principal Investigator, Pfizer Inc., "A 52 week, open extension study evaluating the safety and outcome of 40-80 mg BID oral CP-88, 059-1 daily in the treatment of subjects who have participated in previous CP-88,059-1 clinical trials, 1995 - 1997, \$42,432.

Principal Investigator, SmithKline Beecham, "A 38 week, two phase, multicenter study to investigate the safety and effectiveness of paroxetine in the treatment of children and adolescent outpatients", 1996 - 1997, \$147,584.

Principal Investigator, Bristol Myers Squibb, "A prospective, multicenter study comparing the safety and efficacy of nefazodone HCl to cognitive behavioral therapy-chronic depression (CBT-CD) and combined nefazodone and CBT-CD for the acute, continuation and maintenance treatment of chronic forms of depression", 1996 - 1999, \$1,533,269.

Principal Investigator, SmithKline Beecham, "Double-blind, placebo controlled study of the clinical effects of immediate release paroxetine in the treatment of major depression in elderly patients", 1996 - 1997, \$65,760.

Principal Investigator, Wyeth-Ayerst Laboratories, "Double-blind placebo controlled study of venlafaxine and fluoxetine in inpatients with major depression and melancholia", 1996 - 1997, \$116,160.

Principal Investigator, Wyeth-Ayerst Laboratories, "Double-blind placebo controlled study of venlafaxine and fluoxetine in outpatients with major depression", 1996 - 1997, \$105,360.

Principal Investigator, Eli Lilly Company, "Olanzapine alone and in combination with fluoxetine versus placebo in major depressive disorders with psychotic features", 1998 - 1999, \$41,430.

Principal Investigator, Eli Lilly Company, "The neural correlates of the effects of olanzapine on schizophrenia: a longitudinal positron emission tomography (PET) analysis", 1998 - 1999, \$230,000.

Principal Investigator, Bristol-Myers Squibb Company, "Nefazodone in the treatment of social phobia: functional brain imaging and neuroendocrine correlates", 1998 - 1999, \$100,000.

Principal Investigator, Eli Lilly Company, "Does fluoxetine reverse the effects of early life stress on CNS CRF systems and improve psychological and neuroendocrine function?", 1998 - 2005, \$271,875.

Principal Investigator, Eli Lilly & Company, "Olanzapine in the reduction of hyperprolactinemia and associated morbidity in schizophrenic patients", 1999 - 2000, \$30,000

Principal Investigator, Eli Lilly & Company, "Prevalence of hyperprolactinemia in schizophrenia patients treated with antipsychotic drugs", 1999 - 2000, \$32,496.

Principal Investigator, SmithKline Beecham Pharmaceuticals, "A 12 week, double-blind, placebo controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD)", 1999 - 2000, \$36,000.

Principal Investigator, Wyeth Ayerst Pharmaceuticals, "The development of a positron emission tomography (PET) radioligand for *in vivo* imaging of the brain norepinephrine transporter (NET)", 2002 - 2005, annual direct costs \$164,474.

Principal Investigator, Bristol-Myers-Squibb Pharmaceuticals, "The role of the neurotensin system in the effects of aripiprazole in sensorimotor gating", 2001 - 2004, annual direct costs \$80,492.

EDITORIAL BOARDS

Associate Editor, Psychopharmacology Bulletin, 1988 - 1999; Editor-in-Chief, 2001

Editorial Board, Contemporary Psychiatry, 1985 - 1991

Editorial Board, Regulatory Peptides, 1986 - 2016

Editorial Board, Hormones and Behavior, 1986 - 1993

Editorial Board, Journal of Gerontology, 1987 - 1999

Editorial Board, Progress in Neuroendocrinimmunology, 1988 - 1992

Editorial Board, Molecular and Chemical Neuropathology, 1988 - 1999

Editorial Board, Synapse, 1989 - 2004

Editorial Board, Life Sciences, 1989 - 2012

Editorial Board, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1989 - 2009

Editorial Board, Advances in Neuropsychiatry and Psychopharmacology, 1989 - 1995

Editorial Board, Journal of Neuropsychiatry and Clinical Neurosciences, 1990 - Present

Editorial Board, European Archives of Psychiatry and Clinical Neurosciences, 1990 - Present

Section Editor, Neurosciences and Neuropsychiatry, Current Opinion in Psychiatry, Current Science, 1990 - 1992

Editorial Board, Neuropsychopharmacology, 1991 - 1993; Editor-in-Chief, 2001 - 2006

Co-Editor-in-Chief, Critical Reviews in Neurobiology, 1991 - 2001

Editorial Board, The Emory University Journal of Medicine, 1991 - 1993

Editor-in-Chief, Depression, 1992 - 1996

Editorial Board, Anxiety, 1993 - 1996

Co-Editor-in-Chief, Depression and Anxiety, 1996 - 2001

Editorial Board, Harvard Review of Psychiatry, 1993 - 2008

Editorial Board, Psychoneuroendocrinology, 1992 - Present

Editorial Board, Journal of Psychiatric Research, 1993 - Present

Editorial Board, Video Journal of Psychiatry, 1993 - 1996

Editorial Board, American Journal of Psychiatry, 1995 - 1999

Associate Editor, Journal Watch for Psychiatry, 1995 - 2004

Editorial Board, Molecular Psychiatry, 1995 - 2013

Editorial Board, American Psychiatric Press Inc., 1995 - 2002

Editorial Board, Neuropsychobiology, 1995 - Present

Editorial Board, Directions in Psychopharmacology, 1996 - Present

Editorial Board, Neurobiology of Disease, 1996 - 2004

Editorial Board, The Cortlandt Forum, 1996 - 2002

Editorial Board, CNS Spectrums, 1996 - 2009

Editorial Board, Human Psychopharmacology, 1997 - 2000

Advisory/Editorial Board, Focus On: Psychopharmacology, Institute for Scientific Information, 1996 - 1997

Associate Editor, Biological Psychiatry, 1997 - 2001

Section Editor: Clinical Studies and Clinical Trials, Neuropeptides, 1997 - Present

Advisory Board, Mental Fitness, 1997 - Present

Editorial Board, Essential Psychopharmacology, 1997 - Present

Editorial Board, International Journal of Psychiatry in Clinical Practice, 1998 - Present

Editorial Board, Current Psychiatry Reports, 1998 - 2006

Editorial Board, European Neuropsychopharmacology, 1999 - 2009

Editorial Board, Trends in Evidence-based Neuropsychiatry (formerly The Economics of Neuroscience), 1999 - Present

Associate Editor, Journal of Alzheimer's Disease, 1999 - 2000

Editorial Board, Neuropsychiatry Reviews, 2000 - Present; Editor-in-Chief, 2008 - Present

Editorial Board, Bipolar Disorders and Impulsive Spectrum Letter, 2000 - 2005

Editorial Board, Schizophrenia Research, 2001 - 2015

Editorial Board, L'Encephale, 2001 - Present

Editorial Board, Psychosomatic Medicine, 2002 - 2003

Editorial Advisory Board, The Journal of Applied Research, 2002 - Present

Editorial Advisory Board, Psychiatric UPDATE, 2002 - Present

Editorial Board, Mind & Matter, 2002 - 2009

Editorial Board, Experimental Neurology, 2003 - 2018

Advisory/Editorial Board, The Scientific Review of Mental-Health Practice, 2001 - Present

Editorial Board, Current Psychosis and Therapeutics Reports, 2003 - 2006

Editorial Board, Journal of Traumatic Stress, 2004 - 2008

Editorial Board, Neuropsychiatric Disease and Treatment, 2004 - Present

Editorial Advisory Board, Psychiatry, 2004, 2005

Editorial Board, Current Psychiatry Reviews, 2005 - Present

Editorial Board, Central European Journal of Medicine, 2006 - Present

Editorial Board, Psychiatry, 2006

Editorial Board, Central European Journal of Medicine – Versita, 2007 - Present

Editorial Board, Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2007

Editorial Board, Revista, Argentina de Psiquiatría Biológica

Editorial Board, Depression and Anxiety, 2008 - Present

Editorial Board, World Journal of Biological Psychiatry, 2009 - Present

Editorial Board, Depression Research and Treatment, 2009 - Present

Editorial Board, Mind and Brain, 2009 - Present

Editorial Board, World Journal of Diabetes, 2009 - Present

Editorial Advisory Board, Innovations in Clinical Neuroscience, 2011 - Present

Editorial Board, The Scientific World Journal, 2011 - Present

Editorial Board, BMC Medicine, 2012 - 2018

Editorial Board, Archives of Neuropsychiatry, 2012 - Present

Editorial Board, Journal of Traumatic Stress Disorders and Treatment, 2012 - Present

Editorial Board, Curēus e-Journal of Medicine, 2012 - Present

Editorial Board, Journal of Psychiatry and Neurobiological Sciences (Dusunen Adam), 2013 - Present

Editorial Board, Journal of Addiction Medicine and Therapy, 2013 - Present

Editorial Board, Journal of the International Union of Biochemistry and Molecular Biology, 2013 - Present

Editorial Board, MedZine, 2014 - Present

Editorial Board, Düşünen Adam, The Journal of Psychiatry and Neurological Sciences, 2015 - Present

Co-editor in Chief, Personalized Medicine in Psychiatry, 2016 - Present

Editorial Board, Revista Brasileira de Psiquiatria, 2017 - Present

Section Editor, Current Treatment Options in Psychiatry, 2017 - Present

SUPERVISION OF PHD STUDENTS

1. Michael J. Owens, PhD Pharmacology, Duke University, 1990
2. Beth Levant, PhD Pharmacology, Duke University, 1990
3. James C. Ritchie, PhD Pharmacology, Duke University, 1995
4. Becky Myers Kinkad Pharmacology, Emory University, 1997
5. Steven Stout Neuroscience, MD, PhD, Emory University, PhD, 1999
6. Kelly Hartline-Skelton Neuroscience, MD, PhD Emory University, PhD, 2000
7. Elizabeth Binder, MD Neuroscience, PhD, Emory University, 1999
8. David Gutman Neuroscience, MD, PhD, Emory University, PhD, 2004
9. Ricardo Caceda, MD Neuroscience, PhD, Emory University, 2005
10. Scott Feng Biochemistry, MS Degree, Emory University, 2004
11. Nicola Hanson Neuroscience, PhD, Emory University, 2010
12. Elizabeth Martin Neuroscience, PhD, Emory University, 2009
13. Chase Bourke Molecular and Systems Pharmacology, PhD, Emory University, 2012
14. Lucy Guillory Neuroscience, PhD, Emory University, 2013

SUPERVISION OF POST-DOCTORAL FELLOWS

1. Scott T. Cain, PhD 1983 - 1985
2. Kathleen M. Skoog, PhD 1984
3. Peter J. Elliott, PhD 1985 - 1986
4. Gregory N. Ervin, PhD 1987 - 1988
5. Larry L. Cook, PhD 1988 - 1989
6. Pamela D. Butler, PhD 1989 - 1990
7. Catherine M. Pihoker, MD 1990 - 1991
8. Maria A. Vargas, MD 1990 - 1991
9. Diane Hayden-Hixson, PhD 1991 - 1992
10. Zachary N. Stowe, MD 1992 - 1993
11. Dominique L. Musselman, MD 1993 - 1996
12. James Radke, PhD 1994 - 1997
13. Christine Heim, PhD 1996 - 1999
14. Lotta Arborelius, PhD 1997 - 1999
15. Osvaldo Gayton, MD, PhD 1999 - 2000
16. Kristin Penza, PhD 2002 - 2004
17. Derick Vergne, MD 2005 - 2006
18. Gretchen Neigh, PhD 2005 - 2007

DUKE UNIVERSITY COMMITTEES

1. Research Renaissance III Committee, 1983; Chairman Neurobiology Subcommittee
2. Behavioral Medicine Research Center, Internal Advisory Committee, Duke University Medical Center, 1986 - 1991
3. Search Committee, Chair of Pharmacology, 1988 - 1990
4. Clinical Psychobiology Laboratory Steering Committee, 1987 - 1991
5. Medical Student Research Fellowship Committee, 1989 - 1991
6. Search Committee, Chief of Psychiatric Oncology, 1989 - 1990
7. Internal Advisory Board, Duke University NINCDS Stroke Center, 1990 - 1991

EMORY UNIVERSITY COMMITTEES

1. Emory Medical Care Foundation Board of Directors, 1991 - 2009
2. Search Committee, Director Positron Emission Tomography Center, 1991 - 1992
3. Subcommittee on Research, LCME Institutional Self-Study, 1992
4. The Emory Clinic, Task Force for Network Development, 1992
5. Search Committee, Associate Dean for Research, 1992 - 1993
6. Management Committee (Executive Committee), The Emory Clinic, 1993 - 1994
7. VA Medical Center Shared Equipment Committee, 1993
8. Faculty Relations Committee, 1993-1995; 1997; Ad hoc member, 1998
9. Advisory Committee, Positron Emission Tomography Center, Advanced Imaging Center 1992 - 2006
10. Chair, Impaired Professionals Committee, The Emory Clinic, 1993 - 1997
11. Search Committee, Director, Yerkes Primate Center, 1993 - 1994
12. Research Advisory Council, Emory University School of Medicine, 1994 - 1997
13. Search Committee, Superintendent, Georgia Mental Health Institute, 1994
14. Search Committee, Chair of Pediatrics, 1994 - 1997
15. Board of Directors, The Emory Clinic, 1994 - 1998
16. Search Committee, Endowed Chair in Alzheimer's Disease Research, 1995
17. Chair, Search Committee, Chair of Pathology, 1995 - 1996
18. Ad Hoc Committee for Reengineering the Clinical Research Process at Emory, 1995 - 1997
19. Chair, Winship Cancer Center Review Committee, 1996
20. School of Medicine Research Steering Committee, 1997
21. Chair, Search Committee, Chair of Dermatology, 1997
22. Emory HealthCare Task Force on Hospital Configuration/Operations, 1997
23. Research Advisory Committee, 1997 - 1999
24. LCME Group 2 Self Study Project, 1998 - 1999
25. Search Committee, GRA Endowed Chair in Functional Imaging, 1999
26. Office of Technology Transfer/Office of Sponsored Programs Review Committee, 1999
27. Task Force on the Center for Aging, 1999 - 2009
28. Ad Hoc Committee to Evaluate EMCF Research Grant Policy, 2001
29. Clinical Research Curriculum Award (CRCA) Advisory Committee, 2000 - 2009
30. Search Committee, Chair of Pathology, 2002
31. Chair, Search Committee, Chair of Biochemistry, 2002
32. Emory Healthcare Organizational Reassessment Committee, 2002
33. School of Medicine Faculty Relations Committee, 2002 - 2005
34. Emory University Senate, 2002 - 2004
35. Advisory Council, GDBBS, 2003 - 2009

36. Neuroscience Research Institute Planning Committee, 2003 - 2009
37. Clinical Trials Advisory Committee, 2002 - 2009
38. Search Committee, General Clinical Research Center Director, 2005
39. Subcommittee on Discovery, Medical School Curriculum Committee, 2005
40. Search Committee, Marcus Center Medical Director, 2005
41. Ad Hoc Committee on Grant Processing, 2005 - 2006
42. **Error! Bookmark not defined.**Search Committee, Chair of Ophthalmology, 2005 - 2006
43. Comprehensive Neurosciences Center Executive Committee, 2006 - 2009
44. Search Committee, Chair of Dermatology, 2007 - 2008
45. Woodruff Health Sciences Center Research Advisory Committee, 2007 - 2008

UNIVERSITY OF MIAMI COMMITTEES

1. Associate Member, John P. Hussman Institute for Human Genomics, 2010 - Present
2. Dean's Research Cabinet, 2010 - 2012, 2015 - Present
3. Chairs Executive Committee, 2010 - 2013
4. Member, Search Committee, Director, Sylvester Comprehensive Cancer Center, 2010 - 2011
5. Physician Leadership Group, Jackson Memorial Hospital-University of Miami, 2010 - Present
6. Academic Board, University of Miami Hospital, 2011 - 2012
7. M.D./Ph.D. Program Executive Oversight Committee, 2011 - Present
8. Medical Executive Committee, University of Miami Hospital, 2010 - Present
9. Search Committee, University of Miami Hospital CEO and CMO, 2012
10. Board of Directors, University of Miami Medical Group, 2012 - Present
11. Revenue Cycle Committee, University of Miami Miller School of Medicine, 2012 - 2013
12. Medical Research Enterprise Program (MEDREPS) Committee, University of Miami Miller School of Medicine, 2012 - Present
13. Resource Allocation Committee, Miami Miller School of Medicine, 2012 - 2014
14. Chair, Search Committee, Chair of Department of Pediatrics, 2013 - 2015
15. Chair, Faculty Assistance Committee, 2013 - Present
16. Executive Committee, University of Miami Medical Group, 2013 - Present
17. Board of Directors, UM/VA Oversight Committee, 2013 - Present
18. Search Committee, Senior Associate Dean for Faculty Affairs, 2014 - 2015
19. Associate Member, Sylvester Cancer Center, 2009 - 2014
20. Member, Sylvester Cancer Center, 2014 - Present
21. Scientific Steering Committee, Sylvester Cancer Center, 2014 - Present
22. MD, PhD Program and Executive Committees, 2014 - 2016
23. Search Committee, Chair of Surgery, 2014 - 2015
24. Internal Advisory Board, The Institute for Children and Adolescents with Cancer, Sylvester Cancer Center, 2015 - Present

25. Executive Committee, Board of Directors University of Miami Medical Group, 2014 - Present
26. Regenerative Medicine Cabinet, 2015 - Present
27. Precision Medicine Task Force, Miller School of Medicine, 2015 - Present
28. Research Cabinet, Miller School of Medicine, 2015 - Present
29. Credentials Committee, University of Miami Medical Group, 2017 - Present

PROFESSIONAL SOCIETIES

Society of the Sigma XI
Society for Neuroscience
American Association for the Advancement of Science
New York Academy of Sciences
International Society for Psychoneuroendocrinology
American Society for Neurochemistry
International Society for Neurochemistry
The Endocrine Society
International Society of Neuroendocrinology
Society of Biological Psychiatry
American Medical Association
American Psychiatric Association (Member, 1982; Fellow, 1994; Distinguished Fellow, 2003)
American College of Neuropsychopharmacology (Member, 1983; Fellow, 1986)
American College of Psychiatrists (Member, 1988; Fellow, 1992)
Psychiatric Research Society
American Association for Geriatric Psychiatry
American Association of Chairmen of Departments of Psychiatry
The International Society for the Investigation of Stress
Medical Association of Georgia
The International Neuropeptide Society (Fellow, 1994)
Association for Research in Nervous and Mental Diseases
Society for Behavioral Neuroendocrinology
American Psychosomatic Society
International Society for Traumatic Stress Studies
American Society of Clinical Psychopharmacology
World Psychiatric Association
Florida Psychiatric Society

RESEARCH REPORTS AND REVIEWS

1. **Nemeroff CB** and Crisley FD. 1975. Lack of protection by pyridoxine or hydrazine pretreatment against monosodium L-glutamate-induced seizures. *Pharmacol. Biochem. Behav* 3:927-929.
2. Prange AJ, Jr., Breese GR, Jahnke GD, Martin BR, Cooper BR, Cott JM, Wilson IC, Alltop LB, Lipton MA, Bissette G, **Nemeroff CB** and Loosen PT. 1975. Modification of pentobarbital effects by natural and synthetic polypeptides: dissociation of brain and pituitary effects. *Life Sci.* 16:1907-1914.
3. **Nemeroff CB**, Prange AJ, Jr., Bissette G, Breese GR and Lipton MA. 1975. Thyrotropin-releasing hormone (TRH) and its beta-alanine analogue: potentiation of the anticonvulsant potency of phenobarbital in mice. *Psychopharmacol. Comm* 1:305-317.
4. **Nemeroff CB** and Crisley FD. 1975. Monosodium L-glutamate-induced convulsions: temporary alteration in blood-brain barrier permeability to plasma proteins. *Environ. Physiol. Biochem* 5:389-395.
5. Bissette G, **Nemeroff CB**, Loosen PT, Prange AJ, Jr., Breese GR and Lipton MA. 1976. Comparison of the potency of TRH, ACTH₄₋₁₀, and related peptides to reverse pentobarbital-induced narcosis and hypothermia. In: *Hypothalamus and Endocrine Functions* (F Labrie, J Meites and G Pelletier, Eds). Plenum Press, New York 478-479.
6. Prange AJ, Jr., Lipton MA, Bissette G, **Nemeroff CB**, Breese GR, Loosen PT, Cooper BR and Wilson IC. 1976. Behavioral effects of peptides in animals: further experience with pentobarbital antagonism. *Psychopharmacol Bull* 13:58-59.
7. Lipton MA, Prange AJ, Jr., **Nemeroff CB**, Breese GR and Wilson IC. 1977. Thyrotropin-releasing hormone - central effects in man and animals. In: *Neuroregulators and Psychiatric Disorders* (E Usdin, DA Hamberg and J Barchas, Eds). Asilomar, California, Oxford University Press, New York, 258-266.
8. Bissette G, **Nemeroff CB**, Loosen PT, Prange AJ, Jr. and Lipton MA. 1976. Comparison of the analeptic potency of TRH, ACTH₄₋₁₀, LHRH and related peptides. *Pharmacol. Biochem. Behav.* 5 (Suppl. 1):135-138.
9. Prange AJ, Jr., **Nemeroff CB**, Lipton MA, Breese GR and Wilson IC. 1978. Peptides and the central nervous system. In: *The Handbook of Psychopharmacology, Vol. 13* (LL Iversen, SD Iversen and SH Snyder, Eds). Plenum Press, New York 1-107.
10. Prange AJ, Jr., **Nemeroff CB**, Loosen PT, Lipton MA, Bissette G, Breese GR and Wilson IC. 1977. Hormones in the treatment of nervous and mental disease: present status and development. In: *Neuropsychopharmacology* (P Deniker, C Radouco-Thomas and A Villeneuve, Eds). Pergamon Press, Oxford, 995-1003.
11. Lipton MA, Bissette G, **Nemeroff CB**, Loosen PT and Prange AJ, Jr. 1976. Neurotensin: a possible mediator of thermoregulation in the mouse. In: *Drugs, Biogenic Amines and Body Temperature* (PJ Lomax, Ed). Third International Symposium on the Pharmacology of Thermoregulation, Banff, Alberta, Canada, S Karger, Basel 54-57.

12. Bissette G, **Nemeroff CB**, Loosen PT, Prange AJ, Jr. and Lipton MA. 1976. Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin. *Nature* 262:607-609.
13. Prange AJ, Jr., Lipton MA, **Nemeroff CB** and Wilson IC. 1977. The role of hormones in depression. *Life Sci.* 20:1305-1318.
14. Lipton MA, **Nemeroff CB**, Bissette G and Prange AJ, Jr. 1977. The role of drugs in the prevention and treatment of mental retardation. In: *Proceedings of the International Association for the Study of Mental Deficiency* (M Begab, Ed). Research to Practice in Mental Retardation, Vol. III, Biomedical Aspects, Univ. Park Press, Baltimore 203-212.
15. **Nemeroff CB**, Grant LD, Bissette G, Ervin GN, Harrell LE and Prange AJ, Jr. 1977. Growth, endocrinological and behavioral deficits after monosodium L-glutamate in the neonatal rat: possible involvement of arcuate dopamine neuron damage. *Psychoneuroendocrinology* 2:179-196.
16. **Nemeroff CB**, Bissette G, Prange AJ, Jr., Loosen PT, Barlow TS and Lipton MA. 1977. Neurotensin: central nervous system effects of a hypothalamic peptide. *Brain Res.* 128:485-496.
17. Lipton MA and **Nemeroff CB**. 1978. An overview of the biogenic amine hypothesis of schizophrenia. In: *Phenomenology and Treatment of Schizophrenia* (WE Fann, I Karacan, AD Pokorny and RL Williams, Eds). Spectrum Publications, Inc., New York 431-453.
18. Prange AJ, Jr., **Nemeroff CB** and Lipton MA. 1978. Behavioral effects of peptides: basic and clinical studies. In: *Psychopharmacology: A Generation of Progress* (MA Lipton, A DiMascio and KF Killam, Eds). Raven Press, New York 441-458.
19. **Nemeroff CB**, Diez JA, Bissette G, Prange AJ, Jr., Harrell LE and Lipton MA. 1977. Lack of effect of chronically administered thyrotropin-releasing hormone (TRH) on regional rat brain tyrosine hydroxylase activity. *Pharmacol. Biochem. Behav.* 6:467-469.
20. Carson KA, **Nemeroff CB**, Rone MS, Youngblood WW, Prange AJ, Jr., Hanker JS and Kizer JS. 1977. Biochemical and histochemical evidence for the existence of a tuberoinfundibular cholinergic pathway in the rat. *Brain Res.* 129:169-173.
21. **Nemeroff CB**, Konkol RJ, Bissette G, Youngblood WW, Martin JB, Brazeau P, Rone MS, Prange AJ, Jr., Breese GR and Kizer JS. 1977. Analysis of the disruption in hypothalamic-pituitary regulation in rats treated neonatally with monosodium L-glutamate (MSG): evidence for the involvement of tuberoinfundibular cholinergic and dopaminergic systems in neuroendocrine regulation. *Endocrinology* 101:613-622.
22. **Nemeroff CB**, Loosen PT, Bissette G, Manberg PJ, Wilson IC, Lipton MA and Prange AJ, Jr. 1978. Pharmaco-behavioral effects of hypothalamic peptides in animals and man: focus on thyrotropin-releasing hormone and neurotensin. *Psychoneuroendocrinology* 3:279-310.
23. Prange AJ, Jr., **Nemeroff CB** and Loosen PT. 1978. Behavioral effects of hypothalamic peptides. In: *Centrally Acting Peptides* (J Hughes, Ed). The Macmillan Co., London 99-118.

24. Loosen PT, **Nemeroff CB**, Bissette G, Burnett GB, Prange AJ, Jr. and Lipton MA. 1978. Neurotensin-induced hypothermia in the rat: structure- activity studies. *Neuropharmacology* 17:109-113.
25. Bissette G, **Nemeroff CB**, Loosen PT, Breese GR, Burnett GB, Lipton MA and Prange AJ, Jr. 1978. Modification of pentobarbital-induced sedation by natural and synthetic peptides. *Neuropharmacology* 17:229-237.
26. **Nemeroff CB**, Lipton MA and Kizer JS. 1978. Models of neuroendocrine regulation: use of monosodium glutamate as an investigational tool. *Dev. Neurosci.* 1:102-109.
27. Lipton MA and **Nemeroff CB**. 1978. The biology of aging and its role in depression. In: *Aging: The Process and the People* (G Usdin and CK Hofling, Eds). Brunner/Mazel Publishers, New York 47-95.
28. **Nemeroff CB**, Bissette G and Kizer JS. 1978. Reduced hypothalamic content of immunoreactive LHRH-like activity in genetically obese (ob/ob) mice. *Brain Res.* 146:385-387.
29. **Nemeroff CB** and Prange AJ, Jr. 1978. Peptides and Psychoneuroendocrinology: a perspective. *Arch. Gen. Psychiatry* 35:999-1010.
30. Greeley GH, Jr., Nicholson GF, **Nemeroff CB**, Youngblood WW and Kizer JS. 1978. Direct evidence that the arcuate nucleus-median eminence tuberoinfundibular system is not of primary importance in the feedback regulation of luteinizing hormone and follicle-stimulating hormone secretion in the castrated rat. *Endocrinology* 103:170-175.
31. **Nemeroff CB**, Osbahr AJ, III, Bissette G, Jahnke G, Lipton MA and Prange AJ, Jr. 1978. Cholecystokinin inhibits tail pinch-induced eating in rats. *Science* 200:793-794.
32. Bissette G, Manberg P, **Nemeroff CB** and Prange AJ, Jr. 1978. Neurotensin, a biologically active peptide. *Life Sci.* 23:2173-2182.
33. Kizer JS, **Nemeroff CB** and Youngblood WW. 1978. Neurotoxic amino acids and structurally related analogs. *Pharmacol. Rev.* 29:301-318.
34. Prange AJ, Jr., **Nemeroff CB**, Loosen PT and Wilson IC. 1978. Pharmacobehavioral effects of oligopeptides endogenous to brain. *Psychopharmacol. Bull.* 14:20-23.
35. Carson KA, **Nemeroff CB**, Rone MS, Nicholson GF, Kizer JS and Hanker JS. 1978. Experimental studies on the ultrastructural localization of acetylcholinesterase in the mediobasal hypothalamus of the rat. *J. Comp. Neurol.* 182:201-220.
36. Prange AJ, Jr., **Nemeroff CB**, Loosen PT, Bissette G, Osbahr AJ, III, Wilson IC and Lipton MA. 1979. Behavioral effects of thyrotropin- releasing hormone in animals and man: a review. In: *Central Nervous System Effects of Hypothalamic Hormones and Other Peptides* (R Collu, A Barbeau, JR Ducharme and JG Rochefort, Eds). Raven Press, New York 75-96.
37. **Nemeroff CB**, Bissette G, Greeley GH, Jr., Mailman RB, Martin JB, Brazeau P and Kizer JS. 1978. Effects of acute administration of monosodium L-glutamate (MSG), atropine or haloperidol on anterior pituitary hormone secretion in the rat. *Brain Res* 156:198-201.

38. Lipton MA, Ervin GN, Birkemo LS, **Nemeroff CB** and Prange AJ, Jr. 1979. Neurotensin-neuroleptic similarities: an example of peptide-catecholamine interactions. In: *Catecholamines: Basic and Clinical Frontiers* (E Usdin, IJ Kopin and JD Barchas, Eds), Pergamon Press, New York, 657-662.
39. Lipton MA, Mailman RB and **Nemeroff CB**. 1979. Vitamins, megavitamin therapy and the nervous system. In: *Nutrition and the Brain, Volume III* (RJ Wurtman and JJ Wurtman, Eds), Raven Press, New York 183-264.
40. Manberg PJ, **Nemeroff CB** and Prange AJ, Jr. 1979. Thyrotropin-releasing hormone and amphetamine: a comparison of pharmacological profiles in animals. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 3:303-314.
41. Osbahr AJ, III, **Nemeroff CB**, Manberg PJ and Prange AJ, Jr. 1979. Centrally administered neurotensin: activity in the Julou-Courvoisier muscle relaxation test in mice. *Eur. J. Pharmacol* 54:299-302.
42. Prange AJ, Jr., Loosen PT and **Nemeroff CB**. 1979. Peptides: application to research in nervous and mental disorders. In: *New Frontiers in Psychotropic Drug Research* (S Fielding, Ed). Futura Publishing Co. Inc., New York 117-189.
43. **Nemeroff CB**, Bissette G, Manberg PJ, Moore SI, Ervin GN, Osbahr AJ and Prange AJ. 1980. Hypothermic responses to neurotensin in vertebrates. In: *Thermoregulatory Mechanisms and Their Therapeutic Implications* (B Cox, P Lomax, AS Milton and E Schonbaum, Eds). *Proc. Pharmacology of Thermoregulation 4th Int. Symp.*, Oxford, S. Karger, Basel 180-185.
44. Lipton MA, **Nemeroff CB** and Mailman RB. 1979. Hyperkinesis and food additives. In: *Nutrition and the Brain, Volume 4* (RJ Wurtman and JJ Wurtman, Eds). Raven Press, New York, 1-27.
45. Prange AJ, Jr., **Nemeroff CB**, Bissette G, Manberg PJ, Osbahr AJ, III, Burnett GB, Loosen PT and Kraemer GW. 1979. Neurotensin: distribution of hypothermic response in mammalian and submammalian vertebrates. *Pharmacol. Biochem. Behav.* 11:473-477.
46. **Nemeroff CB**, Osbahr AJ, III, Manberg PJ, Ervin GN and Prange AJ, Jr. 1979. Alterations in nociception and body temperature after intracisternal administration of neurotensin, β -endorphin, other endogenous peptides and morphine. *Proc. Natl. Acad. Sci. USA* 76:5368-5371.
47. **Nemeroff CB**. 1980. Neurotensin: perchance an endogenous neuroleptic? *Biol. Psychiatry* 15:283-302.
48. **Nemeroff CB**, Bissette G, Martin JB, Brazeau P, Vale W, Kizer JS and Prange AJ, Jr. 1980. Effect of chronic treatment with thyrotropin-releasing hormone (TRH) or an analog of TRH (linear β -alanine TRH) on hypothalamic-pituitary-thyroid axis. *Neuroendocrinology* 30:193-199.
49. **Nemeroff CB**, Mason GA, Hatley OL, Jahnke G and Prange AJ, Jr. 1980. Lack of effect of a behaviorally active dose of cholecystokinin octapeptide upon aromatic amino acid levels in plasma and brain. *Brain Res* 184:529-532.

50. **Nemeroff CB**, Bissette G, Manberg PJ, Osbahr AJ, III, Breese GR and Prange AJ, Jr. 1980. Neurotensin-induced hypothermia: evidence for an interaction with dopaminergic systems and the hypothalamic-pituitary-thyroid axis. *Brain Res* 195:69-84.
51. **Nemeroff CB**, Bissette G, Manberg PJ, Luttinger D and Prange AJ, Jr. 1984. Effects of hypothalamic peptides on the central nervous system. In: *Peptides, Hormones and Behavior* (CB Nemeroff and AJ Dunn, Eds). Spectrum Publications, Inc., New York, 217-272.
52. **Nemeroff CB**, Luttinger D and Prange AJ, Jr. 1980. Neurotensin: central nervous system effects of a neuropeptide. *Trends Neurosci* 3:212-215.
53. Mason GA, **Nemeroff CB**, Luttinger D, Hatley OL and Prange AJ, Jr. 1980. Neurotensin and bombesin: differential effects on body temperature of mice after intracisternal administration. *Regul. Pept* 1:53-60.
54. Prange AJ, Jr., **Nemeroff CB** and Loosen PT. 1980. Psychoendocrine aspects of depression. In: *Comparative Aspects of Neuroendocrine Control of Behavior* (C Valverde-Rodriguez and H Arechige, Eds). S Karger, Basel, Front. Hormone Res 6:176-191.
55. Luttinger D, **Nemeroff CB**, King RA, Ervin GN and Prange AJ, Jr. 1981. The effect of injection of neurotensin into the nucleus accumbens on behaviors mediated by the mesolimbic dopamine system in the rat. In: *The Neurobiology of the Nucleus Accumbens* (RB Chronister and JF DeFrance, Eds.). Haer Institute for Electrophysiological Research, 322-332.
56. Grant LD, **Nemeroff CB** and Bissette G. 1984. Distribution of peptides in the central nervous system. In: *Peptides, Hormones and Behavior* (CB Nemeroff and AJ Dunn, Eds.). Spectrum Publications, Inc., New York, 37-97.
57. **Nemeroff CB**. 1981. Monosodium glutamate-induced neurotoxicity: review of the literature and call for further research. In: *Nutrition in Health and Disease* (SA Miller, Ed). Franklin Institute Press, Philadelphia, 117-211.
58. Osbahr AJ, III, **Nemeroff CB**, Luttinger D, Mason GA and Prange AJ, Jr. 1981. Neurotensin-induced antinociception in mice: antagonism by thyrotropin-releasing hormone. *J. Pharmacol. Exp. Ther.* 217:645-651.
59. Ervin GN, Birkemo LS, **Nemeroff CB** and Prange AJ, Jr. 1981. Neurotensin blocks certain amphetamine-induced behaviours. *Nature* 291:73-76.
60. **Nemeroff CB**, Prange AJ, Jr., Luttinger D, Hernandez DE, King, RA and Burgess SK. 1981. Similarities and differences in the effects of centrally administered neurotensin and neuroleptics. *Psychopharmacol. Bull.* 17:145-147.
61. Luttinger D, **Nemeroff CB**, Mason GA, Frye GD, Breese GR and Prange AJ, Jr. 1981. Enhancement of ethanol-induced sedation and hypothermia by centrally administered neurotensin, β -endorphin and bombesin. *Neuropharmacology* 20:305-309.
62. Frye GD, Luttinger D, **Nemeroff CB**, Vogel RA, Prange AJ, Jr. and Breese GR. 1981. Modification of the actions of ethanol by centrally active peptides. *Peptides* 2(Suppl. 1):99-106.

63. Ervin GN, Schmitz SA, **Nemeroff CB** and Prange AJ, Jr. 1981. Thyrotropin-releasing hormone and amphetamine produce different patterns of behavioral excitation in rats. *Eur. J. Pharmacol.* 72:35-43
64. **Nemeroff CB**, Lamartiniere CA, Mason GA, Squibb RE, Hong JS and Bondy SC. 1981. Marked reduction in gonadal steroid hormone levels in rats treated neonatally with monosodium L-glutamate: further evidence for disruption of hypothalamic-pituitary-gonadal axis regulation. *Neuroendocrinology* 33:265-267.
65. **Nemeroff CB**, Luttinger D, Hernandez DE, Kalivas PW, Widerlov E, Breese GR and Prange AJ, Jr. 1981. Neurotensin, a peptide with certain neuroleptic-like properties. In: *Proceedings of the Third World Congress of Biological Psychiatry* (C Perris, G Struwe and B Jansson, Eds.). Elsevier, Amsterdam, 363-367.
66. Burgess SK, Luttinger D, Hernandez DE, Kalivas PW, **Nemeroff CB** and Prange AJ, Jr. 1983. Antagonism of the central nervous system effects of neurotensin by thyrotropin-releasing hormone. In: *Thyrotropin-Releasing Hormone* (EC Griffiths and GW Bennett, Eds.). Raven Press, New York, 291-302.
67. Luttinger D, **Nemeroff CB** and Prange AJ, Jr. 1982. The effects of neuropeptides on discrete-trial conditioned avoidance responding. *Brain Res.* 237:183-192.
68. Kalivas PW, **Nemeroff CB** and Prange AJ, Jr. 1981. Increase in spontaneous motor activity following infusion of neurotensin into the ventral tegmental area. *Brain Res.* 229:525-529.
69. **Nemeroff CB** and Luttinger D. 1982. The anhedonia hypothesis of neuroleptic drug action: basic and clinical considerations. *Behav. Brain Sci.* 5:70-71.
70. **Nemeroff CB**, Luttinger D and Prange AJ, Jr. 1983. Neurotensin and bombesin. In: *Handbook of Psychopharmacology, Vol. 16* (LL Iversen, SD Iversen and SH Snyder, Eds.). Plenum Press, New York, 363-466.
71. Snidjers R, Kramarcy NR, Hurd RW, **Nemeroff CB** and Dunn AJ. 1982. Neurotensin induces catalepsy in mice. *Neuropharmacology* 21:465-468.
72. Hernandez DE, **Nemeroff CB** and Prange AJ, Jr. 1982. Ontogeny of the hypothermic response to centrally administered neurotensin in rats. *Dev. Brain Res.* 3:497-501.
73. **Nemeroff CB**, Hernandez DE, Orlando RC and Prange AJ, Jr. 1982. Cytoprotective effect of centrally administered neurotensin on stress-induced gastric ulcers. *Am. J. Physiol.* 242:G342-G346.
74. Uphouse LL, **Nemeroff CB**, Mason GA, Prange AJ and Bondy SC. 1982. Interactions between "handling" and acrylamide on endocrine response in rats. *Neurotoxicology* 3:121-125.
75. Manberg PJ, Youngblood WW, **Nemeroff CB**, Rossor MN, Iversen LL, Prange AJ, Jr. and Kizer JS. 1982. Regional distribution of neurotensin in human brain. *J. Neurochem.* 38:1777-1780.
76. Kalivas PW, Gau BA, **Nemeroff CB** and Prange AJ, Jr. 1982. Antinociception after microinjection of neurotensin into the central amygdaloid nucleus of the rat. *Brain Res.* 243:279-286.

77. Widerlov E, Kilts CD, Mailman RB, **Nemeroff CB**, McCown TJ, Prange AJ, Jr. and Breese GR. 1982. Increase in dopamine metabolites in rat brain by neurotensin. *J. Pharmacol. Exp. Ther.* 222:1-6.
78. Kalivas PW, **Nemeroff CB** and Prange AJ, Jr. 1982. Neuroanatomical site-specific modulation of spontaneous motor activity by neurotensin. *Eur. J. Pharmacol.* 78:471-474.
79. Prange AJ, Jr. and **Nemeroff CB**. 1982. Peptides in the central nervous system: focus on thyrotropin-releasing hormone and neurotensin. *Ann. Rep. Med. Chem.* 17:31-40.
80. Widerlov E, Lindstrom LH, Besev G, Manberg PJ, **Nemeroff CB**, Breese GR, Kizer JS and Prange AJ, Jr. 1982. Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment. *Am. J. Psychiatry* 139:1122-1126.
81. Luttinger D, King RA, Sheppard D, Strupp J, **Nemeroff CB** and Prange AJ, Jr. 1982. The effect of neurotensin on food consumption in the rat. *Eur. J. Pharmacol.* 81:499-503.
82. Kalivas PW, Hernandez DE, Bisette G, Mason GA, **Nemeroff CB** and Prange AJ, Jr. 1983. Neurotensin induced hypothermia: neuroanatomical and neurochemical mechanisms. In: *Proc. Pharmacology of Thermoregulation Fifth International Meeting. Environment, Drugs and Thermoregulation* (P. Lomax and E. Schonbaum, Eds.). S. Karger, Basel, 108-112.
83. Kalivas PW, Jennes L, **Nemeroff CB** and Prange AJ, Jr. 1982. Neurotensin: topographical distribution of brain sites involved in hypothermia and antinociception. *J. Comp. Neurol.* 210:225-238.
84. Prange AJ, Jr. and **Nemeroff CB**. 1982. The manifold actions of neurotensin: a first synthesis. In: *Neurotensin, a Brain and Gastrointestinal Peptide* (CB Nemeroff and AJ Prange, Jr., Eds.). *Ann. NY Acad. Sci.* 400:368-375.
85. **Nemeroff CB**, Hernandez DE, Luttinger D, Kalivas PW and Prange AJ, Jr. 1982. Interactions of neurotensin with brain dopamine systems. In: *Neurotensin, a Brain and Gastrointestinal Peptide* (CB Nemeroff and AJ Prange, Jr., Eds.). *Ann. NY Acad. Sci.* 400:330-344.
86. Manberg PJ, **Nemeroff CB**, Iversen LL, Rossor MN, Kizer JS and Prange AJ, Jr. 1982. Human brain distribution of neurotensin in normal, schizophrenics and Huntington's choreics. In: *Neurotensin, a Brain and Gastrointestinal Peptide* (CB Nemeroff and AJ Prange, Jr., Eds.). *Ann. NY Acad. Sci.* 400:354-367.
87. Kalivas PW, **Nemeroff CB** and Prange AJ, Jr. 1982. Neuroanatomical sites of action of neurotensin. In: *Neurotensin, a Brain and Gastrointestinal Peptide* (CB Nemeroff and AJ Prange, Jr., Eds.). *Ann. NY Acad. Sci.* 400:307-318.
88. Kalivas PW, Burgess SK, **Nemeroff CB** and Prange AJ, Jr. 1983. Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area of the rat. *Neurosci.* 8:495-505.
89. **Nemeroff CB** and Evans DL. 1983. Concurrent use of antidepressants and propranolol: case report and theoretical considerations. *Biol Psychiatry* 18:237-241.

90. Luttinger D, Frye GD, **Nemeroff CB** and Prange AJ, Jr. 1983. The effects of neurotensin, β -endorphin and bombesin on ethanol-induced behaviors in mice. *Psychopharmacology* 79:357-363.
91. Mason GA, Hernandez DE, **Nemeroff CB**, Adcock JW, Hatley OL and Prange AJ, Jr. 1982. Interaction of neurotensin with prostaglandin E₂ and prostaglandin synthesis inhibitors: effect on colonic temperature in mice. *Regulatory Peptides* 4:285-292.
92. Pilkington JW, **Nemeroff CB**, Mason GA and Prange AJ, Jr. 1983. Increase in plasma β -endorphin-like immunoreactivity at parturition in normal women. *Am. J. Obstet. Gynecol.* 145:111-113.
93. Hernandez DE, **Nemeroff CB**, Orlando RC and Prange AJ, Jr. 1983. The effect of centrally administered neuropeptides on the development of stress-induced gastric ulcers in rats. *J. Neurosci. Res.* 9:145-157.
94. **Nemeroff CB**. 1983. Effects of neurotoxic excitatory amino acids on neuroendocrine regulation. In: *Excitotoxins* (K Fuxe, PJ Roberts and R Schwarcz, Eds.). Macmillan Press, London, 295-305.
95. Evans DL and **Nemeroff CB**. 1983. Use of the dexamethasone suppression test using DSM-III criteria on an inpatient psychiatric unit. *Biol. Psychiatry* 18:505-511.
96. Hernandez DE, Adcock JW, **Nemeroff CB** and Prange AJ, Jr. 1982. The effect of intracisternal administered bombesin on cysteamine-induced duodenal ulcers in rats. *Eur. J. Pharmacol.* 84:205-209.
97. Evans DL and **Nemeroff CB**. 1983. The dexamethasone suppression test in mixed bipolar disorder. *Am J Psychiatry* 140:615-617.
98. Evans DL, Burnett GB and **Nemeroff CB**. 1983. The dexamethasone suppression test in the clinical setting. *Am J Psychiatry* 140:586-589.
99. Luttinger D, Hernandez DE, **Nemeroff CB** and Prange AJ, Jr. 1984. Peptides and nociception. In: *International Review of Neurobiology, Vol. 25* (JR Smythies and RJ Bradley, Eds.). Academic Press, New York, 185-241.
100. Luttinger D, Burgess SK, **Nemeroff CB** and Prange AJ, Jr. 1983. The effects of chronic morphine treatment on neurotensin-induced antinociception. *Psychopharmacology* 81:10-13.
101. **Nemeroff CB**, Luttinger D, Hernandez DE, Mailman RB, Mason GA, Davis SD, Widerlov E, Frye GD, Kilts CA, Beaumont K, Breese GR and Prange AJ, Jr. 1983. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies. *J. Pharmacol. Exp. Ther.* 225:337-345.
102. Adcock JE, Hernandez DE, **Nemeroff CB** and Prange AJ, Jr. 1983. Effect of prostaglandin synthesis inhibitors on neurotensin and sodium salicylate induced gastric cytoprotection in rats. *Life Sci.* 32:2905-2910.

103. **Nemeroff CB**, Youngblood WW, Manberg PJ, Prange AJ, Jr. and Kizer JS. 1983. Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia. *Science* 221:972-975.
104. **Nemeroff CB**, Kalivas PW, Golden RN and Prange AJ, Jr. 1984. Behavioral effects of hypothalamic hypophysiotropic hormones, neurotensin, substance P and other neuropeptides. *Pharmacol. Ther.* 24:1-56.
105. **Nemeroff CB**, Kalivas PW and Prange AJ, Jr. 1984. Interaction of neurotensin and dopamine in limbic structures. In: *Catecholamines: Neuropsychopharmacology and Central Nervous System - Theoretical Aspects* (E Usdin, A Carlsson, A Dahlstrom and J Engel, Eds.). Alan R. Liss, Inc., New York, 199-206.
106. Evans DL, Hsiao JK and **Nemeroff CB**. 1984. Munchausen syndrome, depression and the dexamethasone suppression test. *Am J Psychiatry* 141:570-572.
107. **Nemeroff CB** and Evans DL. 1984. Correlation between the dexamethasone suppression test in depressed patients and clinical response. *Am J Psychiatry* 141:247-249.
108. **Nemeroff CB**, Manberg PJ, Widerlov E, Youngblood WW, Kizer JS and Prange AJ, Jr. 1983. *Neuropeptides* in cerebrospinal fluid and postmortem brain tissue of schizophrenics, Huntington's choreics, and normal controls. *Psychopharmacol. Bull.* 19:369-374.
109. Hernandez DE, **Nemeroff CB**, Valderrama MH and Prange AJ, Jr. 1984. Neurotensin- induced antinociception and hypothermia in mice: antagonism by TRH and structural analogs of TRH. *Regulatory Peptides* 8:41-49.
110. Kalivas PW, **Nemeroff CB** and Prange AJ, Jr. 1984. Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing. *Neurosci.* 11:919-930.
111. Mason GA, Bissette G and **Nemeroff CB**. 1983. Effects of excitotoxic amino acids on pituitary hormone secretion in the rat. *Brain Res.* 289:366-369.
112. Manberg PJ, **Nemeroff CB**, Bissette G, Widerlov E, Youngblood WW, Kizer JS and Prange AJ, Jr. 1985. *Neuropeptides* in CSF and post-mortem brain tissue of normal controls, schizophrenics and Huntington's choreics. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 9:97-108.
113. Hernandez DE, Adcock JW, **Nemeroff CB** and Prange AJ, Jr. 1984. The role of the adrenal gland in cytoprotection against stress-induced gastric ulcers in rats. *J. Neurosci. Res.* 11:193-201.
114. Hernandez DE, Simmons KB, Peiffer RL, Prange AJ, Jr. and **Nemeroff CB**. 1983. Intracameral administration of neurotensin induces meiosis in the rabbit. *Neuropeptides* 4:31-40.
115. Bissette G, Richardson C, Kizer JS and **Nemeroff CB**. 1984. Ontogeny of brain neurotensin in the rat: a radioimmunoassay study. *J Neurochem.* 43:283-287.
116. Jennes L, Stumpf WE, Bissette G and **Nemeroff CB**. 1984. Monosodium glutamate lesions in rat hypothalamus studied by immunohistochemistry for gonadotropin-releasing hormone, neurotensin, tyrosine hydroxylase, and glutamic acid decarboxylase and by autoradiography for [³H]estradiol. *Brain Res.* 308:245-253.

117. **Nemeroff CB.** 1985. Biological Psychiatry. In: *Essentials of Clinical Psychiatry* (JI Walker, Ed). J.B. Lippincott Company, Philadelphia, 13-31.
118. Schultz DW, Kalivas PW, **Nemeroff CB** and Prange AJ, Jr. 1984. Bombesin-induced locomotor hyperactivity: evaluation of the involvement of the mesolimbic dopamine system. *Brain Res.* 304:377-382.
119. Hernandez DE, Richardson CM, **Nemeroff CB**, Orlando RC, St. Pierre S, Rioux F and Prange AJ, Jr. 1984. Evidence for biological activity of two N-terminal fragments of neurotensin₁₋₈ and neurotensin₁₋₁₀. *Brain Res.* 301:153-156.
120. Evans DL and **Nemeroff CB.** 1984. The dexamethasone suppression test in organic affective syndrome. *Am J Psychiatry* 141:1465-1467.
121. Orlando RC, Hernandez DE, Prange AJ, Jr. and **Nemeroff CB.** 1985. Role of the autonomic nervous system in the cytoprotective effect of neurotensin against gastric stress ulcers in rats. *Psychoneuroendocrinology* 10:149-157.
122. **Nemeroff CB** and Bissette G. 1985. Involvement of non-opioid peptides in the pathogenesis of neurological and psychiatric disorders: evidence from CSF and post-mortem studies. In: *Endocoids* (H Lal, F LaBella and J Lane, Eds.). Prog. Clin. Biol. Res. 192. Alan R. Liss Publishers, New York, 333-341.
123. Bissette G and **Nemeroff CB.** 1985. Do neuropeptide systems mediate some of the effects of antipsychotic drugs? In: *Endocoids* (H Lal, F LaBella and J Lane, Eds.). Prog. Clin. Biol. Res. 192. Alan R. Liss, Publishers, New York, 349-353.
124. **Nemeroff CB** and Cain ST. 1985. Neurotensin-dopamine interactions in the CNS. *Trends Pharmacol. Sci.* 6:201-205.
125. Kalivas PW, **Nemeroff CB**, Miller JS and Prange AJ, Jr. 1985. Microinjection of neurotensin into the ventral tegmental area produces hypothermia: evaluation of dopaminergic mediation. *Brain Res.* 326:219-227.
126. Bissette G, **Nemeroff CB** and MacKay A. 1986. *Neuropeptides* and schizophrenia. In: *Peptides and Neurological Disease* (PC Emson, MN Rossor and M Tohyama, Eds.). Prog. Brain Res. 66. Elsevier, Amsterdam, 161-176.
127. **Nemeroff CB**, Widerlov E, Bissette G., Walleus H, Karlsson I, Eklund K, Kilts CD, Loosen PT and Vale W. 1984. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. *Science* 226:1342-1344.
128. Bissette G, **Nemeroff CB**, Decker MW, Kizer JS, Agid Y and Javoy-Agid F. 1985. Alterations in regional brain concentrations of neurotensin and bombesin in Parkinson's disease. *Ann. Neurol.* 17:324-328.
129. Hernandez DE, Adcock JW, Orlando RC, Patrick KS, **Nemeroff CB** and Prange AJ, Jr. 1984. Prevention of stress-induced gastric ulcers by dopamine agonists in the rat. *Life Sci.* 35:2453-2458.

130. Kilts CD, Bissette G, Cain ST, Skoog KM and **Nemeroff CB**. 1986. Neuropeptide-dopamine interactions: focus on neurotensin. In: *Dopaminergic Systems and their Regulation* (GN Woodruff, JA Poat and PJ Roberts, Eds.). Macmillan Press, London 223-242.
131. Decker MW, Towle AC, Bissette G, Mueller RA, Lauder JM and **Nemeroff CB**. 1985. Bombesin-like immunoreactivity in the central nervous system of capsaicin-treated rats: a radioimmunoassay and immunohistochemical study. *Brain Res.* 342:1-8.
132. **Nemeroff CB**. 1987. Neurotensin. In: *Encyclopedia of Neuroscience* (G Adelman, Ed). Birkhauser Boston, Inc. 851-853.
133. **Nemeroff CB**, Mason GA, Bissette G, Parks DA and Schwarcz R. 1985. Effects of intrahypothalamic injection of quinolinic acid on anterior pituitary hormone secretion in the unanesthetized rat. *Neuroendocrinology* 41:332-336.
134. Dunn AJ, Webster EL and **Nemeroff CB**. 1985. Neonatal treatment with monosodium glutamate does not alter grooming behavior induced by novelty or adrenocorticotrophic hormone. *Behav. Neural. Biol.* 44:80-89.
135. **Nemeroff CB**, Simon JS, Haggerty JJ and Evans DL. 1985. Antithyroid antibodies in depressed patients. *Am J Psychiatry* 142:840-843.
136. **Nemeroff CB**. 1986. The interaction of neurotensin with dopaminergic pathways in the central nervous system: basic neurobiology and implications for the pathogenesis and treatment of schizophrenia. (The Curt P. Richter Award, 1985) *Psychoneuroendocrinology* 11:15-37.
137. Morris G, Nadler JV, **Nemeroff CB** and Slotkin TA. 1985. Effects of neonatal treatment with 6-aminonicotinamide on basal and isoproterenol stimulated ornithine decarboxylase activity in cerebellum of the developing rat. *Biochem. Pharmacol.* 34:3281-3284.
138. Hernandez DE, Adcock JW, Orlando RC, **Nemeroff CB** and Prange AJ, Jr. 1987. Influence of brain peptides on the development of stress gastric ulcers. In: *New Pharmacology of Ulcer Disease. Experimental and Therapeutic Approaches* (S Szabo and GY Moszik, Eds.). Elsevier Pub. Co., New York, 375-396.
139. **Nemeroff CB** and Bissette G. 1986. *Neuropeptides* in psychiatric disorders. In: *American Handbook of Psychiatry, Volume VIII* (PA Berger and HKH Brodie, Eds.). Basic Books, Inc., New York, 64-110.
140. Bissette G, Reynolds GP, Kilts CD, Widerlov E and **Nemeroff CB**. 1985. Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type: reduced cortical and striatal concentrations. *JAMA.* 254:3067-3069.
141. Karlsson I, Widerlov E, Melin EV, Nyth A-L, Brane GAM, Rybo E, Rehfeld JF, Bissette G and **Nemeroff CB**. 1985. Changes of CSF neuropeptides after environmental stimulation in dementia. *Nord. Psychiat. J.* 39(Suppl. 11):75-81.
142. Merritt WD, Bissette G, Luttinger D, Prange AJ, Jr. and **Nemeroff CB**. 1986. Adaptation to cold antagonizes neurotensin-induced hypothermia in mice. *Brain Res.* 369:136-142.

143. Smith MA and **Nemeroff CB**. 1988. Behavioral effects of brain peptides. In: *Clinical Neuroendocrinology* (R Collu, GM Brown and GR van Loon, Eds.). Blackwell Scientific Publications, Inc., Boston, 381-414.
144. Krishnan KRR and **Nemeroff CB**. 1986. Peptides of the hypothalamopituitary adrenal axis: basic and clinical studies. In: *Biological Psychiatry 1985* (C Shagass et al., Eds.). Elsevier Pub. Co., Amsterdam, 115-116.
145. Krishnan KRR, **Nemeroff CB**, Manepalli AN, France RD, Ritchie JC and Carroll BJ. 1986. Physiology of human HPA regulation in depression. In: *Biological Psychiatry 1985* (C Shagass et al., Eds.). Elsevier Pub. Co., Amsterdam, 808-810.
146. Widerlov E, Walleus H, Lindstrom LH, Karlsson I, **Nemeroff CB**, Rehfeld JF and Ekman R. 1986. Neuropeptide alterations in cerebrospinal fluid and plasma from psychiatric patients. In: *Biological Psychiatry 1985* (C Shagass et al., Eds.). Elsevier Pub. Co., Amsterdam, 856-858.
147. **Nemeroff CB** and Owens MJ. 1986. Recent advances in the neurobiology of neuropeptides: focus on corticotropin-releasing factor. In: *Biological Psychiatry 1985* (C Shagass et al., Eds.). Elsevier Pub. Co., Amsterdam, 103-105.
148. Elliott PJ and **Nemeroff CB**. 1986. The neurobiology of neurotensin. In: *Neural and Endocrine Peptides and Receptors* (TW Moody, Ed). Plenum Press, New York, 219-245.
149. van Kammen DP, Wood JH and **Nemeroff CB**. 1985. Introduction to symposium on neuropeptides in schizophrenia: spinal fluid and brain studies. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 9:53-54.
150. Noel M and **Nemeroff CB**. 1988. Endogenous opiates in chronic pain. In: *Chronic Pain* (RD France and KRR Krishnan, Eds.). APA Press, Washington, 54-65.
151. **Nemeroff CB**. 1988. Non-opioid peptides and pain processes. In: *Chronic Pain* (RD France and KRR Krishnan, Eds.). APA Press, Washington, 66-75.
152. Cain ST, **Nemeroff CB**, Banki CM, France RD and Krishnan KRR. 1988. Catecholamines and indoleamines: role in nociception and chronic pain. In: *Chronic Pain* (RD France and KRR Krishnan, Eds.). APA Press, Washington, 42-53.
153. Kilts CD, Bissette G, Krishnan KRR, Smith MA, Chappell P and **Nemeroff CB**. 1987. The preclinical and clinical neurobiology of corticotropin-releasing factor (CRF). In: *Hormones and Depression* (U Halbreich, Ed). Raven Press, New York, 297-312.
154. Evans DL, McCartney CF, **Nemeroff CB**, Raft D, Quade D, Golden RN, Haggerty JJ, Holmes V, Simon JS, Droba M, Mason GA and Fowler WC. 1986. Depression in women treated for gynecological cancer: clinical and neuroendocrine assessment. *Am J Psychiatry* 143:447-452.
155. Skoog KM, Cain ST and **Nemeroff CB**. 1986. Centrally administered neurotensin suppresses locomotor hyperactivity induced by d-amphetamine but not by scopolamine or caffeine. *Neuropharmacology* 25:777-782.

156. Smith MA and **Nemeroff CB**. 1987. Behavioral effects of non-opioid peptides in humans. In: *Handbook of Clinical Psychoneuroendocrinology* (CB Nemeroff and PT Loosen, Eds.). Guilford Press, New York, 399-416.
157. Arato M, Banki CM, **Nemeroff CB** and Bissette G. 1986. Hypothalamic- pituitary-adrenal axis and suicide. *Ann. NY Acad. Sci.* 487:263-270.
158. Smith MA, Bissette G, Slotkin TA, Knight DL and **Nemeroff CB**. 1986. Release of corticotropin-releasing factor from rat brain regions in vitro. *Endocrinology* 118:1997-2001.
159. Janowsky DS, Glick ID, Lash L, Mitnick L, Klein DF, Goodwin FK, Hanin I, **Nemeroff CB** and Robins L. 1986. Psychobiology and psychopharmacology: issues in clinical research training. *J. Clin. Psychopharmacol.* 6:1-7.
160. Elliott PJ, Chan J, Parker Y-M and **Nemeroff CB**. 1986. Behavioral effects of neurotensin in the open field: structure-activity studies. *Brain Res.* 381:259-265.
161. **Nemeroff CB**. 1987. Interactions of neurotensin with dopamine neurons in the mammalian central nervous system: focus on limbic system sites. In: *Neurotransmitter Interactions in the Basal Ganglia* (M Sandler, C Feuerstein and B Scatton, Eds.). Raven Press, New York, 155-170.
162. Noel M and **Nemeroff CB**. 1987. The role of non-opioid peptides in pain. In: *Neurotransmitters and Pain Control* (H Akil and JW Lewis, Eds.). S. Karger, Basel, 194-212.
163. Berger PA and **Nemeroff CB**. 1987. Opioid peptides in affective disorders. In: *Psychopharmacology, the Third Generation of Progress* (HY Meltzer, Ed). Raven Press, New York, 637-646.
164. **Nemeroff CB**, Berger PA and Bissette G. 1987. Peptides in schizophrenia. In: *Psychopharmacology, the Third Generation of Progress* (HY Meltzer, Ed). Raven Press, New York, 727-744.
165. Cain ST and **Nemeroff CB**. 1987. Neurotensin alters phosphorylation of neostriatal proteins. In: Third Colloquium in Biological Sciences: Cellular Signal Transduction. *Ann. NY Acad. Sci.* 494:98-100.
166. Elliott PJ and **Nemeroff CB**. 1986. Repeated neurotensin administration in the ventral tegmental area: effects on baseline and d-amphetamine- induced locomotor activity. *Neurosci. Lett.* 68:239-244.
167. Davis MD and **Nemeroff CB**. 1988. Neurotensin, dopamine and schizophrenia. In: *Receptors and Ligands in Psychiatry* (AK Sen and T Lee, Eds.). Cambridge University Press, Cambridge, 167-186.
168. Cain ST and **Nemeroff CB**. 1987. Neuropeptides and neurotransmitters in Alzheimer's disease. In: *Aging: The Universal Human Experience* (GL Maddox and EW Busse, Eds.). Springer Pub. Co., New York, 63-80.
169. Chappell PB, Smith MA, Kilts CD, Bissette G, Ritchie J, Anderson C and **Nemeroff CB**. 1986. Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress. *J. Neurosci.* 6:2908-2914.

170. Elliott PJ, **Nemeroff CB** and Kilts CD. 1986. Evidence for a tonic facilitatory influence of substance P on dopamine release in the nucleus accumbens. *Brain Res.* 383:379-382.
171. Krishnan KRR, Manepalli AN, Ritchie JC, Rayasam K, Thorner MO, Rivier JE, Vale WW and **Nemeroff CB**. 1988. Growth hormone response to growth hormone releasing factor in depression. *Peptides* 9(Suppl. 1):113-116.
172. Prange AJ, Jr., Garbutt JC, Loosen PT, Bissette G and **Nemeroff CB**. 1987. The role of peptides in affective disorders: a review. In: *Neuropeptides in Brain Function*. *Prog. Brain Res.* 72:235-247.
173. Bissette G, Widerlov E, Walleus H, Karlsson I, Eklund K, Forsman A and **Nemeroff CB**. 1986. Alterations in cerebrospinal fluid concentrations of somatostatin-like immunoreactivity in neuropsychiatric disorders. *Arch Gen Psychiatry* 43:1148-1151.
174. **Nemeroff CB**, Walsh TJ and Bissette G. 1987. Somatostatin and behavior: preclinical and clinical studies. In: *Somatostatin* (S Reichlin, Ed). Plenum Press, New York, 157-167.
175. Coffey CE, Hinkle PE, Weiner RD, **Nemeroff CB**, Krishnan KRR, Varia I and Sullivan DC. 1987. Electroconvulsive therapy of depression in patients with white matter hyperintensity. *Biol. Psychiatry* 22:629-636.
176. Evans DL, **Nemeroff CB**, Haggerty JJ, Jr. and Pedersen CA. 1987. Use of the dexamethasone suppression test using DSMIII criteria in psychiatrically hospitalized adolescents. *Psychoneuroendocrinology* 12:203-209.
177. Kilts CD, Knight DL and **Nemeroff CB**. 1996. The simultaneous determination of neurotensin and its major fragments by on-line trace enrichment HPLC with electrochemical detection. *Life Sciences* 59:911-920.
178. Banki CM, Arato M, **Nemeroff CB**, Bissette G and Kilts CD. 1986. Neuroendocrine and neurotransmitter changes in suicidal behavior. In: *Biological Psychiatry 1985* (C Shagass et al, Eds.). Elsevier Pub. Co., Amsterdam, 764-766.
179. **Nemeroff CB** and Bissette G. 1987. The role of neuropeptides in schizophrenia. In: *Handbook of Schizophrenia, Volume 2: The Neurochemistry and Pharmacology of Schizophrenia* (FA Henn and LE DeLisi, Eds.). Elsevier Science Pub., Inc., Amsterdam, 297-317.
180. Banki CM, Bissette G, Arato M, O'Connor L and **Nemeroff CB**. 1987. Cerebrospinal fluid corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. *Am. J. Psychiatry* 144:873-877.
181. Evans DL and **Nemeroff CB**. 1987. The clinical use of the dexamethasone suppression test in DSM-III affective disorders: correlation with the severe depressive subtypes of melancholia and psychosis. *J. Psychiatric Res.* 21:185-194.
182. Evans DL, McCartney CF, Haggerty JJ, **Nemeroff CB**, Golden RN, Simon JS, Quade D, Holmes V, Droba M, Mason GA, Fowler WC and Raft D. 1988. Treatment of depression in cancer patients is associated with improved life adaptation: preliminary findings. *Psychosomatic Med.* 50:72-76.

183. Elliott PJ, Rosen GM and **Nemeroff CB**. 1987. A comparison of cocaine and its metabolite norcocaine: effects on locomotor activity. *Pharmacol. Biochem. Behav.* 26:573-575.
184. Mason GA, Bondy SC, **Nemeroff CB**, Walker CH and Prange AJ, Jr. 1987. The effects of thyroid state on β -adrenergic and serotonergic receptors in rat brain. *Psychoneuroendocrinology* 12:261-270.
185. Levant B and **Nemeroff CB**. 1988. The psychobiology of neurotensin. In: *The Neuroendocrinology of Mood* (D Ganten and D Pfaff, Eds.). Current Topics in Neuroendocrinology, Volume 8, Springer-Verlag, Inc., Berlin, 231-262.
186. Widerlov E, Bissette G and **Nemeroff CB**. 1987. Centrally administered neurotensin inhibits pentobarbital metabolism in mice but not in rats. *Neurosci. Lett.* 77:311-315.
187. Owens MJ and **Nemeroff CB**. 1988. The neurobiology of corticotropin- releasing factor: implications for affective disorders. In: *The Hypothalamic-Pituitary-Adrenal Axis: Physiology, Pathophysiology and Psychiatric Implications* (AF Schatzberg and CB Nemeroff, Eds.). Raven Press, New York, 1-36.
188. Simon JS, Evans DL and **Nemeroff CB**. 1987. The dexamethasone suppression test and antidepressant response in major depression. *J Psychiat Res.* 21:313-318.
189. Steege JF and **Nemeroff CB**. 1987. Thyroid disease and premenstrual syndrome: has the hypothesis been adequately tested. Commentary on: Brayshaw and Brayshaw: Premenstrual Syndrome and Thyroid Dysfunction. *Integrative Psychiatry* 5:185-186.
190. Deutch AY, Bean AJ, Bissette G, **Nemeroff CB**, Robbins RJ and Roth RH. 1987. Stress-induced alterations in neurotensin, somatostatin, and corticotropin-releasing factor in mesotelencephalic dopamine system regions. *Brain Res.* 417:350-354.
191. **Nemeroff CB** and Owens MJ. 1989. Preclinical and clinical investigations of corticotropin-releasing factor: assessment of its role in depressive disorders. In: *New Directions in Affective Disorders* (B Lerer and S Gershon, Eds.). Springer-Verlag, New York 262-266.
192. Simon JS and **Nemeroff CB**. 1987. Psychoneuroendocrinology: A Review. *The McLean Hospital Journal* 7:1-30.
193. Krishnan KRR, Ritchie JC, Manepalli AN, Venkataraman S, France RD, **Nemeroff CB** and Carroll BJ. 1988. What is the relationship between plasma ACTH and plasma cortisol in normal humans and depressed patients? In: *The Hypothalamic-Pituitary-Adrenal Axis: Physiology, Pathophysiology and Psychiatric Implications* (AF Schatzberg and CB Nemeroff, Eds.). Raven Press, New York, 115-132.
194. Kilts CD, Anderson CM, Bissette G, Ely TD and **Nemeroff CB**. 1988. Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei. *Biochem. Pharmacol.* 37:1547-1554.
195. Widerlov E, Bissette G and **Nemeroff CB**. 1988. Monoamine metabolites, corticotropin-releasing factor and somatostatin as CSF markers in depressed patients. *J. Affective Dis.* 14:99-107.

196. **Nemeroff CB.** 1989. Recent advances in the neurochemical modulation of behavior: focus on depression and Alzheimer's disease. In: *Mechanisms of Psychological Influence on Physical Health with Special Attention to the Elderly* (LL Carstensen and JM Neale, Eds.). Plenum Pub. Co., New York, 129-144.
197. Haggerty JJ, Simon JS, Evans DL and **Nemeroff CB.** 1987. Relationship of serum TSH concentration and antithyroid antibodies to diagnosis and DST response in psychiatric inpatients. *Am J Psychiatry* 144:1491-1493.
198. Krishnan KRR, Manepalli AN, Ritchie JC, Rayasam K, Melville ML, Daughtry G, Thorner MO, Rivier JE, Vale W, **Nemeroff CB** and Carroll BJ. 1987. Growth hormone-releasing factor stimulation test in depression. *Am J Psychiatry* 145:90-92.
199. Levant B, Bissette G and **Nemeroff CB.** 1988. Further evidence for neurotensin-dopamine interactions in the central nervous system. In: *Pharmacology and Functional Regulation of Dopaminergic Neurons* (PM Beart, GN Woodruff and DM Jackson, Eds.). MacMillan Press, London, 257-265.
200. Lindstrom LH, Widerlov E, Bissette G and **Nemeroff CB.** 1988. Reduced CSF neurotensin concentration in drug-free schizophrenic patients. *Schizophrenia Research* 1:55-59.
201. Smith MA and **Nemeroff CB.** 1988. Preclinical and clinical evidence for the involvement of corticotropin-releasing factor in the pathogenesis of depression. In: *Mechanisms of Physical and Emotional Stress* (G Chrousos, PW Gold and L Loriaux, Eds.). Plenum Press, New York 479-487.
202. Bissette G and **Nemeroff CB.** 1988. Neurotensin and the mesocorticolimbic dopamine system. *Ann. N.Y. Acad. Sci.* 537:397-404.
203. **Nemeroff CB.** 1988. The role of corticotropin-releasing factor in the pathogenesis of major depression. *Pharmacopsychiatry* 21:76-82.
204. Ervin GN and **Nemeroff CB.** 1988. Interactions of neurotensin with dopamine-containing neurons in the central nervous system. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 12:S53-S69.
205. **Nemeroff CB.** 1989. Chemical messengers of the brain. In: *Geriatric Psychiatry* (EW Busse and DG Blazer, Eds.). APA Press, Washington, 97-134.
206. Krishnan KRR, Ritchie JC, Manepalli AN, **Nemeroff CB** and Carroll BJ. 1988. Adrenocortical sensitivity to ACTH in humans. *Biol. Psychiatry* 24:105-107.
207. Krishnan KRR, Goli V, Ellinwood EH, France RD, Blazer DG and **Nemeroff CB.** 1988. Leukoencephalopathy in patients diagnosed as major depressive. *Biol. Psychiatry* 23:519-522.
208. Antelman SM, Knopf S, Kocan D, Edwards DJ, Ritchie JC and **Nemeroff CB.** 1988. One stressful event blocks multiple actions of diazepam for up to at least a month. *Brain Res.* 445:380-385.
209. France RD, Urban B, Krishnan KRR, Bissette G, Banki CM, **Nemeroff CB** and Spielman FJ. 1988. CSF corticotropin-releasing factor-like immunoreactivity in chronic pain patients with and without major depression. *Biol. Psychiatry* 23:86-88.

210. **Nemeroff CB**, Knight DL, Krishnan KRR, Slotkin TA, Bissette G, Melville ML and Blazer DG. 1988. Marked reduction in the number of platelet [³H]-imipramine binding sites in geriatric depression. *Arch Gen Psychiatry* 45:919-923.
211. **Nemeroff CB**, Owens MJ, Bissette G, Andorn AC and Stanley M. 1988. Reduced corticotropin-releasing factor (CRF) binding sites in the frontal cortex of suicides. *Arch Gen Psychiatry* 45:577-579.
212. Butler PD and **Nemeroff CB**. 1990. Corticotropin-releasing factor as a possible cause of comorbidity in anxiety and depressive disorders. In: *Comorbidity in Anxiety and Mood Disorders* (JD Maser and CR Cloninger, Eds.). Amer. Psychiat. Assn. Press, Washington, DC, 413-435.
213. Owens MJ and **Nemeroff CB**. 1990. Neurotransmitter regulation of CRF secretion *in vitro*. In: *Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide* (EB DeSouza and CB Nemeroff, Eds.). CRC Press, Inc., Boca Raton, FL, 107-114.
214. France RD, Urban BJ, Pelton S, Kilts CD, Hong J-S and **Nemeroff CB**. 1987. CSF monoamine metabolites in chronic pain. *Pain* 31:189-198.
215. **Nemeroff CB**. 1988. The neurobiology of aging and the neurobiology of depression: is there a relationship? *Neurobiol. Aging* 9:120-122.
216. Bissette G and **Nemeroff CB**. 1988. The role of neuropeptides in the pathogenesis and treatment of schizophrenia. In: *Neuropeptides in Psychiatric and Neurological Diseases* (CB Nemeroff, Ed). Johns Hopkins University Press, Baltimore, 49-75.
217. Craighead WE and **Nemeroff CB**. 1989. Advances in biological psychiatry and psychotherapy are not mutually exclusive. *Integrative Psychiatry* 6:152-164.
218. **Nemeroff CB** and Bissette G. 1988. Neuropeptides, dopamine and schizophrenia. *Ann. N.Y. Acad. Sci.* 537:273-291.
219. **Nemeroff CB** and Evans DL. 1989. Thyrotropin-releasing hormone (TRH), the thyroid axis and affective disorder. *Ann. N.Y. Acad. Sci.* 553:304-310.
220. Owens MJ and **Nemeroff CB**. 1988. Preclinical and clinical studies with corticotropin-releasing factor: implications for affective disorders. *Psychopharmacol. Bull.* 24:355-359.
221. Bissette G and **Nemeroff CB**. 1990. Corticotropin-releasing factor: cerebrospinal fluid studies. In: *Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide* (EB DeSouza and CB Nemeroff, Eds.). CRC Press, Inc., Boca Raton, FL, 327-334.
222. Urban BJ, France RD, Bissette G, Spielman FJ and **Nemeroff CB**. 1988. Alterations in cerebrospinal concentrations of somatostatin-like immunoreactivity in pain patients. *Pain* 33:169-172.
223. DeSouza EB, Bissette G, Whitehouse PJ, Powers RE, Price DL, Vale WW and **Nemeroff CB**. 1990. Abnormalities in corticotropin-releasing factor (CRF) in neurodegenerative diseases. In: *Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide* (EB DeSouza and CB Nemeroff, Eds.). CRC Press, Inc., Boca Raton, FL, 335-350.

224. Hedner J, Hedner T, Lundell K-H, Bissette G, O'Connor L and **Nemeroff CB**. 1989. Cerebrospinal fluid concentrations of neurotensin and corticotropin-releasing factor in pediatric patients. *Biol. Neonate* 55:260-267.
225. Ervin GN and **Nemeroff CB**. 1988. Antagonization of the behavioral activation produced by direct stimulation of forebrain dopamine receptors caused by intraaccumbens injections of neurotensin. *Neuropsychopharmacology* 1:243-250.
226. Smith MA, Davidson J, Ritchie JC, Kudler H, Lipper S, Chappell P and **Nemeroff CB**. 1988. The corticotropin-releasing hormone test in patients with post-traumatic stress disorder. *Biol. Psychiatry* 26: 349-355.
227. Bissette G, Dauer WT, Kilts CD, O'Connor L and **Nemeroff CB**. 1988. The effect of stereoisomers of butaclamol on neurotensin content in discrete regions of the rat brain. *Neuropsychopharmacology* 1:329-335.
228. Slotkin TA, Whitmore WL, Barnes GA, Krishnan KRR, Blazer DG, Knight DL and **Nemeroff CB**. 1989. Reduced inhibitory effect of imipramine on radiolabelled serotonin uptake into platelets in geriatric depression. *Biol. Psychiatry* 25:687-691.
229. Cook LL and **Nemeroff CB**. 1989. Neuropeptides in Alzheimer's disease. *J. Clin. Psychiat.* 7, Suppl, 2-12.
230. Banki CM, Arato M, Bissette G and **Nemeroff CB**. 1988. Neuropeptide changes in major depression: significant elevation of CRF and TRH concentration in CSF. *Psychiat. Hung.* 3:35-43.
231. Arato M, Banki CM, Bissette G and **Nemeroff CB**. 1989. Elevated CSF CRF in suicide victims. *Biol Psychiatry* 25:355-359.
232. Banki CM, Bissette G, Arato M and **Nemeroff CB**. 1988. Elevation of immunoreactive CSF TRH in depressed patients. *Am J Psychiatry* 145:1526-1531.
233. Bond PE, Owens MJ, Butler PD, Bissette G and **Nemeroff CB**. 1989. Corticotropin-releasing factor: possible involvement in the pathogenesis of affective disorders. In: *Molecular Biology of Stress* (O Zinder and S Bresnitz, Eds.), 67-76.
234. **Nemeroff CB** and Craighead WE. 1988. Advances in biological psychiatry and psychotherapy are not mutually exclusive. *North Carolina Med. J.* 49:539-541.
235. **Nemeroff CB**, Bissette G, Widerlov E, Beckmann HH, Gerner R, Manberg PJ, Lindstrom L, Prange AJ, Jr. and Gattaz W. 1989. Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia and premenstrual syndrome. *J. Neuropsychiat. Clin. Neurosci.* 1:16-20.
236. Krishnan KRR, **Nemeroff CB** and Carroll BJ. 1989. Hypercortisolemia and mental illness. In: *The Control of the Hypothalamic-Pituitary-Adrenal Axis* (F.C. Rose, Ed), Int. Univ. Press, Inc. Madison, Conn., 419-436.

237. Evans DL, McCartney CF, **Nemeroff CB**, Haggerty JJ, Simon JS, Pedersen CA, Holmes V, Droba M, Mason GA, Raft D, Fowler WC and Golden RN. 1988. Depression in cancer patients: diagnostic and treatment considerations. *North Carolina Med. J.* 49:546-548.
238. Pryor JC and **Nemeroff CB**. 1990. Stress, hypothalamic-pituitary-adrenal function and aging: focus on corticotropin-releasing factor. In: *Endocrine Function and Aging* (HJ Ambrecht, RM Coe and N Wongsurawat, Eds.). Springer-Verlag, New York, 175-185.
239. Kurlan R, Caine E, Rubin A, **Nemeroff CB**, Bissette G, Zaczek R, Coyle J, Spielman FJ, Irvine C and Shoulson I. 1988. Cerebrospinal fluid correlates of depression in Huntington's disease. *Arch. Neurol.* 45:881-883.
240. Banki CM, Arato M, Bissette G and **Nemeroff CB**. 1989. Thyroid axis stimulation tests in psychiatry. In: *Neuropsychopharmacology* (WE Bunney, H Hippus, G Laakmann and M Schmauss, Eds.). Springer-Verlag, Berlin.
241. Cook LL, Bissette G, Dole K and **Nemeroff CB**. 1989. A critical evaluation of cysteamine as a tool to deplete somatostatin in the rat central nervous system. *Endocrinology* 124:855-861.
242. Evans DL and **Nemeroff CB**. 1989. Depression and aging: Psychoneuroendocrinology and psychoneuroimmunology. *Progress in Neuroendocrinimmunology* 1:21-27.
243. Radke JM, MacLennan AJ, Beinfeld MC, Bissette G, **Nemeroff CB**, Vincent SR and Fibiger HC. 1989. Effects of short- and long-term haloperidol administration and withdrawal on regional brain cholecystokinin and neurotensin concentrations in the rat. *Brain Res.* 480:178-183.
244. Ritchie JC, Belkin BM, Krishnan KRR, **Nemeroff CB** and Carroll BJ. 1990. Plasma dexamethasone concentrations and the dexamethasone suppression test. *Biol. Psychiatry* 27:159-173.
245. Pryor JC and **Nemeroff CB**. 1991. Stress associated psychiatric disorders: focus on the role of neuropeptides. In: *Stress Neurobiology and Neuroendocrinology* (MR Brown, GF Koob and C Rivier, Eds.). Marcel Dekker, Inc., New York 375-393.
246. Simon JS and **Nemeroff CB**. 1989. *Neuropeptides* and affective disorder. In: *Neuropsychopharmacology* (WE Bunney, H Hippus, G Laakmann and M Schmauss, Eds.). Springer-Verlag, Berlin.
247. Evans DL, Golden RN, **Nemeroff CB**, Pedersen CA, McCartney CF, Haggarty JJ, Jr., Simon JS and Raft D. 1990. Clinical aspects of neuropeptide research. In: *Neuropsychopharmacology* (WE Bunney, H Hippus, G Laakmann and M Schmauss, Eds.). Springer-Verlag, Berlin, 520-528.
248. **Nemeroff CB**. 1989. Clinical significance of Psychoneuroendocrinology in psychiatry: focus on the thyroid and adrenal. *J. Clin. Psychiatry* 50, Suppl., 13-20.
249. Cook LL, Bissette G and **Nemeroff CB**. 1990. Alterations in neuropeptide systems in Alzheimer's disease. In: *Neuropsychopharmacology* (WE Bunney, H Hippus, G Laakmann and M Schmauss, Eds.). Springer-Verlag, Berlin, 549-562.

250. Pomara N, Singh RR, Deptula D, Lewitt PA, Bissette G, Stanley M and **Nemeroff CB**. 1989. Corticotropin-releasing factor (CRF) in Alzheimer's disease: relationship to severity of dementia and monoamine metabolites. *Biol. Psychiatry* 26:500-504.
251. Cain ST, Abramson M and **Nemeroff CB**. 1988. Neurotensin stimulates the phosphorylation of caudate nucleus synaptosomal proteins. *Ann. N.Y. Acad. Sci.* 537:488-490.
252. Ervin GN and **Nemeroff CB**. 1988. Intraaccumbens injection of neurotensin antagonizes the behavioral supersensitivity to L-DOPA in dopamine-denervated rats. *Ann. N.Y. Acad. Sci.* 537:496-497.
253. Levant B, Bissette G, Parker Y-M and **Nemeroff CB**. 1988. Alterations in neurotensin- and bombesin-like immunoreactivity in MPTP-treated mice. *Ann. N.Y. Acad. Sci.* 537:515-517.
254. **Nemeroff CB**, Kizer JS, Reynolds GP and Bissette G. 1989. Neuropeptides in Alzheimer's disease: a postmortem study. *Regulatory Peptides* 25:123-130.
255. Kilts CD, Butler PD and **Nemeroff CB**. 1990. Corticotropin-releasing factor, the amygdaloid complex and depression: a hypothetical interrelationship. In: *Neuropsychopharmacology* (WE Bunney, H Hippius, G Laakmann and M Schmauss, Eds.). Springer-Verlag, Berlin, 508-519.
256. Leckman JF, Riddle MA, Berrettini WH, Anderson GM, Hardin M, Chappell P, Bissette G, **Nemeroff CB**, Goodman WK and Cohen DJ. 1988. Elevated CSF dynorphin A[1-8] in Tourette's syndrome. *Life Sci.* 43:2015-2023.
257. Dunn L, Kilts CD and **Nemeroff CB**. 1990. Animal behavioral models for drug development in psychopharmacology. In: *Drug Discovery Technologies* (CR Clark and WH Moos, Eds.) 259-280.
258. Evans DL, Stern RA, Golden RN, Haggerty JJ, Jr., Perkins D, Simon JS and **Nemeroff CB**. 1989. Neuroendocrine and peptide challenge tests in primary and secondary depression. In: *Neuropeptides in Psychiatry* (CB Nemeroff, Ed). APA Press, Washington, DC 279-298.
259. Figiel GS, Krishnan KRR, Breitner JC and **Nemeroff CB**. 1989. Radiologic correlates of antidepressant-induced delirium: the possible significance of basal ganglia lesions. *J. Neuropsychiat. Clin. Neurosciences* 1:188-190.
260. Rao VP, Krishnan KRR, Goli V, Saunders WB, Ellinwood EH, Jr., Blazer DG and **Nemeroff CB**. 1989. Neuroanatomic changes and hypothalamo-pituitary- adrenal axis abnormalities. *Biol. Psychiatry* 26:729-732.
261. Fink M and **Nemeroff CB**. 1989. A neuroendocrine view of ECT. *Convulsive Therapy* 5:296-304.
262. Haggerty JJ, Evans DL, Golden RN, Pedersen CA, Simon JS and **Nemeroff CB**. 1990. The presence of anti-thyroid antibodies in patients with affective and non-affective psychiatric disorders. *Biol. Psychiatry* 27:51-60.
263. Owens MJ, Bissette G and **Nemeroff CB**. 1989. Acute effects of alprazolam and adinazolam on the concentrations of corticotropin-releasing factor in rat brain. *Synapse* 4:196-202.

264. Butler PD, Weiss JM, Stout JC and **Nemeroff CB**. 1990. Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. *J. Neuroscience* 10: 176-183.
265. Davidson JRT and **Nemeroff CB**. 1989. Pharmacotherapy in post-traumatic stress disorder: historical and clinical considerations, and future directions. *Psychopharmacol. Bull.* 25:422-425.
266. **Nemeroff CB**, Krishnan KRR, Belkin BM, Ritchie JC, Clark C, Vale WW, Rivier JE and Thorner MO. 1989. The growth hormone response to growth hormone-releasing factor in Alzheimer's disease. *Neuroendocrinology* 50:663-666.
267. Rossitch E, Jr., King RA, Luttinger D and **Nemeroff CB**. 1989. Behavioral effects of neurotensin: operant responding and assessment of 'anhedonia'. *Eur. J. Pharmacol.* 163:119-122.
268. Levant B, Bisette G and **Nemeroff CB**. 1989. Effects of anticholinergic drugs on regional brain neurotensin concentrations. *Eur. J. Pharmacol.* 165:327-330.
269. **Nemeroff CB**, Bisette G., Akil H. and Fink M. 1991. Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy: corticotropin-releasing factor, β -endorphin and somatostatin. *Brit. J. Psychiat.* 158:59-63.
270. Cain ST., Pryor JC. and **Nemeroff CB**. 1989. Cyclic AMP-dependent protein phosphorylation in the rat anterior pituitary. *Synapse* 5:241-246.
271. **Nemeroff CB**, Krishnan KRR, Blazer DG, Knight DL, Benjamin D and Meyerson, LR. 1990. Elevated plasma concentrations of α_1 -acid glycoprotein, a putative endogenous inhibitor of the [3 H]-imipramine binding site in depressed patients. *Arch. Gen. Psychiat.* 47:337-342.
272. Krystal A, Krishnan KRR, Ratiere M, Poland R, Ritchie JC, Dunnick NR, Hanada K and **Nemeroff CB**. 1990. Differential diagnosis and pathophysiology of Cushing's syndrome and primary affective disorder. *J. Neuropsychiat. Clin Neurosciences* 2:34-43.
273. Haggarty JJ, Jr., Garbutt JC, Simon JS, Evans DL, Golden RN, Pedersen C and **Nemeroff CB**. 1990. Subclinical hypothyroidism: a review of neuropsychiatric aspects. *Int J Psychiat Med* 20:193-208.
274. Krishnan KRR, Ritchie JC, Saunders WB, **Nemeroff CB** and Carroll, BJ. 1990. Adrenocortical sensitivity to low dose ACTH administration in depressed patients. *Biol. Psychiatry* 27:930-933.
275. **Nemeroff CB**. 1991. The Neurobiology of Neuropeptides. In: *Neuropeptides in Psychiatric Disorders* (CB Nemeroff, Ed.), APA Press, Washington, 1-12.
276. **Nemeroff CB**. 1991. Corticotropin-releasing factor. In: *Neuropeptides in Psychiatric Disorders* (CB Nemeroff, Ed.), APA Press, Washington, 75-92.
277. Levant B, **Nemeroff CB** and Bisette G. 1991 Neurotensin. In: *Neuropeptides in Psychiatric Disorders* (CB Nemeroff, Ed.), APA Press, Washington, 149-168.

278. McCubbin JA, Surwit RS, Williams RB, **Nemeroff CB** and McNeilly M. 1989. Altered pituitary hormone response to naloxone in hypertension development. *Hypertension* 14:636-644.
279. Krishnan KRR, Manepalli AN, Ritchie JC, Daughtry G, Pelton S, **Nemeroff CB** and Carroll BJ. 1990. Nocturnal and early morning dissociation of ACTH and cortisol secretion in man. *Biol. Psychiatry* 28:47-57.
280. Vargas MA, Owens MJ and **Nemeroff CB**. 1991. Corticotropin-releasing factor: brain and cerebrospinal fluid studies. In: *CNS Peptide Mechanisms in Stress and Depression* (SC Risch, Ed), APA Press, Washington, D.C. 73-92.
281. **Nemeroff CB**. 1991. *Neuropeptides and schizophrenia: a critical review*. In: *Schizophrenia Research Advances in Neuropsychiatry and Psychopharmacology, Volume 1* (CA Tamminga and SC Schulz, Eds.), Raven Press, New York., 77-89
282. Bissette G, Levant B and **Nemeroff CB**. 1991. Neurotensin and its possible significance in the pathophysiology of schizophrenia. In: *Volume Transmission in the Brain: Novel Mechanisms for Neural Transmission* (K Fuxe and L Agnati, Eds.), Raven Press, New York, 549-556.
283. Hussain M and **Nemeroff CB**. 1990. Neuropeptides and Alzheimer's disease. *J. Amer. Geriat. Soc.* 38:918-925.
284. Slotkin TA, Seidler FJ, Crain BJ, Bell JM, Bissette G and **Nemeroff CB**. 1990. Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimer's disease: implications for etiology and therapy. *Proc. Nat'l. Acad. Sc. (USA)*, 87:2452-2455.
285. **Nemeroff CB**. 1990. The rational use of narcotic analgesics, benzodiazepines and psychostimulants in medical practice. *North Carolina Med. J.* 51:240-243.
286. **Nemeroff CB**. 1990. Neuropeptide involvement in affective disorders. *Current Opinion in Psychiatry* 3:108-112.
287. Ritchie JC and **Nemeroff CB**. 1991. Stress, the Hypothalamic-Pituitary- Adrenal Axis and depression. In: *Role of Neuropeptides in Stress Pathogenesis in Systemic Disease*. (JH McCubbin, PG Kaufman and CB Nemeroff, Eds.), Academic Press, Orlando, Florida, 181-197.
288. Ghanbari H, Miller BE, Haigler HJ, Arato M, Bissette G, Davies P, **Nemeroff CB**, Perry EK, Ravid R, Swaab DF, Whetsell WD and Zemlan FP. 1990. Biochemical assay of Alzheimer's disease-associated proteins in human brain tissue: a clinical study. *J. Amer. Med. Ass'n.* 263:2907-2910.
289. Doraiswamy PM, Krishnan KRR and **Nemeroff CB**. 1991 Neuropeptide and neurotransmitters in Alzheimer's disease: focus on corticotropin-releasing factor. In: *Psychoneuroendocrinology* (A. Grossman, Ed.) Baillière's Clinical Endocrinology and Metabolism, Volume 5:59-78.
290. **Nemeroff CB**, Kilts CD, Levant B, Bissette G, Campbell A and Baldessarini RJ. 1991. Effects of the isomers of N-n-propylnorapomorphine and haloperidol on regional concentrations of neurotensin in rat brain. *Neuropsychopharmacology.* 4:27-34.

291. Levant B and **Nemeroff CB**. 1990. Sigma receptor "antagonist" BMY14802 increases neurotensin concentrations in the rat nucleus accumbens and caudate. *J. Pharmacol Exp. Ther* 254:330-335.
292. Alosachie I, Peter JB, Tsuchihashi H, Knight DL and **Nemeroff CB**. 1990. Decreased imipramine binding by platelet membranes in major depression is not associated with plasma autoantibodies to imipramine binding sites. *Biol. Psychiatry* 28:365-368.
293. **Nemeroff CB**, Bissette G, Owens MJ, Vargas MA, Pihoker C, Krishnan KRR, Cain ST and Banki CM. 1990. Corticotropin-releasing factor: preclinical and clinical studies. *Clin Neuropsychopharmacol. Suppl. 2*, 13:595-596.
294. Krishnan KRR, Husain MM, McDonald WM, Doraiswamy PM, Figiel GS, Boyko OB, Ellinwood EH, Jr. and **Nemeroff CB**. 1990. In vivo stereological assessment of caudate volume in men: effect of normal aging. *Life Sciences* 47:1325-1329.
295. Owens MJ, Bartolome J, Schanberg SM and **Nemeroff CB**. 1990. Corticotropin-releasing factor concentrations exhibit a diurnal rhythm in hypothalamic and extrahypothalamic brain regions: differential sensitivity to corticosterone. *Neuroendocrinology* 52:626-631.
296. Owens MJ, Edwards E and **Nemeroff CB**. 1990. The effects of 5HT_{1A} agonists on HPA axis activity and CRF-containing neurons in the rat brain. *Eur. J. Pharmacol.* 190:113-122.
297. Owens MJ, Overstreet DH, Knight DL, Rezvani AH, Ritchie JC, Bissette G, Janowsky DS and **Nemeroff CB**. 1991. Alterations in the hypothalamic-pituitary-adrenal axis in a proposed animal model of depression with genetic muscarinic supersensitivity. *Neuropsychopharmacology* 4:87-93.
298. Husain MM, Knight DL, Doraiswamy PM, Figiel GS, McDonald WM, Boyko OB, Krishnan KRR and **Nemeroff CB**. 1991. Platelet [³H] - imipramine binding and leukoencephalopathy in geriatric depression. *Biological Psychiatry* 29:665-670.
299. Roy A, Bissette G, **Nemeroff CB**, DeJong J, Ravitz B, Adinoff B and Linnoila M. 1990. Cerebrospinal fluid thyrotropin-releasing hormone concentrations in alcoholics and normal controls. *Biological Psychiatry* 28: 767-772.
300. Figiel GS, Krishnan KRR, Rao VP, Doraiswamy PM, Ellinwood EH, Jr., **Nemeroff CB**, Evans D and Boyko OB. 1991. Subcortical hyperintensities on brain magnetic resonance imaging: a comparison of normal and bipolar subjects. *J. Neuropsychiatry Clin. Neurosci* 3:18-22.
301. Figiel GS, Krishnan KRR, Doraiswamy PM, Rao VP, **Nemeroff CB** and Boyko OB. 1991. Subcortical hyperintensities on brain magnetic resonance imaging: a comparison between late age onset and early onset elderly depressed subjects. *Neurobiol. Aging* 26:245-247.
302. Krishnan KRR, Miller MN, Helms MJ, Reed DA, Ritchie JC, **Nemeroff CB** and Carroll BJ. 1993. Dose response relationship between plasma ACTH and cortisol after the infusion of ACTH₁₋₂₄. *Eur. Arch. Psychiat. Clin. Neurosci.* 242:240-243.
303. Gupta SK, Krishnan KRR, Ellinwood EH, Ritchie JC and **Nemeroff CB**. 1991. Pharmacokinetics of human growth hormone secretion in humans induced by growth hormone releasing hormone. *Life Sciences* 47:1887-1893.

304. Cain ST and **Nemeroff CB**. 1991. Neurotensin-sensitive protein phosphorylation in the rodent caudate nucleus. *Prog. Neuro-Psychopharmacol. Biol Psychiat.* 15:83-88.
305. Owens MJ, Knight DL, Ritchie JC and **Nemeroff CB**. 1991. The 5-HT₂ agonist, (±)-1-(2, 5 - dimethoxy-4-bromophenyl) -2- aminopropane (DOB) stimulates the hypothalamic-pituitary-adrenal (HPA) axis: I. Acute effects on HPA axis activity and corticotropin-releasing factor (CRF) containing neurons in the rat brain. *J. Pharmacol. Exp. Ther.* 256:787-794.
306. Owens MJ, Knight DL, Ritchie JC and **Nemeroff CB**. 1991. The 5-HT₂ agonist, (±)-1-(2, 5 - dimethoxy-4-bromophenyl)-2-aminopropane (DOB) stimulates the hypothalamic-pituitary-adrenal (HPA) axis: II. Biochemical and physiological evidence for the development of tolerance after chronic administration. *J. Pharmacol. Exp. Ther.* 256:795-800.
307. Golden RN, McCartney CF, Haggerty JJ, Raft D, **Nemeroff CB**, Ekstrom D, Holmes V, Simon JS, Droba M, Quade D, Fowler WC and Evans DL. 1991. The detection of depression by patient self-report in women with gynecologic cancer. *Int. J. Psychiat. Med.* 21:17-27.
308. Stowe ZN, Bissette G and **Nemeroff CB**. 1991. Neurotensin-dopamine interactions: relevance to schizophrenia and the action of antipsychotic drugs. *Jap. J. Psychopharmacol.* 11:49-59
309. Kasckow JW, **Nemeroff CB** and Bissette G. 1991. Neuropeptide abnormalities in schizophrenia. *Jap. J. Pharmacol suppl. Biological Basis of Schizophrenia Disorders.* 103-132.
310. Krishnan KRR, Doraiswamy PM, Lurie SN, Figiel GS, Husain MM, Boyko OB, Ellinwood EH Jr and **Nemeroff CB**. 1991. Pituitary size in depression. *J. Clin. Endocrinol. Metab.* 72:256-259.
311. Pihoker C, Cain ST, Owens MJ and **Nemeroff CB**. 1991. Postnatal development of brain corticotropin-releasing factor receptors in the rat. In: *Horizons in Endocrinology Vol II. Serono Symposia 76* (M. Maggi and V. Geenen, Eds.), Raven Press, New York, 83-88.
312. Cain ST, Owens MJ and **Nemeroff CB**. 1991. Subcellular distribution of corticotropin-releasing factor-like immunoreactivity in rat central nervous system. *Neuroendocrinology* 54:36-41.
313. Kasckow J, Cain ST and **Nemeroff CB**. 1991. Neurotensin effects on calcium/calmodulin-dependent protein phosphorylation in rat neostriatal slices. *Brain Research* 545:343-346.
314. Krishnan KRR, Doraiswamy PM, Figiel GS, McDonald WM, Husain MM, Shah SA, Boyko OB, Ellinwood EH, Jr and **Nemeroff CB**. 1991. Hippocampal abnormalities in depression. *J. Neuropsychiatry Clin. Neurosciences* 3:387-397.
315. Garver DL, Bissette G, Yao JK and **Nemeroff CB**. 1991. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. *Amer. J. Psychiatry* 148:484-488.
316. Levant B, Bissette G, Widerlov E and **Nemeroff CB**. 1991. Alterations in regional brain neurotensin concentrations produced by atypical antipsychotic drugs. *Regulatory Peptides* 32:193-201.

317. Knight DL, Slotkin TA, Meyerson LR, Krishnan KRR and **Nemeroff CB**. 1991. Alterations in platelet [³H]-imipramine binding, 5HT uptake and plasma α_1 -acid glycoprotein concentrations in patients with major depression. In: *Presynaptic Receptors and Neuronal Transporters* (S.Z. Langer, AM Galzin and J. Constantin, Eds.), Pergamon Press, New York, 185-188.
318. **Nemeroff CB**, Bissette G, Slotkin TA, Seidler FJ, Miller BE and Ghanbari H. 1991. Recent advances in the neurochemical pathology of Alzheimer's disease: studies of neuropeptides, cholinergic function and Alzheimer's disease-associated protein. In: *Alzheimer's Disease: Sensory Systems, Neuronal Growth and Neuronal Metabolism. Ann. New York Acad. Sci.* 640:193-196.
319. Roy-Byrne PP, Cowley DS, Hommer D, Ritchie JC, Greenblatt D and **Nemeroff CB**. 1991. Neuroendocrine effects of diazepam in panic and generalized anxiety disorders. *Biol. Psychiatry* 30:73-80.
320. Lammers C-H, Doraiswamy PM, Husain MM, Figiel GS, Lurie SN, Boyko OB, Ellinwood EH, Jr, **Nemeroff CB** and Krishnan KRR. 1991. MRI of the corpus callosum and septum pellucidum in depression. *Biol. Psychiatry* 29:300-301.
321. McDonald WM and **Nemeroff CB**. 1991. Neurotransmitters and neuropeptides in Alzheimer's disease. *Psychiatric Clinics of North America* 14:421-442.
322. Doraiswamy, PM, Krishnan, KRR and **Nemeroff CB**: 1992. Hormonal effects on brain function. In: *Neuroendocrinology, Concepts in Neurosurgery, Volume 5*. (D.L. Barrow and W. Seldman Eds.), Congress of Neurological Surgeons Publications, Williams and Wilkins, Baltimore, 75-91.
323. Escalona PR, Early B, McDonald WM, Doraiswamy PM, Shah SA, Husain MM, Boyko OB, Figiel GS, Ellinwood EH Jr., **Nemeroff CB** and Krishnan KRR: 1993. Reduction of cerebellar volume in major depression: a controlled MRI study. *Depression* 1:156-158.
324. Owens MJ, Vargas MA, Knight DL and **Nemeroff CB**: 1991. The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: acute time course, chronic treatment and abrupt withdrawal. *J. Pharmacol. Exp. Ther.* 258:349-356.
325. Bissette G, Smith WH, Dole KC, Crain B, Ghanbari H, Miller B and **Nemeroff CB**: 1991. Alterations in Alzheimer's disease associated protein in Alzheimer's disease frontal and temporal cortex. *Arch. Gen. Psychiat.* 115:1009-1012.
326. Appel NM, Owens MJ, Culp S, Zaczek R, Contrera JF, Bissette G, **Nemeroff CB** and De Souza EB: 1991. Role for corticotropin-releasing factor in the weight-reducing effects of chronic fenfluramine treatment in rats. *Endocrinology* 128:3237-3246.
327. **Nemeroff CB**: 1991. Chronic stress and the psychopathology of affective disorders. In: *Stress, Biological Rhythms and Psychiatric Disorders, Third International Symposium Proceedings* (H.G.M. Westenberg, Ed.), Medidact, Houten, The Netherlands, 13-16.
328. **Nemeroff CB** and Krishnan KRR: 1992. Neuroendocrine alterations in psychiatric disorders. In: *Neuroendocrinology* (CB Nemeroff, Ed.), CRC Press, Boca Raton, 413-441.
329. **Nemeroff CB**: 1991. Augmentation regimens for depression. *J. Clin. Psychiatry, Suppl* 52:21-27.

330. Paris JM, Lorens SA, Lee JM, Mitsushio H, Ritchie JC and **Nemeroff CB**: 1991. Muscimol injections into the median raphe nucleus increase serum ACTH and corticosterone concentrations via a non-serotonergic mechanism. *Pharmacol. Biochem. Behav.* 39: 765-768.
331. Husain M, McDonald WM, Doraiswamy PM, Figiel GS, Escalona PR, Boyko OB, **Nemeroff CB** and Krishnan KRR: 1991. MRI evidence of putamen nuclei pathology in major depression. *Psychiatry Research: Neuroimaging* 40:95-99.
332. Keck PE, McElroy SL and **Nemeroff CB**. 1992. Anticonvulsants in the treatment of bipolar disorder. *J. Neuropsychiatry Clin. Neurosci.* 4:395-405.
333. Pihoker C and **Nemeroff CB**: 1993. The role of corticotropin-releasing factor in the pathophysiology of anxiety disorders. In. *Biology of Anxiety Disorders: Recent Developments* (R. Hoehn-Saric, Ed.), APA Press, Washington, 103-120.
334. Adinoff B, **Nemeroff CB**, Bissette G, Martin PR and Linnoila M: 1991. Inverse relationship between CSF TRH concentrations and the TSH response to TRH in abstinent alcoholics. *Amer. J. Psychiat.* 148: 1586-1588.
335. Levant B, Bissette G, Davis MD, Heffner TG and **Nemeroff CB**: 1991. Effects of CI-943, a potential antipsychotic drug, and haloperidol on regional brain neurotensin concentrations. *Synapse* 9:225-230.
336. Levant B, Merchant KM, Dorsa DM and **Nemeroff CB**: 1992. BMV 14802, a potential antipsychotic drug, increases expression of proneurotensin mRNA in the rat striatum. *Molecular Brain Res* 12:279-284.
337. Krishnan KRR, Blazer DG, Knight DL, Benjamin D, Meyerson LR and **Nemeroff CB**: 1991. Putative endogenous inhibitor of the tritiated imipramine binding site in depressed patients. In: *Biological Psychiatry, Vol. 2* (G Racagni, N Brunello and T Fukuda, Eds.) Excerpta Medica, Amsterdam, 642-644.
338. **Nemeroff CB** and Bissette G: 1991. Depression, aging and psychoimmunology: focus on the pituitary-thyroid axis. In: *Biological Psychiatry Vol. 2* (G. Ragagni, N Brunello and T Fukuda, Eds.) Excerpta Medica, Amsterdam, 573-576.
339. **Nemeroff CB**, Bissette G and Krishnan KRR: 1991. The role of corticotropin-releasing factor (CRF) in the pathophysiology of depression. In: *Biological Psychiatry Vol.2* (G. Ragagni N Brunello and T. Fukuda, Eds.,) Excerpta Medica, Amsterdam, 549-552.
340. Bissette G, Owens, MJ, **Nemeroff CB**: 1991. *Neuropeptides* and mental illness: focus on affective disorders. In: *Biological Psychiatry Vol.2* (G. Ragagni et al, Eds.), Elsevier, 543-545.
341. Ehlers CL, Chaplin RI, Wall TL, Lumeng L, Li TK, Owens MJ and **Nemeroff CB**: 1992. Corticotropin-releasing factor (CRF): studies in alcohol preferring and non-preferring rats. *Psychopharmacology* 106:359-364.
342. Stowe ZN and **Nemeroff CB**: 1991. The electrophysiological actions of neurotensin in the central nervous system. *Life Sciences* 49:987-1002.

343. Steege JF, Stout AL, Knight DL and **Nemeroff CB**: 1992. Reduced platelet [³H]-imipramine binding sites in women with premenstrual syndrome. *Amer. J. Obstet. Gynecol.* 167:168-172.
344. **Nemeroff CB**, Krishnan KRR, Reed D, Leder R, Beam C and Dunnick NR: 1992. Adrenal gland enlargement in major depression: a computed tomographic study. *Arch. Gen. Psychiat.* 49:384-387.
345. **Nemeroff CB** and Krishnan KRR: 1993. Hormonal regulation of behavior. In: *Current Psychiatric Therapy* (D.L. Dunner, Ed.), W.B. Saunders Co., Philadelphia, 31-35.
346. **Nemeroff CB**: 1992. New vistas in neuropeptide research in neuropsychiatry: focus on corticotropin-releasing factor. *Neuropsychopharmacology* 6:69-76.
347. Beyer J, Burke M, Meglin D, Fuller A, Krishnan KRR and **Nemeroff CB**: 1993. Organic anxiety disorder: iatrogenic hyperthyroidism. *Psychosomatics* 34:181-184.
348. Kasckow J and **Nemeroff CB**: 1991. The neurobiology of neurotensin: focus on neurotensin-dopamine interactions. *Regulatory Peptides* 36:153-164.
349. Figiel GS, Krishnan KRR, Doraiswamy M and **Nemeroff CB**: 1991. Caudate hyperintensities in elderly depressed patients with neuroleptic-induced Parkinsonism. *Journal of Geriatric Psychiatry and Neurology* 4:86-89.
350. Jolkkonen J, Hartikainen P, Soikkeli R, Bisette G, Nemeroff C and Reikkinen P: 1991. A correlation study of CSF neuropeptides in Alzheimer's and Parkinson's disease. *Neuropeptides* 19:97-102.
351. Churchill CM, Priolo CV, **Nemeroff CB**, Krishnan KRR and Breitner JCS: 1991. Occult subcortical magnetic resonance findings in elderly depressives. *Int. J. Geriatr. Psychiat.* 6:213-216.
352. Owens MJ and **Nemeroff CB**: 1991. The physiology and pharmacology of corticotropin-releasing factor. *Pharmacol Revs.* 43:425-473.
353. Vargas MA, Bisette G, Owens MJ, Ehlers CL and **Nemeroff CB**: 1992. Effects of chronic ethanol and benzodiazepine treatment and withdrawal on corticotropin-releasing factor (CRF) neural systems. *Ann. New York Acad. Sci.* 654:145-152.
354. **Nemeroff CB**, Escalona PR, Krishnan KRR and Reynolds CF: 1993. The biology of late life depression. In: *The Biology of Depressive Disorders* (JJ Mann and DJ Kupfer, Eds.), Plenum Press, New York 59-73.
355. Owens MJ, Vargas MA, Knight DL and **Nemeroff CB**: 1993. The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: implications for a role for CRF in the pathogenesis of anxiety disorders. *J. Psychiat. Res.* 27, suppl 1:209-220.
356. Yehuda R and **Nemeroff CB**: 1994. Neuropeptide alterations in affective and anxiety disorders. In: *Handbook on Depression and Anxiety* (J.A. denBoer and J.M.A. Sitsen, Eds.), Marcel Dekker, Inc., New York, 543-571.

357. Slotkin TA, McCook EC, **Nemeroff CB** and Seidler, FJ. 1991. Species differences in α_2 -adrenergic regulation of platelet adenylate cyclase. *Res. Comm. Chem. Pathol. Pharmacol.* 72:259-272.
358. Owens MJ, Ritchie JC and **Nemeroff CB**: 1992. 5 α -pregnane-3 α , 21-diol-20-one (THDOC) attenuates mild stress-induced increases in plasma corticosterone via a non-glucocorticoid mechanism: comparison with alprazolam. *Brain Research* 573:353-355.
359. Pihoker C, **Nemeroff CB**, Owens MJ, Bissette G, Weiss JM, and Krishnan KRR. 1992. The role of corticotropin-releasing factor (CRF) in the pathogenesis of anxiety and affective disorders: preclinical and clinical studies. In: *Stress, Neuroendocrine and Molecular Approaches* (R. Kvetnansky, R. McCarty and J. Axelrod, Eds.), Gordon and Breach Science, New York, 915-925.
360. Pryor JC, Cain ST, and **Nemeroff CB** 1992. Calcium-, calcium/calmodulin-, and calcium/phospholipid-stimulated protein phosphorylation in the rat anterior pituitary. *Synapse* 11:140-145.
361. Myers B, Levant B, Bissette G and **Nemeroff CB** 1992. Pharmacological specificity of the increase in neurotensin concentrations after antipsychotic drug treatment. *Brain Research* 575:325-328.
362. Krishnan KRR, McDonald WM, Escalona PR, Doraiswamy PM, Na C, Husain MM, Figiel GS, Boyko OB, Ellinwood EH and **Nemeroff CB**. 1992. Magnetic resonance imaging of the caudate nuclei in depression: preliminary observations. *Arch. Gen. Psychiatry* 49:553-557.
363. Cain ST, Abramson M and **Nemeroff CB**. 1992. Effects of neurotensin on caudate nucleus protein phosphorylation. *Regulatory Peptides* 39:55-65.
364. Levant B and **Nemeroff CB**. 1992. Further studies on the modulation of regional brain neurotensin concentrations by antipsychotic drugs: focus on haloperidol and BMY 14802. *J. Pharmacol. Exp. Ther.* 262:348-355.
365. **Nemeroff CB**, Levant B, Myers B and Bissette G. 1992. Neurotensin, antipsychotic drugs and schizophrenia: basic and clinical studies. *Ann. New York Acad. Sci.* 668:146-156.
366. **Nemeroff CB** and Goodman S. 1992. A new psychobiological theory of attachment: primum non nocere. *Brain Behav. Sci.* 15:520-521.
367. Hayden-Hixson DM and **Nemeroff CB**. 1993. Role(s) of neuropeptides in responding and adapting to stress: a focus on corticotropin-releasing factor and opioid peptides. In: *Stress: From Synapse to Syndrome* (S.C. Stanford and P. Salmon, Eds.), Academic Press, London 355-391.
368. Owens MJ and **Nemeroff CB**. 1993. The role of CRF in the pathophysiology of affective disorders: laboratory and clinical studies. *CIBA Foundation Symposium 172: Corticotropin-releasing Factor*, John Wiley & Sons, New York, 296-316.

369. Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrino F, Green AI, Glick IB, Kahn RS, Sharma T, Tohen M, McEvoy JP, Weiden PJ, Lieberman JA, **Nemeroff CB**, Cohen B, Tollefson G, Sanger T, Kuldau J, Rothschild AJ, Patel JK, Gur RE, , Daskalakis ZJ, Strakowski SM, De Quardo J, Murray R 2006. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. *Schizophrenia Research*, volume 83, issue 1, 53–63.
370. Kilts CD, Coco ML, Ely TD, Bissette G and **Nemeroff CB**. 1992. Differential effects of conditioned and unconditioned stress on the neurotensin content of dopamine cell body groups of the ventral mesencephalon. *Ann. New York Acad. Sci.* 668:266-276.
371. Bissette G and **Nemeroff CB**. 1995. Neuropeptides: Biology and Regulation. In: *Comprehensive Textbook of Psychiatry VI* (H.J. Kaplan and B.J. Sadock, Eds.), Williams and Wilkins, Baltimore, Maryland 41-52.
372. Banki CM, Karmacsi L, Bissette G and **Nemeroff CB**. 1992. Cerebrospinal fluid neuropeptides in mood disorder and dementia. *J. Affective Dis.* 25:39-46.
373. Banki CM, Karmacsi L, Bissette G and **Nemeroff CB**. 1992. CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse. *European Neuropsychopharmacol.* 2:107:114.
374. Banki CM, Karmacsi L, Bissette G and **Nemeroff CB**. 1992. CSF corticotropin-releasing hormone, somatostatin and thyrotropin-releasing hormone in schizophrenia. *Psychiatry Research* 43:13-21.
375. Risch SC, and **Nemeroff CB**. 1992. Neurochemical alterations of serotonergic neuronal systems in depression. *J. Clin. Psychiat.* 53:10, 3-7 Suppl.
376. Stowe ZN and **Nemeroff CB**. 1993. Non-dopaminergic mechanisms relevant to antipsychotic activity. In: *New Generation of Antipsychotic Drugs: Novel Mechanisms of Action* (G. Racagni, J. Mendlewicz and S.Z. Langer, Eds.), S. Karger, Basel, 4:15-26.
377. Gulley LR and **Nemeroff CB**. 1993. The neurobiological basis of mixed depression-anxiety states. *J. Clin. Psychiatry* 54:1 Suppl 16-19.
378. Krishnan KRR, Ritchie JC, Manepalli AN, Saunders W, Li SW, Venkataraman S, **Nemeroff CB** and Carroll BJ. 1991. Fast feedback regulation of ACTH by cortisol. *Prog. Neuropsychopharmacol. Biol. Psychiat.* 15:523-529.
379. Krishnan KRR, Reed DR, Wilson WH, Saunders W, Ritchie JC, **Nemeroff CB** and Carroll BJ. 1992. RU486 in depression. *Prog. Neuropsychopharmacol. Biol. Psychiat.* 16:913-920.
380. **Nemeroff CB**. 1992. The role of neuropeptides in the pathophysiology of affective disorders. *Clin. Neuropharmacol.* 15, Suppl 1, Pt. A, 6-7.
381. Bissette G and **Nemeroff CB**. 1992. Biochemical and neuropeptide alterations in Alzheimer's disease. *Clin. Neuropharmacol.* 15, Suppl 1, Pt. A, 33-34.
382. Owens MJ, and **Nemeroff CB**. 1992. Stress, corticotropin-releasing factor neurons, and the actions of benzodiazepines. *Clin. Neuropharmacol.* 15, Suppl 1, Pt. A 155-156.

383. **Nemeroff CB**, Knight DL and Bissette G. 1992. Somatostatin: a neuropeptide system pathologically altered in Alzheimer's disease and depression. *Clin. Neuropharmacol.* 15, Suppl 1, Pt. A, 311-312.
384. **Nemeroff CB**. 1992. The presynaptic serotonin uptake site in depression. *Clin. Neuropharmacol.* 15, Suppl 1, Pt. A, 347-348.
385. Auchus AP, Green RC and **Nemeroff CB**. 1994. Cortical and subcortical neuropeptides in Alzheimer's disease. *Neurobiol. Aging* 15:589-595.
386. Cain ST, Bissette G, Kilts CD and **Nemeroff CB**. 1992. A commentary on methods in peptide neurobiology: focus on neurotensin. *Crit. Revs. Neurobiol.* 16:233-241.
387. Blazer DG, Malmrose LC, Wallsten SM, **Nemeroff CB**, Reed DA, Ritchie JC and Tyrey ME. 1993. Rhythmicity and response to AM and PM CRH challenge in elderly subjects. *Neurobiol. Aging* 14:101-106.
388. Hartley PR, Owens MJ and **Nemeroff CB**. 1992. Corticotropin-releasing factor in depression. *Directions in Psychiatry* 13:1-8.
389. Shah SA, Doraiswamy PM, Husain M, Escalona PR, Na C, Figiel GS, Patterson LJ, Ellinwood EH, McDonald WM, Boyko OB, **Nemeroff CB** and Krishnan KRR. 1992. Posterior fossa abnormalities in major depression: a controlled magnetic resonance imaging study. *Acta Psychiatrica Scandinavica* 85:474-479.
390. West S and **Nemeroff CB**. 1992. Alterations in serotonin neural systems in depression. *Psyche* 1:4-10.
391. Lisanby SH, McDonald WM, Massey EW, Doraiswamy PM, Rozear M, Boyko OB, Krishnan KRR and **Nemeroff CB**. 1993. Diminished subcortical nuclei volumes in Parkinson's disease by MR imaging. *J. Neural Transmission* 40:13-21.
392. Banki CM, Karmacsi L, Bissette G and **Nemeroff CB**. 1992. Cerebrospinal fluid neuropeptides: a biochemical subgrouping approach. *Neuropsychobiology* 26:37-42.
393. McDaniel JS and **Nemeroff CB**. 1993. Depression in the cancer patient: diagnostic, biological and treatment aspects. In: *Current and Emerging Issues in Cancer Pain: Research and Practice* (CR Chapman and KM Foley, Eds.) Raven Press, New York, 1-19.
394. Veith RC, Lewis N, Langohr JJ, Murburg MM, Ashleigh EA, Castillo S, Peskind ER, Pascualy M, Bissette G, **Nemeroff CB** and Raskind M. 1992. Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. *Psychiatry Research* 46:1-8.
395. Krishnan KRR, Doraiswamy PM, Axelson DA, Lurie SN, Figiel GS, Husain MM, Patterson L, Boyko OB, Ellinwood EH and **Nemeroff CB**. 1991. Pituitary changes in depression. In: *Biological Psychiatry, Vol. 1* (G. Racagni, N. Brunello and T. Fukuda, Eds.). Excerpta Medica, Amsterdam, 213-216.
396. Gislason T, Hedner J, Terenius L, Bissette G and **Nemeroff CB**. 1992. Substance P, thyrotropin-releasing hormone and monoamine metabolites in cerebrospinal fluid. *Am. Rev. Respir. Dis* 146:784-786.

397. Axelson DA, Doraiswamy PM, Boyko OB, Escalona PR, McDonald WM, Ritchie JC, Patterson LJ, Ellinwood EH Jr, **Nemeroff CB** and Krishnan KRR. 1992. *In Vivo* assessment of pituitary volume with magnetic resonance imaging and systematic stereology: relationship to dexamethasone suppression test results in patients. *Psychiatry Research* 46:63-70.
398. Koegler-Muly SM, Owens MJ, Ervin GN, Kilts CD and **Nemeroff CB**. 1993. Potential corticotropin-releasing factor pathways in the rat brain as determined by bilateral electrolytic lesions of the central amygdaloid nucleus and the paraventricular nucleus of the hypothalamus. *J Neuroendocrinol* 5:95-98.
399. Kinkead BL, Owens MJ and **Nemeroff CB**. 1993. Serotonin antagonists as antipsychotics. In: *Serotonin: From Cell Biology to Pharmacology and Therapeutics* (P.M. Vanhoutte, P.R. Saxena, R. Raoletti, N. Brunello and A.S. Jackson, Eds.) Kluwer Academic Publications, Dordrest, 289-296.
400. Cain ST, Griff D, Joyner CM, Ellinwood EH and **Nemeroff CB**. 1992. Chronic continuous or intermittent infusion of cocaine differentially alter the concentration of neurotensin-like immunoreactivity in specific rat brain regions. *Neuropsychopharmacology* 8:259-266.
401. Ohkubo Y, Owens MJ and **Nemeroff CB**. 1992. The role of corticotropin-releasing factor in the pathophysiology of depression and eating disorders: basic and clinical studies. In: *Primary and Secondary Eating Disorders: A Psychoneuroendocrine and Metabolic Approach* (E Ferrari, F Brambilla and SB Solerte, Eds.), Pergamon Press, Oxford, 419-424.
402. Banki CM, Karmacsi L, Bissette G and **Nemeroff CB**. 1992. Cerebrospinal fluid neuropeptides in dementia. *Biol Psychiatry* 32:452-456.
403. Pihoker C, Cain ST and **Nemeroff CB**. 1992. Postnatal development of regional binding of corticotropin-releasing factor and adenylate cyclase activity in the rat brain. *Prog. Neuropsychopharmacol. Biol Psychiatry* 16:581-586.
404. Freeman AM, Stankovic SMI, Bradley RJ, Zhang GZ, Libb JW and **Nemeroff CB**. 1993. Tritiated platelet imipramine binding and treatment response in depressed outpatients. *Depression* 1:20-23.
405. Figiel GS and **Nemeroff CB**. 1993. Magnetic resonance imaging of the basal ganglia in depression. In: *Limbic Motor Circuits and Neuropsychiatry*. PW Kalivas and CD Barnes, Eds., CRC Press, Boca Raton, FL 351-357.
406. Levy ST and **Nemeroff CB**. 1993. From psychoanalysis to neurobiology. *National Forum* 73:18-21.
407. Powchik P, Davidson M, **Nemeroff CB**, Haroutunian V, Purohit D, Losonczy M, Bissette G, Perl D, Ghanbari H, Miller B and Davis K. 1993. Alzheimer's disease related protein in elderly, cognitively impaired schizophrenic patients. *Am J Psychiat* 150:1726-1727.
408. Jolkonen J, Lepola U, Bissette G, **Nemeroff CB** and Riekkinen P. 1993. CSF corticotropin-releasing factor is not affected in panic disorder. *Biol Psychiatry* 33:136-138.

409. Molchan SE, Hill JL, Martinez RA, Lawlor BA, Mellow AM, Rubinow DR, Bissette G, **Nemeroff CB** and Sunderland T. 1993. CSF somatostatin in Alzheimer's disease and major depression: relationship to hypothalamic-pituitary-adrenal axis and clinical measures. *Psychoneuroendocrinology* 18:509-519.
410. Fossey MD, Lydiard BR, Ballenger JC, Laraia MT, Bissette G and **Nemeroff CB**. 1993. Cerebrospinal fluid thyrotropin-releasing hormone concentrations in patients with anxiety disorders. *J. Neuropsychiatry Clin. Neurosci.* 5:335-337.
411. McDaniel JS and **Nemeroff CB**. 1995. Psychological distress and depression. *In: Clinical Oncology* (MD Abeloff, JO Armitage, AS Lichter and JE Niederhuber, Eds.), Churchill Livingstone, Inc., New York 373-391.
412. Wall TL, **Nemeroff CB**, Ritchie JC and Ehlers CL. 1994. Cortisol responses following placebo and alcohol in Asians with different ALDH² genotypes. *J. Stud. Alcohol* 55:207-213.
413. Rothbaum BO and **Nemeroff CB**. 1994. Psychological and neurobiological consequences of trauma. *In: Brain Control of Responses to Trauma* (N.J. Rothwell and F. Berkenbosch, Eds.), Cambridge Univ. Press, Cambridge, 123-151.
414. West SA and **Nemeroff CB**. 1993. Atypical antipsychotic drugs: current status and future directions. *Drugs of Today* 29:183-188.
415. Ehlers CL, Kaneko WM, Owens MJ and **Nemeroff CB**. 1993. Effects of gender and social isolation on electroencephalogram and neuroendocrine parameters in rats. *Biol. Psychiatry* 33:358-366.
416. Musselman DL and **Nemeroff CB**. 1993. The role of corticotropin-releasing factor in the pathophysiology of psychiatric disorders. *Psychiatric Annals* 23:676-681.
417. Krishnan KRR, Rayasam K, Reed D, Smith M, Chappell P, Saunders WB, Ritchie JC, Carroll BJ and **Nemeroff CB**. 1993. The corticotropin-releasing factor stimulation test in patients with major depression: relationship to dexamethasone suppression test results. *Depression* 1:133-136.
418. **Nemeroff CB**. 1993. Diagnosis and treatment of depression in medical practice. *J. Med. Assn. Georgia* 82:461-464.
419. Musselman DL and **Nemeroff CB**. 1993. The neuroendocrinology of depression. *Clinical Neuroscience* 1:115-121.
420. Breslin NA, Suddath RL, Bissette G, **Nemeroff CB**, Lowrimore P and Weinberger DL. 1994. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates. *Schizophrenia Research* 12:35-41.
421. Pihoker C, Owens MJ, Kuhn CM, Schanberg SM and **Nemeroff CB**. 1993. Maternal separation in neonatal rats elicits activation of the hypothalamic-pituitary-adrenocortical axis: a putative role for corticotropin-releasing factor. *Psychoneuroendocrinology* 18:485-493.

422. **Nemeroff CB.** 1993. The role of corticotropin-releasing factor in the pathogenesis of depression: laboratory and clinical investigations. In: *Neurobiology of Affective Disorders*. The Third Annual Bristol-Myers Squibb Symposium on Neuroscience Research, 61-64.
423. **Nemeroff CB.** 1993. Paroxetine: an overview of the efficacy and safety of a new SSRI in the treatment of depression. *J. Clin. Psychopharmacol* 13, 2 suppl 10S-17S.
424. Owens MJ and **Nemeroff CB.** 1994. The role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. *Clinical Chemistry* 40:288-295.
425. Virkkunen M, Rawlings R, Tokola R, Poland RE, Guidotti A, **Nemeroff CB**, Bissette G, Kalogeras K, Karonen S-L and Linnoila M. 1994. CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholics, violent offenders, impulsive fire setters, and healthy volunteers. *Arch. Gen. Psychiat.* 51:20-27.
426. Virkkunen M, Kallio E, Rawlings R, Tokola R, Poland RE, Guidotti A, **Nemeroff CB**, Bissette G, Kalogeras K, Karonen S-L and Linnoila M. 1994. Personality profiles and state aggressiveness in Finnish alcoholics, violent offenders, impulsive fire setters, and healthy volunteers. *Arch. Gen. Psychiat.* 51:28-33.
427. Axelson DA, Doraiswamy PM, McDonald WM, Boyko OB, Tupler LA, Patterson LJ, **Nemeroff CB**, Elinwood EH and Krishnan KRR. 1993. Hypercortisolemia and hippocampal changes in depression. *Psychiatry Research* 47:163-174.
428. Lessem MD, Kaye WH, Bissette G, Jimerson DC and **Nemeroff CB.** 1994. Cerebrospinal fluid TRH immunoreactivity in anorexia nervosa. *Biol Psychiatry* 35:48-53.
429. Wenk GL, O'Leary M, **Nemeroff CB**, Bissette G, Moser H and Naidu S. 1993. Neurochemical alterations in Rett Syndrome. *Developmental Brain Res.* 74:67-72.
430. **Nemeroff CB.** 1994. The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor. *Pharmacotherapy* 14:127-138.
431. Weiss JM, Stout J, Aaron M, Owens MJ and **Nemeroff CB.** 1994. Experimental studies of depression and anxiety: role of locus coeruleus and corticotropin-releasing factor. *Brain Research Bull* 35:561-572.
432. Plotsky PM, Owens MJ and **Nemeroff CB.** 1995. Neuropeptide alterations in affective disorders. In: *Neuropsychopharmacology: The Fourth Generation of Progress* (F.E. Bloom and D.J. Kupfer, Eds.), Raven Press, New York, 971-981.
433. Roy A, Wolkowitz OM, Bissette G and **Nemeroff CB.** 1994. Differences in CSF concentrations of thyrotropin-releasing hormone in depressed patients and normal subjects: negative findings. *Amer J Psychiatry* 151:600-602.
434. Donahoe RM, Madden JJ, Oleson DR and **Nemeroff CB.** 1995. Immunological, pharmacological and electrophysiological detection of T-cell modulating properties of substances of abuse. In: *Neuroimmunology* (M.I. Phillips and D.L. Evans, Eds.) Methods in Neurosciences, Vol 24, Academic Press, Orlando, 410-423.

435. Owens MJ, Plotsky PM and **Nemeroff CB**. 1994. Peptides and affective disorders. In: *Biology of Schizophrenia and Affective Disease* (S.J. Watson, Ed.), APA Press, Washington DC, 259-293.
436. Boyer W and **Nemeroff CB**. 1994. Somatic approaches to treatment-resistant depression. In: *Inpatient Psychiatry in the 90's* (J. Docherty, Ed.), APA Press, Washington DC.
437. Figiel GS and **Nemeroff CB**. 1994. Brain imaging. In: *Alzheimer's Disease, A Handbook for Caregivers* (R.C. Hamdy, J.M. Turnbull, W. Clark and M.M. Lancaster, Eds.), Mosby, St. Louis, 65-70.
438. Sharma RP, Bissette G, Janicak P, Davis JM and **Nemeroff CB**. 1994. Cerebrospinal fluid somatostatin concentrations in schizophrenia and schizoaffective disorder: the effects of antipsychotic drug treatment. *Schizophrenia Research* 13:173-178.
439. Bissette G and **Nemeroff CB**. 1995. The Neurobiology of Neurotensin. In: *Neuropsychopharmacology, The Fourth Generation of Progress* (F.E. Bloom and D.J. Kupfer, Eds.), Raven Press, New York, 573-582.
440. Kasckow JW, Owens MJ, Stipetic M, Han J-H and **Nemeroff CB**. 1994. Corticotropin-releasing factor is secreted in the BE(2)-C neuroblastoma cell and is responsive to forskolin. *Life Sciences* 54:1825-1829.
441. Forman SD, Bissette G, Yao J, **Nemeroff CB** and van Kammen DP. 1994. Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia. *Schizophrenia Research* 12:43-51.
442. Clement R, Griff D, Banks B, **Nemeroff CB**, Kitabgi P and Bissette G. 1994. The effects of haloperidol, quinelorane and lithium on regional neurotensin/neuromedin N concentrations: further evidence for neurotensin/neuromedin N-dopamine interactions. *Synapse* 17:241-246.
443. Kinkead B and **Nemeroff CB**. 1994. The effects of typical and atypical antipsychotic drugs on neurotensin-containing neurons in the central nervous system. *J. Clin. Psychiat.* 55, Suppl B, 30-32.
444. Kasckow JW and **Nemeroff CB**. 1996. Peptidergic alterations in stress: focus on corticotropin-releasing factor. In: *Advances in the Neurobiology of Anxiety Disorders* (H.G.M. Westenberg, D.L. Murphy and J.A. DenBoer, Eds.), Wiley and Sons, Ltd, London, 405-422.
445. Owens MJ, Dole KC, Knight DL and **Nemeroff CB**. 1993. Preclinical evaluation of the putative antidepressant nefazodone. *Depression* 1:315-323.
446. Musselman DL and **Nemeroff CB**. 1996. Depression and endocrine disorders: focus on the thyroid and adrenal. *British Journal of Psychiatry* 168: (suppl 30)123-128.
447. Slotkin TA, **Nemeroff CB**, Bissette G and Seidler FJ. 1994. Overexpression of the high affinity choline transporter in cortical regions affected by Alzheimer's Disease: evidence from rapid autopsy studies. *J Clin Investigation* 94:696-702.
448. **Nemeroff CB**, Knight DL, Franks J, Craighead WE and Krishnan KRR. 1994. Further studies on platelet serotonin transporter binding in depression. *Am J Psychiat* 151:1623-1625.

449. Stout SC and **Nemeroff CB**. 1994. Stress and psychiatric disorders. *Seminars in Neuroscience* 6:271-280.
450. Kasckow JW, Parkes DG, Owens, MJ, Stipetic MD, Han J-H, **Nemeroff CB** and Vale W. 1994. The BE(2)-M17 neuroblastoma cell line synthesizes and secretes corticotropin-releasing factor. *Brain Research* 654:159-162.
451. Hawley RJ, **Nemeroff CB**, Bissette G, Guidotti A, Rawlings R and Linnoila M. 1994. Neurochemical correlates of sympathetic activation during severe alcohol withdrawal. *Alcoholism: Clinical and Experimental Research* 18:1312-1316.
452. Kasckow JW, Mulcahey JJ, Han J-H, Owens MJ, Stipetic MD, Breitman D and **Nemeroff CB**. 1994. Interleukin-1 α induces corticotropin-releasing factor secretion and synthesis from NPLC-KC cells through various second messenger pathways. *Synapse* 18:354-358.
453. Andrews JM and **Nemeroff CB**. 1994. Contemporary management of depression. *Amer J Medicine* 97, suppl 6A 24S-32S.
454. Stowe ZN and **Nemeroff CB**. 1995. Psychopharmacology during pregnancy and lactation. In: *Textbook of Psychopharmacology* (A.F. Schatzberg and C.B. Nemeroff, Eds.), American Psychiatric Association Press, Washington DC, 823-838.
455. Stout SC, Kilts CD and **Nemeroff CB**. 1995. *Neuropeptides* and stress: preclinical findings and implications for pathophysiology. In: *Neurobiological Consequences of Stress: From Normal Adaptation to Post-Traumatic Stress Disorders* (M. Friedman, A.Y. Deutch and D.L. Charney, Eds.), Raven Press, New York, New York 103-123.
456. Musselman DL and **Nemeroff CB**. 1995. Adrenal function in major depression. *The Endocrinologist* 5:91-96.
457. Stowe ZN and **Nemeroff CB**. 1995. Women at risk for postpartum onset major depression. *Amer J Obstet Gynecol* 173:639-645.
458. Shah SA, Doraiswamy PM, McDonald WM, Husain MM, Escalona PR, Figiel GS, Boyko OB, **Nemeroff CB**, Ellinwood EH and Krishnan KRR. 1991. Assessment of posterior fossa structures with midsagittal MRI: the effects of age. *Neurobiol Aging* 12:371-374.
459. **Nemeroff CB**. 1994. Evolutionary trends in the pharmacotherapeutic management of depression. *J Clin Psychiat* 55, Suppl., 3-17.
460. Cowley DS, Roy-Byrne PP, Radant A, Ritchie JC, Greenblatt DJ, **Nemeroff CB** and Hommer, DW. 1995. Benzodiazepine sensitivity in panic disorder: effects of chronic alprazolam treatment. *Neuropsychopharmacology* 12:147-157.
461. McDaniel JS, Musselman DL, Porter MR, Reed DA and **Nemeroff CB**. 1995. Depression in patients with cancer: diagnosis, biology and treatment. *Arch Gen Psychiat* 52:89-99.
462. **Nemeroff CB**. 1999. Neurotensin. In: *The Encyclopedia of Neuroscience, Second Edition* (G. Adelman and B. Smith, Eds.), Elsevier Science Inc., Amsterdam, 1455-1456.

463. Thase ME, Rush AJ, Kasper S and **Nemeroff CB**. 1995. Tricyclics and newer antidepressant medications: treatment options for treatment-resistant depression. *Depression* 2:152-168.
464. Kinkead B, Owens MJ and **Nemeroff CB**. 1995. Ontogeny of the effect of antipsychotic drug treatment on neurotensin concentrations in the rat brain. *Synapse* 20:244-248.
465. Bissette G, Seidler FJ, **Nemeroff CB** and Slotkin TA. 1996. High affinity choline transporter status in Alzheimer's disease tissue from rapid autopsy. In: *The Neurobiology of Alzheimer's Disease* (R Wurtman, S Corkin, J Growden and Nitsch RM, Eds.). *Ann New York Acad Sci* 777:197-204.
466. Risby E, Donnigan D and **Nemeroff CB**. 1997. Pharmacotherapeutic considerations for psychiatric disorders: depression. *Hospital Formulary* 32:46-59.
467. Nathan KI, Musselman DL, Schatzberg AF and **Nemeroff CB**. 1995. Biology of Mood Disorders. In: *Textbook of Psychopharmacology* (A.F. Schatzberg and C.B. Nemeroff, Eds.), APA Press, Washington DC 439-478.
468. Owens MJ, Mulcahey JJ, Kasckow JW, Plotsky PM and **Nemeroff CB**. 1995. Exposure to an antisense oligonucleotide decreases CRF receptor binding in rat pituitary cultures. *J Neurochem* 64:2358-2361.
469. Boyer W and **Nemeroff CB**. 1995. Suicide. In: *Medicine for the Practicing Physician* (J.W. Hurst, Ed.), Appleton and Lange, Stamford Connecticut, 11-15.
470. Boyer W and **Nemeroff CB**. 1996. Mood Disorders: depression and mania. In: *Medicine for the Practicing Physician* (J.W. Hurst, Ed.), Appleton and Lange, Stamford, Connecticut, 22-28.
471. Stowe ZN, Casarella J, Landry J and **Nemeroff CB**. 1995. Sertraline in the treatment of women with post-partum major depression. *Depression* 3:49-55.
472. Lambert PD, Gross R, **Nemeroff CB** and Kilts CD. 1995. Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system. *Ann New York Acad Sci* 757:377-389.
473. Anand KJS and **Nemeroff CB**. 1996. Developmental Psychoneuroendocrinology. In: *Textbook of Child and Adolescent Psychiatry, Second Edition* (M. Lewis, Ed.) Williams and Wilkins, Baltimore, 64-86.
474. Fossey MD, Lydiard RB, Ballenger JC, Laraia MT, Bissette G and **Nemeroff CB**. 1996. Cerebrospinal fluid corticotropin-releasing factor in patients with anxiety disorders and normal comparison subjects. *Biol Psychiatry* 39:703-707.
475. Essom CR and **Nemeroff CB**. 1996. The treatment of depression in adulthood. In: *Mood Disorders Throughout the Lifespan* (K.I. Shulman, M. Tohen, and S.P. Kutcher Eds.), John Wiley & Sons, Inc., New York 251-264.
476. Hartline KM, Owens MJ and **Nemeroff CB**. 1996. Postmortem and cerebrospinal fluid studies of corticotropin-releasing factor in humans. *Ann New York Acad Sci* 780:96-105.

477. Pitts AF, Samuelson SD, Meller WH, Bissette G, **Nemeroff CB** and Kathol RG. 1995. Cerebrospinal fluid corticotropin-releasing hormone, vasopressin, and oxytocin concentrations in treated patients with major depression and controls. *Biol Psychiat* 38:330-335.
478. See RE, Lynch AM, Aravagiri M, **Nemeroff CB** and Owens MJ. 1995. Chronic haloperidol-induced changes in regional dopamine release and metabolism and neurotensin content in rats. *Brain Research* 704:202-209.
479. **Nemeroff CB**, DeVane CL and Pollack BG. 1996. Newer antidepressants and the cytochrome P450 system. *Am J Psychiatry* 153:311-320.
480. Owens MJ, Ieni JR, Knight DL, Winders K and **Nemeroff CB**. 1995. The serotonergic antidepressant nefazodone inhibits the serotonin transporter: *in vivo* and *ex vivo* studies. *Life Sciences* 57:373-380.
481. Pariante CM, **Nemeroff CB** and Miller AH. 1995. Glucocorticoid receptors in depression. *Israel J Med Sci* 31:705-712.
482. **Nemeroff CB**, Ninan PT, Ballenger J, Lydiard RB, Feighner J, Patterson WM and Greist JH. 1995. A double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients. *Depression* 3:163-169.
483. Furman AC and **Nemeroff CB**. 1996. Selective serotonin reuptake inhibitors in the treatment of depression. *Expert Opinion on Investigational Drugs* 5:101-108.
484. Sharma RP, Bissette G, Janicak PG, Davis JM and **Nemeroff CB**. 1995. Elevation of CSF somatostatin concentrations in mania. *Amer J Psychiat* 152:1807-1809.
485. Dell ML and **Nemeroff CB**. 1997. Psychiatric and psychological aspects of gynecological surgery. In: *Operative Gynecology, Eighth Edition* (J.D. Thompson and J.A. Rock, Eds.), J.P. Lippincott Co.
486. Coplan JD, Andrews MW, Rosenblum LA, Owens MJ, Friedman S, Gorman JM and **Nemeroff CB**. 1996. Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult non-human primates exposed to early life stressors: implications for the pathophysiology of mood and anxiety disorders. *Proc Natl Acad Sci* 93:1619-1623.
487. Ladd CO, Owens MJ and **Nemeroff CB**. 1996. Persistent changes in corticotropin-releasing factor neuronal systems induced by maternal deprivation. *Endocrinology* 137:1212-1218.
488. **Nemeroff CB**, Musselman DL, Schatzberg AF, Knable MB, Kleinman JE, Weinberger DR, Kilts CD and Weiss JM. 1996. Pathophysiologic basis of psychiatric disorders: focus on depression and schizophrenia. In: *Psychiatry* (A. Tasman, J. Kay and J. Lieberman, Eds.), WB Saunders Co, Orlando, Florida 258-311.
489. Adinoff B, Anton R, Linnoila M, Guidotti A, **Nemeroff CB** and Bissette G. 1996. Cerebrospinal fluid concentrations of corticotropin-releasing hormone (CRH) and diazepam-binding inhibitor (DBI) during alcohol withdrawal and abstinence. *Neuropsychopharmacology* 15:288-295.
490. Musselman DL, McDaniel JS, Anderson G, Porter MF and **Nemeroff CB**. 1996. Depression in patients with cancer. *Directions in Psychiatry* 16:1-11.

491. Kasckow JW, Han JH, Parkes DG, Mulcahey JJ, Owens MJ, Risby ED, Fisher J and **Nemeroff CB**. 1995. Regulation of corticotropin-releasing factor secretion and synthesis in the human neuroblastoma clones-BE(2)-M17 and BE(2)-C. *J Neuroendocrinol* 7:461-467.
492. Small GW, Schneider LS, Hamilton SL, Bystritsky A, Meyers BS, **Nemeroff CB** and the Fluoxetine Collaborative Study Group. 1996. Site variability in a multisite geriatric depression trial. *Int J Geriatric Psychiatry* 11:1089-1095.
493. Pariante CM, **Nemeroff CB** and Miller AH. 1996. Hormonal regulation of behavior. In: *Current Psychiatric Therapy II* (D.L. Dunner, Ed.), WB Saunders Co, Philadelphia, 44-51.
494. Anfinson TJ, Boswell E and **Nemeroff CB**. 1997. Psychiatric manifestations of endocrine disorders. In: *Textbook of Neuropsychiatry, 2nd Edition* (S. Yudofsky and R. Hales, Eds.), American Psychiatric Association Press, Inc. Washington, DC, 725-750.
495. Small GW, Hamilton SH, Bystritsky A, Meyers BS, **Nemeroff CB**, and the fluoxetine collaborative study group. 1995. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. *Int Psychogeriatrics* 7: Suppl 41-53.
496. McDonald WM and **Nemeroff CB**. 1996. The diagnosis and treatment of mania in the elderly. *Bulletin of the Menninger Clinic* 60:174-196.
497. Tollefson G, Heiligenstein JH, Tollefson SL, Birkett MA, Knight DL and **Nemeroff CB**. 1996. Is there a relationship between baseline and treatment-associated changes in [³H]-imipramine platelet binding and clinical responses in major depression. *Neuropsychopharmacol* 14:47-54.
498. Boswell EG, Anfinson TJ and **Nemeroff CB**. 1997. Depression associated with endocrine disorders. In: *Depression and Physical Illness* (M. Robertson and C. Katona, Eds.), John Wiley & Sons, Ltd., Sussex, Vol 6; 255-292.
499. Heit S and **Nemeroff CB**. 1996. Migraine and affective disorders. *Psychiatric Annals* 26:S460-S463.
500. Brunello N, Burrows GD, Jonsson B, Judd LL, Kasper S, Keller M, Kupfer DJ, Lecrubier Y, Mendlewicz J, Montgomery SA, **Nemeroff CB**, Preskorn S, Racagni G and Rush AJ. 1996. Critical issues in the treatment of affective disorders. *Depression* 3:187-198.
501. Porter MR, Musselman DL, McDaniel JS and **Nemeroff CB**. 1998. From sadness to major depression: assessment and management in patients with cancer. In: *Topics in Palliative Care, Volume 3* (R. Portenoy and E. Bruera, Eds.), Oxford University Press, New York, 191-212.
502. Small GW, Birkett M, Myers BS, Koran LM, Bystritsky A, **Nemeroff CB** and the Fluoxetine Collaborative Study Group. 1996. Impact of physical illness on quality of life and antidepressant response in geriatric major depression. *J Amer Geriatrics Soc* 44:1220-1225.
503. Plotsky PM and **Nemeroff CB**. 1998. Molecular Mechanisms Regulating Behavior. In: *Principles of Molecular Medicine* (J.L. Jameson, Ed.), Humana Press, Inc., Totowa NJ, 979-987.

504. Risby ED, Hartline K, Owens MJ and **Nemeroff CB**. 1996. *Neuropeptides* in Bipolar Disorder. In: *Bipolar Disorder: Neurobiology and Clinical Applications* (T. Young and R. Joffe, Eds.), Marcel Dekker, Inc., New York, 161-178.
505. Owens MJ, Ballenger CA, Knight DL and **Nemeroff CB**. 1996. Platelet 5-hydroxytryptamine (5-HT) transporter and 5HT_{2A} receptor binding after chronic hypercorticotestosterone, (±)-1- (2,5-dimethoxy-4-iodophenyl)-2-aminopropane administration or neurotoxin-induced depletion of central nervous system 5-HT in the rat. *J Pharmacol Exp Ther* 278:1040-1049.
506. Musselman DL and **Nemeroff CB**. 2003. Neuropeptides and Hypothalamic Releasing Factors in Psychiatric Illness. In: *Psychoneuroendocrinology: The Scientific Basis of Clinical Practice* (O.M. Wolkowitz and A.J. Rothschild, Eds.), American Psychiatric Publishing, Washington DC, 29-82.
507. Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR, Kasey S, Marza CU, Harker LA and **Nemeroff CB**. 1996. Exaggerated platelet reactivity in major depression. *Am J Psychiat* 153:1313-1317.
508. Krishnan KRR, Tupler LA, Ritchie JC Jr., McDonald WM, Knight DL, **Nemeroff CB** and Carroll BJ. 1996. Apolipoprotein E-ε4 frequency in geriatric depression. *Biological Psychiatry* 40:69-71.
509. Llewellyn AM, Stowe ZN and **Nemeroff CB**. 1996. Depression during pregnancy and the puerperium. *J Clin Psychiat* 58(Suppl)15:26-32.
510. Musselman DL, McDaniel JS, Porter MR and **Nemeroff CB**. 1998. Psychoneuroendocrinology and Cancer. In: *Psycho-Oncology* (J. C. Holland, Ed.), Oxford University Press, 135-143.
511. Schneider LS, Small GW, Hamilton SH, Bystritsky A, **Nemeroff CB**, Myers BS and the Fluoxetine Collaborative Study Group. 1997. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. *Am J Geriatric Psychiatry* 5:97-106.
512. **Nemeroff CB**. 1996. The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. *Molecular Psychiatry* 1:336-342.
513. Musselman DL, Anderson G, Porter MR and **Nemeroff CB**. 1998. The hypothalamic-pituitary-adrenocortical system. In: *Women's Health: Hormones, Emotions and Behavior* (R. Casper, Ed.), Cambridge University Press, Cambridge, United Kingdom, 109-121.
514. Engelman M, Thirivikramen KV, Su Y, **Nemeroff CB**, Montkowski A, Landgraf R, Holsboer F and Plotsky PM. 1996. Endocrine and behavioral effects of airpuff startle in rats. *Psychoneuroendocrinology* 21:391-400.
515. Heim C, Owens MJ, Plotsky PM and **Nemeroff CB**. 1997. The role of early adverse life events in the etiology of depression and post-traumatic stress disorder: focus on corticotropin-releasing factor. *Ann New York Acad Sci* 821:194-207.
516. Green JP, Newman NJ, Stowe ZN and **Nemeroff CB**. 1996. "Normal Pressure" Pseudotumor Cerebri. *J Neuro-Ophthalmol* 16:241-246.
517. Andrews JM, Ninan PT and **Nemeroff CB**. 1996. Venlafaxine: a novel antidepressant that has a dual mechanism of action. *Depression* 4:48-56.

518. Risby E, Donnigan D and **Nemeroff CB**. 1997. Pharmacotherapeutic considerations for psychiatric disorders: schizophrenia. *Hospital Formulary* 32:142-155.
519. Stowe ZN, Levy ST and **Nemeroff CB**. 1997. Comorbid postpartum depression and bereavement: a complicated case. *Am J Psychiat* 154:418-422.
520. Heit S, Owens, MJ, Plotsky P and **Nemeroff CB**. 1997. Corticotropin-releasing factor, stress and depression. *The Neuroscientist* 3:186-194.
521. Bremner JD, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, **Nemeroff CB** and Charney DS. 1997. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. *Am J Psychiat* 154:624-629.
522. **Nemeroff CB**. 1997. Augmentation strategies in patients with refractory depression. *Anxiety and Depression* 4:169-181.
523. **Nemeroff CB** and Schatzberg AF. 1997. Pharmacological treatment of unipolar depression. In: *A Guide to Treatments That Work* (P.E. Nathan and J.M. Gorman, Eds.), Oxford University Press, New York, 210-223.
524. McDaniel JS, Musselman DL and **Nemeroff CB**. 1997. Cancer and depression: theory and treatment. *Psychiatric Annals* 27:360-364.
525. **Nemeroff CB**. 1997. Dosing the antipsychotic medication olanzapine. *J Clin Psychiat* 15:24-26.
526. Coplan JD, Trost R, Owens MJ, Cooper T, Gorman JM, **Nemeroff CB** and Rosenblum LA. 1998. Cerebrospinal fluid concentrations of somatostatin and biogenic amines in grown primates reared by mothers exposed to manipulated foraging conditions. *Arch Gen Psychiat* 55:473-477.
527. Behan DP, Khongsaly O, Owens MJ, Chung HD, **Nemeroff CB** and DeSouza EB. 1997. Corticotropin-releasing factor (CRF), CRF-binding protein (CRF-BP) and CRF/CRF-BP complex in Alzheimer's disease and normal post-mortem human brain. *J Neurochem* 68:2053-2060.
528. **Nemeroff CB**. 1997. Depression with comorbid anxiety. *Primary Psychiatry* 4:53-67.
529. Owens MJ, **Nemeroff CB** and Bissette G. 1999. Neuropeptides: biology, regulation, and role in neuropsychiatric disorders. In: *Comprehensive Textbook of Psychiatry, Seventh Edition* (V. Sadock and B. Sadock, Eds.), Williams and Wilkins, Baltimore, 60-70.
530. Newport DJ and **Nemeroff CB**. 1998. Assessment and treatment of depression in the cancer patient. *J Psychosomatic Res* 45:215-237.
531. Garlow SJ and **Nemeroff CB**. 1999. Selective serotonin reuptake inhibitors: trazodone. In: *Comprehensive Textbook of Psychiatry, Seventh Edition* (V. Sadock and B. Sadock, Eds.), Williams and Wilkins, Baltimore, 2482-2490.
532. Heit S and **Nemeroff CB**. 1998. Lithium augmentation of antidepressants in treatment-refractory depression. *J Clinical Psychiatry* 59 (suppl 6):28-33.

533. Garlow SJ, Owens MJ and **Nemeroff CB**. 1999. Selective serotonin reuptake inhibitors: nefazodone. In: *Comprehensive Textbook of Psychiatry, Seventh Edition* (V. Sadock and B. Sadock, Eds.), Williams and Wilkins, Baltimore, 2412-2418.
534. Stowe ZN, Strader JR and **Nemeroff CB**. 1998. Psychopharmacology during pregnancy and lactation. In: *Textbook of Psychopharmacology, Second Edition* (A.F. Schatzberg and C.B. Nemeroff, Eds.), APA Press, Washington, D.C. 979-996.
535. Sharma RP, Janicak PG, Bissette G and **Nemeroff CB**. 1997. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. *Am J Psychiat* 154:1019-1021.
536. Heim C, Owens MJ, Plotsky PM and **Nemeroff CB**. 1997. Persistent changes in corticotropin-releasing factor systems due to early life stress: relationship to the pathophysiology of major depression and post-traumatic stress disorder. *Psychopharm Bulletin* 33:185-192.
537. Heit S, Graham Y and **Nemeroff CB**. 1999. Neurobiological effects of early trauma. *The Harvard Mental Health Letter* 16:4-6.
538. Owens MJ and **Nemeroff CB**. 1998. The serotonin transporter and depression. *Depression and Anxiety* 8 (suppl 1):5-12.
539. **Nemeroff CB**. 1997. Dosing the antipsychotic medication olanzapine. *J Clin Psychiat* 58: suppl 10, 45-49.
540. Ninan PT, Knight B, Kirk L, Rothbaum BO, Kelsey J and **Nemeroff CB**. 1998. A controlled trial of venlafaxine in trichotillomania: interim phase I results. *Psychopharm Bull* 34:221-224.
541. Newport DJ and **Nemeroff CB**. 1999. Treatment of depression in the cancer patient. *Clinical Geriatrics* 7:40-55.
542. Owens MJ, Morgan WN, Plott SJ and **Nemeroff CB**. 1997. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. *J Pharmacol Exp Ther* 283:1305-1322.
543. **Nemeroff CB**, Musselman DL and Evans, DL. 1998. Depression and cardiac disease. *Depression and Anxiety* 8 (suppl 1):71-79.
544. Garlow SJ, Musselman DL and **Nemeroff CB**. 1999. Neurochemistry of mood disorders: clinical studies. In: *The Neurobiology of Mental Illness* (D.S. Charney, E.J. Nestler and B.S. Bunney, Eds.), Oxford University Press, 348-364.
545. Stowe ZN, Owens MJ, Landry JC, Kilts CD, Ely T, Llewellyn A and **Nemeroff CB**. 1997. Sertraline and desmethylsertraline in human breast milk and nursing infants. *Amer J Psychiat* 154:1255-1260.
546. Newport DJ and **Nemeroff CB**. 1998. Depression in the medically ill. In: *Comorbidity of Affective Disorders* (M. Tohen, Ed.), Marcel Dekker, Inc., New York, New York, 57-104.

547. Slotkin TA, Hays JC, **Nemeroff CB** and Carroll BJ. 1997. Dexamethasone suppression test identifies a subset of elderly depressed patients with reduced platelet serotonin transport and resistance to imipramine inhibition of transport. *Depression and Anxiety* 6:19-25.
548. Compton MT and **Nemeroff CB**. 2000. The treatment of bipolar depression. *J Clin Psychiat* 61:57-67.
549. **Nemeroff CB**. 1998. Psychopharmacology of affective disorders in the 21st century. *Biol Psychiat* 44:517-525.
550. Kelsey JE and **Nemeroff CB**. 1998. Affective Disorders. In: *Pharmacological Management of Neurological and Psychiatric Disorders* (S.J. Enna and J.T. Coyle, Eds.), 95-136.
551. Musselman DL and **Nemeroff CB**. 1998. Women, depression and cardiovascular disease. *The Female Patient* 23:23-30.
552. Lee DO, Abramowitz AJ and **Nemeroff CB**. 1999. Attention deficit hyperactivity disorder. In: *Treatment Algorithms in Psychopharmacology* (K. Jobson, D. Stein and J. Fawcett, Eds.), John Wiley & Sons, Ltd., 165-179.
553. Owen JR and **Nemeroff CB**. 1998. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone and mirtazapine. *Depression and Anxiety* 7(Suppl 1):24-32.
554. Kelsey JE and **Nemeroff CB**. 1999. Selective serotonin reuptake inhibitors: an overview. In: *Comprehensive Textbook of Psychiatry, VII edition* (V. Sadock and B. Sadock, Eds.), Williams & Wilkins, Baltimore, 2432-2435.
555. Kelsey JE and **Nemeroff CB**. 1999. Selective serotonin reuptake inhibitors: fluoxetine. In: *Comprehensive Textbook of Psychiatry, VII edition* (V. Sadock and B. Sadock, Eds.), Williams & Wilkins, Baltimore, 2438-2444.
556. Kelsey JE and **Nemeroff CB**. 1999. Selective serotonin reuptake inhibitors: fluvoxamine. In: *Comprehensive Textbook of Psychiatry, VII edition* (V. Sadock and B. Sadock, Eds.), Williams & Wilkins, Baltimore, 2444-2446.
557. Kelsey JE and **Nemeroff CB**. 1999. Selective serotonin reuptake inhibitors: sertraline. In: *Comprehensive Textbook of Psychiatry, VII edition* (V. Sadock and B. Sadock, Eds.), Williams & Wilkins, Baltimore, 2451-2455.
558. Kelsey JE and **Nemeroff CB**. 1999. Selective serotonin reuptake inhibitors: paroxetine. In: *Comprehensive Textbook of Psychiatry, VII edition* (V. Sadock and B. Sadock, Eds.), Williams & Wilkins, Baltimore, 2447-2451.
559. Musselman DL, Evans DL and **Nemeroff CB**. 1998. The relationship of depression to cardiovascular disease: epidemiology, biology, treatment. *Arch Gen Psychiat* 55:580-592.
560. Heuser I, Bissette G, Dettling M, Schweiger U, Gotthardt U, Schmider J, Lammers C-H, **Nemeroff CB** and Holsboer F. 1998. Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment. *Depression and Anxiety* 8:71-79.

561. Mandell AJ, Owens MJ, Selz KA, Morgan WN, Shlesinger MF and **Nemeroff CB**. 1998. Mode matches in hydrophobic free energy eigenfunctions predict peptide-protein interactions. *Biopolymers* 46:89-101.
562. Graham Y, Heim C, Goodman SH, Miller AH and **Nemeroff CB**. 1999. The effects of neonatal stress on brain development: implications for psychopathology. *Development and Psychopathology* 11:545-565.
563. Stowe ZN, Llewellyn A, Hostetter A and **Nemeroff CB**. 2000. The use of psychiatric medications during breastfeeding. In: *Mood Disorders in Women* (M. Steiner, K. Yonkers E. Eriksson, Eds.), 329-351.
564. **Nemeroff CB**. 1998. The neurobiology of depression. *Scientific American* 278:42-49.
565. McDaniel JS, Musselman DL and **Nemeroff CB**. 1998. Psychological distress and depression. In: *Clinical Oncology, 2nd Edition* (M.D. Abeloff, J.O. Armitage, A.S. Lichter and J.E. Niederhuber, Eds.), Churchill Livingstone, New York, 556-578.
566. Musselman DL and **Nemeroff CB**. 2000. Depression really does hurt your heart: stress, depression and cardiovascular disease. In: *The Biological Basis for Mind/Body Interactions. Progress in Brain Research* (E. Mayer and C. Saper, Eds.), Elsevier Press 122:43-60.
567. Bona JR, Fackler SM, Fendley MJ and **Nemeroff CB**. 1998. Neurosarcoidosis as a cause of refractory psychosis: complicated case report. *Am J Psychiat* 155:1106-1108.
568. Musselman DL, DeBattista C, Nathan KI, Kilts CD, Schatzberg AF and **Nemeroff CB**. 1998. Biology of Mood Disorders. In: *Textbook of Psychopharmacology, 2nd Edition* (A.F. Schatzberg and C.B. Nemeroff, Eds.), American Psychiatric Press, Washington DC, 549-588.
569. Radke JM, Owens MJ, Ritchie JC and **Nemeroff CB**. 1998. Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions. *Proceedings of the National Academy of Sciences, USA* 95:11462-11464.
570. Plotsky PM, Owens MJ and **Nemeroff CB**. 1998. *Psychoneuroendocrinology* of depression: hypothalamic-pituitary-adrenal axis. In: *Psychiatric Clinics of North America* (CB Nemeroff, Ed), WB Saunders, Philadelphia, 21:293-307.
571. Malison RT, Price LH, Berman R, van Dyck CJ, Pelton GH, Carpenter L, Sanacora G, Owens MJ, **Nemeroff CB**, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB and Charney DS. 1998. Reduced brain serotonin transporter availability in major depression as measured by [¹²³I]-2β-CIT SPECT. *Biol Psychiat* 44:1090-1098.
572. Arborelius L, Owens, MJ, Plotsky PM and **Nemeroff CB**. 1999. The role of corticotropin-releasing factor (CRF) in depression and anxiety disorders. *J Endocrinol* 160:1-12.
573. Musselman DL and **Nemeroff CB**. 1998. Depression and cardiovascular disease: increasing evidence of a connection. *Cardiovascular Reviews and Reports* 12:34-42.
574. Ninan PT, Rothbaum BO, Mansueto C, O'Sullivan RL and **Nemeroff CB**. 1998. Challenges in the classification and treatment of trichotillomania. *CNS Spectrums* 3:30-35.

575. Ladd CO, Huot RL, Thirivikraman KV, **Nemeroff CB**, Meaney MJ and Plotsky PM. 2000. Long-term behavioral and neuroendocrine adaptations to adverse early experience. In: *The Biological Basis for Mind/Body Interactions. Progress in Brain Research* (E.A. Mayer and C. Saper, Eds.), Elsevier Press, Amsterdam 122:81-103.
576. Musselman DL, McDaniel JS, Porter MR and **Nemeroff CB**. 1999. Screening for depression in the medical setting. *Journal of the Medical Association of Georgia* 2:47-53.
577. DeVane CL and **Nemeroff CB**. 1998. Guide to psychotropic drug interactions. *Primary Psychiatry* 5:36-75.
578. Dinan TG, Kelsey JE and **Nemeroff CB**. 1998. Selective serotonin reuptake inhibitors: clinical use and experience. In: *Schizophrenia and Mood Disorders: the New Drug Therapies in Clinical Practice* (P. Buckley and J. Waddington, Eds.), Butterworth-Heinemann, 100-108.
579. Kinkead B, Binder E and **Nemeroff CB**. 1999. Does neurotensin mediate the effects of antipsychotic drugs? *Biol Psychiat* 46:340-351.
580. DeVane CL and **Nemeroff CB**. 1999. Psychotropic drug interactions. In: *Psychiatric Treatment of the Medically Ill* (R.G. Robinson and W.R. Yates, Eds.), Marcel Dekker, Inc., New York, 523-543.
581. **Nemeroff CB**. 1999. The preeminent role of early untoward experience on vulnerability to major psychiatric disorders: the nature-nurture controversy revisited and soon to be resolved. News and Views, *Molecular Psychiatry* 4:106-108.
582. VanSant SP, Risby ED and **Nemeroff CB**. 1999. Stress, hormones and aging. In: *Endocrinology of Aging* (J.E. Morley, Ed.), 63-71.
583. Bissette G, Cook L, Smith W, Dole KC, Crain B and **Nemeroff CB**. 1998. Regional neuropeptide pathology in Alzheimer's disease: corticotropin-releasing factor and somatostatin. *J Alzheimer's Disease* 1:91-105.
584. McDonald WM, Tupler LA, Marsteller FA, Figiel GS, DiSouza, **Nemeroff CB** and Krishnan KRR. 1999. Hyperintense lesions on magnetic resonance images in bipolar disorder. *Biol Psychiat* 45:965-971.
585. Goodman MM, Chen P, Plisson C, Martarello L, Galt J, Votaw JR, Kilts CD, Malveux G, Camp VM, Shi B, Ely TD, Howell H, McConathy J and **Nemeroff CB**. 2003. Synthesis and characterization of iodine-123 labeled 2 β -carbomethoxy-3 β -(4-((Z)-2-iodoethenyl) phenyl) nortropane. A ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography. *J Med Chem* 46:925-935.
586. **Nemeroff CB**, Kilts CD and Berns GS. 1999. Functional brain imaging: 21st century phrenology or psychobiological advance for the millennium. Editorial, *Am J Psychiat* 156:671-673.
587. Ressler KJ and **Nemeroff CB**. 1999. Role of norepinephrine in the pathophysiology and treatment of mood disorders. *Biol Psychiat* 46:1219-1233.

588. Kelsey JE and **Nemeroff CB**. 1999. Selective serotonin reuptake inhibitors: citalopram. In: *Comprehensive Textbook of Psychiatry, VII edition* (V. Sadock and B. Sadock, Eds.), Williams & Wilkins, Baltimore, 2435-2438.
589. Heim C and **Nemeroff CB**. 1999. The impact of early adverse experiences on brain systems involved in anxiety and affective disorders. *Biol Psychiat* 46:1509-1522.
590. Stowe ZN, Cohen LS, Hostetter AM, Ritchie JC, Owens MJ and **Nemeroff CB**. 2000. Paroxetine in human breast milk and nursing infants. *Am J Psychiat* 157:185-189.
591. Berns GS and **Nemeroff CB**. 1999. The neurobiology of bipolar disorder. *Odyssey* 5:36-41.
592. **Nemeroff CB** and Owens MJ. 2001. Contribution of modern neuroscience to developing new treatments for psychiatric disorders. In: *Treatment of Depression: Bridging the 21st Century* (M. Weissman, Ed.), APA Press, Washington DC, 61-81.
593. Kinkead B, Binder EB and **Nemeroff CB**. 2000. Olanzapine and neurotensin. In: *Olanzapine (Zyprexa) – A Novel Antipsychotic* (P.V. Tran, F. Bymaster, N. Tye, J. Herrera, A. Breier and G. Tollefson, Eds.), Lippincott Williams & Wilkins Healthcare, Philadelphia, 197-213.
594. Owens MJ and **Nemeroff CB**. 1999. Corticotropin-releasing factor antagonists: therapeutic potential in the treatment of affective disorders. *CNS Drugs* 12:85-92.
595. Ehlers CL, Somes C, Li T-K, Lumeng L, Kinkead B, Owens MJ and **Nemeroff CB**. 1999. Neurotensin studies in alcohol naive, preferring and non-preferring rats. *Neurosci* 93:227-236.
596. Gumnick J and **Nemeroff CB**. 2000. Problems with currently available antidepressants. *J Clin Psychiat* 61:5-15.
597. Anand KJS, Coskun V, Thiruvikraman KV, **Nemeroff CB** and Plotsky, PM. 1999. Long-term behavioral effects of repetitive pain in neonatal rat pups. *Physiol Behav* 66:627-637.
598. **Nemeroff CB**. 2000. Neuroendocrinology. In: *New Oxford Textbook of Psychiatry* (M.G. Gelder, J.J. Lopez-Ibor and N.C. Andreasen, Eds.), Oxford University Press, New York, New York 1:181-188.
599. **Nemeroff CB**. 1999. The preeminent role of neuropeptide systems in the early pathophysiology of Alzheimer's disease: up with CRF, down with acetylcholine. *Arch Gen Psychiat* 56:991-992.
600. Owens MJ and **Nemeroff CB**. 1999. Corticotropin-releasing factor antagonists in affective disorders. *Expert Opinion on Investigational Drugs* 8:1849-1858.
601. O'Brien D, Skelton KH, Owens MJ and **Nemeroff CB**. 2001. Are CRF receptor antagonists potential antidepressants? *Human Psychopharmacol* 16:81-87.
602. Owens MJ, Knight DL and **Nemeroff CB**. 2000. Paroxetine binding to the rat norepinephrine transporter in vivo. *Biol Psychiat* 47:842-845.

603. Vythilingam M, Anderson GM, Owens MJ, Halaszynski TM, Bremner JD, Carpenter LL, Heninger GR, **Nemeroff CB** and Charney DS. 2000. Cerebrospinal fluid corticotropin-releasing hormone (CRH) in healthy humans: effects of yohimbine and naloxone. *J Clin Endocrinol Metab* 85:4138-4145.
604. Newport DJ and **Nemeroff CB**. 2000. Neurobiology of posttraumatic stress disorder. *Current Opinion in Neurobiology* 10:211-218.
605. Ressler KJ and **Nemeroff CB**. 2001. Peptides and psychiatry. In: *International Encyclopedia of the Social & Behavioral Sciences* (N.J. Smelser and P.B. Baltes, Eds.), Pergamon, Oxford, 11189-11195.
606. Skelton KH, **Nemeroff CB**, Knight DL and Owens MJ. 2000. Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems. *J Neurosci* 20:1240-1248.
607. Ninan PT, McElroy SL, Kane CP, Knight BT, Casuto LS, Rose SE, Marsteller FA and **Nemeroff CB**. 2000. Placebo-controlled study of fluvoxamine in the treatment of patients with compulsive buying. *J Clin Psychopharmacol* 20:362-366.
608. Musselman DL, McDonald W and **Nemeroff CB**. 2000. Effects of mood and anxiety disorders on the cardiovascular system. In: *Hurst's The Heart, 10th Edition* (V. Fuster, R.W. Alexander and R.A. O'Rourke, Eds.), McGraw-Hill Publishers, 2227-2250.
609. **Nemeroff CB** and Musselman DL. 2000. Are platelets the link between depression and ischemic heart disease? *Am Heart Journal* 140:S57-62.
610. Heim C, Newport DJ, Heit S, Graham YP, Wilcox M, Bonsall R, Miller AH and **Nemeroff CB**. 2000. Pituitary-adrenal and autonomic responses to stress in adult women after sexual and physical abuse in childhood. *JAMA* 284:592-597.
611. Garlow SJ and **Nemeroff CB**. 2003. Neurobiology of depressive disorders. In: *Handbook of Affective Sciences* (R.J. Davidson K.R. Scherer and H.H. Goldsmith, Eds.), Oxford University Press, 1021-1043.
612. Arborelius L and **Nemeroff CB**. 2002. Preclinical models of anxiety. In: *Textbook of Anxiety* (D. Stein and E. Hollander, Eds.), American Psychiatric Publishing, 29-42.
613. Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, **Nemeroff CB**, Russell JM, Thase ME, Trivedi MH and Zajecka J. 2000. A comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination for treatment of chronic depression. *New Engl J Med* 342:1462-1470.
614. Newport DJ, Stowe ZN and **Nemeroff CB**. 2002. Parental depression: animal models of an adverse life event. *Am J Psychiat* 159:1265-1283.
615. Thivikraman KV, **Nemeroff CB** and Plotsky PM. 2000. Sensitivity to glucocorticoid-mediated fast-feedback regulation of the hypothalamic-pituitary-adrenal axis is dependent upon stressor specific neurocircuitry. *Brain Res* 870:87-101.

616. Kaufman J, Plotsky PM, **Nemeroff CB** and Charney D. 2000. Effects of early adverse experiences on brain structure and function: clinical implications. *Biol Psychiat* 48:778-790.
617. Coplan JD, Smith ELP, Trost RC, Scharf BA, Altemus M, Bjornson L, Owens MJ, Gorman JM **Nemeroff CB** and Rosenblum LA. 2000. Growth hormone response to clonidine in adversely reared young adult primates: relationship to serial cerebrospinal fluid corticotropin-releasing-factor concentrations. *Psychiatric Res* 95:93-102.
618. Bouwer C, Claassen J, Dinan TG and **Nemeroff CB**. 2000. Prednisone augmentation in treatment-resistant depression with fatigue and hypocortisolemia: a case series. *Depression and Anxiety* 12:44-50.
619. Musselman DL, Marzec UM, Manatunga A, Penna S, Reemsnyder A. Knight BT, Baron A, Hanson SR and **Nemeroff CB**. 2000. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. *Arch Gen Psychiat* 57:875-882.
620. Newport DJ and **Nemeroff CB**. 2002. Stress. In: *Encyclopedia of the Human Brain* (V.S. Ramachandran, Ed.), Elsevier Science, Vol. 4, 449-462.
621. Ressler KJ and **Nemeroff CB**. 2000. The role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. *Depression and Anxiety* 12:2-19.
622. Kinkead B, Shahid S, Owens MJ and **Nemeroff CB**. 2000. Effects of acute and subchronic administration of typical and atypical antipsychotic drugs on the neurotensin system of the rat brain. *J Pharmacol Exp Ther* 295:67-73.
623. Kinkead B, Lorch SM, Owens MJ and **Nemeroff CB**. 2000. Sex- and estrous cycle-related differences in the effects of acute antipsychotic drug administration on neurotensin-containing neurons in the rat brain. *J Pharmacol Exp Ther* 295:205-211.
624. Gutman DA, Owens MJ and **Nemeroff CB**. 2000. Corticotropin-releasing factor antagonists as novel psychotherapeutics. *Drugs of the Future* 25:923-931.
625. Stout SC, Owens MJ and **Nemeroff CB**. 2001. Neurokinin₁ receptor antagonists as potential antidepressants. *Annu Rev of Pharmacol and Toxicol* 41:877-906.
626. Skelton KH and **Nemeroff CB**. 2000. A comparison of plasma alprazolam concentrations following different routes of chronic administration in the Sprague-Dawley rat: implications for psychotropic drug research. *Psychopharmacol* 151:72-76.
627. Raison CL and **Nemeroff CB**. 2000. Cancer and depression: prevalence, diagnosis and treatment. *Home Health Consultant* 7; 9:34-41.
628. Berger J, Compton MT and **Nemeroff CB**. 2001. Treating the depressed suicidal patient. *Directions in Psychiatry* 21:33-43.
629. **Nemeroff CB**, Compton MT, and Berger J. 2001. The depressed suicidal patient assessment and treatment. *Ann N Y Acad Sci* 932:1-23.
630. **Nemeroff CB**. 2000. Unmet needs in depression. *Family Practice Recertification*, 10:3-7.

631. Compton MT, Raison CL and **Nemeroff CB**. 2003. Affective disorders: depression and mania. In: *Encyclopedia of Cognitive Science* (L. Nadel Ed.), Macmillan Reference Ltd., London, 1:51-57.
632. Stout SC, Mortas P, Owens MJ, **Nemeroff CB** and Moreau JL. 2000. Increased corticotropin-releasing factor concentrations in the bed nucleus of the stria terminalis of anhedonic rats. *Eur J Pharmacol* 401:39-46.
633. **Nemeroff CB**. 2000. An ever-increasing pharmacopoeia for the management of patients with bipolar disorder. *J Clin Psychiat* 61:19-25.
634. Stout SC, Owens MJ, Lindsey KP, Knight DL and **Nemeroff CB**. 2001. Effects of sodium valproate on corticotropin-releasing factor systems in rat brain. *Neuropsychopharmacol* 24:624-631.
635. Skelton KH, Owens MJ and **Nemeroff CB**. 2000. The neurobiology of urocortin. *Regulatory Peptides* 93:85-92.
636. Radke JM, Owens MJ and **Nemeroff CB**. 2001. The effects of glutamate receptor agonists on neurotensin release using *in vivo* microdialysis. *Eur J Pharmacol* 411:129-134.
637. Binder EB, Kinkead B, Owens MJ, Kilts CD and **Nemeroff CB**. 2001. Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. *J Neurosci* 21:601-608.
638. Montgomery SA, Schatzberg AF, Guelfi JD, Kasper S, **Nemeroff CB**, Swann A, Zajecka S. 2000. Pharmacotherapy of depression and mixed states in bipolar disorder. *J Affect Dis* 59:S39-S56.
639. **Nemeroff CB**, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, Oakes R and Pitts CD. 2001. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. *Am J Psychiat* 158:906-12.
640. Musselman DL, Lawson DH, Gumnick JF, Manatunga A, Penna S, Goodkin R, Greiner K, **Nemeroff CB** and Miller AH. 2001. Paroxetine for the prevention of depression induced by high dose interferon-alfa. *N Engl J Med* 344:961-966.
641. Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S, Pearce BD, Landry J, Glover S, McDaniel JS and **Nemeroff CB**. 2001. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. *Am J Psychiat* 158:1252-1257.
642. Heim C, Newport DJ, Bonsall R, Miller AH and **Nemeroff CB**. 2001. Altered pituitary-adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse. *Am J Psychiat* 158:575-581.
643. Schatzberg AF, Garlow SJ and **Nemeroff CB**. 2002. Molecular and cellular mechanisms in depression. In: *Neuropsychopharmacology, The Fifth Generation of Progress* (D.S. Charney, J.T. Coyle, K.L. Davis and C.B. Nemeroff, Eds.), 1039-1050.

644. Boswell EB, Anfinson TJ and **Nemeroff CB**. 2002. Neuropsychiatric aspects of endocrine disorders. In: *Textbook of Neuropsychiatry and Clinical Neurosciences, 4th Edition* (S. Yudofsky and R. Hales, Eds.), American Psychiatric Association Press, Inc. Washington, DC, 851-875.
645. Kinkead B, Owens MJ, and **Nemeroff CB**. 2000. The effects of acute antipsychotic drug administration on the neurotensin system of the developing rat brain. *Dev Brain Res* 124:1-10.
646. Binder EB, Kinkead B and **Nemeroff CB**. 2001. Neuropeptides. In: *Current Issues in the Psychopharmacology of Schizophrenia* (A. Brier, P.V. Tran, J. Herrera, F. Bymaster, G. Tollefson, Eds.), Lippincott Williams & Wilkins, Baltimore MD, 349-371.
647. Kujawa MJ and **Nemeroff CB**. 2000. The biology of bipolar disorder. In: *Bipolar Disorders: 100 years after manic-depressive insanity* (A. Marneros and J. Angst, Eds.), Kluwer Academic Publishers, Great Britain, 281-314.
648. Cummins TK, Anand KJS and **Nemeroff CB**. 2002. Developmental Psychoneuroendocrinology. In: *Child and Adolescent Psychiatry: A Comprehensive Textbook, 3rd Edition* (M. Lewis, Ed.), Lippincott Williams & Wilkins, Baltimore, 93-119.
649. Owens MJ, Knight DL and **Nemeroff CB**. 2001. Second generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. *Biol Psychiat* 50:345-350.
650. DeVane CL and **Nemeroff CB**. 2001. An evaluation of risperidone drug interactions. *J Clin Psychopharmacol* 21:408-416.
651. DeVane CL and **Nemeroff CB**. 2001. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. *Clin Pharmacokinetics* 40:509-522.
652. Martarello L, Kilts CD, Ely T, Owens MJ, **Nemeroff CB**, Camp M and Goodman MM. 2001. Synthesis and characterization of fluorinated and iodinated pyrrolopyrimidines as PET/SPECT ligands for the CRF1 receptor. *Nuclear Med and Biol* 28:187-195.
653. Compton M and **Nemeroff CB**. 2001. The evaluation and treatment of depression in primary care. *Clin Cornerstone* 3:10-22.
654. Heim C and **Nemeroff CB**. 2001. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. *Biol Psychiat* 49:1023-1039.
655. Heim C and **Nemeroff CB**. 2002. Neurobiology of early-life stress and its disorders. In: *Textbook of Pediatric Psychopharmacology* (A. Martin, L. Scahill, D. Charney and J.F. Leckman, Eds.), Oxford University Press 110-124.
656. **Nemeroff CB** and Gutman DA. 2002. Neuroendocrinological research in psychiatry. In: *Psychiatry as a Neuroscience* (J.J. Lopez-Ibor, W. Gaebel, M. Maj and N. Sartorius, Eds.) John Wiley & Sons 91-124.
657. Gutman DA and **Nemeroff CB**. 2002. Neuroendocrinology. In: *Biological Psychiatry* (H. D'haenen, J.A. den Boer and P. Willner, Eds.), John Wiley & Sons, 97-110.

658. Gutman DA, Owens MJ and **Nemeroff CB**. 2001. CRF receptor antagonists: a new approach to the treatment of depression. *Pharmaceutical News* 8:18-25.
659. Newport DJ and **Nemeroff CB**. 2001. Hypothalamic-pituitary-adrenal axis: normal physiology and disturbances in depression. In: *Physical Consequences of Depression* (J. Thakore, Ed.), Wrightson Biomedical Publishing, Ltd, Great Britain, 1-22.
660. Rosenblum LA, Smith ELP, Altemus M, Scharf BA, Owens MJ, **Nemeroff CB**, Gorman JM and Coplan JD. 2002. Differing concentrations of corticotropin-releasing factor and oxytocin in the cerebrospinal fluid of bonnet and pigtail macaques. *Psychoneuroendocrinology* 27:651-660.
661. Charney DS, **Nemeroff CB** and the NDMDA Consensus Development Panel. 2002. National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. *Arch Gen Psychiat* 59:262-270.
662. Sharma RP, Martis B, Jonalagada J, Bissette G and **Nemeroff CB**. 2001. CSF thyrotropin-releasing hormone concentrations differ in patients with schizoaffective disorder from patients with schizophrenia or mood disorders. *J Psychiat Res* 35:287-291.
663. Coplan JD, Smith ELP, Altemus M, Scharf BA, Owens MJ, **Nemeroff CB**, Gorman JM and Rosenblum LA. 2001. Variable foraging demand rearing: sustained elevations in cisternal cerebrospinal fluid corticotropin-releasing factor concentrations in adult primates. *Biol Psychiat* 50:200-204.
664. Hirschfeld RMA, Dunner DL, Keitner G, Klein DN, Koran LM, Kornstein SG, Markowitz J, Miller I, **Nemeroff CB**, Ninan PT, Rush AJ, Schatzberg AF, Thase ME, Trivedi MH, Borian FE, Crits-Christoph P and Keller MB. 2002. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. *Biol Psychiat* 51:123-133.
665. **Nemeroff CB** and Schatzberg AF. 2002. Pharmacological treatment of unipolar depression. In: *A Guide to Treatments That Work, 2nd Edition* (P.E. Nathan and J.M. Gorman, Eds.), Oxford University Press, New York, 229-243.
666. Capuron L, Gumnick JF, Musselman DL, Lawson D, Reemsnyder A, **Nemeroff CB** and Miller AH. 2002. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. *Neuropsychopharmacol* 26:643-652.
667. Ressler KJ and **Nemeroff CB**. 2001. Role of norepinephrine in the pathophysiology of neuropsychiatric disorders. *CNS Spectrums* 6:663-670.
668. Marcin MS and **Nemeroff CB**. 2003. The neurobiology of social anxiety disorder: the relevance of fear and anxiety. *Acta Psychiatr Scand* 108:51-64.
669. Binder EB, Kinkead B, Owens MJ and **Nemeroff CB**. 2001. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs. *Biol Psychiat* 50:856-872.
670. Binder EB, Kinkead B, Owens MJ and **Nemeroff CB**. 2001. Neurotensin and dopamine interactions. *Pharmacol Rev* 53:453-486.

671. Percy A and **Nemeroff CB**. 2001. Chromosome 22q and the mind-brain interface: bedside to bench to bedside. *Neurology* 57:377-378.
672. **Nemeroff CB**. 2001. Progress in the Battle with the Black Dog: Advances in the Treatment of Depression. Editorial, *Am J Psychiat* 158:1555-1557.
673. **Nemeroff CB**. 2002. Comorbidity of mood and anxiety disorders: the rule, not the exception? Editorial, *Am J Psychiat* 159:3-4.
674. Heim C, Newport DJ, Wagner D, Wilcox MS, Miller AH and **Nemeroff CB**. 2002. The role of early adverse experience and adulthood stress in the prediction of neuroendocrine stress reactivity in women: a multiple regression analysis. *Depression & Anxiety* 15:117-125.
675. Kinkead B and **Nemeroff CB**. 2002. Neurotensin: an endogenous antipsychotic? Current Opinion in Pharmacology 2:99-103.
676. Gutman DA and **Nemeroff CB**. 2002. Neurobiology of early life stress: rodent studies. *Seminars in Clinical Neuropsychiatry* 7:89-95.
677. **Nemeroff CB** and Putnam JS. 2005. Anticholinergics and amantadine. In: *Comprehensive Textbook of Psychiatry, Eighth Edition* (B. Sadock and V. Sadock, Eds.), Lippincott, Williams & Wilkins, 2727-2731.
678. Musselman DL, Marzec U, Davidoff M, Manatunga AM, Gao F, Reemsnyder A, Duggirala S, Larsen H, Taylor RW, Hanson and **Nemeroff CB**. 2002. Platelet activation and secretion in patients with major depression, thoracic aortic atherosclerosis, or renal dialysis treatment. *Depression and Anxiety* 15:91-101.
679. **Nemeroff CB**. 2002. Recent advances in the neurobiology of depression. *Psychopharmacol Bull* 36:6-23.
680. Stout SC, Owens MJ and **Nemeroff CB**. 2002. Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. *J Pharmacol Exp Ther* 300:1085-1092.
681. Coyle, JT, Pine DS, Charney, DS, Lewis L, **Nemeroff CB**, Carlson GA, Joshi PT, Reiss D, Todd RD, Hellander M and the Depression and Bipolar Support Alliance Consensus Development Panel. 2003. Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in children and adolescents. *J Am Acad Child Adolesc Psychiat* 42:1494-1503.
682. Davidson JT, **Nemeroff CB** and the Hypericum Depression Trial Study Group. 2002. Effect of hypericum perforatum (St. John's Wort) in major depressive disorder: a randomized controlled trial. *JAMA* 287:1807-1814.
683. Heim C and **Nemeroff CB**. 2002. Neurobiology of early life stress: clinical studies. *Seminars in Clin. Neuropsychiat* 7:147-159.
684. Golden RN, **Nemeroff CB**, McSorley P, Pitts CD and Dube EM. 2002. Efficacy and tolerability of controlled release and immediate release paroxetine in the treatment of depression. *J Clin Psychiat* 63:577-584.

685. Gutman DA, Musselman DL and **Nemeroff CB**. 2003. Neuropeptide alterations in depression and anxiety disorders. *In: Handbook of Depression and Anxiety*, 2nd edition, (S Kasper, JA denBoer, and JM AdSitsen, eds), Marcel Dekker, Inc. 229-265.
686. Ressler KJ and **Nemeroff CB**. 2003. Depression. *In: The Molecular and Genetic Basis of Neurologic and Psychiatric Disease*, 3rd edition. (RN Rosenberg, SB Prusiner, S DiMauro, RL Barchi and EJ Nestler, Eds), Butterworth-Heinemann, Philadelphia, 725-740.
687. Ritchie JC, Davis TP and **Nemeroff CB**. 2003. Action of three ectopeptidases on corticotropin-releasing factor: metabolism and functional aspects. *Neuropsychopharmacol* 28:22-33.
688. Tamminga CA and **Nemeroff CB**, Blakeley RD, Brady L, Carter CS, Davis KL, Dingledine R, Gorman JM, Grigoriadis D, Henderson D, Innis R, Killen J, Langhren TP, McDonald WM, Murphy G, Paul SM, Rudorfer M, Sausville E, Schatzberg A, Scolnick E and Suppes T. 2002. Developing novel treatments for mood disorders: accelerating discovery. *Biol Psychiat* 52:589-609.
689. Hamid EH, Hyde TM, Egan MF, Wolf SS, Herman MM, **Nemeroff CB** and Kleinman JE. 2002. Neurotensin receptor binding abnormalities in the entorhinal cortex in schizophrenia and affective disorders. *Biol Psychiat* 51:795-800.
690. Wang X and **Nemeroff CB**. 2003. Biological distinction between unipolar and bipolar disorder. *In: Handbook of Medical Psychiatry*, (JC Soares and S Gershon, eds), Marcel Dekker, Inc, New York, 407-422.
691. Heim C, Meinlschmidt G and **Nemeroff CB**. 2003. The neurobiology of early-life stress and its relationship to PTSD. *Psychiatric Annals* 33:18-26
692. Vythilingam M, Heim C, Newport DJ, Miller AH, Anderson E, Vermetten E, Bronen R, Staib L, Charney DS, **Nemeroff CB** and Bremner JD. 2002. Childhood trauma associated with smaller hippocampal volume in women with major depression. *Am J Psychiat* 159:2072-2080.
693. Gilmor M, Owens MJ and **Nemeroff CB**. 2002. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. *Am J Psychiat* 159:1702-1710.
694. **Nemeroff CB**, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y and Tran PV. 2002. Duloxetine for the treatment of major depressive disorder. *Psychopharmacol Bull* 36:106-132.
695. **Nemeroff CB**. 2002. New directions in the development of antidepressants: the interface of neurobiology and psychiatry. *Hum Psychopharmacol Clin Exp* 17:S13-S16.
696. **Nemeroff CB**. 2003. Safety of available agents used to treat bipolar disorders: focus on weight gain. *J Clin Psychiat* 64:532-539.
697. Newport DJ, Heim C, Owens MJ, Ritchie JC, Ramsey C, Bonsall R, Miller AH and **Nemeroff CB**. 2003. Cerebrospinal fluid corticotropin-releasing factor (CRF) and vasopressin concentrations predict pituitary response in the CRF stimulation test: a multiple regression analysis. *Neuropsychopharmacol* 28:569-576.

698. Hirschfeld RMA, Montgomery SA, Aguglia E, Amore M, Delgado P, Gastpar M, Hawley C, Kasper S, Linden M, Massana J, Mendlewicz J, Moller HJ, **Nemeroff CB**, Saiz J, Such P, Torta R and Versiani, M. 2002. Partial response and non-response to antidepressant therapy: current approaches and treatment options. *J Clin Psychiat* 63:826-837.
699. Garlow SJ and **Nemeroff CB**. 2004. The neurochemistry of depressive disorders: clinical studies. In: *Neurobiology of Mental Illness, Oxford University Press, 2nd Edition* (D.S. Charney and E. Nestler, Eds.), 440-460.
700. **Nemeroff CB** and Owens MJ. 2002. Treatment of mood disorders. *Nature Neurosci*, Suppl 5:1068-1070.
701. Schlaepfer TE, Kosel M and **Nemeroff CB**. 2003. Efficacy of repetitive transcranial magnetic stimulation (rTMS) in the treatment of affective disorders. *Neuropsychopharmacol* 28:201-205.
702. **Nemeroff CB** and Putnam JS. 2005. α_2 -Adrenergic receptor agonists: clonidine and guanfacine. In: *Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Eighth Edition* (B. Sadock and V. Sadock, Eds.), Lippincott Williams & Wilkins, 2718-2722.
703. **Nemeroff CB** and Putnam JS. 2005. β -adrenergic receptor antagonists. In: *Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Eighth Edition* (B. Sadock and V. Sadock, Eds.), Lippincott Williams & Wilkins, 2722-2727.
704. **Nemeroff CB** and Putnam JS. 2005. Antihistamines. In: *Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Eighth Edition* (B. Sadock and V. Sadock, Eds.), Lippincott Williams & Wilkins, 2772-2775.
705. **Nemeroff CB** and Putnam JS. 2005. Barbiturates and similarly acting substances. In: *Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Eighth Edition* (B. Sadock and V. Sadock, Eds.), Lippincott Williams & Wilkins. 2775-2781.
706. Binder EB, Gross RE, **Nemeroff CB** and Kilts CD. 2002. Effects of neurotensin receptor antagonism on latent inhibition in Sprague-Dawley rats. *Psychopharmacol* 161:288-295.
707. **Nemeroff CB**. 2003. Anxiolytics: past, present, and future agents. *J Clin Psychiat* 64:3-6.
708. Gutman DA, Owens MJ, Skelton KH, Thiruvikraman KV and **Nemeroff CB**. 2003. The CRF₁ receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. *J Pharmacol Exp Therapeut* 304:874-880.
709. Purselle DC and **Nemeroff CB**. 2003. The serotonin transporter: a potential substrate in the biology of suicide. *Neuropsychopharmacol* 28:613-619.

710. Gyulai L, Bowden CL, McElroy SL, Calabrese JR, Petty F, Swann AC, Chou JC-Y, Wassef A, Risch CS, Hirschfeld RMA, **Nemeroff CB**, Keck PE, Evans DL and Wozniak PJ. 2003. Maintenance efficacy of divalproex in the prevention of bipolar depression. *Neuropsychopharmacol* 28:1374-1382.
711. Penza KM, Heim C and **Nemeroff CB**. 2003. Neurobiological effects of childhood abuse: implications for the pathophysiology of depression and anxiety. *Arch Women's Ment Health* 6:15-22.
712. **Nemeroff CB**, Kinkad B and Goldstein J. 2002. Quetiapine: preclinical studies, pharmacokinetics, drug interactions and dosing. *J Clin Psychiat* 63:5-11.
713. Kinkad B and **Nemeroff CB**. 2003. Neurotensin. In: *Encyclopedia of Neuroscience, 3rd Edition* (G. Adelman and B.H. Smith, Eds.), Elsevier Press
714. Berns GS and **Nemeroff CB**. 2003. The neurobiology of bipolar disorder. *Amer J Medical Genetics* 123C:76-84.
715. Mathew SJ, Coplan JD, Smith EL, Scharf BA, Owens MJ, **Nemeroff CB**, Mann JJ, Gorman JM and Rosenblum LA. 2002. Cerebrospinal fluid concentrations of biogenic amines and corticotropin-releasing factor in adolescent non-human primates as a function of the timing of adverse early rearing. *Stress* 5:185-193.
716. Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P, Sommerville KW and **Nemeroff CB**. 2003. Divalproex in the treatment of impulsive aggression: efficacy in Cluster B personality disorders. *Neuropsychopharmacol* 28:1186-1197.
717. Young LJ, Owens MJ and **Nemeroff CB**. 2005. Neuropeptides: biology, regulation and role in neuropsychiatric disorders. In: *Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Eighth Edition* (B. Sadock and V. Sadock, Eds.), Lippincott, Williams and Wilkins, 72-84.
718. Owens MJ and **Nemeroff CB**. 2003. Neuropharmacology of paroxetine. *Psychopharm Bull* 37:8-18.
719. Gilmor ML, Skelton KH, **Nemeroff CB** and Owens MJ. 2003. The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systems. *J Pharmacol Exp Therapeut* 305:434-439.
720. Stowe ZN, Hostetter AL, Owens MJ, Ritchie JC, Sternberg K, Cohen LS and **Nemeroff CB**. 2003. The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. *J Clin Psychiat* 64:73-80.
721. Capuron L, Raison CL, Musselman DL, Lawson DH, **Nemeroff CB** and Miller AH. 2003. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. *Am J Psychiat* 160:1342-1345.
722. McConathy J, **Nemeroff CB** and Owens MJ. 2004. Chiral antidepressants: single enantiomers versus mixtures of enantiomers. *Essential Psychopharmacol* 5:297-306.

723. Musselman DL and **Nemeroff CB**. 2003. *Neuropeptides* and hypothalamic releasing factors in psychiatric illness. In: *Psychoneuroendocrinology: The Scientific Basis of Clinical Practice* (O.M. Wolkowitz and A.J. Rothschild, Eds.), American Psychiatric Press, 29-82.
724. **Nemeroff CB**. 2003. Unmet needs and the neurobiology of depression. *Mental Fitness* 2:26-32.
725. **Nemeroff CB**. 2003. Improving antidepressant adherence. *J Clin Psychiat* 64(suppl 18):25-30.
726. **Nemeroff CB**. 2003. Overview of the safety of citalopram. *Psychopharmacol Bull* 37:96-121.
727. Goldberg S, Levitan RD, Leung E, Masellis M, Basile VS, **Nemeroff CB** and Atkinson L. 2003. Cortisol Concentrations in 12- to 18-Month-Old Infants: Stability over Time, Location, and Stressor. *Biol Psychiat* 54:719-726.
728. Serebruany VL, Glassman AH, Malinin AI, **Nemeroff CB**, Musselman DL, vanZyl, LT, Finkel MS, Krishnan KRR, Gaffney M, Harrison W, Califf RM and O'Connor CM. 2003. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) platelet substudy. *Circulation* 108:939-944.
729. Compton MT and **Nemeroff CB**. 2004. Depression and bipolar disorder. In: *ACP Medicine* (D.C. Dale and D.D. Federman, Eds.), WebMD, Inc., Vol 2:2543-2554; updated February 2006.
730. Rudisch B and **Nemeroff CB**. 2003. The epidemiology of comorbid coronary artery disease and depression. *Biol Psychiat* 54:227-240.
731. Keller MB, **Nemeroff CB** and Thase ME. 2003. Trends in the treatment of major depressive disorder and generalized anxiety disorder. *Psychopharm Bull*.
732. **Nemeroff CB**. 2003. Psychopharmacology in the new millennium. *Psychopharm Bull*.
733. Gutman DA and **Nemeroff CB**. 2003. Persistent central nervous system effects of an adverse early environment: clinical and preclinical studies. *Physiol Behav* 79:471-478.
734. Herr KD and **Nemeroff CB**. 2004. Paroxetine. In: *Textbook of Psychopharmacology, 3rd Edition* (A.F. Schatzberg and C.B. Nemeroff, Eds), American Psychiatric Publishing, 259-281.
735. Newport DJ, Heim C, Bonsall R, Miller AH and **Nemeroff CB**. 2004. Pituitary-adrenal responses to standard and low dose dexamethasone suppression tests in adult survivors of child abuse. *Biol Psychiat* 55:10-20.
736. McConathy J, Owens MJ, Kilts CV, Malveaux EJ, Camp VM, Votaw JR, **Nemeroff CB** and Goodman MM. 2004. Synthesis and biological evaluations of [¹¹C]talopram and [¹¹C]talsupram: candidate PET ligands for the norepinephrine transporter. *Nuclear Medicine and Biology* 31:705-718.
737. Kinkead B and **Nemeroff CB**. 2004. Neurotensin, schizophrenia and antipsychotic drug action. In: *Disorders of Synaptic Plasticity and Schizophrenia* (J. Smythies, Ed.), International Review of Neurobiology 59:327-349.

738. Vaishnavi SN, **Nemeroff CB**, Plott SJ, Rao SG, Kranzler J and Owens MJ. 2004. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. *Biol Psychiat* 55:320-322.
739. **Nemeroff CB**. 2003. The role of GABA in the pathophysiology and treatment of anxiety disorders. *Psychopharm Bull* 37:133-146.
740. Gutman DA, Owens MJ and **Nemeroff CB**. 2005. Corticotropin-releasing factor receptor and glucocorticoid receptor antagonists: new approaches to antidepressant treatment. In: *Current and Future Developments in Psychopharmacology* (J.A. denBoer, M.S. George and G.J. terHorst, Eds.), Benecke N.I., Amsterdam, The Netherlands, 133-158.
741. Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Marshall RD, **Nemeroff CB**, Shalev AY and Yehuda R. 2004. Consensus statement update on posttraumatic stress disorders from the International Consensus Group on Depression and Anxiety. *J Clin Psychiat* 65:55-62.
742. **Nemeroff CB**, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF, Ninan PT, McCullough JP, Weiss P, Dunner DL, Rothbaum BO, Kornstein S, Keitner G and Keller MB. 2003. Differential responses to psychotherapy versus pharmacotherapy in the treatment of patients with chronic forms of major depression and childhood trauma. *Proc Natl Acad Sci* 100:14293-14296.
743. **Nemeroff CB**. 2004. Neurobiological consequences of childhood trauma. *J Clin Psychiat* 65:18-28.
744. Capuron L, Neutrauer G, Musselman DL, Lawson DH, **Nemeroff CB**, Fuchs D and Miller AH. 2003. Interferon-alpha-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. *Biol Psychiat* 54:906-914.
745. Flores BH, Musselman DL, DeBattista C, Garlow SJ, Schatzberg AF and **Nemeroff CB**. 2004. Biology of Mood Disorders. In: *Textbook of Psychopharmacology, 3rd Edition* (A.F. Schatzberg and C.B. Nemeroff, Eds.), American Psychiatric Publishing, 717-763.
746. Carpenter LL, Tyrka AR, McDougle CJ, Malison RT, Owens MJ, **Nemeroff CB** and Price LH. 2004. Cerebrospinal fluid corticotropin-releasing factor and perceived early-life stress in depression patients and healthy control subjects. *Neuropsychopharmacol* 29:777-784.
747. Pomara N, Willoughby LM, Ritchie JC, Sidtis JJ, Greenblatt DJ and **Nemeroff CB**. 2004. Interdose elevation in plasma cortisol associated with tolerance development after chronic alprazolam administration in normal healthy elderly: a preliminary study. *Neuropsychopharmacol* 29:605-611.
748. Musselman DL, Rudisch B, McDonald WM and **Nemeroff CB**. 2004. Effects of mood and anxiety disorders on the cardiovascular system. In: *Hurst's the Heart, 11th Edition* (V. Fuster, R.W. Alexander and R.O. O'Rourke, Eds.), McGraw-Hill, 2189-2209.
749. Owens MJ and **Nemeroff CB**. 2003. Pharmacology of divalproex. *Psychopharmacol Bull* 37:17-24.

750. Heim C, Plotsky PM and **Nemeroff CB**. 2004. The importance of studying the contributions of early adverse experience to neurobiological findings in depression. *Neuropsychopharmacol* 29:641-648.
751. Arborelius L, Hawks BW, Owens MJ, Plotsky PP and **Nemeroff CB**. 2004. Increased responsiveness of 5-HT cell firing to citalopram in adult rats previously subjected to maternal deprivation. *Psychopharmacol* 176:248-255.
752. Penza KM, Heim C and **Nemeroff CB**. 2005. Loss and deprivation: from animal models to clinical presentation. In: *Biology of Depression: From Novel Insights to Therapeutic Strategies, Vol 2* (J. Licinio and M. Wong, Eds.), Wiley-VCH, 689-714.
753. Ladd CO, Huot RL, Thirivikraman KV, **Nemeroff CB** and Plotsky PM. 2004. Long-term adaptations in glucocorticoid receptor and mineralocorticoid receptor mRNA and negative feedback on the hypothalamo-pituitary-adrenal axis following neonatal maternal separation. *Biol Psychiat* 55:367-375.
754. **Nemeroff CB**. 2004. Advancing the treatment of mood and anxiety disorders: the first 10 years' experience with paroxetine. *Psychopharmacol Bull* 37:6-7.
755. Caceda R, Kinkead B and **Nemeroff CB**. 2003. Do neurotensin receptor agonists represent a novel class of antipsychotic drugs? *Seminars in Clinical Neuropsychiatry* 8:94-108.
756. **Nemeroff CB**. 2005. Use of atypical antipsychotics in refractory depression and anxiety. *J Clin Psychiat* 66(suppl 8):13-21.
757. Frick B, Capuron L, Schrocksnadel K, Musselman DL, Lawson DH, **Nemeroff CB**, Miller AH and Fuchs D. 2004. Plasma homocysteine and immune activation in patients with malignant melanoma undergoing treatment with Interferon- α . *J Interferon and Cytokine Res* 24:311-317.
758. Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, Naito S, Shimizu T, Itoh K, Inoue K, Suzuki T and **Nemeroff CB**. 2004. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. *Am J Psychiat* 161:1575-1580.
759. Penza K, Heim C and **Nemeroff CB**. 2004. Trauma and depression. In: *Handbook for the Social, Behavioral, and Biomedical Sciences, Women and Depression: Social, Political, and Economic Models of Risk* (C.L.M. Keyes and S.H. Goodman, Eds.) Cambridge University Press, 360-381.
760. Golden RN, Gaynes BN, Ekstrom RD, Hamer RM, Jacobsen FM, Suppes T, Wisner KL and **Nemeroff CB**. 2005. The efficacy of phototherapy in the treatment of mood disorders: a review and meta-analysis of the evidence. *Am J Psychiat* 162:656-662.
761. Tyrka AR, Carpenter LL, McDougale CJ, Kirwin PD, Owens MJ, **Nemeroff CB**, Strong DR and Price LH. 2004. Increased CSF corticotropin-releasing factor concentrations during tryptophan depletion in healthy adults. *Biol Psychiat* 56:531-534.
762. **Nemeroff CB** and Owens MJ. 2004. Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis. *CNS Spectrums* 9:23-31.

763. Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, Woolwine BJ, Jacobson IM, **Nemeroff CB** and Miller AH. 2005. Depressive symptoms and viral clearance in patients receiving interferon- α and ribavirin for Hepatitis C. *Brain Behav Immunity* 19:23-27.
764. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, **Nemeroff CB** and Miller AH. 2005. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. *J Clin Psychiat* 66:41-48.
765. Gillespie CF and **Nemeroff CB**. 2005. Hypercortisolemia and depression. *Psychosomatic Med* 1:S26-S28.
766. Bremner JD, Fani N, Ashraf A, Votaw JR, Brummer ME, Cummins T, Vaccarino V, Goodman MM, Reed L, Siddiq S and **Nemeroff CB**. 2005. Functional brain imaging alterations in acne patients treated with isotretinoin. *Am J Psychiat* 162:983-991.
767. Bremner JD, Mletzko T, Welter S, Siddiq S, Reed L, Williams C, Heim CM and **Nemeroff CB**. 2004. Treatment of post-traumatic stress disorder with phenytoin: an open label pilot study. *J Clin Psychiat* 65:1559-1564.
768. Binder EB, Kinkead B, Owens MJ and **Nemeroff CB**. 2004. The neurotensin receptor antagonist SR 142948A alters Fos expression and extrapyramidal side effect profile of typical and atypical antipsychotic drugs. *Neuropsychopharmacol* 29:2200-2207.
769. Lieberman JA, Greenhouse J, Hamer RM, Krishnan KRR, **Nemeroff CB**, Sheehan DV, Thase ME and Keller MB. 2005. Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. *Neuropsychopharmacol* 30:445-460.
770. Skelton KH, **Nemeroff CB** and Owens MJ. 2004. Spontaneous withdrawal from the triazolobenzodiazepine alprazolam increases cortical corticotropin-releasing factor mRNA expression. *J Neurosci* 24:9303-9312.
771. McElroy SL, Kotwal R, Malhotra S, Nelson EG, Keck PE and **Nemeroff CB**. 2004. Are mood disorders and obesity related? A review for the mental health professional. *J Clin Psychiat* 65:634-651.
772. Newport DJ, Owens MJ, Knight DL, Ragan K, Morgan N, **Nemeroff CB** and Stowe ZN. 2004. Alterations in platelet serotonin transporter binding in women with postpartum onset major depression. *J Psychiat Res* 38:467-473.
773. Sanchez MM, Noble PM, Lyon CK, Plotsky PM, Davis M, **Nemeroff CB** and Winslow JT. 2005. Alterations in diurnal cortisol rhythm and acoustic startle response in non-human primates with adverse rearing. *Biol Psychiat* 57:373-381.
774. Rush AJ, Trivedi MH, Carmody TJ, Ibrahim HM, Markowitz JC, Keitner GI, Kornstein SG, Arnow B, Klein DN, Manber R, Dunner DL, Gelenberg AJ, Kocsis JH, **Nemeroff CB**, Fawcett J, Thase ME, Russell JM, Jody DN, Borian FE and Keller MB. 2005. Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients. *Neuropsychopharmacol* 30:405-416.

775. Herr KD and **Nemeroff CB**. 2006. Paroxetine. In: *Essentials of Clinical Psychopharmacology, 2nd Edition* (A.F. Schatzberg and C.B. Nemeroff, Eds.), American Psychiatric Publishing, 59-87.
776. Claes SJ and **Nemeroff CB**. 2005. Corticotropin-releasing factor (CRF) and major depression: towards an integration of psychology and neurobiology in depression research. In: *The Theory and Treatment of Depression: Towards a Dynamic Interactionism Model* (J. Corveleyn, P. Luyten and S.J. Blatt, Eds.), Leuven University Press and Lawrence Erlbaum Associates, 227-252.
777. Garlow SJ, Boone E, Li W, Owens MJ and **Nemeroff CB**. 2005. Genetic analysis of the hypothalamic corticotropin releasing factor (CRF) system. *Endocrinol* 146:2362-2368.
778. Carson WH, Kitagawa H and **Nemeroff CB**. 2005. Drug development for anxiety disorders: new roles for atypical antipsychotics. *Psychopharmacol Bull*; 38 Suppl 1:38-45.
779. Cowles MK and **Nemeroff CB**. 2006. Depression – A Systemic Illness. In: *Psychosomatic Medicine* (M. Blumenfield and J.J. Strain, Eds.), Lippincott Williams & Wilkins, 47-65.
780. Craighead WE and **Nemeroff CB**. 2005. The impact of early trauma on response to psychotherapy. *Clin Neurosci Res* 4:405-411.
781. Coplan JD, Altemus M, Mathew SJ, Smith ELP, Scharf B, Coplan PM, Kral JS, Gorman JM, Owens MJ, **Nemeroff CB** and Rosenblum LA. 2005. Synchronized maternal-infant elevations of primate CSF CRF concentrations in response to variable foraging demand. 2005. *CNS Spectrums* 10:530-536.
782. Evans DL, Charney DS, Lewis L, Golden RB, Gorman JM, Krishnan KRR, **Nemeroff CB**, Bremner JD, Carney RM, Coyne JC, DeLong MR, Frasurre-Smith N, Glassman AH, Gold PW, Grant I, Gwyther L, Ironson G, Johnson RL, Kanner AM, Katon WJ, Kaufmann PG, Keefe FJ, Ketter T, Laughren TP, Leserman J, Lyketsos CG, McDonald WM, McEwen BS, Miller AH, Musselman D, O'Connor C, Petitto JM, Pollock BG, Robinson RG, Roose SP, Rowland J, Sheline Y, Sheps DS, Simon G, Spiegel D, Stunkard A, Sunderland T, Tibbits P and Valvo WJ. 2005. Mood disorders in the medically ill: scientific review and recommendations. *Biol Psychiat* 58:175-189.
783. Jarkas N, Votaw JR, Voll RJ, Williams L, Camp VM, Owens MJ, Purselle DC, Bremner JD, Kilts CD, **Nemeroff CB** and Goodman MM. 2005. Carbon-11 HOMADAM: a novel PET radiotracer for imaging serotonin transporters. *Nuclear Med Biol* 32:211-224.
784. Geraciotti TD, Carpenter L, Owens MJ, Baker DG, Ekhaton N, Horn PS, Strawn J, Sanacora G, Kinkead B, Price LH and **Nemeroff CB**. 2006. Elevated cerebrospinal fluid substance P concentrations in post-traumatic stress disorder and major depression. *Am J Psych* 163:637-643.
785. Plotsky PM, Thirivikraman KV, **Nemeroff CB**, Caldji C, Sharma S and Meaney MJ. 2005. Long-term consequences of neonatal rearing on central corticotropin releasing factor systems in adult male rat offspring. *Neuropsychopharmacol* 30:2192-2204.
786. Kinkead B and **Nemeroff CB**. 2006. Novel treatments of schizophrenia: targeting the neurotensin system. *CNS and Neurological Disorders - Drug Targets* 5:205-218.

787. Davidson J, Watkins L, Owens MJ, Dube E, Krulewicz S, Connor K, Carpenter D, Krishnan KRR and **Nemeroff CB**. 2005. Effects of paroxetine and venlafaxine-XR on heart rate variability in depression. *J Clin Psychopharmacol* 25:480-484.
788. McConathy J, Owens MJ, Kilts CD, Malveaux EJ, Votaw JR, **Nemeroff CB** and Goodman MM. 2005. Synthesis and biological evaluation of trans-3-phenyl-1-indanamines as potential norepinephrine transporter imaging agents. *Nuclear Med Biol* 32:593-605.
789. Pomara NP, Willoughby LM, Ritchie JC, Sidtis JJ, Greenblatt DJ and **Nemeroff CB**. 2005. Gender-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance. *Psychopharmacol* 182:414-419.
790. Stowe ZN, Landry JC, Tang Z, Owens MJ, Kinkead B and **Nemeroff CB**. 2005. The electrophysiological effects of neurotensin on spontaneously active neurons in the nucleus accumbens: an *in vivo* study. *Synapse* 58:165-172.
791. Bremner JD, Mletzko T, Welter S, Quinn S, Williams C, Brummer M, Siddiq S, Reed L, Heim CM and **Nemeroff CB**. 2005. Effects of phenytoin on memory, cognition and brain structure in post-traumatic stress disorder: a pilot study. *J Psychopharmacol* 19:159-165.
792. Kinkead B, Dobner PR, Egnatashvili V, Murray T, Deitemeyer N and **Nemeroff CB**. 2005. Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine or quetiapine. *J Pharmacol Exp Ther* 315:256-264.
793. Garlow SJ, Boone E, Kinkead B and **Nemeroff CB**. 2006. Genetic analysis of the hypothalamic neurotensin system. *Neuropsychopharmacol* 31:535-543.
794. Simon JS and **Nemeroff CB**. 2005. Aripiprazole augmentation of antidepressants for the treatment of partially responding and non-responding patients with major depressive disorder. *J Clin Psychiat* 66:1216-1220.
795. **Nemeroff CB**, Bremner JD, Foa EB, Mayberg HS, North CS and Stein MB. 2005. Posttraumatic stress disorder: a state-of-the-science review. *J Psychiatric Res* 40:1-21.
796. **Nemeroff CB** and Thase ME. 2007. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. *J Psychiatric Res* 41:351-359.
797. **Nemeroff CB** and Wagner KD. 2005. Developmental neurobiology and psychiatry: challenges and best practices for studies in children and adolescents. *J Clin Psychiatry* 66(suppl 7):3-4.
798. **Nemeroff CB** and Vale WW. 2005. The neurobiology of depression: inroads to treatment and new drug discovery. *J Clin Psychiat* 66 (suppl 7):5-13.
799. Evans DL, Beardslee W, Biederman J, Brent D, Charney D, Coyle J, Craighead WE, Crits-Christoph P, Findling R, Garber J, Johnson R, Keller M, **Nemeroff CB**, Rynn MA, Wagner K, Weissman M and Weller E. 2005. Defining depression and bipolar disorder. In: *Treating and Preventing Adolescent Mental Health Disorders* (D.L. Evans, E.B. Foa, R.E. Gur H Hendin, C.P. O'Brien, M.E.P. Seligman and B.T. Walsh, Eds.), Oxford University Press, 4-27.

800. Evans DL, Beardslee W, Biederman J, Brent D, Charney D, Coyle J, Craighead WE, Crits-Christoph P, Findling R, Garber J, Johnson R, Keller M, **Nemeroff CB**, Rynn MA, Wagner K, Weissman M and Weller E. 2005. Treatment of depression and bipolar disorder In: *Treating and Preventing Adolescent Mental Health Disorders* (D.L. Evans, E.B. Foa, R.E. Gur H Hendin, C.P. O'Brien, M.E.P. Seligman and B.T. Walsh, Eds.), Oxford University Press, 30-54.
801. Evans DL, Beardslee W, Biederman J, Brent D, Charney D, Coyle J, Craighead WE, Crits-Christoph P, Findling R, Garber J, Johnson R, Keller M, **Nemeroff CB**, Rynn MA, Wagner K, Weissman M and Weller E. 2005. Prevention of depression and bipolar disorder In: *Treating and Preventing Adolescent Mental Health Disorders* (D.L. Evans, E.B. Foa, R.E. Gur H Hendin, C.P. O'Brien, M.E.P. Seligman and B.T. Walsh, Eds.), Oxford University Press, 56-67 .
802. Evans DL, Beardslee W, Biederman J, Brent D, Charney D, Coyle J, Craighead WE, Crits-Christoph P, Findling R, Garber J, Johnson R, Keller M, **Nemeroff CB**, Rynn MA, Wagner K, Weissman M and Weller E. 2005. Research agenda for depression and bipolar disorder In: *Treating and Preventing Adolescent Mental Health Disorders* (D.L. Evans, E.B. Foa, R.E. Gur H Hendin, C.P. O'Brien, M.E.P. Seligman and B.T. Walsh, Eds.), Oxford University Press, 70-74.
803. Gillespie CF and **Nemeroff CB**. 2005. Early life stress and depression. *Current Psychiatry* 4:15-30.
804. Cowles MK, Boswell EB, Anfinson TJ and **Nemeroff CB**. 2005. Neuropsychiatric aspects of endocrine disorders. In: *Textbook of Neuropsychiatry, 5th Edition* (S.C. Yudofsky and R.E. Hales, Eds.), American Psychiatric Publishing, Inc. Washington, DC, 799- 833.
805. Guo Y, Musselman DL, Manatunga A, Gilles N, Porter MR, McDaniel S and **Nemeroff CB**. 2006. The diagnosis of major depression in patients with cancer: a comparative approach. *Psychosomatics* 47:376-384.
806. Holtzheimer PE and **Nemeroff CB**. 2006. Advances in the treatment of depression. *NeuroRx* 3:42-56.
807. Musselman DL, Somerset WI, Guo Y, Manatunga AK, Porter MR, Penna S, Lewison B, Goodkin R, Lawson DH, Evans DL and **Nemeroff CB**. 2006. A double-blind, multicenter, parallel group study of paroxetine, desipramine, or placebo in breast cancer patients (Stages I, II, III & IV) with major depression. *J Clin Psychiat* 67:288-296.
808. Capuron I, Pagnoni G, Demetrashvili M, Woolwine BJ, **Nemeroff CB**, Berns GS and Miller AH. 2005. Anterior cingulate activation and error processing during interferon-alpha treatment. *Biol Psychiat* 58:190-196.
809. **Nemeroff CB**, Lieberman JA, Masand PS, Weiden PJ, Harvey PD, Newcomer JW, Schatzberg AF, Kilts CD and Daniel DG. 2005. From clinical research to clinical practice: a 4-year review of ziprasidone. *CNS Spectrums* 10(suppl 17) 1-19.
810. McIntyre RS, Konarski JZ, Mancini DA, Fulton KA, Parikh SV, Grigoriadis S, Grupp LA, Bakish D, Filteau MJ, Gorman C, **Nemeroff CB** and Kennedy SH. 2005. Measuring the severity of depression and remission in primary care: validation of the HAM-D-7 scale. *Canadian Med Assoc Journal (CMAJ)* 173:1327-1334.

811. Holtzheimer PE and **Nemeroff CB**. 2006. Future prospects in depression research. *Dialogues in Clinical Neuroscience* 8:175-189.
812. Neigh GN and **Nemeroff CB**. 2006. Reduced glucocorticoid receptors: consequence or cause of depression? *Trends in Endocrinology and Metabolism* 17:124-125.
813. Ressler KJ and **Nemeroff CB**. 2006. Molecular mechanisms regulating behavior: focus on genetic and environmental influences. In: *Principles of Molecular Medicine, 2nd Edition* (M.S. Runge and C. Patterson, Eds.), Humana Press, 1175-1183.
814. Heim C, Bremner JD and **Nemeroff CB**. 2006. Trauma spectrum disorders. In: *Principles of Molecular Medicine, 2nd Edition* (M.S. Runge and C. Patterson, Eds.), Humana Press, 1203-1210.
815. Caceda R, Kinkead B, Owens MJ and **Nemeroff CB**. 2005. Virally mediated increased neurotensin 1 receptor in the nucleus accumbens decreases behavioral effects of mesolimbic system activation. *J Neurosci* 25:11748-11756.
816. Coplan JD, Smith ELP, Altemus M, Mathew SJ, Perera T, Kral JG, Gorman JM, Owens MJ, **Nemeroff CB** and Rosenblum LA. 2006. Maternal-infant response to variable foraging demand in nonhuman primates: effects of timing of stressor on cerebrospinal fluid corticotropin-releasing factor and circulating glucocorticoid concentrations. *Ann NY Acad Sci* 1071:525-533.
817. Saal D and **Nemeroff CB**. 2007. Novel pharmacologic treatment of stress and addiction: the role of CRF and glucocorticoid antagonists. In: *Stress and Addiction: Biological and Psychological Mechanisms* (Mustafa Al'Absi, Ed.) Elsevier Neuroscience, 333-343
818. Shilling PD, Kinkead B, Murray T, Melendez G **Nemeroff CB** and Feifel D. 2006. Upregulation of striatal dopamine-2 receptors in Brattleboro rats with prepulse inhibition deficits. *Biol Psychiat* 60:1278-1281.
819. Kilts CD, Kelsey JE, Knight B, Ely TD, Bowman FD, Gross RE, Selvig A, Gordon A, Newport DJ and **Nemeroff CB**. 2006. The neural correlates of social anxiety disorder and response to pharmacotherapy. *Neuropsychopharmacol* 31:2243-2253.
820. Wang X, Savage R, Borisov A, Rosenberg J, Woolwine B, Tucker M, May R, Feldman J, **Nemeroff CB** and Miller AH. 2006. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. *J Psychiat Res* 40:669-676.
821. **Nemeroff CB**, Mayberg HS, Kahl SE, McNamara J, Frazer A, Henry TR, George MS, Charney DS and Brannen SK. 2006. VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. *Neuropsychopharmacol* 31:1345-1355.
822. Welberg LAM, Kinkead B, Thrivikraman KV, Huerkamp MJ, **Nemeroff CB** and Plotsky PM. 2006. Ketamine-xylazine-acepromazine anesthesia and postoperative recovery in rats. *J Am Assoc Laboratory Animal Science* 45:13-20.
823. Nicolson SE, Mayberg HS, Pennell PB and **Nemeroff CB**. 2006. Persistent auditory hallucinations that are unresponsive to antipsychotic drugs. *Am J Psychiat* 163:1153-1159.

824. Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, Turkoz I, Lasser RA, Loescher A and **Nemeroff CB**. 2006. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. *Neuropsychopharmacol* 31: 2505-2513.
825. Dunlop BW and **Nemeroff CB**. 2007. The role of dopamine in the pathophysiology of depression. *Arch Gen Psychiat* 64:327-337.
826. Pace TWW, Mletzko TC, Alagbe O, Musselman DL, **Nemeroff CB**, Miller AH and Heim CM. 2006. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. *Am J Psychiat* 163:1630-1633.
827. **Nemeroff CB**. 2006. The burden of severe depression: A review of diagnostic challenges and treatment alternatives. *J Psychiat Res* 41:189-206
828. **Nemeroff CB**, Kalali A, Keller MB, Charney DS, Lenderts SE, Cascade EF, Stephenson H and Schatzberg AF. 2007. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. *Arch Gen Psychiat* 64:466-472.
829. Holtzheimer PE and **Nemeroff CB**. 2006. Emerging treatments for depression. *Expert Opinion on Pharmacotherapy* 7:2323-39.
830. Caceda R, Kinkead B and **Nemeroff CB**. 2006. Neurotensin: Role in psychiatric and neurological diseases. *Peptides* 27:2385-2404.
831. Gillespie CF and **Nemeroff CB**. 2007. Corticotropin-Releasing Factor and the Psychobiology of Early Life Stress. *Current Directions in Psychological Sciences* 16:85-89.
832. **Nemeroff CB**. 2008. The discovery of endogenous opiates and their receptors: a Snyderian saga of skill and judgment. In: *Science and Psychiatry* (S.H. Snyder, Ed.), American Psychiatric Press Inc., Washington DC, 49-52.
833. Zeng F, Jarkas N, Owens MJ, Kilts CD, **Nemeroff CB** and Goodman MM. 2006. Synthesis and monoamine transporter affinity of front bridged tricyclic 3 β -(4'-halo or 4'-methyl) phenyltropanes bearing methylene or carbomethoxymethylene on the bridge to the 2 β -position. *Bioorganic & Medicinal Chem Lett* 16: 4661-4663.
834. **Nemeroff CB** and Schatzberg AF. 2006. Pharmacological treatments for unipolar depression. In: *A Guide to Treatments that Work, 3rd Edition* (P.E. Nathan and J.M. Gorman, Eds.), Oxford University Press, New York 271-287.
835. Gutman DA and **Nemeroff CB**. 2006. CRF circuitry in the brain: relevance for affective disorders and anxiety. In: *The Encyclopedia of Stress* (G. Fink, Ed.), Elsevier Publishing, 630-634.
836. Vergne DE and **Nemeroff CB**. 2006. The interaction of serotonin transporter gene polymorphisms and early adverse life events on vulnerability for major depression. *Curr Psychiatry Reports* 8:452-457.

837. Haas AP, Koestner BS, Rosenberg J, Moore D, Garlow SJ, Sedway J, Nicholas L, Hendin H, Mann JJ, **Nemeroff CB**. 2008. An interactive web-based method of outreach to college students at risk for suicide. *J American College Health* 57:15-22.
838. Musselman DL, Cowles MK, McDonald W and **Nemeroff CB**. 2007. Effects of mood and anxiety disorders on the cardiovascular system. In: *Hurst's the Heart, 12th Edition* (V. Fuster, R.W. Alexander, R.O. O'Rourke, Eds.) McGraw-Hill, New York 2169-2187.
839. Gutman DA and **Nemeroff CB**. 2009. *Neuroendocrinology* of affective disorders. In: *Encyclopedia of Neuroscience* (P.E. Sawchenko, J. DeSouza, Eds.) Elsevier Oxford: Academic Press 6:355-366.
840. Skelton KH, Gutman DA, Thiruvikraman KV, **Nemeroff CB** and Owens MJ. 2007. The CRF1 receptor antagonist R121919, attenuates the neuroendocrine and behavioral effects of precipitated lorazepam withdrawal. *Psychopharmacology* 192:385-396.
841. Garlow S, Rosenberg J, Moore J, Haas A, Koestner G, Hendin H and **Nemeroff CB**. 2008. Depression, desperation and suicidal ideation in college students: Results from the American Foundation for Suicide Prevention College Screening Project at Emory University. *Depression and Anxiety* 25:482-488.
842. Binder EB and **Nemeroff CB**. 2006. Implications for the practice of psychiatry. In: *Functional Genomics and Proteomics in the Clinical Neurosciences* (S.E. Hemby and S. Bahn, Eds.), Elsevier, Oxford 13:275-289.
843. Monteggia LM, Lippmann M, Bress A, **Nemeroff CB**, Plotsky PM. 2007. Long-term behavioural and molecular alterations associated with maternal separation in rats. *European Journal of Neuroscience* 25:3091-3098.
844. Caceda R, Kinkead B, and **Nemeroff CB**. 2007. Involvement of Neuropeptide Systems in Schizophrenia: Human Studies. In: *Integrating the Neurobiology of Schizophrenia* (A. Abi-Dargham and O. Guillin, Eds.), Elsevier Publishing, Boston 78:327-376.
845. Keller MB, Trivedi MH, Thase ME, Shelton R, Kornstein S, **Nemeroff CB**, Friedman ES, Gelenberg. 2007. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Two-Year and Combined Maintenance Phases. *Journal of Clinical Psychiatry* 68:1246-1256.
846. **Nemeroff CB**, Preskorn SH, and DeVane CL. 2007. Antidepressant Drug-Drug Interactions: Clinical Relevance and Risk Management. *CNS Spectrums* 12:5 (Suppl 7) 1-15.
847. Carpenter L, Bayat L, **Nemeroff CB**, Owens MJ, Price LH, Moreno F, Kling M and Tyrka A. 2007. Decreased Cerebrospinal Fluid Concentrations of Substance P in Treatment Resistant Depression and Lack of Alteration after Acute Adjunct Vagus Nerve Stimulation Therapy. *Psychiatry Research* 157:123-129.
848. Martin EI and **Nemeroff CB**. 2010. The Biology of Generalized Anxiety Disorder and Major Depressive Disorder: Commonalities and Distinguishing Features. In: *Diagnostic Issues in Depression and Generalized Anxiety Disorder: Refining the Research Agenda for DSM-V* (D. Goldberg, K.S. Kendler, P.J.Sirovatka, D.A. Regier, Eds.), American Psychiatric Association: 45-70.

849. Felger JC, Algabe O, Hu F, Mook D, Freeman AA, Sanchez MM, Kalin NH, Ratti E, **Nemeroff CB** and Miller AH. 2007. Effects of Interferon-alpha on Rhesus Monkeys: A Non-Human Primate Model of Cytokine-Induced Depression. *Biological Psychiatry* 62:1324-1333.
850. Ressler KJ and **Nemeroff CB**. 2007. Depression. In: *The Molecular and Genetic Basis of Neurological and Psychiatric Disease, 4th edition* (R.N. Rosenberg, S. DiMauro, H. Paulson, L. Ptacek, E.J. Nestler, Eds.) Lippincott Williams & Wilkins, Philadelphia, 761-777.
851. Skelton KH, Oren D, Gutman DA, O'Brien D, Easterling K, Holtzman SG, **Nemeroff CB** and Owens MJ. 2007. The CRF receptor antagonist, R121919, attenuates the severity of precipitated morphine withdrawal. *European Journal of Pharmacology*, 571:17-24.
852. **Nemeroff CB** and Neigh G. 2008. Neuroendocrinology. In: *The New Oxford Textbook of Psychiatry* (M. Gelder, N.C. Andreasen, J.J. Lopez-Ibor, Jr, and J.R. Geddes Eds.), Oxford University Press, New York, 160-167.
853. Gillespie CF and **Nemeroff CB**. 2008. Biology of Depression. In: *Psychiatric and Metabolic Disorders: Research Synthesis and Clinical Translation* (R.S. McIntyre and J.Z. Konarski, Eds.) Nova Science Publishers Inc., New York. 2007, 147-172.
854. **Nemeroff CB**, Entsuah R, Benattia I, Demitrack M, Sloan DM and Thase ME. 2008. Comprehensive Analysis of Remission (COMPARE) With Venlafaxine vs SSRIs. *Biological Psychiatry* 63:424-434.
855. Heim C, Mletzko T, Purselle D, Musselman DL and **Nemeroff CB**. 2008. The Dexamethasone/CRF Test in Men with Major Depression: Role of Childhood Trauma. *Biological Psychiatry* 63:398-405.
856. Heim C, Newport DJ, Mletzko T, Miller AH and **Nemeroff CB**. 2008. The link between childhood trauma and depression: Insights from HPA axis studies in humans. *Psychoneuroendocrinology* 33:693-710.
857. Kocis JH, Thase ME, Trivedi MD, Shelton RC, Kornstein SG, **Nemeroff CB**, Friedman ES, Gelenberg AJ, Dunner DL, Hirshfeld RMA, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, M.T., Ninan PT and Keller MB. 2007. Prevention of Recurrent Episodes of Depression With Venlafaxine-ER in a One-Year Maintenance Phase from the PREVENT Study. *J Clinical Psychiat* 68:1014-1023.
858. Newport DJ, Calamaras MR, DeVane CL, Donovan J, Beach AJ, Winn S, Knight BT, Gibson BB, Viguera AC, Owens MJ, **Nemeroff CB**, and Stowe ZN. 2007. Atypical Antipsychotic Administration During Late Pregnancy: Placental Passage and Obstetrical Outcomes. *Am J Psychiatry* 164:1214-1220.
859. Dunlop BW, Garlow SJ and **Nemeroff CB**. 2008. The Neurochemistry of Depressive Disorders. In: *The Neurobiology of Mental Illness Third Edition* (D.S. Charney and E.J. Nestler, Eds.) Oxford University Press, New York, 435-460.
860. **Nemeroff CB**. 2007. Prevalence and Management of Treatment-Resistance Depression. *J Clin Psychiatry* 68 (Suppl 8): 17-25.

861. Nicolson SE and **Nemeroff CB**. 2007. Ziprasidone in the Treatment of Mania in Bipolar Disorder. *Neuropsychiatric Disease and Treatment* 3:823-834.
862. Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, **Nemeroff CB**, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Dunlop BW, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen R, Yan B, Ahmed S, Schmidt M and Ninan PT. 2007. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases. *Biological Psychiatry* 62:1371-1379.
863. **Nemeroff CB**. 2008. Medicine in Psychiatry: Closer Together than Ever. Forward. In: *Metabolic Syndrome in Psychiatric Illness* (S. Mendelson, Ed.), Academic Press, New York.
864. **Nemeroff CB**. 2007. Stress and Depression. *World Psychiatric Association (WPA) Bulletin* 11:2-4.
865. **Nemeroff CB**. 2007. Stress, Menopause and Vulnerability for Psychiatric Illness. *Expert Rev Neurotherapeutics* 7, S11-S13.
866. Zeng F, Jarkas N, Stehouwer JS, Voll RJ, Owens MJ, Kilts CD, **Nemeroff CB** and Goodman MM. 2008. Synthesis, in vitro characterization, and radiolabeling of reboxetine analogues as potential PET radioligands for imaging the norepinephrine transporter. *Bioorganic & Medicinal Chemistry* 16:783-793.
867. Hanson ND and **Nemeroff CB**. 2009. Preclinical Models of Anxiety. In: *The American Psychiatric Publishing Textbook of Anxiety Disorders, 2nd Edition* (D.J. Stein and E. Hollander, Eds.), American Psychiatric Press, Inc, Washington, DC, 35-54.
868. Young LJ, Owens MJ and **Nemeroff CB**. 2009. Neuropeptides: Biology, Regulation, and Role in Neuropsychiatric Disorders. In: *Comprehensive Textbook of Psychiatry, Ninth Edition* (B.J. Sadock, V.A. Sadock and P. Ruiz, Eds.), Lippincott Williams and Wilkins, New York, 84-96.
869. Bradley RG, Binder EB, Epstein MP, Tang Y, Nair HP, Liu W, Gillespie CF, Berg T, Evces M, Newport DJ, Stowe ZN, Heim CM, **Nemeroff CB**, Schwartz A, Cubells JF and Ressler KJ. 2008. Influence of Child Abuse on Adult Depression. *Moderation by the Corticotropin-Releasing Hormone Receptor Gene*. *Arch Gen Psychiat* 65:190-200.
870. Capuron L, Pagnoni G, Demetrashvili MF, Lawson DH, Fornwalt FB, Woolwine B, Berns GS, **Nemeroff CB** and Miller AH. 2007. Basal Ganglia Hypermetabolism and Symptoms of Fatigue during Interferon- α Therapy. *Neuropsychopharmacol* 32:2384-2392.
871. Gillespie CF, Garlow SJ, Schatzberg AF and **Nemeroff CB**. 2009. Biology of Mood Disorders. In: *Textbook of Psychopharmacology, 4th Edition* (A.F. Schatzberg and C.B. Nemeroff, Eds.), American Psychiatric Publishing Inc, Washington, D.C. 903-944.
872. Hylton B and **Nemeroff CB**. 2008. An Update on the Neurobiology of Depression. *Directions in Psychiatry* 28:201-209.
873. Kinkead B, Yan F, Owens MJ and **Nemeroff CB**. 2008. Endogenous neurotensin is involved in estrous cycle related alterations in prepulse inhibition of the acoustic startle reflex in female rats. *Psychoneuroendocrinology* 33:178-187.

874. Bruce EC, Guo Y, Lawson KC, Manatunga AK, Auyeung SF, McDonald WM, Rushing N, Brown, AR, Gilles N, Emery M, Bonsall R, Porquez J, Stowe Z, **Nemeroff CB** and Musselman DL. 2009. Platelet Thromboxane A₂ Secretion in Patients with Major Depression Responsive to Electroconvulsive Therapy. *Psychosomatic Medicine* 70:319-327.
875. Ader M, Garvey WT, Phillips LS, **Nemeroff CB**, Gharabawi G, Mahmoud R, Greenspan A, Berry SA, Musselman DL, Morein J, Zhu Y, Mao L and Bergman RN. 2008. Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. *Journal of Psychiatric Research* 42:1076-1085.
876. Holtzheimer PE and **Nemeroff CB**. 2009. Somatic Therapies In: *Clinical Psychiatry for Medical Students and Residents, 4th Edition* (L. W. Roberts, J.G. Hoop and T.W. Heinrich, Eds.), Lippincott, Williams & Wilkins 3:443-462.
877. Dunlop BD and **Nemeroff CB**. 2009. Depression: Neuroscientific Investigations. In: *Handbook of Neuroscience for the Behavioral Sciences* (G.G. Berntson and J.T. Cacioppo, Eds.), John Wiley and Sons, Hoboken, Vol. 2, 1060-1089.
878. Heim C and **Nemeroff CB**. 2009. Biology, Neurochemistry. In: *Encyclopedia of Psychological Trauma* (G. Reyes, J. Elhai, J. Ford, Eds.), John Wiley and Sons, Inc. New York, NY. 93-100.
879. Binder, EB, Bradley RG, Liu W, Epstein MP, Deveau TC, Mercer KB, Tang Y, Gillespie CF, Heim CM, **Nemeroff CB**, Schwartz AC, Cubells JF, and Ressler KJ. 2008. Association of FKBP5 Polymorphisms and Childhood Abuse with Risk of Posttraumatic Stress Disorder Symptoms in Adults. *JAMA*, 299:1291-1305.
880. Owens MJ, Krulewicz S, Simon JS, Sheehan DV, Thase ME, Carpenter DJ, Plott SJ and **Nemeroff CB**. 2008. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. *Neuropsychopharmacology* 33, 3201-3212.
881. **Nemeroff CB**. 2008. Recent findings in the pathophysiology of depression. *Focus* 6:3-14.
882. Martin EI and **Nemeroff CB**. 2008. The Role of Corticotropin-Releasing Factor in the Pathophysiology of Depression: Implications for Antidepressant Mechanisms of Action. *Psychiatric Annals* 38:260-266.
883. Sandhu MJ, Garlow SJ and **Nemeroff CB**. 2009. Psychopharmacological Therapies. In: *Clinical Psychiatry Essentials* (L.W. Roberts, J.G. Hoop and T.W. Heinrich, Eds.), Lippincott, Williams and Wilkins. 3:371-416.
884. Gutman DA and **Nemeroff CB**. 2009. Stress and Depression. In: *Handbook of Stress Science* (R.J. Contrada and A. Baum, Eds.), Springer, 345-357.
885. DeOreo E and **Nemeroff CB**. 2009. The Hypothalamic-Pituitary-Thyroid Axis and Depression. In: *International Encyclopedia of Depression* (R. Ingram, Ed.), 336-339.
886. Pariente C and **Nemeroff CB**. 2009. Unipolar Depression. In: *Handbook of Clinical Neurology. Neurobiology of Psychiatric Disorders* (T. Schlaepfer and C.B. Nemeroff, Eds.), Springer, 106:239-249.

887. Keitner GI, Garlow SJ, Ryan CE, Ninan PJ, Solomon DA, **Nemeroff CB** and Keller MB. 2009. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. *J. Psychiatric Res.* 43:205-214.
888. Cowles M, **Nemeroff CB** and Parente C. 2009. Depression in the Medically Ill. In: *Understanding Depression: A Translational Approach* (C.M. Pariente, R. Nesse, D. Nutt, L. Wolpert, Eds.), Oxford University Press, 7-16.
889. Claes S, Binder E, **Nemeroff CB**, and Parente C. 2009. Genetic factors in stress and major depression. In: *Understanding Depression: A Translational Approach* (C.M. Pariente, R. Nesse, D. Nutt, L. Wolpert, Eds.), Oxford University Press, 55-56.
890. **Nemeroff CB**. 2008. Fostering Foster Care Outcomes. Quality of Intervention Matters in Overcoming Early Adversity. *Arch Gen Psychiatry* 65:623-624.
891. Gutman D, Coyer J, Boss-Williams K, Owens A, **Nemeroff CB** and Weiss M. 2008. Behavioral Effects of the CRF1 Receptor Antagonist R121919 in Rats Selectively Bred For High and Low Activity in the Swim Test. *Psychoneuroendocrinology* 33:1093-1101.
892. Neigh G, Gillespie C and **Nemeroff CB**. 2009. Biological impact of war exposure early in life. In: *Children and War – the impact of war and terror on Middle Eastern children and adolescents. 1st Edition* (S. Muntasser, Munoz, Eds.), Springer.
893. **Nemeroff CB**. 2009. Understanding the Pathophysiology of Postpartum Depression: Implications for the Development of Novel Treatments. *Neuron* 59:185-186.
894. Ehmke CJ and **Nemeroff CB**. 2009. Paroxetine. In: *Textbook of Psychopharmacology, 4th Edition* (A.F. Schatzberg and C.B. Nemeroff, Eds.), American Psychiatric Press, Inc., Washington, DC, 321-352.
895. Keen-Rhinehart E, Michopoulos V, Toufexis D, Martin E, Nair H, Ressler K, Davis M, Owens M, **Nemeroff CB**, Wilson M. 2009. Continuous expression of corticotropin releasing factor in the central nucleus of the amygdala emulates the dysregulation of the stress and reproductive axes. *Molecular Psychiatry* 14, 37–50.
896. **Nemeroff CB**. 2008. The Curiously Strong Relationship between Cardiovascular Disease and Depression in the Elderly. *Amer J Geriatric Psychiatry* 16:857-860.
897. Bhandari S and **Nemeroff CB**. 2009. Endocrine and Metabolic Disorders. In: *Handbook of Pediatric Neuropsychology* (A. Davis, Ed.), 833-849.
898. **Nemeroff CB**. 2008. Personalized Medicine in Psychiatry. *NeuroPsychiatry Reviews* 9:6.
899. Holtzheimer PE and **Nemeroff CB**. 2009. Novel targets for antidepressant therapies. *Current Psychiatry Reports*, 10:465-473.
900. Heim C, Young LJ, Newport DJ, Mletzko T, Miller AH and **Nemeroff CB**. 2009. Lower CSF Oxytocin Concentrations in Women with a History of Childhood Abuse. *Molecular Psychiatry* 14:954-958.

901. Dunlop BW, **Nemeroff CB**. 2009. The Role of Dopamine in the Pathophysiology and Treatment of Major Depressive Disorder. In: *Dopamine Handbook* (L. Iversen, S. Iversen, S. Dunnett, A. Bjorklund, Eds.), Oxford University Press, 10.5:572-589.
902. Nye JA, Votaw JR, Jarkas N, Purselle D, Camp V, Bremner JD, Kilts CD, **Nemeroff CB** and Goodman MM. 2008. Compartmental Modeling of 11C-HOMADAM Binding to the Serotonin Transporter in the Healthy Human Brain. *J Nuclear Med* 49:2018-2025.
903. Gatt JM, **Nemeroff CB**, Dobson-Stone C, Paul RH, Bryant RA, Schofield PR, Gordon E, Kemp A, Williams LM. 2009. Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. *Molecular Psychiatry* 14:681-695.
904. Zeng F, Mun J, Jarkas N, Stehouwer J, Voll R, Tamagnan G, Howell L, Votaw J, Kilts C, **Nemeroff CB**, Goodman M. 2009. Synthesis, Radiosynthesis, and Biological Evaluation of Carbon-11 and Flurine-18 Labeled Reboxetine Analogues: Potential Positron Emission Tomography Radioligands for the Vivo Imaging of the Norepinephrine Transporter. *J Med Chem* 52:62-73.
905. James GA, Kelley ME, Craddock RC, Holtzheimer PE, Dunlop B, **Nemeroff CB**, Mayberg HS and Hu X.P. 2009. Exploratory structural equation modeling of resting-state fMRI: applicability of group models to individual subjects. *Neuroimage* 45:778-787.
906. Neigh GN, Gillespie CF and **Nemeroff CB**. 2009. The Neurobiological Toll of Child Abuse and Neglect. *Trauma, Violence & Abuse* 10:369-410.
907. Heim C and **Nemeroff CB**. 2009. Neurobiology of Posttraumatic Stress Disorder. *CNS Spectrums*. 14:13-24.
908. Stein DJ, Cloitre M, **Nemeroff CB**, Nutt DJ, Shalev A, Wittchen U and Zohar J 2009. Cape Town Consensus on Posttraumatic Stress Disorder. *CNS Spectrums* 14:52-58.
909. LaPrairie JL, Heim CM and **Nemeroff CB**. 2010. The Neuroendocrine Effects of Early Life Trauma In: *The Effects of Early Life Trauma on Health and Disease* (R.Lanius and E. Vermetten, Eds.), Cambridge University Press, New York, New York, 157-165.
910. Martin EI, Ressler KJ, Binder E and **Nemeroff CB**. 2009. The Neurobiology of Anxiety Disorders: Brain Imaging, Genetics, and Psychoneuroendocrinology. *Psychiatric Clinics of North America* 32:549-575 and in *Clinics in Laboratory Medicine* 30:865–891.
911. Young A and **Nemeroff CB**. 2010. Pharmacological Treatment of Bipolar Depression. In: *Bipolar Disorder: Clinical and Neurobiological Foundations* (L.N. Yatham and M. Maj, Eds.), Wiley Blackwell, London, 294-303.
912. Sheehan DV, **Nemeroff CB**, Thase ME and Ensua R. 2009. Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features. *Int Clin Psychopharmacol* 2:61-86.
913. Rakofsky JJ, Holtzheimer PE and **Nemeroff CB**. 2009. Emerging Targets for Antidepressant Therapies. *Current Opinion in Chemical Biology*, Special Issue on Next Generation Therapeutics. 13:291-302.

914. **Nemeroff CB** and Owens MJ 2009. The Role of Serotonin in the Pathophysiology of Depression: As Important As Ever. *Clin Chem* 55:1578-1579.
915. Guillery LC, Kinkead B and **Nemeroff CB**. 2010. Neurotensin. In: *Encyclopedia of Psychopharmacology* (I.P. Stolerman, Ed.), Springer.
916. Neigh GN, Karelina K, Zhang N, Glaspar ER, Owens MJ, Plotsky PM, **Nemeroff CB** and Devries AC. 2009. Cardiac arrest and cardiopulmonary resuscitation dysregulates the hypothalamic – pituitary-adrenal axis. *J Cerebral Blood Flow and Metabolism* 29:1673-1682.
917. Heim C, Bradley-Davino BG, Mletzko TC, Deveau TC, Musselman DL, **Nemeroff CB**, Ressler KJ and Binder EB. 2009. Effect of Childhood Trauma on Adult Depression and Neuroendocrine Function: Sex-Specific Moderation by CRH Receptor 1 Gene. *Frontiers in Behavioral Neurosciences* 3:41.
918. Binder EB, Owens MJ, Liu W, Deveau TJ, Rush AJ, Trivedi MH, Fava M, Bradley RG, Ressler KJ and **Nemeroff CB**. 2010. Association of Polymorphisms in Genes Regulating the Corticotropin-Releasing Factor System with Antidepressant Treatment Response. *Arch General Psychiatry* 67:369-379.
919. Palaszynski KM and **Nemeroff CB** 2009. The Medical Consequences of Child Abuse and Neglect. *Psychiatric Annals* 39:1004-1012.
920. Viamonte GI and **Nemeroff CB**. 2009. Brain-body interactions: The Physiological Impact of Mental Processes Part 1: The Neurobiology of the stress response. *Psychiatric Annals* 39:975-984.
921. Young LJ, Owens MJ, **Nemeroff CB**. 2009. Neuropeptides: Biology, Regulation, and Role in Neuropsychiatric Disorders. In: *Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Ninth Edition* (B. Sadock, V. Sadock, and P. Ruiz Eds.), Lippincott Williams & Wilkins, 84-95.
922. Ressler K, Bradley B, Mercer K, Deveau T, Smith A, Gillespie C, **Nemeroff CB**, Cubells J, and Binder E. 2010. Polymorphisms in CRHR1 and the serotonin transporter loci: gene x gene x environment interactions on depressive symptoms. *Amer Jour of Medical Genetics Part B: Neuropsychiatric Genetics*, 153B:812-824.
923. Martin EI, Ressler KJ, Jasnow AM, Dabrowska J, Hazra R, Rainnie DG, **Nemeroff CB** and Owens MJ 2010. A novel transgenic mouse for gene-targeting within cells that express corticotrophin-releasing factor. *Biological Psychiatry* 67:1212-1216.
924. Binder EB and **Nemeroff CB** 2010. The CRF system, stress, depression and anxiety—insights from human genetic studies. *Molecular Psychiatry*, 15:574-588.
925. Neigh GN, Owens MJ, Taylor WR and **Nemeroff CB**. 2010. Changes in vascular area fraction of the hippocampus and amygdala are induced by prenatal dexamethasone and/or adult stress. *J Cerebral Blood Flow Metab* 30: 1100-1104.
926. Gillespie CF, Binder EB, Holtzheimer PE and **Nemeroff CB**. 2010. Stress and the Impact of Personalized Medicine. In: *Integrative Neuroscience and Personalized Medicine* (E. Gordon, and S.H. Koslow, Eds.), Oxford University Press, New York, 5:73-92.

927. Cowles MK, Musselman DL, McDonald WM and **Nemeroff CB**. 2010. Effects of mood and anxiety disorders on the cardiovascular system. In: *Hurst's the Heart, 13th Edition* (V. Fuster, R.W. Alexander, R.O. O'Rourke, Eds.), McGraw-Hill, New York, 96:2128-2145.
928. Balon R, Guerra E, Meador-Woodruff JH, Oquendo MA, Salloum IM, Casiano DE and **Nemeroff CB**. 2011. Innovative approach to research training: research colloquium for junior investigators. *Academic Psychiatry* 35:11-14.
929. Currier MB and **Nemeroff CB**. 2010. Inflammation and Mood Disorders: Proinflammatory Cytokines and the Pathogenesis of Depression. Anti-Inflammatory and Anti-Allergy Agents in *Medicinal Chemistry* 9:212-220.
930. Dunlop BW, Betancourt Y, Binder EB, Heim C, Holsboer F, Ising M, McKenzie M, Mletzko T, Pfister H, **Nemeroff CB**, Craighead WE and Mayberg HS. 2010. Tolerability of the Dexamethasone-Corticotropin Releasing Hormone Test in Major Depressive Disorder. *J Psychiatric Res* 45:24-28.
931. Juul SH and **Nemeroff CB**. 2012. Psychiatric Epidemiology. In: *Handbook of Clinical Neurology. Volume on Psychiatric Disorders* (T. Schlaepfer and C.B. Nemeroff, Eds.), Springer, 10:167-192.
932. Coplan JD, Abdallah CG, Kaufman J, Gelernter J, Smith EL, Perera TD, Dwork AJ, Kaffman A, Gorman JM, Rosenblum LA, Owens MJ and **Nemeroff CB**. 2010. Early-life Stress, Corticotropin-Releasing Factor, and Serotonin Transporter Gene: A Pilot Study. *Psychoneuroendocrinology*. 36:289-293.
933. Bale TL, Baram TZ, Brown AS, Goldstein JM, Insel TR, McCarthy MM, **Nemeroff CB**, Reyes TM, Simerly RB, Susser ES and Nestler EJ. 2010. Early life programming and neurodevelopmental disorders. *Biological Psychiatry*. 68:314-319.
934. Gatt JM, Williams LM, Schofield PR, Dobson-Stone C, Paul RH, Grieve S, Clark C R, Gordon E and **Nemeroff CB**. 2010. Impact of the HTR3A gene with early life trauma on emotional networks and depressed mood. *Depression and Anxiety* 27:752-759.
935. **Nemeroff CB** and Goldschmidt-Clermont PJ. 2011 In the Aftermath of Tragedy: Medical and Psychiatric Consequences. *Academic Psychiatry* 35:4-7.
936. Myers AJ and **Nemeroff CB**. 2010. New Vistas in the Management of Treatment Refractory Psychiatric Disorders: Genomics and Personalized Medicine. *Focus* 8:525-535.
937. Guinjoan SM, Mayberg HS, Costanzo EY, Fahrner RD, Tenca E, Antico J, Cerquetti D, Smyth E, Leiguarda RC and **Nemeroff CB**. 2010. Asymmetrical Contribution of Brain Structures to Treatment-Resistant Depression as Illustrated by Effects of Right Subgenual Cingulum Stimulation. *Journal of Neuropsychiatry and Clinical Neurosciences* 22:265-267.
938. Viamontes GI and **Nemeroff CB**. 2010. Brain-body interactions: The Physiological Effect of Mental Processes on Major Body Systems. *Psychiatric Annals* 40:367-380.
939. Heim C, Shugart M, Craighead WE, and **Nemeroff CB**. 2010. Neurobiological and Psychiatric Consequences of Child Abuse and Neglect. *Developmental Psychobiology* 52:671-690.

940. Gutman DA, Owens MJ, Thrivikraman KV and **Nemeroff CB**. 2010. Persistent anxiolytic effects after chronic administration of the CRF₁ receptor antagonist R121919 in rats. *Neuropharmacology* 60:1135-1141.
941. Neigh GN, Ritschel LA and **Nemeroff CB**. 2010. Biological Consequences and Transgenerational Impact of Violence and Abuse. *Psychiatric Times* 27:49-52.
942. Gatt JM, **Nemeroff CB**, Schofield PR, Paul RH, Clark CR, Gordon E and Williams LM. 2010. Early Life Stress Combined with Serotonin 3A Receptor and Brain-Derived Neurotrophic Factor Valine 66 to Methionine Genotypes Impacts Emotional Brain and Arousal Correlates of Risk for Depression. Awarded the Westmead Millennium Institute Science Prize for 2010. *Biological Psychiatry* 68:818–824.
943. Williams LM, Rush AJ, Koslow SH, Wisnicioski SR, Cooper N, **Nemeroff CB**, Schatzberg AF and Gordon E. 2011. International study to predict optimized treatment for depression (ISPD-D), a randomized clinical trial: rationale and protocol. *Trials* 12:4.
944. Hanson ND, **Nemeroff CB** and Owens MJ. 2011. Lithium, but not fluoxetine or the CRF1 receptor antagonist R121919, increases cell proliferation in the adult dentate gyrus. *Journal of Pharmacology and Experimental Therapeutics* 337:180–186.
945. Lloyd RB and **Nemeroff CB**. 2011. The role of corticotropin-releasing factor in the pathophysiology of depression: therapeutic implications. *Current Topics in Medicinal Chemistry* 11:609-617.
946. Smith AK, Newport DJ, Ashe MP, Brennan PA, LaPrairie JL, Calamaras M, **Nemeroff CB**, Ritchie JC, Cubells JF and Stowe ZN. 2011. Predictors of Neonatal Hypothalamic-Pituitary-Adrenal Axis Activity at Delivery. *Clinical Endocrinology* 75:90–95.
947. Schienle A, Hettner JM, Caceda R and **Nemeroff CB**. 2011. Neurobiology and genetics of generalized anxiety disorder. *Psychiatric Annals* 41:113-123.
948. Wade AG, Crawford GM, **Nemeroff CB**, Schatzberg AF, Schlaepfer T, McConnachie A, Haazen L and Buntinx E. 2011. Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response. *Psychological Medicine* 41:2089-2097.
949. Rustad J, Musselman DL and **Nemeroff CB**. 2011. The Relationship of Depression and Diabetes: Pathophysiological and Treatment Implications. *Psychoneuroendocrinology* 36:1276-1286.
950. Coplan JD, Abdallah CG, Mathew SJ, Shungu DC, Mao X, Smith EL, Kaufman D, Gorman JM, Owens MJ, **Nemeroff CB**, Banerji MA, Rosenblum LA and Kral JG. 2011. Metabolic Syndrome and Neurometabolic Asymmetry of Hippocampus in Adult Bonnet Monkeys. *Physiology and Behavior* 103:535–539.
951. Primeau MM, Henry J and **Nemeroff CB**. 2013. Paroxetine. In: *Essentials of Clinical Psychopharmacology, 3rd Edition* (A.F. Schatzberg and C.B. Nemeroff, Eds.), American Psychiatric Press, Inc. Washington, D.C., 69-93.

952. Hanson ND, Owens MJ, Boss-Williams KA, Weiss JA and **Nemeroff CB**. 2011. Stress and neurogenesis: Several stressors fail to reduce adult hippocampal neurogenesis. *Psychoneuroendocrinology* 36:1520-1529.
953. Flandreau EI, Ressler KJ, Owens MJ and **Nemeroff CB**. 2012. Chronic overexpression of corticotropin-releasing factor from the central amygdala produces HPA axis hyperactivity and behavioral anxiety associated with gene-expression changes in the hippocampus and paraventricular nucleus of the hypothalamus. *Psychoneuroendocrinology* 37:27-38.
954. Sherin JE and **Nemeroff CB**. 2011. PTSD: The Neurobiological Impact of Psychological Trauma. *Dialogues in Clinical Neuroscience* 13:263-78.
955. Hanson ND, Owens MJ and **Nemeroff CB**. 2011. Depression, antidepressants, and neurogenesis: a critical reappraisal. *Neuropsychopharmacology* 36:2589–2602.
956. Parr LA, Boudreau M, Hecht E, Winslow JT, **Nemeroff CB** and Sanchez MM. 2011. Early life stress affects cerebral glucose metabolism in adult rhesus monkeys (*Macaca mulatta*). *Developmental Cognitive Neuroscience* 2:181-193.
957. Brothers SP, Wahlestedt C and **Nemeroff CB**. 2012. Modulation of HPA Axis Function for Treatment of Mood Disorders In: *Drug Discovery for Psychiatric Disorders* (Z. Rankovic, M. Bingham, R. Hargreaves and E. Nestler, Eds.), Royal Society of Chemistry, London 11:276-279.
958. Caceda R, Binder EB, Kinkead B and **Nemeroff CB**. 2011. The role of endogenous neurotensin in psychostimulant-induced disruption of prepulse inhibition and locomotion. *Schizophrenia Research* 136:88-95.
959. Dunlop BW, DeFife JA, Marx L, Garlow SJ, **Nemeroff CB** and Lilienfeld SO. 2011. The effects of sertraline on psychopathic traits. *International Clinical Psychopharmacology* 26:329-337.
960. Saveanu R and **Nemeroff CB**. 2012. Etiology of Depression: Genetic and Environmental Factors. *Psychiatric Clinics of North America* 35:51–71.
961. de Achával D, Villarreal MF, Costanzo EY, Douer J, Castro MN, Mora MC, **Nemeroff CB**, Chu E, Bär K and Guinjoan SM. 2011. Decreased activity in right-hemisphere structures involved in social cognition in siblings discordant for schizophrenia. *Schizophrenia Research* 134:171–179.
962. Ryan M, Grenier E, Campo A, Castro A and **Nemeroff CB**. 2012. New onset psychosis in an adolescent female associated with Dandy-Walker variant. *Journal of Neuropsychiatry Clinical Neurosciences* 24:241-246.
963. Caceda R, Strassnig M and **Nemeroff CB**. 2012. Advances in the Neuropsychobiology of Suicide. *Minerva Psichiatrica* 53:61-78.
964. Gould F, Clarke J, Heim C, Harvey PD, Majer M and **Nemeroff CB**. 2012. The Effects of Child Abuse and Neglect on Cognitive Functioning in Adulthood. *Journal of Psychiatric Research* 46:500-506.

965. Dunlop BW, Binder EB, Cubells JF, Goodman MM, Kelley ME, Kinkead B, Kutner M, **Nemeroff CB**, Newport DJ, Owens MJ, Pace TWW, Ritchie JC, Rivera VA, Westen D, Craighead WE and Mayberg HS. 2012. Predictors of Remission in Depression to Individual and Combined Treatments (PREdict): Study Protocol for a Randomized Controlled Trial. *Trials* 13:106.
966. Coccaro EF, Lee R, Owens MJ, Kinkead B, **Nemeroff CB**. 2012. Cerebrospinal Fluid Substance P-Like Immunoreactivity Correlates with Aggression in Personality Disordered Subjects. *Biological Psychiatry* 72:238-243
967. **Nemeroff CB** and Goldschmidt-Clermont PJ. 2012. Heartache and Heartbreak: The link Between Depression and Cardiovascular Disease. *Nature Reviews Cardiology* 9:526–539.
968. Myers AJ and **Nemeroff CB**. 2012. APOE: a risk factor for multiple disorders. *American Journal of Geriatric Psychiatry* 20:545-548.
969. Buford UJ and **Nemeroff CB**. 2012. Current Treatment Options for Insomnia. *Drugs of Today* 48:415-423.
970. Rustad JK, Musselman DL, Kyler JS, Matheson D, Delamater A, Kenyon NS, Caceda R and **Nemeroff CB**. 2012. Decision making in Type I Diabetes. *J. Neuropsychiatry Clin. Neurosci.* 25:40-50.
971. Nemeth CL, Shurte MS, McTigue DM, **Nemeroff CB**, and Neigh GM. 2012. Microembolism infarcts lead to delayed changes in affective-like behaviors followed by spatial memory impairment. *Behavioural Brain Research* 234:259-266.
972. Cisler JM, James GA, Steele JS, Mletzko T, Henry C, Hu XP, Mayberg HS, **Nemeroff CB** and Kilts CD. 2013. Differential functional connectivity within an emotion regulation neural network among individuals resilient and susceptible to the depressogenic effects of early life stress. *Psychological Med.* 43:507-518.
973. Ozbolt LB and **Nemeroff CB**. 2012. HPA Axis Modulation in the Treatment of Mood Disorders. *Psychiatric Disorders - New Frontiers in Affective Disorders* 2:21-40.
974. La Riche CL, Prestia D, and **Nemeroff CB**. 2012. The Hypothalamic-Pituitary-Adrenal Axis and Depression. In: *Neurobiology of Mood Disorders* (B. Girard, Ed.)
975. Bremner JD, Cheema FA, Ashraf A, Afzal N, Fani N, Reed L, Musselman DL, Richie JC, Faber T, Votaw JR, **Nemeroff CB** and Vaccarino V. 2009. Effects of a cognitive stress challenge on myocardial perfusion and plasma cortisol in coronary heart disease patients with depression. *Stress and Health* 25:267-278.
976. Bunevicius R, Staniute M, Gintauskiene V, Buneviciute, **Nemeroff CB** and Brozaitiene J. 2013. Endocrine associations with health-related quality of life in coronary artery disease patients. *Int J Cardiol.* 164:246-248.
977. Garlow SJ, Dunlop BW, Neyman K, Ninan PT and **Nemeroff CB**. 2012. The Combination of Triiodothyronine (T3) and Sertraline is Not Superior to Sertraline Monotherapy in the Treatment of Major Depressive Disorder. *Journal of Psychiatric Research* 46:1406-1413.

978. Klengel T, Mehta D, Anacker C, Rex-Haffner M, Pruessner JC, Pariante CM, Pace TWW, Mercer KB, Mayberg HS, Bradley B, **Nemeroff CB**, Holsboer F, Heim CM, Ressler KJ, Rein T, and Binder EB. 2013. Allele-specific FKBP5 DNA demethylation mediates gene–childhood trauma interactions. *Nature Neuroscience* 16:33-41.
979. Flandreau EI, Bourke CH, Ressler KJ, Vale WW, **Nemeroff CB**, and Owens MJ. 2013. Escitalopram alters gene expression and HPA axis reactivity in rats following chronic overexpression of corticotropin-releasing factor from the central amygdala. *Psychoneuroendocrinology* 38, 1349-1361.
980. Nye JA, Purselle D, Plisson C, Voll RJ, Stehouwer JS, Votaw JR, Kilts CD, Goodman MM, and **Nemeroff CB**. 2013. Decreased Brainstem and Putamen SERT Binding Potential in Depressed Suicide Attempters using [¹¹C]-ZIENT PET Imaging. *Depression and Anxiety* 30:902–907.
981. de Achával D, Villarreal MF, Salles A, Bertomeu MJ, Costanzo EY, Goldschmidt M, Castro MN, van der Poel I, **Nemeroff CB**, Guinjoan SM. 2012. Activation of brain areas concerned with social cognition during moral decisions is abnormal in schizophrenia patients and unaffected siblings. *Journal of Psychiatric Research* 47:774-782.
982. Caceda R, **Nemeroff CB**, and Harvey PD. 2013. Toward an understanding of decision making in severe mental illness. *Journal of Neuropsychiatry and Clinical Neurosciences* 26:196-213.
983. Jope RS and **Nemeroff CB**. 2012. The Ups and Downs of Bipolar Disorder Research. *Biological Psychiatry* 73:597-599.
984. Mavrides N and **Nemeroff CB**. 2013. Treatment of Depression In Cardiovascular Disease. *Depression and Anxiety* 30:328-341.
985. Heim CM, Mayberg HS, Mletzko T, **Nemeroff CB**, and Pruessner JC. 2013. Decreased Cortical Representation of Genital Somatosensory Field after Childhood Sexual Abuse. *American Journal of Psychiatry* 170:616-623
986. **Nemeroff CB**. 2013. Neuroscience and Psychiatry: The Path Ahead. In *The American College of Psychiatrists 50th Anniversary Past, Present, and Future*. (J.H. Shore, Ed.), The American College of Psychiatrist, Chicago, Illinois, 106-110.
987. **Nemeroff CB**. 2013. Psychoneuroimmunoendocrinology: The Biological Basis of Mind-Body Physiology and Pathophysiology. *Depression and Anxiety* 30:285-287.
988. Perna G, Alciati A, Prestia D, Torti T, **Nemeroff CB**. 2013. Is there a link between child abuse and neglect and anxiety disorders? *Minerva Psichiatrica* 54:137-148.
989. Ozomaro U, Wahlestedt C, and **Nemeroff CB**. 2013. Personalized Medicine in Psychiatry: Problems and Promises. *BMC Medicine* 11:132.
990. Kornstein SG, Pedersen RD, Holland PJ, **Nemeroff CB**, Rothschild AJ, Thase ME, Trivedi MH, Ninan PT, and Keller MB. 2014. Influence of Sex and Menopausal Status on Response, Remission, and Recurrence in Patients with Recurrent Major Depressive Disorder Treated with Venlafaxine Extended Release or Fluoxetine: Analysis of Data from the PREVENT Study. *The Journal of Clinical Psychiatry* 75:62-68.

991. Currier MB and **Nemeroff CB**. 2013. Depression as a Risk Factor for Cancer: From Pathophysiological Advances to Treatment Implications. *Annual Review of Medicine* 65:203-221.
992. **Nemeroff CB** and Seligman F. 2013. The Pervasive and Persistent Neurobiological and Clinical Aftermath of Child Abuse and Neglect. *Journal of Clinical Psychiatry* 74:10.
993. **Nemeroff CB**, Weinberger D, Rutter M, MacMillan HL, Bryant RA, Wessely S, Stein DJ, Pariente CM, Seemüller F, Berk M, Malhi GS, Preisig M, Brüne M and Lysaker P. 2013. DSM-5: a collection of psychiatrist views on the changes, controversies, and future directions *BMC Medicine* 11:202.
994. Chappell JC, Eisenhofer G, Owens MJ, Haber H, Lachno DR, Dean RA, Knadler MP, **Nemeroff CB**, Mitchell MI, Detke MJ, Iyengar S, Pangallo B, and Lobo AD. 2014. Effects of Duloxetine on Norepinephrine and Serotonin Transporter Activity in Healthy Subjects. *Journal of Clinical Psychopharmacology* 34:9-16.
995. Ryan M and **Nemeroff CB**. 2013. Antidepressants. In *A Concise Guide to Understanding Suicide*. (S. Koslow, P. Ruiz, and C.B. Nemeroff, Eds.), Cambridge University Press, New York, NY. 237-243.
996. Grieve SM, Korgaonkar MS, Etkin A, Harris A, Koslow SH, Wisniewski S, Schatzberg A, **Nemeroff CB**, Gordon E, and Williams LM. 2013. Brain imaging predictors and the International Study to Predict Optimized Treatment for Depression, a randomized controlled trial. *Trials* 14:224.
997. Riva Posse P, **Nemeroff CB**. 2013. The Problem of Treatment-Resistant Psychiatric Disorders. In *Management of Treatment-Resistant Major Psychiatric Disorders*. (C.B. Nemeroff, Ed.), Oxford University Press, New York, NY. 3-21.
998. Ozomaro U, **Nemeroff CB**, Wahlestedt C. 2013. Personalized Medicine in Psychiatry: Dream or Reality? *Psychiatric Times* 30:26-29.
999. Goldschmidt MG, Villarreal MF, de Achával D, Drucaroff LJ, Costanzo EY, Castro MN, Pahissa J, Camprodon J, **Nemeroff CB**, Guinjoan SM. 2014 Cluster B Personality Symptoms in Person at Genetic Risk for Schizophrenia are Associated with Social Competence and Activation of the Right Temporo-Parietal Junction During Emotion Processing. *Psychiatry Research: Neuroimaging* 221:30-36.
1000. Idell R and **Nemeroff CB**. 2013. The Neurobiology of Child Abuse and Neglect. *Directions in Psychiatry* 33:75-84.
1001. Guillory LC, Kinkead B and **Nemeroff CB**. 2013. Neurotensin. In: *Encyclopedia of Psychopharmacology*, 2nd Edition (I.P. Stolerman, Ed.), Springer.
1002. Sotelo JL, Musselman DL and **Nemeroff CB**. 2014. The Biology of Depression in Cancer and the Relationship Between Depression and Cancer Progression. *International Review of Psychiatry* 26:16-30.

1003. Beurel E and **Nemeroff CB**. 2013. Interaction of Stress, Corticotropin-Releasing Factor, Arginine, Vasopressin and Behaviour. In: *Behavioral Neurobiology of Stress-Related Disorders*. M.D.L. Bluhm and C. Pariente, Eds., Current Topics in Behavioral Neurosciences, Springer, Germany 67-80.
1004. Prendes-Alvarez S, Schatzberg AF, and **Nemeroff CB**. 2015. Pharmacological Treatments for Unipolar Depression. In: *A Guide to Treatments that Work*, 4th Edition (P.E. Nathan and J.M. Gorman, Eds.), Oxford University Press 327-353..
1005. Szabo ST and **Nemeroff CB**. 2013. Depression. In: *Rosenberg's Molecular and Genetic Basis of Neurobiological and Psychiatric Disease*, 5th Edition (J.M. Pascual and R.N. Rosenberg, Eds.), Elsevier 1253-1274.
1006. La Riche CL, Prestia D, Block SG and **Nemeroff CB**. 2013. Pathophysiology of Mood Disorders: Neuroendocrine Mechanisms. In: *Neurobiology of Mood Disorders* (B. Girard, Ed.), 8:174-209.
1007. Short ATO and **Nemeroff CB**. 2014. Early Life Trauma and Suicide . In: *Suicide: Phenomenology and Biology* (T. Hudzik and K. Cannon, Eds.), Springer Production 187-205.
1008. Jope RS, Beurel E, Pardo M, Abrial E and **Nemeroff CB**. 2015. The Role of Signal Transduction Systems in the Pathophysiology and Treatment of Bipolar Disorder. In: *The Bipolar Book: History, Neurobiology and Treatment* (A. Yildiz, P.Ruiz and C.B. Nemeroff, Eds.), Oxford University Press.
1009. **Nemeroff CB** and Binder E. 2014. The Preeminent Role of Childhood Abuse and Neglect in Vulnerability to Major Psychiatric Disorders: Towards Elucidating the Underlying Neurobiological Mechanisms. *Journal of American Academy of Child and Adolescent Psychiatry*, 53:395-397.
1010. Doraiswamy PM, Reeder KP, Logue PE, Husain MM, Krishnan KR, **Nemeroff CB**. 1993. Corpus callosal involvement in late-onset depression: MR findings. *Depression*, 1:108-109.
1011. Villareal MF, Drucaroff L, Goldschmidt MG, de Achával D, Constanzo EY, Castro MN, Abrevaya S, Filho GB, **Nemeroff CB** and Guinjoan SM. 2014. Pattern of activation during social cognitive tasks is correlated with deficits in social competence in siblings discordant for schizophrenia. *J. Psychiatr Res*. 56:120-129.
1012. Guinjoan SM and **Nemeroff CB**. 2014. Depression. In: *Brain Mapping: An Encyclopedic Reference* (A. Toga, Ed.), Elsevier 965-970.
1013. Dunlop BW, Rothbaum BO, Binder EB, Duncan E, Harvey PD, Jovanovic T, Kelley ME, Kinkad B, Kutner M, Iosifescu DV, Mathew SJ, Neylan TC, Kilts CD, **Nemeroff CB**, Mayberg HS. 2014. Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. *Trials* 15:240.
1014. Caceda R, Durand D, Cortes E, Prendes-Alvarez S, Moskociak T, Harvey PD, and **Nemeroff CB**. 2014. Impulsive Choice and Psychological Pain in Acutely Suicidal Depressed Patients. *Psychological Medicine*. 76:445-451.
1015. **Nemeroff CB**. 2014. Psychopharmacology and the Future of Personalized Treatment. *Depression and Anxiety* . 31:906–908.

1016. Kumar AM, Kumar M, Lahey BB, Katz DA, Fernandez B, Shaw JA, Campo A and **Nemeroff CB**. 2014. Marked Reduction in Serotonergic Activity in a Sexually Aggressive Adolescent Male. *J Neuropsychiatry Clin Neurosci* 26:262-270.
1017. Coplan JD, Fathy HM, Jackowski AP, Tang CY, Perera TD, Mathew SJ, Martinez J, Abdallah CG, Dwork AJ, Pantol G, Carpenter D, Gorman JM, **Nemeroff CB**, Owens MJ, Kauffman A, Gelernter J and Kaufman J. 2014. Early Life Stress and Macaque Amygdala hypertrophy: Preliminary evidence for a role for serotonin transporter gene. *Frontiers in Behavioral Neuroscience*. 8:1-10.
1018. Reidy LJ, Junquera P, Van Dijck K, Steele BW, and **Nemeroff CB**. 2014. Underestimation of Substance Abuse in Psychiatric Patients by Conventional Hospital Screening. *J. Psychiatric Research*. 59:206-212.
1019. Myers AJ, Williams L, Gatt JM, McAuley-Clark E, Dobson-Stone C, Schofield P, and **Nemeroff CB** 2014. Variation in the Oxytocin Receptor Gene is Associated with Increased Anxiety in Individuals with a History of Exposure to Early Life Stress. *J. Psychiatric Research*. 59:93-100.
1020. Block SG, **Nemeroff CB**. 2014. Emerging antidepressants to treat major depressive disorder. *Asian J. Psychiatry*. 12:7-16.
1021. Seligman F and **Nemeroff CB**. 2014. The interface of Depression and Cardiovascular Disease: Therapeutic Implications. *New York Academy of Sciences*. 1345:25-35.
1022. Luca L and **Nemeroff CB**. 2015. The Role of the Hypothalamic-Pituitary-Adrenal Axis in Anxiety Disorders. In: *Anxiety Disorders* (K. Ressler, D. Pine, and B. Rothbaum, Eds.) Oxford University Press, New York, NY. 401-411.
1023. Chastain LG, Qu H, Bource CH, Iuvone MP, Dobner PR, **Nemeroff CB**, Kinkead B. 2014. Striatal dopamine receptor plasticity in neurotensin deficient mice. *Behavioral Brain Research*. 280:160-171.
1024. Mavrides N and **Nemeroff CB**. 2015. Treatment of Affective Disorders in Cardiac Disease. *Dialogues in Clinical Neuroscience*. 17:127-140.
1025. **Nemeroff CB** and Duman RA. 2015. Inflammation and Psychiatric Disorders. *Psychiatric Annals*. 45:222-224.
1026. Alhajji L and **Nemeroff CB**. 2015. Personalized Medicine and Mood Disorders. In: *Psychiatric Clinics of North America*. (D.A. Baron and L. S. Gross Eds.) Elsevier, Philadelphia, Pennsylvania. 395-403.
1027. Rueda-Lara M and **Nemeroff CB**. 2015. Neuropsychiatric Aspects of Endocrine Disorders. In: *The Textbook of Neuropsychiatry and Behavioral Neurosciences, 6th Edition* (S. Yudofsky, Ed.) American Psychiatric Press Inc., Washington, DC.
1028. Costanzo EY, Villareal M, Drucaroff LJ, Ortiz-Villafañe M, Castro MN, Goldschmidt M, Wainsztein AE, Ladron-de-Guevara MS, Romero C, Brusco LI, Camprodon JA, **Nemeroff CB**, Guinjoan SM. 2015. Hemispheric specialization in affective responses, cerebral dominance for language, and handedness. Lateralization of emotion, language, and dexterity. *Behavioural Brain Research*. 288:11-19.

1029. Butnoriene J, Bunevicius A, Saudargiene A, **Nemeroff CB**, Norjus Antanas, Cicenienė V, Bunevicius R. 2015. Metabolic syndrome, major depression, generalized anxiety disorder, and ten-year all-cause and cardiovascular mortality in middle aged and elderly patients. *International Journal of Cardiology*. 190: 360-366.
1030. Brothers, S, Young L, and **Nemeroff CB**. 2017. Neuropeptides: Biology, regulations and Role in Neuropsychiatric Disorders. In: *Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Tenth Edition* (B. Sadock, V. Sadock and P. Ruiz, Eds.), Lippincott Williams & Wilkins. 84-97.
1031. Guinjoan SM, de Achával D, Villarreal MF, Abussamra V and **Nemeroff CB**. 2015. From Semantic to Social Deficits: Dysfunction of the Nondominant Posterior Perisylvian Area in Schizophrenia. *J Neuropsychiatry Clin Neurosci*. 27:254-261.
1032. Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M and **Nemeroff CB**. 2015. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. *Amer J Psychiatry*. 172:950–966.
1033. Neuhut R, Benton T, Crits-Christoph P, Davila M, Weissman M, and **Nemeroff CB**. 2018. Defining Depression and Bipolar Disorder. In: *Treating and Preventing Adolescent Mental Health Disorders, 2nd Edition* (Dwight L. Evans, Edna B. Foa, Raquel E. Gur, Herbert Hendin, Charles P. O'Brian, Daniel Romer, Martin E.P. Seligman and Timothy Walsh, Eds.) 3-43.
1034. Heim C and **Nemeroff CB**. 2015. Neurobiological Pathways Involved in Fear, Stress, and PTSD. In: *Neurobiology of PTSD: From Brain to Mind, Section 2: Biological Findings in PTSD* (I. Liberzon and K. Ressler, Eds.), Oxford University Press, New York, NY. 220-238.
1035. Westfall NC and **Nemeroff CB**. 2015. The Preeminence of Early Life Trauma as a Risk Factor for Worsened Long-Term Health Outcomes in Women. In: *Current Psychiatric Reports, Volume 17* (Dwight L. Evans and Robert O. Friedel, Eds.) Springer. 17:90.
1036. Castro MN, Villarreal MF, Bolotinsky N, Papávero E, Goldschmidt MG, Costanzo EY, Drucaroff L, Wainsztein A, de Achával D, Pahissa J, Bär J-K, **Nemeroff CB**, and Guinjoan SM. 2015. Brain Activation Induced by Psychological Stress in Patients with Schizophrenia. *Schizophrenia Research* 168:313-321.
1037. Tafet GE and **Nemeroff CB**. 2015. The Links Between Stress and Depression: Psychoneuroendocrinological, Genetic and Environmental Interactions. *J Neuropsychiatry Clin Neurosci*. 28:77-88.
1038. **Nemeroff CB**. 2015. The Holy Grail of Psychiatry. In: *Cerebrum 2015*. (B. Glovin, Ed.) Dana Press, New York. 81-89.
1039. Lopez-Patton M, Kumar M, Jones D, Fonseca M, Kumar AM, and **Nemeroff CB**. 2015. Childhood trauma and METH abuse among men who have sex with men: Implications for intervention. *Journal of Psychiatric Research*. 72:1-5.
1040. Ahmadi N, Moss L, Simon E, **Nemeroff CB**, and Atre-Vaida N. 2015. Efficacy and Long-Term Clinical Outcome of Comorbid Posttraumatic Stress Disorder and Major Depressive Disorder after Electroconvulsive Therapy. *Depression and Anxiety*. 33:640-647.

1041. Steibliene V, Bunevicius A, Savickas A, Prange AJ, **Nemeroff CB**, and Bunevicius R. 2015. Triiodothyronine accelerates and enhances the antipsychotic effect of risperidone in acute schizophrenia. *Journal of Psychiatric Research*. 73:9-16.
1042. Zannas AS, Arloth J, Carrillo-Roa T, Iurato S, Röh S, Ressler KJ, **Nemeroff CB**, Smith AK, Bradley B, Heim C, Menke A, Lange JF, Brückl, Ising M, Wray NR, Erhardt A, Binder EB, Mehta D. 2015. Lifetime stress accelerates epigenetic aging in an urban, African American cohort: relevance of glucocorticoid signaling. *Genome Biology*. 16:266.
1043. Jope RS and **Nemeroff CB**. 2015. Lithium to the Rescue. *Cerebrum*. 1-11.
1044. **Nemeroff CB**. 2016. Paradise Lost: The Neurobiological and Clinical Consequences of Child Abuse and Neglect. *Neuron* 89:892-909.
1045. Houtepen LC, Vinkers CH, Carrillo-Roa T, Hiemstra M, va Lier P, Meeus W, Branje S, Heim CM, **Nemeroff CB**, Mill J, Schalkwyk LC, Creyghton MP, Kahn RS, Joëls M, Binder EB, and Boks MPM. 2016. Genome-wide DNA methylation levels and altered cortisol stress reactivity following childhood trauma in humans. *Nature Communications*. 7:10967.
1046. Williams LM, DeBattista C, Duchemin AM, Schatzberg AF, and **Nemeroff CB**. 2016. Childhood Trauma Predicts Antidepressant Response in Adults with Major Depression: Data from the Randomized International Study to Predict Optimized Treatment for Depression. *Translational Psychiatry* 6:1-7.
1047. Menke A, Arloth J, Best J, Namendorf C, Gerlach T, Cazmara D, Lucae S, Dunlop BW, Crowe TM, Garlow SJ, **Nemeroff CB**, Ritchie JC, Craighead WE, Mayberg HS, Rex-Haffner M, Binder EB, and Uhr M. 2016. Time-dependent effects of dexamethasone plasma concentrations on glucocorticoid receptor challenge tests. *Psychoneuroendocrinology* 69:161–171.
1048. **Nemeroff CB** and Rasgon N. 2016. More Time for Science and Less Time for Administration? *Neuropsychopharmacology*, 41:2625-2626.
1049. Newport JD, Schatzberg AF and **Nemeroff CB**. 2016. Whither Ketamine as an Antidepressant: Panacea or Toxin?. *Depression and Anxiety* 33:685-688.
1050. Kalin M and **Nemeroff CB**. 2016. Mood Disorders. In: *The SAGE Encyclopedia of Theory in Psychology* (H.L. Miller Ed.) SAGE Publications, Inc., Thousand Oaks. 560-563.
1051. Howlett JR, Stein MB and **Nemeroff CB**. 2017. Paroxetine. In: *Textbook of Psychopharmacology, 5th Edition* (A.F. Schatzberg and C.B. Nemeroff, Eds.), American Psychiatric Press, Inc., Washington DC. 385-418.
1052. **Nemeroff CB**. 2016. Understanding Post-Traumatic Stress Disorder (PTSD): From Diagnosis and Neurobiology to Treatment. *Psychiatric Annals*. 9:494-496.
1053. Albrahim S, Henry JH and **Nemeroff CB**. 2017. Cariprazine. In: *Textbook of Psychopharmacology, 5th Edition* (A.F. Schatzberg and C.B. Nemeroff, Eds.), American Psychiatric Press, Inc., Washington DC. 831-854.
1054. Sotelo JL and **Nemeroff CB**. 2017. Depression as a Systemic Disease. *Personalized Medicine in Psychiatry* 1-2:11-25.

1055. Westfall NC and **Nemeroff CB**. 2016. State of the Art Prevention and Treatment of PTSD – Pharmacotherapy, Psychotherapy and Non-pharmacological Somatic Therapies. *Psychiatric Annals* 46:533-549.
1056. Sanacora G, Heimer H, Hartman D, Mathew SJ, Frye M, **Nemeroff CB** and Robinson Beale R. 2016. Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders. *Neuropsychopharmacology*. 42:1179-1181.
1057. Goldstein-Piekarski AN, Korgaonkar MS, Green E, Suppes T, Schatzberg AF, Hastie T, **Nemeroff CB** and Williams LM. (2016). Human Amygdala Engagement moderated by Early Life Stress Exposure is a Biobehavioral Target for Predicting Recovery on Antidepressants. *PNAS*. 113:11955-11960.
1058. Sanders J and **Nemeroff CB**. 2016. The CRF as a Therapeutic Target for Neuropsychiatric Disorders. *Trends in Pharmacological Sciences*. 12:1045-1054.
1059. Prendes-Alvarez and **Nemeroff CB**. 2016. Personalized Medicine: Prediction of Disease Vulnerability in Mood Disorders. *Neuroscience Letters*. 669:10-13.
1060. Berg JM, Kennedy JC, Dunlop BW, Ramirez CL, Stewart LM, **Nemeroff CB**, Mayberg HS and Craighead WE. 2016. The Structure of Personality Disorders within a Depressed Sample: Implications for Personalizing Treatment. *Personalized Medicine in Psychiatry*. 1-2:59-64.
1061. Dunlop BW, Rajendra JK, Craighead WE, Kelley ME, McGrath CL, Choi KS, Kinkead B, **Nemeroff CB**, and Mayberg HS. 2016. Functional Connectivity of the Subcallosal Cingulate Cortex Identifies Differential Outcomes to Treatment with Cognitive Behavior Therapy or Antidepressant Medication for Major Depressive Disorder. *American J Psychiatry* 174:533-545.
1062. Stevens JS, Kim YJ, Galanter-Levy IR, Reddy R, Ely TD, **Nemeroff CB**, Hudak LA, Javonavic T, Rothbaum BO and Ressler KJ. 2016. Amygdala reactivity and anterior cingulate habituation predict PTSD symptom maintenance after acute civilian trauma. *Biological Psychiatry*. 81:1023-1029.
1063. Sabbag S, Alhajji L, Saveanu RV, Stahl S and **Nemeroff CB**. 2017. Teaching Neurobiology in Psychiatry. In: *Mental Health and Illness Worldwide. Education about Mental Health and Illness* (M.H.M. Hermans, T.C. Hoon, E. Pi, Eds.), Springer. 1-42.
1064. Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrand P, **Nemeroff CB**, American Psychiatric Association Council of Research Task Force on Novel Biomarkers and Treatments. 2017. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. *JAMA Psychiatry* 74:399-405.
1065. Gonzalez SD, Williams AJ, Blacker CJ, Vande Voort JL, Schak KM, **Nemeroff CB**, Widge AS and Tohen M. 2017. Putative Biological Predictors of Treatment Response in Bipolar Disorders. *Personalized Medicine in Psychiatry*. 1-2:39-58.
1066. Dunlop BW, Kelley ME, Aponte-Rivera V, Mletzko-Crowe T, Kinkead B, Ritchie JC, **Nemeroff CB**, Craighead WE, Mayberg HS, for the PRedICT Team. 2017. Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PRedICT) Study. *American J Psychiatry* 174:546-556.

1067. Coplan JD, Rozenboym AV, Fulton SL, Panthangi V, Tang J, Thiramangalakdi L, Perera TD, Liu Y, Kamran H, Owens MJ, **Nemeroff CB**, Rosenblum LA, Kral JG, Saliccioli L and Lazar J. 2017. Reduced left ventricular dimension and function following early life stress: A thrifty phenotype hypothesis engendering risk for mood and anxiety disorders. *Neurobiology of Stress*; 8:202-210.
1068. Syed SA, Smith ELP, Batuman O, Rosenblum LA, Owens MJ, **Nemeroff CB**, and Coplan JD. 2017. Adult Glucocorticoid Receptor mRNA Expression Volatility in Response to an Acute Stressor and Juvenile CSF Corticotropin-Releasing Factor: A Pilot Neurodevelopmental Study. *Neuroscience Letters* 647:20-25.
1069. Syed AS and **Nemeroff CB**. 2017. Early Life Stress, Mood and Anxiety Disorders. *Chronic Stress* 1:1-16.
1070. Perna G, Balletta R, and **Nemeroff CB**. 2017. Precision Psychiatry: Personalized Clinical Approach to Depression. In: *Understanding Depression: Contemporary Issues* (Yong-Ku Kim, Ed.) Springer-Nature. Chapter 21:245-261.
1071. Dunlop BW, Binder EB, Iosifescu DV, Mathew SJ, Neylan TC, Pape JC, Carrillo-Roa T, Green C, Kinkead B, Grigoriadis D, Rothbaum BO, **Nemeroff CB**, and Mayberg HS. 2017. Corticotropin-Releasing Factor Type 1 Receptor Antagonist is Ineffective for Women with Posttraumatic Stress Disorder. *Biological Psychiatry* 82:866-874.
1072. Perna G, Grassi M, Caldirola D, and **Nemeroff CB**. 2017. The revolution of personalized psychiatry: will technology make it happen sooner? *Psychological Medicine*.1-9.
1073. Bernanke J, Galfalvy H, Mortali M, Hoffman L, Moutier C, **Nemeroff CB**, Stanley B, Clayton P, Harkavy-Friedman J, and Oquendo M. 2017. Suicidal Ideation and Behavior in Institutions of Higher Learning: A Latent Class Analysis. *Journal of Psychiatric Research* 95:253-259.
1074. O'Connell CP, Goldstein-Piekarski AN, **Nemeroff CB**, Schatzberg AF, Debattista C, Carrillo-Roa T, Binder EB, Dunlop BW, Craighead WE, Mayberg HS, and Williams LM. 2017. Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin Releasing Hormone Binding Protein. *American Journal of Psychiatry*. 175:251-261.
1075. Sanchez SM, Abulafia C, Duarte-Abritta B, Ladron de Guevara MS, Castro MN, Drucaroff L, Seivlever G, **Nemeroff CB**, Vigo DE, Loewenstein DA, Villarreal MF, and Guinjoan SM. 2017. Failure to Recover from Proactive Semantic Interference and Abnormal Limbic Connectivity in Asymptomatic Middle-Aged Offspring of Patients with Late-Onset Alzheimer's Disease. *Journal of Alzheimer's Disease*. 60:1183-1193.
1076. Castro MN, Vigo DE, Gustafson DR, Vila-Perez I, Massaro P, Garcia C, **Nemeroff CB**, Guinjoan SM, and Ladron de Guevara MS. 2017. Acute and six-month depression-related abnormalities in the sleep-wake rhythm of cardiac autonomic activity in survivors of acute coronary syndromes. *Personalized Medicine in Psychiatry*; 4-6:13-18.
1077. Syed SA, Cranshaw M, and **Nemeroff CB**. 2017. Molecular and Behavioral Aspects – Child Abuse and Neglect: Stress Responsivity and Resilience. In: *Stress Resilience* (Alon Chen, Ed.) Elsevier. (in press).

1078. Heim C, Schultebraucks K, Marmar CR and **Nemeroff CB**. 2017. Neurobiological Pathways Involved in Fear, Stress, and PTSD. In: *Posttraumatic Stress Disorder* (C. Marmar and C.B. Nemeroff, Eds.) (in press).
1079. Kennedy JC, Dunlop BW, Craighead LW, **Nemeroff CB**, Mayberg HS and Craighead WE. 2017. Follow-up of Monotherapy Remitters in the PRedICT Study: Maintenance Treatment Outcomes and Clinical Predictors of Recurrence. *Journal of Consulting and Clinical Psychology*; 86:189-199.
1080. Carrillo-Roa T, Labermaier C, Weber P, Herzog DP, Laureau C, Santarelli S, Wagner KV, Rex-Haffner M, Harbich D, Scharf SH, **Nemeroff CB**, Dunlop BW, Craighead WE, Mayberg HS, Schmidt MV, Uhr M, Holsboer F, Sillaber I, Binder EB, and Müller MB. 2017. Common genes associated with antidepressant response in mouse and man identify key role of glucocorticoid receptor sensitivity. *PLoS Biol*; 15(12):e2002690.
1081. **Nemeroff CB**. 2017. Ketamine: Quo vadis? *American J. Psychiatry*; 175:4.
1082. Khalsa SS, Adolphs R, Cameron OG, Critchley HD, Davenport P, Feinstein JS, Feusner JD, Garfinkel SN, Lane RD, Mehling WE, AE Meuret, **Nemeroff CB**, Oppenheimer S, Petzschner FH, Pollatos O, Rhudy JL, Schramm LP, Simmons WK, Stein MB, Stephan KE, Van Den Bergh O, Van Diest I, von Leupoldt A, and Paulus MP. 2017. Interception and Mental Health: a Roadmap. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*; 3:501-513.
1083. Dunlop BW, Cole SP, **Nemeroff CB**, Mayberg HS, and Craighead WE. 2017. Differential Change on Depressive Symptom Factors with Antidepressant Medication and Cognitive Behavior Therapy for Major Depressive Disorder. *Journal of Affective Disorders*; 229:111-119.
1084. Tan SK, Jermakowicz A, Mookhtiar A, **Nemeroff CB**, Schürer SC, and Ayad NG. 2017. Drug Repositioning in Glioblastoma: A Pathway Perspective. *Frontiers in Pharmacology*; 9:218.
1085. Zeier Z, Carpenter LL, Kalin NH, Rodriguez CI, McDonald WM, Widge AS, and **Nemeroff CB**. 2018. Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing. *American J. Psychiatry*; AJP in Advance (doi: 10.1176/appi.ajp.2018.17111282).
1086. Botros M, Hodgins G, and **Nemeroff CB**. 2018. The Long-Lasting Neurobiological Scars of Early Life Stress: Implications for the Neurobiology of Depression. In: *Neurobiology of Depression: Road to Novel Therapeutics* (João Quevedo, André F. Carvalho, and Carlos Zarate, Eds.)
1087. Coplan JD, Lu D, El Sehamy AM, Tang C, Jackowski AP, Abdallah CG, **Nemeroff CB**, Owens MJ, Mathew SJ and Gorman JM. 2018. Early Life Stress Associated with Increased Striatal *N*-Acetyl-Aspartate: Cerebrospinal Fluid Corticotropin-Releasing Factor Concentrations, Hippocampal Volume, Body Mass, and Behavioral Correlates. *Chronic Stress*; 2:1-15
1088. Mavrides N and **Nemeroff CB**. 2018. Biological Effects of Depression in Cardiac Illness. In: *Depression as a Systemic Illness* (James J. Strain and Michael Blumenfeld, Eds.); 61-83.
1089. **Nemeroff CB**. 2018. The Search for Treatments for Depressed Veterans – Of Paramount Importance, Yet Still Elusive. *JAMA*; E1-E2.

1090. Abulafia C, Loewenstein D, Curiel, R, Duarte-Abritta B, Sanchez SM, Castro MN, Drucaroff LJ, Gustavo S, **Nemeroff CB**, Guinjoan SM and Villareal MF. 2018. Brain Structural and Amyloid Correlates of Recovery from Semantic Interference in Cognitively Normal Individuals with or without Family History of Late-Onset Alzheimer's Disease. *J. Neuropsychiatry Clin. Neurosciences* (in press).

BOOKS

1. **Nemeroff CB** and Dunn AJ, Eds. 1984. Peptides, Hormones and Behavior. Spectrum Press, New York, New York.
2. **Nemeroff CB** and Prange AJ, Jr., Eds. 1982. Neurotensin, a Brain and Gastrointestinal Peptide. Ann. NY Acad. Sci., Vol. 400.
3. **Nemeroff CB** and Loosen PT, Eds. 1987. Handbook of Clinical Psychoneuroendocrinology. Guilford Press, New York, New York.
4. **Nemeroff CB**, Ed. 1988. Neuropeptides in Psychiatric and Neurological Disorders. Johns Hopkins University Press, Baltimore, Maryland.
5. Schatzberg AF and **Nemeroff CB**, Eds. 1988. The Hypothalamic-Pituitary- Adrenal Axis: Physiology, Pathophysiology and Psychiatric Implications. Raven Press, New York, New York.
6. Kalivas PW and **Nemeroff CB**, Eds. 1988. Mesocorticolimbic Dopamine System. Ann. New York Acad. Sci., vol. 537.
7. DeSouza EB and **Nemeroff CB**, Eds. 1989. Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide. CRC Press, Inc., Boca Raton, Florida.
8. **Nemeroff CB**, Ed. 1991. Neuropeptides in Psychiatric Disorders. American Psychiatric Association Press, Washington, DC.
9. **Nemeroff CB**. 1990. Psychoneuroendocrinology. Current Concepts Monograph, The UpJohn Company.
10. McCubbin JA, Kaufman PG and **Nemeroff CB**, Eds. 1991. Stress, Neuropeptides and Systemic Disease. Academic Press, Orlando, Florida.
11. **Nemeroff CB**, Ed. 1992. Neuroendocrinology, CRC Press, Boca Raton, Florida.
12. Kitabgi P and **Nemeroff CB**. 1992. The Neurobiology of Neurotensin: Ann. New York Acad. Sci., Vol 668.
13. Bowden CL, **Nemeroff CB** and Potter WZ. 1991. Practical Clinical Guidelines for the Management of Bipolar Disorder. Volume 1: Diagnosis, Volume 2: Treatment, Volume 3: Special Topics. Abbott Laboratories.
14. Schatzberg AF and **Nemeroff CB**, Eds. Textbook of Psychopharmacology, First Edition 1995; Second Edition, 1998; Third Edition, 2004, Fourth Edition, 2009, Fifth Edition, 2017. American Psychiatric Publishing, Inc., Washington, DC.
15. **Nemeroff CB**. 1994. The Psychoneuroendocrinology of Depression: Hypothalamic-Pituitary-Adrenal Axis Dysregulation. The Thirtieth Annual Institute of Pennsylvania Hospital Award Lecture in Memory of Edward A. Strecker. Monograph.
16. **Nemeroff CB**. 1998. Psychoneuroendocrinology: The Psychiatric Clinics of North America. WB Saunders, Philadelphia, Pennsylvania, Volume 21.

17. **Nemeroff CB** and Schatzberg AF, Eds. 1999. Recognition and Treatment of Psychiatric Disorders. American Psychiatric Press, Washington, DC.
18. Schatzberg AF and **Nemeroff CB**, Eds. Essentials of Clinical Psychopharmacology. First Edition, 2001. American Psychiatric Press, Washington, DC.
19. **Nemeroff CB**, Ed. 2001. Advances in the pathophysiology and treatment of psychiatric disorders: implications for internal medicine. Medical Clinics of North America 85:3.
20. Craighead WE and **Nemeroff CB**, Eds. 2001. The Corsini Encyclopedia of Psychology and Behavioral Science, Third Edition, Volumes 1-4, John Wiley & Sons, New York, New York.
21. Davis KL, Charney DS, Coyle JT, and **Nemeroff CB**, Eds. 2002. Neuropsychopharmacology: The Fifth Generation of Progress, Lippincott Williams and Wilkins, Philadelphia, Pennsylvania.
22. Newport DJ and **Nemeroff CB**, Guest Editors. 2002. Seminars in Clinical Neuropsychiatry, Vol 7.
23. Purselle DC, **Nemeroff CB** and Jongsma, Jr. AE, Eds. 2003. The Psychopharmacology Treatment Planner, John Wiley & Sons, Hoboken, New Jersey.
24. Charney DS and **Nemeroff CB**. 2004. The Peace of Mind Prescription. Houghton Mifflin Company, Boston Massachusetts.
25. Craighead WE and **Nemeroff CB**. 2004. The Concise Corsini Encyclopedia of Psychology and Behavioral Science, Third Edition, John Wiley & Sons, New York, New York.
26. Kelsey JE, Newport DJ and **Nemeroff CB**. 2006. Principles of Psychopharmacology for Mental Health Professionals. John Wiley & Sons, Inc., Hoboken, New Jersey.
27. Schatzberg AF and **Nemeroff CB**, Eds. Essentials of Clinical Psychopharmacology. Second Edition, 2006. American Psychiatric Press, Washington, DC.
28. Hales RE, Shahrokh NC, Schatzberg AF and **Nemeroff CB**. 2009. Study Guide to Psychopharmacology, A Companion to The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, American Psychiatric Association Press, Washington, DC.
29. Schlaepfer T and **Nemeroff CB**, Eds. 2012. Handbook of Clinical Neurology, Volume 106: Neurobiology of Psychiatric Disorders, Springer-Verlag.
30. **Nemeroff CB**, Ed. 2012. Management of Treatment Resistant Major Psychiatric Disorders. Oxford University Press, New York, New York.
31. Schatzberg AF and **Nemeroff CB**, Eds. 2013. Essentials of Clinical Psychopharmacology. Third Edition. American Psychiatric Press, Washington, DC.
32. Koslow SH, Ruiz P and **Nemeroff CB**, Eds. 2014 A Concise Guide to Understanding Suicide. Cambridge University Press, New York and Cambridge.
33. Yildiz A, Ruiz P and **Nemeroff CB**, Eds. 2015. The Bipolar Disorder Book: History, Neurobiology and Treatment. Oxford University Press, New York.

BOOK REVIEWS, LETTERS TO THE EDITOR, AUDIO TAPES AND OTHER PUBLICATIONS

1. **Nemeroff CB.** 1979. Review of: Endocrinology: A Logical Approach for Clinicians (W Jubiz, Ed), McGraw-Hill Book Co., New York, 1979. The New Physician 28:38-39.
2. **Nemeroff CB.** 1980. Review of: Practical Drug Therapy (Richard IW Wang, Ed), J.B. Lippincott Co., Philadelphia, 1979. The New Physician 29:49.
3. **Nemeroff CB.** 1982. Hormones and mental illness. Review of: Neuroendocrine Regulation and Altered Behavior (PD Hrdina and RL Singhal, Eds). Contemporary Psychiatry 1:137-140.
4. **Nemeroff CB.** 1983. A how to guide of new methods for psychopharmacologists and neurochemists. Review of: Handbook of Psychopharmacology, Volume 15: New Techniques in Psychopharmacology (LL Iversen, SD Iversen and SH Snyder, Eds). Contemporary Psychiatry 2:252.
5. Widerlov E, Lindstrom LH, Besev G, Manberg PJ, **Nemeroff CB**, Breese GR, Kizer JS and Prange AJ, Jr. 1983. Neurotensin, schizophrenia and common sense: reply. Amer. J. Psychiatry. 140:658.
6. Simon JS and **Nemeroff CB.** 1984. Psychiatric endocrinology: an overview. Review of: Handbook of Psychiatry and Endocrinology (PJC Beaumont and G Burrows, Eds). Contemporary Psychiatry 3:101-104.
7. Smith MA and **Nemeroff CB.** 1985. A window into the brain: endocrine abnormalities in psychiatric disease. Review of: Psychoneuroendocrine Dysfunction (NS Shah and AG Donald, Eds). Contemporary Psychiatry 4:6-9.
8. Elliott PJ and **Nemeroff CB.** 1985. [Just about] everything you ever wanted to know about receptors but were too afraid to ask. Review of: Handbook of Psychopharmacology, Volume 17: Biochemical Studies of CNS Receptors (LL Iversen, SD Iversen and SH Snyder, Eds). Contemporary Psychiatry 4:105-108.
9. Banki CM and **Nemeroff CB.** 1985. Review of: The Anterior Pituitary Gland. Book Reviews in the Neurosciences, Summer 1985, Number 10.
10. Banki CM and **Nemeroff CB.** 1985. Laboratory tests in psychiatry: one step closer to the mainstream of medicine. Review of: Handbook of Psychiatric Diagnostic Procedures, Volume 1 (RCW Hall and TP Beresford, Eds). Contemporary Psychiatry 4:157-158.
11. Skoog KM and **Nemeroff CB.** 1985. Review of: Frontiers in Neuroendocrinology, Volume 8 (L Martini and WF Ganong, Eds). Book Reviews in the Neurosciences, Summer 1985, Number 52.
12. **Nemeroff CB**, Simon JS, Haggerty JJ and Evans DL. 1986. Anti-thyroid antibodies in depressed patients: reply to letter. Am J Psychiatry 143:555-556.
13. **Nemeroff CB.** 1986. The hypothalamic-pituitary-adrenal axis in depression. Review of: Cortisol Changes in Depression: Parts 1 and 2. Psychiatric Medicine, Vol. 3, Nos. 1 and 2 (RG Kathol, Ed). Contemporary Psychiatry 5:168-171.

14. **Nemeroff CB.** 1986. Neurotensin: Immunohistochemical Localization in Central and Peripheral Nervous System and in Endocrine Cells and its Functional Role as Neurotransmitter and Endocrine Hormone. Progress in Histochemistry and Cytochemistry (M. Reinecke, Ed). J. Neurosci. Res. 16:445-446.
15. Pryor JC and **Nemeroff CB.** 1987. An introductory Tour de Force in Central Nervous System Pharmacology. Review of: The Biochemical Basis of Neuropharmacology, 5th ed. (JR Cooper, FE Bloom and RH Roth, Eds). Contemporary Psychiatry 6:248-249.
16. Figiel G and **Nemeroff CB.** 1987. A Brief Update on Schizophrenia. Review of: Can Schizophrenia be Localized in the Brain (NC Andreasen, Ed). Contemporary Psychiatry 6:130-131.
17. Chappell PB and **Nemeroff CB.** 1987. A high-tech primer for the new psychiatry. Review of: Diagnostic and Laboratory Testing in Psychiatry (MS Gold and ALC Pottash, Eds), Plenum Press. Contemporary Psychiatry 6:153-157.
18. McGough JJ and **Nemeroff CB.** 1988. Food, drugs and behavior: you are what you eat and beyond. Review of: Psychopharmacology of Food (M Sandler, Ed). Contemporary Psychiatry 7:109-111.
19. **Nemeroff CB** and Knight DL. 1987. Platelet receptor binding studies in psychiatry. The Psychiatric Times 4:37-38.
20. Lundberg D and **Nemeroff CB.** 1988. Chemical neurotransmission in the brain and mental illness. Review of: Psychiatric Disorders, Neurotransmitters and Neuropeptides (JM van Ree and S Matthyse, Eds), Elsevier. Contemporary Psychiatry 7:35-37.
21. Owens MJ and **Nemeroff CB.** 1988. God vs. man: who created valium first. Review of: The Benzodiazepine Receptor (WE Muller, Ed), Cambridge Univ. Press, 1987. Contemporary Psychiatry 7:224-227.
22. Bissette G and **Nemeroff CB.** 1988. Somatostatin immunoreactivity in postmortem brain from depressed suicides - reply. Arch. Gen. Psychiatry 45:597-598.
23. Brown HE and **Nemeroff CB.** 1988. Immune and neuroendocrine reciprocation. Review of: Explorations in Psychoneuroimmunology (R Lloyd, Ed) Grune and Stratton, 1987. Contemporary Psychiatry 7:228-230.
24. Kasckow J and **Nemeroff CB.** 1989. Opiates and behavior. Review of: Endorphins, Opiates and Behavioral Processes (RJ Rodgers and SJ Cooper, Eds), John Wiley & Sons, 1988. Contemporary Psychiatry 8:57-59.
25. **Nemeroff CB.** 1991. Review of: Animal Models of Depression (GF Koob, CL Ehlers and DJ Kupfer, Eds), Neuropsychopharmacology 37:197-199.
26. **Nemeroff CB,** Evans DL and Morihisa JM. 1991. The laboratory in clinical psychiatric practice. Amer. College Psychiatrists, Psychiatric Update Audiocassette Series.
27. Krishnan, KRR, Ellinwood, EH, Jr. and **Nemeroff CB.** 1992. Tricyclic antidepressants reveal SIADH secondary to oat cell carcinoma. J. Clin. Psychopharmacol. 12:68-69.

28. **Nemeroff CB.** 1991. Anxiety Disorders. Software Program. Cardinal Health Care Systems, Edina, Minnesota.
29. **Nemeroff CB.** 1993. Review of: Refractory Depression. (J Amsterdam, Ed). Neuropsychopharmacology 8:281-283.
30. **Nemeroff CB.** 1994. Review of: Research in Psychiatry: Issues, Strategies and Methods (LK George Hsu and M Hersen, Eds), Plenum Press, New York, Academic Psychiatry 18:53-55.
31. Winn SS, Stowe ZN and **Nemeroff CB.** 1996. Diagnosis and treatment of postpartum depression. In: Clinical Advances in the Treatment of Psychiatric Disorders, 10:1-3.
32. **Nemeroff CB.** 1996. The Role of Specific Neurotransmitter Systems in the Pathophysiology and Treatment of Depression: Implications for Serotonin-Norepinephrine Reuptake Inhibitors. Monograph, Wyeth-Ayerst Laboratories.
33. **Nemeroff CB.** 1996. Reply to Gamon and Lane. J Clin Psychiat 57:267-269.
34. **Nemeroff CB.** 1997. Too Much Stuff, Too Little Time. Guest editorial, CNS Spectrums. 2:70.
35. **Nemeroff CB.** 1997. Depression Must be Invisible. Guest editorial, CNS Spectrums. 6:70.
36. Kinkead B and **Nemeroff CB.** 1997. Die Rolle von Neurotensin bei der Schizophrenia und der Wirkungs-mechanismus von Neuroleptika. ZNS Journal, August, 1997 pp 3-8.
37. **Nemeroff CB.** 1997. Striking a Balance Between Clinical Medical School Departments and the Industry. Guest editorial, CNS Spectrums. 8:65.
38. **Nemeroff CB.** 1997. Striking a Balance with the Pharmaceutical Industry: Part II. Guest editorial, CNS Spectrums. 9:68.
39. **Nemeroff CB.** 1997. Reply to Jefferson J. J Clin Psychiat 58:450-452.
40. **Nemeroff CB.** 1997. Managed Care in Psychiatry: Panacea or Pariah? Guest editorial, CNS Spectrums. 10:13.
41. **Nemeroff CB** and Preskorn S. 1997. A Debate: Are CYP450 drug interactions really important, or is it all just marketing hype? American Society of Clinical Psychopharmacology Progress Notes, 8:57-63.
42. **Nemeroff CB.** 1998. On Mentoring. Guest editorial, CNS Spectrums 1:17.
43. **Nemeroff CB.** 1998. The importance of longitudinal studies in psychiatric disorders. Guest editorial, CNS Spectrums 3:19.
44. **Nemeroff CB.** 1998. Polypharmacology in psychiatry: good or bad? Guest editorial, CNS Spectrums 4:19.
45. **Nemeroff CB.** 1998. The escalating pharmaceutical company wars: where is an academic to hide? Guest editorial, CNS Spectrums 5:17.

46. **Nemeroff CB.** 1999. Images in Psychiatry: Morris A. Lipton, MD, PhD. *Am J Psychiat* 156:941-942.
47. **Nemeroff CB.** 1998. Treating depression in the bipolar patient. In: *Perennial Issues in the Management of Depression*, Monograph, Wyeth-Ayerst Laboratories.
48. **Nemeroff CB.** 1998. Depression with comorbid anxiety. In: *Interactive Treatment Algorithms for Anxiety Disorders*, Monograph, SmithKline Beecham.
49. **Nemeroff CB.** 1998. The Greatest Kid Ever. Guest editorial, *CNS Spectrums* 6:14-15.
50. **Nemeroff CB.** 1998. Psychoanalysis, psychodynamic psychotherapy, and psychopharmacology. Guest editorial, *CNS Spectrums* 7:18.
51. **Nemeroff CB.** 1998. Placebo in the evaluation of psychiatric treatments. Guest editorial, *CNS Spectrums* 8:18-19.
52. **Nemeroff CB.** 1998. Symptoms vs syndromes in the treatment of psychiatric disorders. Guest editorial, *CNS Spectrums* 9:21.
53. **Nemeroff CB.** 1998. The National Bioethics Advisory Commission and its report. Guest editorial, *CNS Spectrums* 10:13.
54. **Nemeroff CB.** 1999. A major step backward for the American Medical Association. Guest editorial, *CNS Spectrums* 2:16.
55. **Nemeroff CB.** 1999. Review of: *Malignant Sadness: The Anatomy of Depression*. Farber & Farber, 1999. *Nature*, 775-776.
56. **Nemeroff CB**, Heim, C, Owens MJ, Newport DJ, Miller AH and Plotsky PM. 1999. Neurochemical mechanisms underlying depression and anxiety disorders: the influence of early trauma. In: *New Developments in Understanding Depression and Its Treatment*, Monograph, Wyeth-Ayerst Laboratories.
57. Berns G S and **Nemeroff CB.** 1999. Review of : *The Neuropsychiatry of Limbic and Subcortical Disorders* (S Salloway, P Malloy, JL Cummings, Eds). *J Psychiat and Neurosci* 24:251-252.
58. **Nemeroff CB** and Schatzberg. 1999. The phenomenology and treatment of aggression across psychiatric illnesses. *J Clin Psychiat* 60 (suppl 15):3-4.
59. Charney DS, Innis RB, Nestler EJ, Davis KL, **Nemeroff CB** and Weinberger DR. 1999. Increasing public trust and confidence in psychiatric research. *Biol Psychiat* 46:1-2.
60. Marder SR and **Nemeroff CB.** 1999. *Common Problems in the Diagnosis and Treatment of Schizophrenia*. Monograph, Janssen Pharmaceutica.
61. **Nemeroff CB.** 1999. How Are You? Guest Editorial, *CNS Spectrums* 9:18.
62. **Nemeroff CB.** 2000. Cuba: A Land Stuck in Time. Guest editorial, *CNS Spectrums* 1:17.
63. **Nemeroff CB.** 2000. The role of patient advocacy in funding policy. Guest Editorial, *CNS Spectrums* 3:17.

64. **Nemeroff CB.** 2000. Cuba II: A Land Stuck in Time. Guest Editorial, *CNS Spectrums* 7:17.
65. **Nemeroff CB** and O'Connor C. 2000. Are platelets the link between depression and ischemic heart disease? Introduction, *Am Heart Journal* 140:555-556.
66. **Nemeroff CB.** 2000. Fifty years of lithium use in the treatment of bipolar disorder. Introduction, *J. Clin Psychiatry* 61(9):3-4.
67. **Nemeroff CB.** 2000. Optimal use of antidepressants. Teaching Monograph: A Grand Rounds Series. *Primary Psychiatry* 7(Suppl 6):42.
68. DeVane CL and **Nemeroff CB.** 2000. 2000 Guide to Psychotropic Drug Interactions. Monograph, SmithKline Beecham Pharmaceuticals.
69. Owens MJ, **Nemeroff CB** and Knight DL. 2000. Paroxetine binding to the rat norepinephrine transporter in vivo: Reply to Rubin RT. *Biol Psychiat* 48:954-956.
70. **Nemeroff CB.** 2000. Path of Discovery: Stress and Mood. In: *Neuroscience: Exploring the Brain*, 2nd Edition, (MF Bear, BW Connors, MA Paradiso, Eds), Lippincott Williams & Wilkins, USA, 691.
71. **Nemeroff CB.** 2000. Norepinephrine: neurotransmitter for the millennium. Introduction, *J Clin Psychiat* 61(10):3-4
72. **Nemeroff CB** and O'Connor CM. 2000. Depression as a risk factor for cardiovascular and cerebrovascular disease: emerging data and clinical perspectives. Introduction, *Am Heart Journal*, 140(4):55-56.
73. **Nemeroff CB.** 2001. The development of new technologies in medicine: what will the impact be in psychiatry? First Person, *CNS Spectrums* 1:21.
74. **Nemeroff CB.** 2001. The rage to know, the rage to teach, and the rage to heal: what is the proper balance? First Person, *CNS Spectrums* 6:459.
75. **Nemeroff CB.** 2001. New perspectives on the neurobiology of schizophrenia and the role of atypical antipsychotics. Introduction, *Biol Psychiat* 50:823-824.
76. **Nemeroff CB.** 2001. An old transmitter in a new millennium. Introduction, *CNS Spectrums* 6:655.
77. **Nemeroff CB.** 2001. How will we solve the critical shortage of clinician-scientists in psychiatry? First Person, *CNS Spectrums* 11:889.
78. **Nemeroff CB.** 2002. Molecular neuropharmacology for the new millennium. Review of: *Molecular Neuropharmacology: A Foundation for Clinical Neuroscience*, EJ Nestler, SE Hyman and RC Malenka, Eds, McGraw-Hill. *TRENDS in Neurosciences* 25:326.
79. Stout SC, Owens MJ and **Nemeroff CB.** 2002. Response to Carroll. *Neuropsychopharmacol* 26:413-414.
80. **Nemeroff CB.** 2002. Foreword: Pharmacotherapy for Child and Adolescent Psychiatric Disorders, 2nd Edition (DR Rosenberg, PA Davanzo, S Gershon, Eds), Marcel Dekker, Inc.

81. **Nemeroff CB.** 2003. Beating the black dog of depression: a multidisciplinary approach. Introduction, Mental Fitness, 2(Suppl 1):7.
82. **Nemeroff CB.** 2004. Review of: The Biochemical Basis of Neuropharmacology, Eighth Edition (J Cooper, F Bloom and R Roth, Eds). Am J Psychiat 161:379.
83. **Nemeroff CB.** 2004. Review of: Brain Circuitry and Signaling in Psychiatry, (G Kaplan and R Hammer, Jr., Eds), Am J Psychiat 161:1140-1141.
84. Ferentz K, Jain R and **Nemeroff CB.** 2004. Depression in Family Medicine: Using the Mind-Body Connection to Improve Detection and Treatment. CNS News 6:47-52.
85. **Nemeroff CB,** Radford MHB and Golden RN. 2004. Introduction. Advances in the treatment of mood and anxiety disorders. CNS Spectrums 9:5
86. **Nemeroff CB.** 2004. Atypical antipsychotics: weighing the benefits. New Findings in Schizophrenia: An Update on Causes and Treatment. Supplement to Clinical Psychiatry News, 9-11.
87. Martin EI and **Nemeroff CB.** 2005. Review of: The War of the Soups and the Sparks: The Discovery of Neurotransmitters and the Dispute Over How Nerves Communicate (ES Valenstein), NEJM 353:2093-2094.
88. Gutman DA and **Nemeroff CB.** 2005. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study – effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy and safety outcomes of the CATIE trial. Medscape online publication, December, 2005.
89. Culpepper L, Judd CR, Moller MD, **Nemeroff CB,** Rapaport MH. 2006. Clinicians on the front line: active management of depression and anxiety in primary care. Monograph, Haymarket Medical.
90. Nemeroff CB. Future shock in psychiatry: the next 50 years. New Scientist. www.newscientist.com/article/dn10559-charles-nemeroff-forecasts-in-the-future.html
91. McDonald WC, Eley JW, **Nemeroff CB.** 2007. The New Medical School Curriculum at Emory University. Psychiatric Research Report 23 (1):6-7
92. Robinowitz C and **Nemeroff CB.** 2008. Depression, Heart Disease: The Curiously Strong Relationship. Psychiatric News 43:3
93. Bourke CH and **Nemeroff CB.** 2009. Review of: Brain Rules. Psychiatric Times 26:47
94. **Nemeroff CB.** 2008. Personalized Medicine in Psychiatry. NeuroPsychiatry Reviews 9:6
95. **Nemeroff CB.** 2009. Review of: The Neurobiological Basis of Post-Traumatic Stress Disorder and its Treatment. (P.J. Shiromani, T.M. Keane and J.E. LeDoux, Eds), Humana Press. Neuron 63(4): 426-428.
96. **Nemeroff CB.** 2012. Obituary Wylie W Vale. Neuropsychopharmacology 37:2886.

97. **Nemeroff CB** (Otto MA, article). 2013. Bipolar disorder and schizophrenia probably not the same disease. Clinical Psychiatry News Digital Network, 02/22/13.
<http://www.currentpsychiatry.com/home/article/bipolar-disorder-and-schizophrenia-probably-not-the-same-disease/11ac1c1c32c10420cb03224ba63afaa6.html>.
98. **Nemeroff CB**, Marder SR and Lieberman J. 2015. In Memoriam Ellen Stover. Neuropsychopharmacology 39:3132.
99. **Nemeroff CB**. 2016. The Ins and Outs of Depression and Alcohol. The Sober World.

ABSTRACTS

1. **Nemeroff CB** and Crisley FD. 1974. Temporary alteration in blood-brain barrier permeability to plasma proteins during monosodium L-glutamate-induced seizures. *Fed. Proc.* 33:233.
2. **Nemeroff CB**, Ervin GN, Bissette G, Harrell LE and Grant LD. 1975. Growth and endocrine alterations after neonatal monosodium L-glutamate in the rat: evaluation of the relationship to arcuate dopamine neuron damage. *Soc. Toxicology 14th Annual Meeting, Williamsburg, Virginia.*
3. **Nemeroff CB**, Prange AJ, Jr., Bissette G and Lipton MA. 1975. Thyrotropin-releasing hormone (TRH): potentiation of the anticonvulsant properties of phenobarbital sodium. *Fed. Proc.* 34:322.
4. **Nemeroff CB**, Grant LD, Harrell LE, Bissette G, Ervin GN and Prange AJ, Jr. 1975. Neonatal monosodium L-glutamate: permanent destruction of arcuate dopamine neurons with subsequent growth and endocrinological deficits. *Sixth International Congress of Psychoneuroendocrinology, Aspen, Colorado.*
5. **Nemeroff CB**, Grant LD, Harrell LE, Bissette G, Ervin GN and Prange AJ, Jr. 1975. Histochemical evidence for the permanent destruction of arcuate dopamine neurons by neonatal monosodium L-glutamate in the rat. *Soc. Neurosci. Abst.* 1:434.
6. **Nemeroff CB**, Diez JA, Harrell LE, Prange AJ, Jr., Grant LD, Summer GK, Breese GR and Lipton MA. 1975. The effect of chronic treatment with thyrotropin-releasing hormone (TRH) on regional rat brain tyrosine hydroxylase activity. *Society of Experimental Biology and Medicine. Southeastern Section, 1975-1976 Annual Meeting, Durham, North Carolina.*
7. **Nemeroff CB**, Bissette G, Prange AJ, Jr., Loosen PT and Lipton MA. 1976. Centrally administered neurotensin potentiates the depressant actions of pentobarbital. *The Endocrine Society Annual Meeting, San Francisco, California, 312.*
8. **Nemeroff CB**, Konkol RJ, Martin JB, Bissette G, Brazeau P, Breese GR, Grant LD, Prange AJ, Jr. and Kizer JS. 1976. Microchemical analysis of the hypothalamic lesion induced by monosodium L-glutamate (MSG) in the neonatal rat: evidence for a dopaminergic role in neuroendocrine regulation. *Soc. Neurosci. Abst.* 2:654.
9. Bissette G, **Nemeroff CB**, Loosen PT, Barlow TS, Prange AJ, Jr. and Lipton MA. 1976. Neurotensin: central nervous system effects of a hypothalamic peptide. *Soc. Neurosci. Abst.* 2:645.
10. **Nemeroff CB**, Carson KA, Rone MS, Youngblood WW, Prange AJ, Jr., Hanker JS and Kizer JS. 1977. Biochemical and histochemical evidence for a tuberoinfundibular cholinergic pathway. *American Society for Neurochemistry, Eighth Annual Meeting, Denver, Colorado, March, 172.*
11. **Nemeroff CB**, Prange AJ, Jr., Bissette G, Martin JB, Brazeau P and Kizer JS. 1977. The effect of chronic treatment with thyrotropin-releasing hormone (TRH) or a tetrapeptide analog of TRH (beta-alanine TRH) on the hypothalamic-pituitary-thyroid axis in rats and mice. *Proc. Endocrine Society 58th Annual Meeting, Chicago, Illinois, 286.*

12. **Nemeroff CB**, Prange AJ, Jr., Bissette G, Loosen PT, Burnett GB, Kraemer GW, McKinney WT, Jr. and Lipton MA. 1977. Effects of neurotensin on thermoregulatory processes: comparative phylogenetic studies. International Society for Psychoneuroendocrinology, Eighth Annual Meeting, Atlanta, Georgia.
13. Prange AJ, Jr., **Nemeroff CB**, Bissette G, Loosen PT, Burnett GB and Lipton MA. 1977. Effects of neurotensin on mammalian thermoregulatory processes. XXVII International Congress of Physiological Sciences, Satellite Symposium on Temperature Regulation, Lille, France, July.
14. Carson KA, **Nemeroff CB**, Rone MS, Kizer JS and Hanker JS. 1977. Ultrastructural localization of AChE in the arcuate nucleus and median eminence of the rat. Proceedings 35th Electron Microscope Society of America (EMSA) Annual Meeting, Boston.
15. **Nemeroff CB**, Bissette G and Kizer JS. 1977. Reduced levels of immunoreactive LHRH in genetically obese mice (ob/ob). Soc Neurosci Abst 3:353.
16. Lipton MA, Osbahr AJ, III, **Nemeroff CB**, Jahnke GD, Bissette G and Prange AJ, Jr. 1977. Cholecystokinin (CCK) inhibits tail-pinch induced eating in rats. Soc. Neurosci. Abst. 3:164.
17. Grant LD, Sar M, Stumpf WE, **Nemeroff CB** and Kizer JS. 1978. Monosodium glutamate (MSG) destruction of estrogen-feedback neurons in hypothalamic arcuate nucleus-median eminence. Fed. Proc. 37:297.
18. Manberg PJ, Bissette G, **Nemeroff CB**, Loosen PT, Burnett GB, Prange AJ, Jr. 1978. Neurotensin-induced hypothermia in the rat: structure activity studies. Fed. Proc. 27:665.
19. **Nemeroff CB**, Bissette G, Manberg PJ, Osbahr AJ, III, Breese GR, Loosen PT, Lipton MA and Prange AJ, Jr. 1978. Effects of pharmacological and endocrinological manipulation on neurotensin-induced hypothermia. Soc. Neurosci. Abst. 4:412.
20. **Nemeroff CB**, Osbahr AJ, III, Ervin GN and Prange AJ, Jr. 1979. Evaluation of the analgesic effect of centrally administered neuropeptides. Amer. Soc. Neurochemistry Tenth Annual Meeting, Charleston, South Carolina, 105.
21. **Nemeroff CB**, Ervin GN, Manberg PJ, Osbahr AJ, III, Felts S, Birkemo LS and Prange AJ, Jr. 1979. Further studies on central nervous system effects of neurotensin, an endogenous peptide. Soc. Neurosci. Abst. 5:535.
22. Birkemo LS, Ervin GN, **Nemeroff CB** and Prange AJ, Jr. 1979. Neurotensin, like neuroleptics, block certain dopamine-mediated behaviors. Soc. Exp. Biol. Med., Southeastern Section, Oak Ridge, Tennessee.
23. **Nemeroff CB**, Osbahr AJ, III, Birkemo LS, Bissette G, Mailman RB, Frye GD, Breese GR and Prange AJ, Jr. 1980. Effects of neurotensin (NT) on brain neurotransmitter systems, anterior pituitary hormone secretion and behavior. Proc. Endocrine Soc., 62nd Annual Meeting, Washington DC, 192.
24. Luttinger D, Mason GA, Frye GD, Osbahr AJ, III, **Nemeroff CB** and Prange AJ, Jr. 1980. Potentiation of ethanol-induced narcosis and hypothermia by neurotensin. Trans. Amer. Soc. Neurochem. 11:246.

25. Osbahr AJ III, **Nemeroff CB**, Luttinger D, Mason G and Prange AJ, Jr. 1980. The effects of naloxone and thyrotropin-releasing hormone (TRH) on neurotensin (NT)-induced analgesia in mice. *Clin. Res.* 28:241A.
26. **Nemeroff CB**, Luttinger D, Mason GA, Frye GD, Breese GR and Prange AJ, Jr. 1980. Effects of intracisternal neurotensin, β -endorphin or bombesin on ethanol-induced sedation and hypothermia. *Drug Alcohol Dependence* 6:112-113.
27. **Nemeroff CB**, Luttinger D, Osbahr AJ, III, Bissette G and Prange AJ, Jr. 1980. Neurotensin and thyrotropin-releasing hormone (TRH) are "antagonists" in several behavioral and pharmacological paradigms. *Int. Soc. Psychoneuroendocrinology 11th Annual Meeting*, Florence, Italy, 107.
28. **Nemeroff CB**, Luttinger D, Osbahr AJ, III and Prange AJ, Jr. 1980. Neurotensin blocks behaviors induced by indirect, but not direct dopamine agonists: evidence for mediation at a mesolimbic dopamine termination site, the nucleus accumbens. *Soc. Neurosci. Abst.* 6:843.
29. Luttinger D, Wiggins R, King RA, **Nemeroff CB** and Prange AJ, Jr. 1980. Inhibition of conditioned avoidance responding and rewarding electrical self-stimulation of the brain by centrally-administered neurotensin. *Soc. Neurosci. Abst.* 5:843.
30. Luttinger D, **Nemeroff CB**, Gau B and Prange AJ, Jr. 1981. Investigations of the interactions of ethanol with neuropeptides. In: *Alcoholism: Clinical and Experimental Research. Seventh Ann. Symp. on Alcoholism*, Raleigh, NC.
31. Manberg PJ, Youngblood WW, Rossor N, Iversen LL, **Nemeroff CB**, Prange AJ, Jr. and Kizer JS. 1981. Distribution of neurotensin in human brain and cerebrospinal fluid. *Trans. Amer. Soc. Neurochem.* 12:100.
32. Kalivas PW, **Nemeroff CB**, Gau BA and Prange AJ, Jr. 1981. Brain regions mediating neurotensin-induced antinociception. *Pain Suppl.* 1:5105.
33. Orlando RC, Hernandez DE, **Nemeroff CB** and Prange AJ, Jr. 1981. Cytoprotective effect of intracisternally administered neurotensin on cold + restraint-induced gastric ulcers in the rat. *Gastroenterology* 80:1244.
34. Hernandez DE, **Nemeroff CB**, Orlando RC and Prange AJ, Jr. 1981. Prevention of cold-restraint stress-induced gastric ulcers by intracisternally administered neurotensin. *Proc. Endocrine Soc. 63rd Annual Meeting*, Cincinnati, Ohio, 304.
35. Burgess SK, **Nemeroff CB** and Prange AJ, Jr. 1981. The effect of thyrotropin-releasing hormone (TRH) on the content and release of endogenous dopamine in the nucleus accumbens and corpus striatum in vitro. *Eighth International Society of Neurochemistry Meeting*, Nottingham, England.
36. **Nemeroff CB**, Luttinger D, Hernandez DE, Widerlov E, Breese GR and Prange AJ, Jr. 1981. Neurotensin, a peptide with certain neuroleptic-like properties. *Third World Congress of Biological Psychiatry*, Vol. 1, S272.
37. Luttinger D, **Nemeroff CB** and Prange AJ, Jr. 1981. Inhibition of neurotensin-induced antinociception in morphine tolerant mice. *The Pharmacologist* 23:120.

38. Widerlov E, Kilts C, Mueller R, Mailman R, **Nemeroff CB**, Prange AJ, Jr. and Breese GR. 1981. Neurotensin increases dopamine metabolites in rat brain. *The Pharmacologist* 23:139.
39. Bissette G, Luttinger D, **Nemeroff CB** and Prange AJ, Jr.. 1981. The effects of d-amphetamine, methylphenidate and apomorphine on neurotensin-induced hypothermia in mice. *Soc. Neurosci. Abst.* 7:32.
40. **Nemeroff CB**, Hernandez DE, Orlando RC, Mason GA and Prange AJ, Jr. 1981. Cytoprotection by intracisternally administered neurotensin against cold restraint stress-induced gastric ulcers: correlation of time course with effects on gastric pH and anterior pituitary hormone levels. *Soc. Neurosci. Abst.* 7:31.
41. Kalivas PW, Burgess SK, **Nemeroff CB** and Prange AJ, Jr. 1981. Stimulant effects of neurotensin microinjection into the ventral tegmental area. *Soc. Neurosci. Abst.* 7:31.
42. **Nemeroff CB**, Luttinger D and Prange AJ, Jr. 1981. Blockade of neurotensin-induced antinociception by thyrotropin-releasing hormone in mice. *Int. Soc. Psychoneuroendocrinology 12th Annual Meeting, Montreal, Canada, Neuroendocrinology Letters* 3:107.
43. Jennes L, Stumpf WE, Beckman WC, Burgess SK, Luttinger D, **Nemeroff CB** and Prange AJ, Jr. 1981. Neurotensin immunoreactive systems in the central nervous system of rats. *Soc. Neurosci. Abst.* 7:223.
44. Widerlov E, Lindstrom LH, Besev G, Manberg PJ, **Nemeroff CB**, Breese GR, Kizer JS and Prange AJ, Jr. 1981. Bimodal distribution of neurotensin in cerebrospinal fluid from schizophrenics. *13th Cong. Int. Neuropsychopharmacol., Jerusalem, Israel*, 763.
45. **Nemeroff CB**, Manberg PJ, Youngblood WW, Prange AJ, Jr. and Kizer JS. 1982. Alterations in regional brain levels of neurotensin, thyrotropin-releasing hormone and somatostatin in schizophrenia and Huntington's chorea. *Soc. Neurosci. Abst.* 8:153.
46. Lipton MA, **Nemeroff CB** and Prange AJ, Jr. 1982. Central nervous system effects of neurotensin and thyrotropin-releasing hormone. *13th Cong. Int. Neuropsychopharmacol., Jerusalem, Israel*, 843.
47. Luttinger D, Hernandez DE, Mailman RB, **Nemeroff CB** and Prange AJ, Jr. 1982. Interactions of neurotensin with direct and indirect dopamine agonists: neurochemical and behavioral measures. *Soc. Neurosci. Abst.* 8:369.
48. Hernandez DE, Adcock JW, **Nemeroff CB**, Orlando RC and Prange AJ, Jr. 1982. The effect of adrenalectomy and hypophysectomy on neurotensin-induced cytoprotection against stress-induced gastric ulcers in rats. *Soc. Neurosci. Abst.* 8:460.
49. Bissette G, Luttinger D, **Nemeroff CB**, Miller VM and Prange AJ, Jr. 1982. Regional brain distribution of neurotensin-like immunoreactivity in the woodchuck (*Marmota monax*). *Soc. Neurosci. Abst.* 8:584.
50. Schultz DW, Kalivas PW, **Nemeroff CB** and Prange AJ, Jr. 1982. Bombesin effects on the mesolimbic dopamine system of the rat. *Soc. Neurosci. Abst.* 8:145.

51. Hernandez DE, Pfeiffer RL, Jr., Prange AJ, Jr. and **Nemeroff CB**. 1983. Intracameral injection of neurotensin induces miosis in rabbits. *Invest. Ophthalmol. Visual Sci. Suppl.* 24:151.
52. Jennes L, Stumpf WE, Beckman WC, Jr., Kalivas PW, **Nemeroff CB** and Prange AJ, Jr. 1982. Topography and functional implications of neurotensin-containing structures in the rat brain. In: *Neurotensin, a Brain and Gastrointestinal Peptide* (CB Nemeroff and AJ Prange, Jr., Eds), *Ann. NY Acad. Sci.* 400:403-404.
53. Widerlov E, Lindstrom LH, Besev G, Manberg PJ, **Nemeroff CB**, Breese GR, Kizer JS and Prange AJ, Jr. 1982. Subnormal CSF levels of neurotensin in a subgroup of schizophrenics and normalization after neuroleptic treatment. In: *Neurotensin, a Brain and Gastrointestinal Peptide* (CB Nemeroff and AJ Prange, Jr., Eds), *Ann. NY Acad. Sci.* 400:418-419.
54. Orlando RC, Hernandez DE, **Nemeroff CB** and Prange AJ, Jr. 1982. Role of the autonomic nervous system in neurotensin's cytoprotective effect for gastric stress ulcers in rats. In: *Neurotensin, a Brain and Gastrointestinal Peptide* (CB Nemeroff and AJ Prange, Jr., Eds), *Ann. NY Acad. Sci.* 400:432.
55. Bissette G, Richardson C, Kizer JS and **Nemeroff CB**. 1983. Regional brain concentration of immunoreactive neurotensin (INT) in developing rats. *Int. Soc. Neurochem. 9th Annual Meeting, Vancouver, Canada. J. Neurochem.* 41(Suppl.):582.
56. Hernandez DE, Adcock JW, **Nemeroff CB**, Orlando RC and Prange AJ, Jr. 1983. Blockade of neurotensin-induced gastric cytoprotection by indomethacin and acetylsalicylic acid in rats. *Gastroenterology* A-48.
57. Hernandez DE, Orlando RC, Adcock JW, Patrick KS, **Nemeroff CB** and Prange AJ, Jr. 1983. Gastric cytoprotection by dopamine agonists. *Clin. Res.* 31:683A.
58. Hernandez DE, **Nemeroff CB** and Prange AJ, Jr. 1983. Neurotensin-induced antinociception and hypothermia in mice: antagonism by TRH and structural analogs of TRH. *Neurosci. Lett.* 14:162.
59. **Nemeroff CB**, Bissette G, Busby WH, Jr., Youngblood WW, Rossor M, Roth M and Kizer JS. 1983. Regional brain concentrations of neurotensin, thyrotropin-releasing hormone and somatostatin in Alzheimer's disease. *Soc. Neurosci. Abst.* 9:1052.
60. Bissette G, Jennes L, Prange AJ, Jr., Breese GR and **Nemeroff CB**. 1983. Neurotensin and dopamine are not co-localized in rat brain. *Soc. Neurosci. Abst.* 9:290.
61. Merritt WD, Bissette G, Luttinger D, Prange AJ, Jr. and **Nemeroff CB**. 1983. Prior cold exposure antagonizes neurotensin-induced hypothermia in mice. *Soc. Neurosci. Abst.* 9:141.
62. Jennes L, Stumpf WE, Bissette G and **Nemeroff CB**. 1983. Immunohistochemical and autoradiographic analysis of the mediobasal hypothalamus of rats treated neonatally with monosodium glutamate. *Soc. Neurosci. Abst.* 9:1018.
63. Manberg PJ, **Nemeroff CB**, Bissette G, Prange AJ, Jr. and Gerner RH. 1983. Cerebrospinal fluid levels of neurotensin-like immunoreactivity in normal controls and in patients with affective disorder, anorexia nervosa and premenstrual syndrome. *Soc. Neurosci. Abst.* 9:1034

64. Nath A, Haber B, Bissette G, Jennes L, Manberg PJ and **Nemeroff CB**. 1983. Evidence for the presence of neurotensin-like immunoreactivity in a schwannoma cell line. Soc. Neurosci. Abst. 9:295.
65. Bissette G, **Nemeroff CB**, Youngblood WW, Manberg PJ, Prange AJ, Jr. and Kizer JS. 1983. Alterations in neuropeptide concentrations in post-mortem brain tissue from patients with Huntington's chorea, Alzheimer's disease and schizophrenia. Proc. Peptides and Neurological Disease. Cambridge, England, August 7-10, 1983.
66. Hernandez DE, Richardson CM, **Nemeroff CB**, Orlando RC, St. Pierre S, Rioux F and Prange AJ, Jr. 1983. Neurotensin-induced gastric cytoprotection: structure-activity studies. Clin. Res. 31:854.
67. Bissette G, **Nemeroff CB**, Manberg PJ, Kizer JS, Prange AJ, Jr., Decker M, Agid Y and Javoy-Agid F. 1983. Regional brain neurotensin and bombesin concentration in Parkinson's disease. Proc. Amer. Coll. Neuropsychopharmacol., 82.
68. Evans DL and **Nemeroff CB**. 1983. The dexamethasone suppression test in DSM-III affective disorders. Proc. Amer. Coll. Neuropsychopharmacol., 116.
69. **Nemeroff CB**, Widerlov E, Bissette G, Walleus H, Eklund K, Karlsson I, Loosen PT, Kilts CD and Vale W. 1984. Elevated cerebrospinal fluid concentrations of corticotropin-releasing factor-like immunoreactivity (CRF-LI) in major depression. Soc. Neurosci. Abst. 10:1093.
70. Decker MW, Bissette G, Towle AC, Mueller RA, Lauder JM and **Nemeroff CB**. 1984. Effects of neonatally administered capsaicin on bombesin-like immunoreactivity in rat spinal cord, medulla and thalamus. Soc. Neurosci. Abst. 10:430.
71. **Nemeroff CB**. 1984. Peptides, hormones and behavior: an overview of recent findings. Fifteenth Int. Cong. Psychoneuroendocrinology, Vienna, Austria, 59.
72. Widerlov E, Walleus H, Bissette G, Loosen PT, Kilts CD, Vale W and **Nemeroff CB**. 1984. Corticotropin-releasing factor-like immunoreactivity (CRF-LI) in cerebrospinal fluid (CSF) in normal controls and major depression: relationship to CSF monoamine metabolites, DST and TRH stimulation test results. Soc. Neurosci. Abst. 10:1093.
73. Bissette G, Walleus H, Widerlov E, Karlsson I, Eklund K, Loosen PT and **Nemeroff CB**. 1984. Reductions of cerebrospinal fluid concentrations of somatostatin-like immunoreactivity (SRIF-LI) in dementia, major depression and schizophrenia. Soc. Neurosci. Abst. 10:1093.
74. Widerlov E, Walleus W, Bissette G, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W and **Nemeroff CB**. 1984. Elevated cerebrospinal fluid (CSF) concentrations of corticotropin-releasing factor-like immunoreactivity (CRF-LI) in major depression and relationship to CSF monoamine metabolites, DST and TRH stimulation test results. Fifteenth Int. Cong. Psychoneuroendocrinology, Vienna, Austria, 74.
75. Anderson CM, Bissette G, **Nemeroff CB** and Kilts CD. 1984. Microtopographic distribution of neurotensin and catecholamine concentrations at the level of individual rat brain nuclei. Soc. Neurosci. Abst. 10:437.

76. Cain ST, Ely T, Kilts CD and **Nemeroff CB**. 1984. Neurotensin effects on dopamine metabolism in micropunched rat brain nuclei. Soc. Neurosci. Abst. 10:536.
77. Skoog KM, Cain ST, Kenner J and **Nemeroff CB**. 1984. Neurotensin suppresses locomotor hyperactivity induced by amphetamine but not by scopolamine. Soc. Neurosci. Abst. 10:172.
78. Parks DA, Bissette G, **Nemeroff CB**, Mason GA and Schwarcz R. 1984. Neuroendocrine and behavioral effects of intrahypothalamic injections of quinolinic acid. Soc. Neurosci. Abst. 10:679.
79. Smith M and **Nemeroff CB**. 1984. Release of corticotropin-releasing factor (CRF) from rat brain in vitro. Ann. NY Acad. Sci.
80. **Nemeroff CB**. Neuropeptides and neurotransmitters in senile dementia. Thirteenth Int. Cong. Gerontology, New York, 6.
81. **Nemeroff CB**, Bissette G, Widerlov E, Daughtry G and Reynolds GA. 1984. Corticotropin-releasing factor-like immunoreactivity in human cerebrospinal fluid and post-mortem brain tissue. Proc. Amer. Coll. Neuropsychopharmacol., 64.
82. **Nemeroff CB**, Kilts CD, Chappell P, Smith M and Bissette G. 1984. Interactions of neurotensin with brain dopamine systems: biochemical behavioral and human post-mortem studies. Proc. Amer. Coll. Neuropsychopharmacol., 39.
83. Bissette G, Knight DL, Kilts CD, Widerlov E, Gerner R and **Nemeroff CB**. 1984. Neurotensin-like immunoreactivity in human cerebrospinal fluid. Proc. Amer. Coll. Neuropsychopharmacol., 65.
84. Kilts CD, Anderson C, Bissette G, Ely T, Davidson J and **Nemeroff CB**. 1984. Differential effects of antipsychotic drugs on the neurotensin content of individual rat brain nuclei. Proc. Amer. Coll. Neuropsychopharmacol., 102.
85. Simon JS, Evans DL, Haggerty JJ and **Nemeroff CB**. 1984. Anti-thyroid antibodies in patients with depressive symptoms. Proc. Amer. Coll. Neuropsychopharmacol., 124.
86. Walsh TJ, Bissette G and **Nemeroff CB**. 1985. Cognitive deficits associated with a selective depletion of somatostatin in the hippocampus. Proc. Endocrine Soc. 67th Ann. Meeting, 72.
87. Elliott PJ, Parker Y-M, Chan J and **Nemeroff CB**. 1985. The effects of intracerebroventricular neurotensin on open-field behavior in adult rats: structure-activity studies. In Proc. Neural and Endocrine Peptides and Receptors Symposium, Washington, DC, 196.
88. Bissette G, Reynolds GP, Widerlov E and **Nemeroff CB**. 1985. Alterations in the concentration of corticotropin-releasing factor (CRF)-like immunoreactivity in neuropsychiatric disease. In Proc. Neural and Endocrine Peptides and Receptors Symposium, Washington, DC, 58.
89. France RD, Urban BJ, Krishnan KRR, **Nemeroff CB** and Kilts CD. 1985. Monoamine metabolites in chronic pain and depression. Proc. IVth World Cong. of Biol. Psychiat. 177.
90. **Nemeroff CB**. 1985. Recent advances in the neurobiology of neuropeptide. Proc. IV World Congress of Biol. Psychiat. 16.

91. **Nemeroff CB**, Bissette G and Widerlov E. 1985. Measurement of neuropeptides in cerebrospinal fluid of patients with psychiatric disorders: focus on depression. Proc. IV World Congress of Biol. Psychiat. 233.
92. Urban BJ, France RD, Krishnan KRR, **Nemeroff CB**, Bissette G and Banki C. 1985. CRF levels in cerebrospinal fluid in chronic pain patients as compared to normal controls and patients with major depression. Proc. Fifth Ann. Meeting of the Amer. Pain Soc.
93. Cain ST and **Nemeroff CB**. 1985. Hypolocomotion induced by activation of dopamine autoreceptors: effects of neurotensin. Soc. Neurosci. Abst. 11:340.
94. **Nemeroff CB**, Smith MA, Slotkin TA and Bissette G. 1985. Release of corticotropin-releasing factor (CRF)-like immunoreactivity from rat brain regions in vitro. Soc. Neurosci. Abst. 11:487.
95. Elliott PJ, Kilts CD and **Nemeroff CB**. 1985. Evidence supporting a role of endogenous intra-nucleus accumbens substance-P in d-amphetamine-induced locomotor activity: use of a monoclonal antibody against substance-P. Soc. Neurosci. Abst. 11:341.
96. Chappell PB, Smith MA, Anderson CM, Bissette G, Kilts CD and **Nemeroff CB**. 1985. Distribution of corticotropin-releasing factor-like immunoreactivity (CRF-LI) in microdissected areas of the rat brain. Soc. Neurosci. Abst. 11:682.
97. Smith MA, Chappell PB, Bissette G, Ritchie J, Kilts CD and **Nemeroff CB**. 1985. Stress-induced alterations in corticotropin-releasing factor-like immunoreactivity (CRF-LI) in rat brain. Soc. Neurosci. Abst. 11:1269.
98. Bissette G, Spielman F, Stanley M, Banki C, Fink M, Stanley B, Traskman-Bendz L, Golden RN, Arato M and **Nemeroff CB**. 1985. Further studies of corticotropin-releasing factor-like immunoreactivity (CRF-LI) in CSF of patients with affective disorders. Soc. Neurosci. Abst. 11:133.
99. Knight DL, **Nemeroff CB** and Kilts CD. 1985. Electrochemical detection of neurotensin (NT) and NT fragments in human cerebrospinal fluid (CSF) following on-line trace enrichment and gradient elution high performance liquid chromatography (HPLC). Soc. Neurosci. Abst. 11:563.
100. Walsh TJ, Emerich DF, Winokur A, Banki C, Bissette G and **Nemeroff CB**. 1985. Intrahippocampal injection of cysteamine depletes somatostatin and produces cognitive impairments in the rat. Soc. Neurosci. Abst. 11:621.
101. Smith MA and **Nemeroff CB**. 1986. Release of corticotropin-releasing factor (CRF) from rat brain in vitro. Ann. NY Acad. Sci. 463:231-233.
102. **Nemeroff CB**. 1985. Neuropeptides and neurotransmitters in senile dementia. Proc. XIII Int. Congress Gerontology, 6.
103. **Nemeroff CB**, Bissette G, Reynolds GA, Kizer JS, Kilts CD, Knight D, Daughtry G and Widerlov E. 1985. Analysis of the integrity of neuropeptide-containing neural systems in senile dementia of the Alzheimer's type: evidence for degeneration of somatostatinergic and corticotropin-releasing factor-containing neurons. In Proc. 42nd Ann. Meeting Amer. Geriatrics Society, 58-59.

104. Banki CM, **Nemeroff CB**, Bissette G, Kilts CD and Arato M. 1985. Neuroendocrine and neurotransmitter changes in suicidal behavior. Proc. IV World Cong. Biol. Psychiat., 132.
105. Krishnan KRR, Carroll BJ, Manepalli AN, Ritchie JC and **Nemeroff CB**. 1985. Physiology of human HPA regulation in depression. Proc. IV World Cong. Biol. Psychiat., 230.
106. **Nemeroff CB**, Bissette G, Smith MA, Chappell P and Kilts CD. 1985. The neurobiology of corticotropin-releasing factor: preclinical studies. Proc. World Psychiatric Association Regional Symposium on Affective Disorders, Athens, Greece, 25.
107. Krishnan KRR, Carroll BJ, Manepalli AN, Ritchie JC and **Nemeroff CB**. 1985. ACTH and cortisol secretion in depression. Proc. World Psychiatric Association Regional Symposium on Affective Disorders, Athens, Greece, 25.
108. **Nemeroff CB**, Bissette G, Kilts CD and Slotkin TA. 1985. Alzheimer's disease. Proc. Amer. Coll. Neuropsychopharmacol., 41.
109. Bissette G and **Nemeroff CB**. 1985. The neurochemical pathology of Parkinson's disease and schizophrenia. Proc. Amer. Coll. Neuropsychopharmacol., 42.
110. **Nemeroff CB**. 1985. The neurobiology of corticotropin-releasing factor: implications for affective disorders. Proc. Amer. Coll. Neuropsychopharmacol., 79.
111. Krishnan KRR, Ritchie JC, Manepalli AN, France RD, **Nemeroff CB** and Carroll BJ. 1985. What is the relationship between ACTH and cortisol in normal and depressed patients? Proc. Amer. Coll. Neuropsychopharmacol., 84.
112. Simon JS, **Nemeroff CB** and Evans DL. 1986. The dexamethasone suppression test and antidepressant response in major depression. Soc. Biol. Psychiat. Ann. Meeting, 243.
113. Haggerty JJ, Jr., Simon J, Evans DL and **Nemeroff CB**. 1986. Thyroid abnormalities in DST suppressors and non-suppressors. Soc. Biol. Psychiat. Ann. Meeting, 233.
114. Krishnan KRR, Ritchie JC, Manepalli AN, France RD, **Nemeroff CB** and Carroll BJ. 1986. ACTH and cortisol dissociation in depression. Proc. 139th Ann. Meeting Amer. Psychiat. Assn., 92.
115. Krishnan KRR, Manepalli AN, Ritchie JC, Rayasam K, Rivier J, Vale W, Thorner M and **Nemeroff CB**. 1986. GRH stimulation test in depression. Proc. 139th Ann. Meeting Amer. Psychiat. Assn., 93.
116. Smith MA, Deutch AY, Chappell PB, Bissette G, O'Connor L, Roth RH and **Nemeroff CB**. 1986. Stress-induced alterations in neurotensin-like immunoreactivity (NTLI) in rat brain and adrenals. Proc. First Int. Cong. Neuroendocrinology 99.
117. Owens MJ, Smith MA and **Nemeroff CB**. 1986. Cholinergic and serotonergic stimulation of hypothalamic CRF release in vitro. Proc. First Int. Cong. Neuroendocrinology 97.
118. Coffey CE, Hinkle P, Weiner RD, **Nemeroff CB**, Krishnan KRR, Varia I and Drayer BP. 1986. ECT in subcortical arteriosclerotic encephalopathy. Proc. Ann. Meeting Amer. Psychiat. Assn., 110.

119. Chappell PB, Smith MA, Ritchie JC, Krishnan KRR, Reed D, Rivier J, Vale WW and **Nemeroff CB**. 1986. Effects of corticotropin-releasing factor on plasma ACTH and cortisol concentrations in schizophrenia. Soc. Neurosci. Abst. 12:1443.
120. Bissette G, Dauer WT, Kilts CD, O'Connor L and **Nemeroff CB**. 1986. Effect of d-amphetamine and dopamine receptor antagonists on neurotensin concentrations in microdissected rat brain regions. Soc. Neurosci. Abst. 12:33.
121. **Nemeroff CB**, Krishnan KRR, Owens MJ, Bissette G, Manepalli AN, Ritchie JC, Rayasam K, Daughtry G, Kalin NH, Rivier JE, Vale WW and Thorner MO. 1986. Growth hormone-releasing factor (GRF): endocrine and cerebrospinal fluid studies. Soc. Neurosci. Abst. 12:566.
122. Owens MJ, Smith MA and **Nemeroff CB**. 1986. Neurotransmitter regulation of release of hypothalamic corticotropin-releasing factor (CRF). Soc. Neurosci. Abst. 12:1494.
123. Cain ST and **Nemeroff CB**. 1986. Neurotensin alters the phosphorylation of caudate nucleus synaptosomal proteins. Soc. Neurosci. Abst. 12:802.
124. Knight DL, Krishnan KRR, Blazer DG and **Nemeroff CB**. 1986. Tritiated imipramine binding to platelets is markedly reduced in elderly depressed patients. Soc. Neurosci. Abst. 12:1251.
125. Belkin BM, Ritchie J, Rayasam K, Krishnan KRR, Kegelmeyer AE, **Nemeroff CB** and Carroll BJ. Plasma dexamethasone concentrations and the dexamethasone suppression test. Soc. Neurosci. Abst. 12:606.
126. **Nemeroff CB**. 1986. Peptide-monoamine interactions: basic and clinical studies. Proc. 139th Ann. Meeting Amer. Psychiat. Assn., 75.
127. Allen C, Davidson M, Mohs RC, Horvath TB, Davis BM, **Nemeroff CB** and Davis KL. 1986. CSF neurotensin in schizophrenic patients. Soc. Biol. Psychiat. 41st Ann. Meeting, 98.
128. Cain ST and **Nemeroff CB**. 1986. Caudate nucleus protein phosphorylation: actions of neurotensin. VIth International Conference on Cyclic Nucleotides, Calcium and Protein, Sept. 2-7, 1986.
129. **Nemeroff CB**. 1986. Recent advances in the neurobiology of peptides. Proc. Int. Union Physiol. Sci. Vol. XVI, 57.
130. Bissette G and **Nemeroff CB**. 1986. Neurotensin-dopamine interactions in the central nervous system. Proc. Int. Union Physiol. Sci. Vol. XVI, 57.
131. Krishnan KRR, Manepalli A, Rayasam K, Melville ML, Daughtry G, Rivier J, Vale W, Thorner MO and **Nemeroff CB**. 1986. Somatotroph response to GHRF in depression. Proc. CIMP 15th Ann. Meeting, San Juan, Puerto Rico, 206.
132. Ritchie JC, Owens MJ, O'Connor LW, Kegelmeyer AE, Walker JT, Stanley M, Bissette G and **Nemeroff CB**. 1986. Measurement of ACTH and CRF immunoreactivity in adrenal gland and lymphocytes. Soc. Neurosci. Abst. 12:1041.

133. Koob GF and **Nemeroff CB**. 1986. Recent developments in the regulation of the mesolimbic and mesocortical dopamine systems: basic and clinical implications. Proc. 25th Ann. Meeting of the Amer. Coll. Neuropsychopharmacol., 23.
134. **Nemeroff CB**, Bissette G and Berger PA. 1986. Peptides in schizophrenia. Proc. 25th Ann. Meeting of the Amer. Coll. Neuropsychopharmacol., 77.
135. Owens MJ, Stanley M, Bissette G and **Nemeroff CB**. 1986. CRF receptor number is decreased in the frontal cortex of suicide victims. Proc. 25th Ann. Meeting of the Amer. Coll. Neuropsychopharmacol., 189.
136. Urban BJ, France RD, Bissette G and **Nemeroff CB**. 1987. Alterations in CSF concentrations of somatostatin-like immunoreactivity in chronic pain patients. Proc. V World Congress on Pain of the Int. Assn. for the Study of Pain, Hamburg, Fed. Rep. Germany.
137. Slotkin TA, Barnes GA, Blazer DG, Knight DL, Krishnan KRR, Whitmore WL and **Nemeroff CB**. 1987. Biogenic amine uptake and [³H]imipramine binding in platelets of depressed elderly patients: evidence for biological differences from depression in a younger cohort. Sixth Int. Catecholamine Symposium, Jerusalem, Israel, 131.
138. Cain ST, Abramson M, Pryor JC and **Nemeroff CB**. 1987. Protein phosphorylation in the brain and anterior pituitary: effects of neuropeptides and stimulation by cAMP-, calmodulin-, and phospholipid- dependent protein kinases. Soc. Neurosci. Abst. 13:791.
139. **Nemeroff CB**, Owens MJ, Stanley M, Andorn A and Bissette G. 1987. Reduced corticotropin-releasing factor (CRF) receptor number in frontal cortex of suicide victims. Soc. Neurosci. Abst. 13:216.
140. Evans DL, Golden RN, **Nemeroff CB**, McCartney C, Haggarty JJ, Simon J and Raft D. 1987. Depression and adaptation in cancer patients. Proc. Ann. Meeting Amer. Psychiat. Assn.
141. Ritchie JC, Liu PK, **Nemeroff CB** and Davis MD. 1987. Simultaneous determination of CRF and ACTH release from hypothalamic-pituitary blocks perfused in vitro: responses to physiological and pharmacological manipulation. Soc. Neurosci. Abst. 13:1371.
142. Pomara N, Lewitt PA, Stanley M, Galloway M, Badalamenti A, Brown GM, Bissette G and **Nemeroff CB**. 1987. No alteration in CSF levels of corticotropin-releasing factor (CRF) in patients with probable Alzheimer's disease. Proc. Soc. Biol. Psychiat. 42nd Ann. Meeting, 391.
143. **Nemeroff CB** and Simon JS. 1987. Abnormal thyroid function in psychiatric patients. Proc. Amer. Psychiat. Assn. 140th Ann. Meeting, 145.
144. **Nemeroff CB**. 1987. Platelet receptor binding studies in psychiatry. Proc. Amer. Psychiat. Assn. 140th Ann. Meeting, 160.
145. Owens MJ, Maynor B and **Nemeroff CB**. 1987. Release of corticotropin-releasing factor (CRF) from rat prefrontal cortex in vitro. Soc. Neurosci. Abst. 13:1110.
146. **Nemeroff CB**. 1987. Preclinical and clinical studies with corticotropin- releasing factor. J. Neurochem. 78:S24.

147. Lee J, Mitsushio H, Paris JM, Lorens SA, Ritchie JC and **Nemeroff CB**. 1987. Differential behavioral and endocrine effects produced by intra-raphé administration of the neurokinin agonist DiMe-C7 and the GABA agonist, muscimol. Soc. Neurosci. Abst. 13:613.
148. **Nemeroff CB**. 1987. Neuropeptide alterations in aging and Alzheimer's disease. Neuroendocrinol. Lett. 9:138.
149. Krishnan KRR, **Nemeroff CB**, Manepalli AH, Venkataraman SS, Ritchie JC and Carroll BJ. 1987. Patterns of hormone secretion in normal volunteers and psychotic patients. Neuroendocrinol. Lett. 9:155.
150. Cain ST, Pryor JC and **Nemeroff CB**. 1987. Adenosine 3'-5'-monophosphate (cAMP) stimulates the phosphorylation of specific protein substrates in the anterior pituitary. Neuroendocrinol. Lett. 9:185.
151. Lee JE, Gilbert JR, Bissette G, **Nemeroff CB** and Roses AD. 1987. Corticotropin releasing factor gene expression in Alzheimer's disease cerebral cortex. Neuroendocrinol. Lett. 9:202.
152. Pellemounter M, Decker M, Gallagher M, Ritchie JC and **Nemeroff CB**. 1987. Changes in plasma corticosteroids after place training in the Morris Water Maze. Neuroendocrinol. Lett. 9:178.
153. Smith MA, Davidson J, Ritchie J, Kudler H, Smith B, Reed D, Lipper S, Chappell P and **Nemeroff CB**. 1987. The corticotrophin-releasing hormone stimulation test in patients with post-traumatic stress disorder. Proc. 26th Ann. Meeting of the Amer. Coll. Neuropsychopharmacol., 172.
154. Banki CM, Arato M, Bissette G and **Nemeroff CB**. 1987. Cerebrospinal fluid neuropeptides in depression and suicide. Neuroscience 22, Suppl., S16.
155. Levant B, Bissette G, Parker Y-M and **Nemeroff CB**. 1987. Alterations in regional neuropeptide concentration in MPTP-treated mice. Soc. Neurosci. Abst. 13:567.
156. Kurlan R, Shoulson I, Caine E, Rubin A, **Nemeroff CB**, Bissette G, Zaczek R, Coyle J and Spielman F. 1987. Cerebrospinal fluid correlates of depression in Huntington's disease. Soc. Neurosci. Abst. 13:1473.
157. Knight DL, Kilts CD, Bissette G and **Nemeroff CB**. 1987. Artifacts in the measurement of somatostatin binding sites in cortical tissue: The effects of freezing. Soc. Neurosci. Abst. 13:1523.
158. Owens MJ, Bissette G, Lundberg D and **Nemeroff CB**. 1987. Acute effects of antidepressant and anxiolytic drugs on CRF-LI in microdissected rat brain regions. Proc. 26th Ann. Meeting of the Amer. Coll. Neuropsychopharmacol., 167.
159. Haggerty JJ, Evans DL, Golden RN, Pedersen CA, Simon JS and **Nemeroff CB**. 1987. Effect of lithium treatment on the prevalence of symptomless autoimmune thyroiditis in bipolar affective disorder. Proc. 26th Ann. Meeting of the Amer. Coll. Neuropsychopharmacol., 193.
160. Bissette G and **Nemeroff CB**. 1987. Implications of peptidergic abnormalities in Alzheimer's disease. Proc. 26th Ann. Meeting of the Amer. Coll. Neuropsychopharmacol., 105.

161. Bissette G and **Nemeroff CB**. 1987. Acute and chronic stress regulation of corticotropin-releasing factor. Proc. 26th Ann. Meeting of the Amer. Coll. Neuropsychopharmacol., 72.
162. **Nemeroff CB**, Knight DL, Kilts CD and Bissette G. 1987. Neuropeptides and neuropeptide receptors in postmortem tissue: fact or artifact. Proc. 26th Ann. Meeting of the Amer. Coll. Neuropsychopharmacol., 51.
163. **Nemeroff CB** and Bissette G. 1987. Preclinical and clinical studies with corticotropin-releasing factor: implications for affective disorders. Proc. 26th Ann. Meeting of the Amer. Coll. Neuropsychopharmacol., 32.
164. Cain ST, Pryor JC and **Nemeroff CB**. 1988. Concentration dependent cAMP-stimulated protein phosphorylation in the rat anterior pituitary. Eighth Int. Cong. Endocrinol., 622.
165. Davis MD, **Nemeroff CB** and Ritchie JC. 1988. Dynamics of concomitant CRF, AVP and ACTH secretion from perfused hypothalamic-hypophyseal explants in vitro after electrical stimulation and drug infusion. Proc. Endocrine Soc.
166. Cain ST, Abramson M and **Nemeroff CB**. 1988. Stimulation by neurotensin of caudate nucleus in vitro protein phosphorylation. Sixth Int. Symp. on Calcium-binding Proteins in Health and Disease, 183.
167. Leckman JF, Riddle MA, Berrettini WH, Anderson GM, Hardin M, Chappell P, Bissette G, **Nemeroff CB**, Goodman WH and Cohen DJ. 1988. Elevated CSF levels of dynorphin A [1-8] in Tourette's syndrome. Psychopharmacol. 96, Suppl., 32.
168. **Nemeroff CB**, Bissette G, Owens MJ, Butler PD and Kilts CD. 1988. Preclinical and clinical studies with corticotropin-releasing factor: implications for affective disorders. J. Cell Biochem. Suppl., 20:299.
169. **Nemeroff CB**, Krishnan KRR, Knight DL, Benjamin D and Meyerson LR. 1988. Increased plasma concentrations of α -acid glycoprotein, an endogenous modulator of the platelet [3 H]-imipramine/5HT transport complex in patients with major depression. Soc. Neurosci. Abst. 14:372.
170. Levant B, Bissette G and **Nemeroff CB**. 1988. Anticholinergic drugs do not alter neurotensin concentrations in the nucleus accumbens or striatum. Soc. Neurosci. Abst. 14:114.
171. Cook LL, Bissette G and **Nemeroff CB**. 1988. A critical analysis of the use of cysteamine to deplete somatostatin-like immunoreactivity in the central nervous system. Soc. Neurosci. Abst. 14:877.
172. Pryor JC, Cain ST and **Nemeroff CB**. 1988. Effects of cAMP and corticotropin-releasing factor (CRF) on protein phosphorylation and ACTH release in the anterior pituitary. Soc. Neurosci. Abst. 14:1284.
173. Butler PD, Weiss JM, Stout JC, Kilts CD, Cook LL and **Nemeroff CB**. 1988. Corticotropin-releasing factor produces anxiogenic and behavioral activating effects following microinfusion into locus coeruleus. Soc. Neurosci. Abst. 14:288.

174. Bissette G, Dole K, Johnson M, Knight DL and **Nemeroff CB**. 1988. Antipsychotic drugs increase neurotensin concentrations after destruction of dopamine neurons by 6-hydroxydopamine. Soc. Neurosci. Abst. 14:1211.
175. Cain ST, Johnson M and **Nemeroff CB**. 1988. Neurotensin: effects on the dephosphorylation of neostriatal phosphoproteins. Soc. Neurosci. Abst. 14:15.
176. Krishnan KRR, Goli V, Ellinwood E, France R, **Nemeroff CB** and Blazer D. 1988. Leukoencephalopathy in patients with major depression. Proc. Soc. Biol. Psychiat. 43rd Ann. Meeting, 378.
177. Radke JM, MacLennan AJ, Beinfeld MC, Bissette G, **Nemeroff CB**, Vincent SR and Fibiger HC. 1988. Comparison of short- and long-term haloperidol administration and withdrawal on peptide levels in the rat. Soc. Neurosci. Abst. 14:1241.
178. **Nemeroff CB**. 1988. Neuropeptide alterations in Alzheimer's disease. Proc. 141st Ann. Meeting Amer. Psychiat. Assn., 25.
179. Bissette G and **Nemeroff CB**. 1988. The preclinical biology of CRF. Proc. 141st Ann. Meeting Amer. Psychiat. Assn., 119.
180. **Nemeroff CB** and Bissette G. 1988. The clinical biology of CRF. Proc. 141st Ann. Meeting Amer. Psychiat. Assn., 119-120.
181. **Nemeroff CB**. 1988. Recent advances in the neurobiology of peptides. Proc. 141st Ann. Meeting Amer. Psychiat. Assn., 212.
182. Evans DL, **Nemeroff CB**, Golden RN, McCartney CF, Haggerty JJ and Simon JS. 1988. Neuroendocrine tests in medicine and psychiatry. Proc. 141st Ann. Meeting Amer. Psychiat. Assn., 212.
183. Bissette G and **Nemeroff CB**. 1988. Peptides in cerebrospinal fluid and brain in psychiatric disease. Proc. 141st Ann. Meeting Amer. Psychiat. Assn., 213.
184. **Nemeroff CB**. 1988. CRF: a role in the pathophysiology of anxiety. Proc. 141st Ann. Meeting Amer. Psychiat. Assn., 252-253.
185. Evans DL, Golden RN, Haggarty JJ, Jr., McCartney CF, Ekstrom DR and **Nemeroff CB**. 1988. Self-report of depression in cancer patients. Proc. World Psychiatric Association Regional Symposium, Washington, DC.
186. Knight DL, Bissette G, Kilts CD, Reynolds GP and **Nemeroff CB**. 1988. Selective reductions in cerebrocortical somatostatin receptor binding density in Alzheimer's disease. Soc. Neurosci. Abst. 14:667.
187. Urban BJ, France RD, Bissette G and **Nemeroff CB**. 1988. Do CSF concentrations of somatostatin change with pain clinic therapy? Proc. 42nd Post-graduate Assembly, The N.Y. State Society of Anesthesiologists.
188. **Nemeroff CB**. 1988. Use of platelet receptor binding studies in neuropsychiatry. Clin. Chem. 34, 1143.

189. **Nemeroff CB**, Owens MJ and Bissette G. 1988. The role of corticotropin-releasing factor (CRF) in the pathogenesis of depression. *Psychopharmacol.* 96, Suppl., 59.
190. **Nemeroff CB**. 1988. Brain neuropeptides and their possible role in the etiology of depression. *Psychopharmacol.* 96, Suppl., 109.
191. Banki CM, Arato M, Bissette G and **Nemeroff CB**. 1988. The TRH stimulation test in psychiatry. *Psychopharmacol.* 96, Suppl., 111.
192. Bissette G and **Nemeroff CB**. 1988. Alterations in neuropeptide systems in Alzheimer's disease. *Psychopharmacol.* 96, Suppl., 111.
193. Krishnan KRR, Goli V, Ellinwood EH, France R, **Nemeroff CB** and Blazer D. 1988. Leukoencephalopathy in patients with major depression. *Psychopharmacol.* 96, Suppl., 143.
194. Bond PE, Owens MJ, Bissette G and **Nemeroff CB**. 1988. Serotonergic regulation of corticotropin-releasing factor (CRF) neuronal activity in vivo. *Soc. Neurosci. Abst.* 14:446.
195. Bissette G and **Nemeroff CB**. 1988. Neuropeptide-neuroleptic interactions. *Proc. 27th Ann. Meeting of the Amer. Coll. Neuropsychopharmacol.*, 28.
196. **Nemeroff CB**, Butler PD, Owens MJ, Weiss JM and Bissette G. 1988. Stress, corticotropin-releasing factor (CRF) and the locus coeruleus. *Proc. 27th Ann. Meeting of the Amer. Coll. Neuropsychopharmacol.*, 3.
197. Cain ST, Owens M, Johnson M and **Nemeroff CB**. 1989. Subcellular distribution of corticotropin-releasing factor in the rodent central nervous system. *Soc. Neurosci. Abst.* 15:839.
198. **Nemeroff CB**, Kilts CD, Levant B, Campbell A, Bissette G, Neumeyer JL and Baldessarini RJ. 1989. Effects of aporphines on regional brain neurotensin concentrations: implications for development of novel antipsychotic drugs. *Soc. Neurosci. Abst.* 15:1122.
199. Owens MJ, Bartolome J and **Nemeroff CB**. 1989. Corticotropin-releasing factor (CRF) concentrations exhibit a circadian rhythm in both hypothalamic and extrahypothalamic brain regions: differential sensitivity to corticosterone. *Soc. Neurosci. Abst.* 15:800.
200. Cook LL, Faux GA, Knight DL, Bissette G and **Nemeroff CB**. 1989. Assessment of somatostatin-acetylcholine interactions in the rat cerebral cortex. *Soc. Neurosci. Abst.* 15:990.
201. Levant B, Bissette G and **Nemeroff CB**. 1989. Sigma antagonist MJ14802 increases neurotensin concentration in the rat nucleus accumbens and caudate nucleus. *Soc. Neurosci. Abst.* 15:811.
202. DeSouza EB, Zaczek R, Owens M, Culp S, Appel NM and **Nemeroff CB**. 1989. Effects of fenfluramine treatment on corticotropin-releasing factor (CRF) activity in rat brain. *Soc. Neurosci. Abst.* 15:800.
203. Kasckow JW, Cain ST and **Nemeroff CB**. 1989. Cyclic AMP and Ca/calmodulin stimulated protein phosphorylation in rat cerebellum, striatum and hippocampus. *Soc. Neurosci. Abst.* 15:834.

204. Knight DL, Meyerson LR, Benjamin D, Krishnan KRR, Blazer DG and **Nemeroff CB**. 1989. Increased plasma α -acid glycoprotein in depression: biologic, clinical and demographic correlations. Soc. Neurosci. Abst. 15:30.
205. Bissette G, Garver D, Kelly K and **Nemeroff CB**. 1989. CSF neurotensin concentrations in psychoses. Soc. Neurosci. Abst. 15:1122.
206. Pryor JC, Cain ST and **Nemeroff CB**. 1989. Calcium-dependent protein phosphorylation in the rodent anterior pituitary. Soc. Neurosci. Abst. 15:1079.
207. Ritchie JC, Scotch RL, Walker JT, Krishnan KRR, Reed DA and **Nemeroff CB**. 1989. Human growth hormone response to ovine corticotropin-releasing factor. Soc. Neurosci. Abst. 15:1373.
208. **Nemeroff CB**. 1989. The neurochemistry of affective disorders. J. Neurochem. S2, Suppl., S11.
209. Knight DL, Faux GA, Kilts CD, Reynolds GP and **Nemeroff CB**. 1989. Reduced somatostatin receptor binding in post-mortem Alzheimer's brain tissue. J. Neurochem. S2, Suppl., S202.
210. **Nemeroff CB**. 1989. New horizons for depression associated with medical illness. Proc. 142nd Ann. Meeting Amer. Psychiat. Assn., 38.
211. **Nemeroff CB**, Barki CM and Bissette G. 1989. CSF concentrations of thyrotropin-releasing hormone in depression. Proc. 142nd Ann. Meeting Amer. Psychiat. Assn., 209.
212. Simon JS, **Nemeroff CB**, Evans DL, Haggarty JJ. 1989. Thyroid antibodies and depression. Proc. 142nd Ann. Meeting Amer. Psychiat. Assn., 208.
213. Evans DL, Pedersen CA, Golden RN, Haggarty JJ, Simon JS, McCartney CF and **Nemeroff CB**. 1989. The thyrotropin-releasing hormone stimulation test in psychiatry and medicine. Proc. 142nd Ann. Meeting Amer. Psychiat. Assn., 209.
214. **Nemeroff CB**, Bissette G, Banki CM and Owens MJ. 1989 Corticotropin- releasing factor: CSF and brain studies. Proc. 142nd Ann. Meeting Amer. Psychiat. Assn., 257.
215. Arato M, Banki C, Toth L, Bissette G, **Nemeroff CB** and Akil H. 1989. CSF neuropeptide changes in depression and suicide. Proc. 142nd Ann. Meeting Amer. Psychiat. Assn., 136.
216. **Nemeroff CB**, Langer SZ, Egeland J, Weiss JM and Sulser F. 1989. Recent advances in the biology of affective disorders. Soc. Neurosci. Abst. 15:479.
217. Urban BJ, France RD, Bissette G and **Nemeroff CB**. 1990. Do CSF concentrations of somatostatin change with pain clinic therapy in chronic low back pain patients? VI World Congress of Pain, Adelaide, Australia.
218. Krishnan KRR, Dunnick NR and **Nemeroff CB**. 1989. Imaging of the Adrenal Gland. Proc. 27th Annual Meeting of the Amer. College of Neuropsychopharmacology, 14.
219. **Nemeroff CB**, Krishnan KRR, Leder RA and Dunnick NR. 1989. The adrenal gland in depressed patients: a pilot computed tomography study. Proc. 27th Ann. Meeting of the Amer. Coll. of Neuropsychopharmacology, 14.

220. **Nemeroff CB**, Levant B and Bissette G. 1989. Peptidergic modulation of midbrain dopamine neurons: focus on neurotensin. Proc. 27th Ann. Meeting of the Amer. Coll. of Neuropsychopharmacology, 22.
221. Cain ST, Abramson M and **Nemeroff CB**. 1989. Neurotensin-sensitive protein phosphorylation in the rodent caudate nucleus. Proc. Amer. Coll of Neuropsychopharmacology, 134.
222. Garver DL, Bissette G and **Nemeroff CB**. 1990. Psychosis and neurotensin deficit: symptoms and response. Proc. 143rd. Ann. Meeting Amer. Psychiat. Ass'n., 90.
223. Bissette G, Seidler F, **Nemeroff CB** and Slotkin TA. 1989. High affinity choline uptake in Alzheimer's disease brain tissue. Proc. 27th Ann. Meeting of the American College of Neuropsychopharmacology, 151.
224. Appel NM, Zaczek R, Owens M, Culp S, **Nemeroff CB** and DeSouza EB. 1989. Relationships between brain serotonin (5HT) and corticotropin-releasing hormone (CRH) in the anti-obesity effects of fenfluramine. Proc. 27th Ann. Meeting of the American College of Neuropsychopharmacology.
225. **Nemeroff CB** and Bissette G. 1990. Neuropeptide alterations in Alzheimer's Disease. Proc. 143rd Ann. Meeting of the Amer. Psychiat. Assn., 249.
226. **Nemeroff CB** and Owens MJ. 1990. The role of neurohormones in anxiety. Proc. 143rd Ann. Meeting of the Amer. Psychiat. Assn., 210.
227. Ritchie JC, Scotch RL, **Nemeroff CB** and Carroll BJ. 1990. The effect of age on DST status and plasma dexamethasone concentration in depressed patients. Biol. Psychiatry 27, Suppl., 45-46A.
228. Lammers C-H, Doraiswamy M, Husain M, Lurie S, Goli V, Boyko O, Figiel G, **Nemeroff CB** and Krishnan R. 1990. MRI of the corpus callosum in depression. Biol. Psychiatry 27, Suppl., 62A.
229. Doraiswamy M, Lurie S, Figiel G, Husain M, Boyko O, **Nemeroff CB** and Krishnan R. 1990. Pituitary enlargement in depression. Biol. Psychiatry 27, Suppl., 155A.
230. Figiel G, Krishnan R, Doraiswamy M, Boyko O and **Nemeroff CB**. 1990. Brain MRI subcortical structural changes in late age onset depression. Biol. Psychiatry 27, Suppl., 61A.
231. Husain M, Doraiswamy M, Figiel G, Knight D, Boyko O, Krishnan R and **Nemeroff CB**. 1990. Platelet [³H]-impramine binding and leukoencephalopathy in geriatric depression. Biol. Psychiatry 27, Suppl., 124A.
232. Roy A, Adinoff B, Bissette G, **Nemeroff CB** and Linnoila M. 1990. CSF TRH in alcoholics and normal controls. Biol. Psychiatry 27, Suppl., 177A.
233. Seidler FJ, **Nemeroff CB** and Slotkin TA. 1990. Auto-destruction of cholinergic neurons in Alzheimer's disease? Rapid autopsy evidence for extreme neuronal hyperactivity. FASEB J. 3: A875.

234. Fossey MD, Lydiard RB, Larara MT, Bissette G, **Nemeroff CB** and Ballenger JC. 1990. CSF thyrotropin-releasing hormone in patients with anxiety disorders. *Biol. Psychiatry* 27, Suppl., 167A.
235. Fossey MD, Lydiard RB, Larara MT, **Nemeroff CB**, Bissette G and Ballenger JC. 1990. CSF corticotropin-releasing factor (CRF) in patients with anxiety disorders. *Biol. Psychiatry* 27, Suppl., 148A.
236. Doraiswamy M, Shah SJA, Figiel GS, Husain MM, McDonald WM, Boyko OB, Ellenwood EH, Jr, **Nemeroff CB** and Krishnan KRR. 1990. Hippocampal pathology in major depression. *Proc. 143rd Ann Meeting of the Amer. Psychiatric Ass'n., New Research Abstracts*, 74.
237. McDonald W, Husain M, Doraiswamy PM, Figiel GS, Boyko OB, Ellenwood EH, **Nemeroff CB** and Krishnan KRR. 1990. Diminished caudate volume in major depression. *Proc. 143rd Ann Meeting of the Amer. Psychiat. Ass'n, New Research Abstracts*, 70.
238. Levant B, Bissette G, Davis MD, Heffner TG and **Nemeroff CB**. 1990. Effects of CI-943, a putative antipsychotic drug, and haloperidol on regional brain neurotensin concentrations. *Soc. Neurosci. Abst.* 16: 250.
239. Fossey MD, Lydiard RB, Laraia MT, Bissette G, **Nemeroff CB** and Ballenger JC. 1990. CRF and TRH in the CSF of panic patients. *Proc. 143rd Ann Meeting of the Amer. Psychiat. Assn., New Research Abstracts*, 165.
240. Pihoker C, Owens MJ, Kuhn CM and **Nemeroff CB**. 1990. Maternal separation evokes CRF release and HPA axis activation in neonatal rat pups. *Soc. Neurosci. Abst.* 16: 324.
241. **Nemeroff CB**, Dunnick NR, Boyko O, Figiel G, Reed D, Doraiswamy PM and Krishnan KRR. 1990. Pituitary and adrenal alterations in major depression: MRI and CT studies. *Soc. Neurosci. Abst.* 16: 139.
242. Kasckow JW, Cain ST and **Nemeroff CB**. 1990. Neurotensin incubation with rat striatal slices: effects on calcium/calmodulin-dependent protein phosphorylation. *Soc. Neurosci. Abst.* 16: 1179.
243. Smith WH, Bissette G, Cook L, Crain B, Dole K and **Nemeroff CB**. 1990. Regional differences in corticotropin-releasing factor (CRF) and somatostatin (SRIF) in Alzheimer's disease. *Soc. Neurosci. Abst.* 16: 1263.
244. Bissette G, Smith W, Dole K, Ghanbari H, Miller B, Crain B and **Nemeroff CB**. 1990. Measurement of Alzheimer's disease associated protein (ADAP) with a sandwich enzyme immunoassay incorporating ALZ-50. *Soc. Neurosci. Abst.* 16.
245. Ritchie JC, **Nemeroff CB**, Knight DL and Owens MJ. 1990. Evidence for the enzymatic degradation of CRF in cortex, hypothalamus, and plasma. *Soc. Neurosci. Abst.* 16: 791.
246. **Nemeroff CB**, Knight DL, Slotkin TA, Hussain M, Meyerson L and Krishnan, KRR. 1990. Altered platelet [³H] imipramine binding, 5HT uptake and plasma α 1- acid glycoprotein concentrations in depressed patients. *Proc Int. Symp Presynaptic Receptors and Neuronal Transporters*, 76.

247. Vargas MA, Owens MJ, Ritchie JC and **Nemeroff CB**. 1990. Time-course of action of the triazobenzodiazepine, alprazolam, on HPA axis function in rats. Soc. Neurosci. Abst. 16: 92.
248. Knight DL, Owens MJ, Ritchie JC and **Nemeroff CB**. 1990. Time-course of action of the 5HT₂ agonist; DOB, on the down-regulation of CRF and 5HT₂ receptors during chronic infusion. Soc. Neurosci. Abst. 16: 454.
249. Owens MJ, Ritchie JC, Knight DL and **Nemeroff CB**. 1990. Acute and chronic effects of the 5HT₂ agonist, (±)-1-(2,5-Dimethoxy-4- Bromophenyl)-2-aminopropane (DOB) on HPA axis activity. Soc. Neurosci. Abst. 16: 454.
250. Lessem MD, Kaye WH, Bissette G, Jimerson DC and **Nemeroff CB**. 1990. Low CSF Immunoreactive-TRH Levels in Anorexia. Proc. Amer Psychiatric Ass'n. 143rd Ann Meeting, New Research Abstracts 240.
251. Ehlers CL, Chaplin RF, Wall TL, Owens MJ, **Nemeroff CB**, Lumeng L and Li TK. 1990. Corticotropin-releasing factor (CRF): Studies in P and NP rats. Research Society for Alcoholism.
252. Finestone DH, Knight DL and **Nemeroff CB**. 1990. Platelet 3H-imipramine binding in fibromyalgia. Proc 143rd Ann. Meeting of the Amer. Psychiat. Ass'n., New Research Abstracts, 209.
253. Levant B and **Nemeroff CB**. 1990. Effects of sigma receptor blockade on regional brain neurotensin concentrations. Eur. J. Pharmacol. 183:2323.
254. **Nemeroff CB**. 1990. Corticotropin-releasing hormone, mood and behavior: basic and clinical studies. Proc 21st Congress of the Int. Soc. Psychoneuroendocrinology 27.
255. Krishnan KRR, Doraiswamy PM, Lurie S, Figiel G, Husain M, Rockwell W, Boyko O, McDonald W, Ellinwood EH and **Nemeroff CB**. 1990. Pituitary gland morphology in normal aging, anorexia nervosa and major depression: a pilot study. Proc 21st Congress of the Int. Soc. Psychoneuroendocrinology, 62.
256. Krishnan KRR, Ritchie JC, Reed D, Owens MJ, Allen D, **Nemeroff CB** and Carroll BJ. 1990. CRF stimulation test results before and after the administration of dexamethasone in depressed patients and normal controls. Proc 21st Congress of the Int Soc. Psychoneuroendocrinology, 62-63.
257. Adinoff B, **Nemeroff CB**, Bissette G, Martin PR, Bone GHA and Linnoila M. 1990. Relationship between cerebrospinal fluid TRH and pituitary TSH response to TRH infusion. Proc 21st Congress of the Int. Soc. Psychoneuroendocrinology, 78-79.
258. Haggerty JJ, Jr, Evans DL, Simon JS, Golden RN, Pedersen GA and **Nemeroff CB**. 1990. Thyroid Autoimmunity and psychiatric illness. Proc. 21st Congress of the Int. Soc. Psychoneuroendocrinology, 226-227.
259. Pitts AF, Kathol RJ, Gehris TL, Samuelson SD, Carroll BT, Meller WH, Carter J, **Nemeroff CB** and Bissette G. 1990. Elevated cerebrospinal fluid corticotropin-releasing hormone and arginine vasopressin in depressed patients with dexamethasone non-suppression. Soc. Neurosci. Abst. 16:454.

260. Owens MJ, Vargas AM and **Nemeroff CB**. 1990. The effects of alprazolam on CRF neurons following chronic treatment and abrupt withdrawal. Proc. 28th Ann Meeting of the American College of Neuropsychopharmacology, 176.
261. Pihoker C, Cain ST and **Nemeroff CB**. 1990. Postnatal development of regional adenylate cyclase activity in the rat brain. Proc 28th Ann Meeting of the American College of Neuropsychopharmacology, 102.
262. **Nemeroff CB**. 1990. New Vistas in neuropeptide research in neuropsychiatry. Proc. 29th Ann. Meeting of the American College of Neuropsychopharmacology, 43.
263. **Nemeroff CB** and Bissette G. 1990. Neuropeptide alterations in major depression: state or trait markers? Proc. 29th Ann. Meeting of the American College of Neuropsychopharmacol. 9.
264. Krishnan KRR, Doraiswamy PM, McDonald W, Figiel G, Husain M, Boyko O, Ellinwood EH and **Nemeroff CB**. 1990. Brain magnetic resonance imaging: studies in geriatric depression. Proc. 29th Ann. Meeting of the American College of Neuropsychopharmacology, 47.
265. **Nemeroff CB**, Knight DL, Slotkin TA and Krishnan KRR. 1990. Platelet measures of serotonergic function in depressed patients. Proc. 29th Ann. Meeting of the American College of Neuropsychopharmacol, 48.
266. Bissette G and **Nemeroff CB**. 1990. Somatostatin in depression and Alzheimer's disease. Proc. 29th Ann. Meeting of the American College of Neuropsychopharmacol, 49.
267. Pihoker C, Kuhn CM, Cain ST and **Nemeroff CB**: 1991. Regional changes in brain corticotropin-releasing factor receptors during postnatal development in the rat. Proc. Endocrine Soc. 73rd Ann. Meeting, 40.
268. Levant B, Merchant KM and **Nemeroff CB**: 1991. Haloperidol and sigma receptor ligand BMY 14802 increase regional brain neurotensin and proneurotensin mRNA concentrations. Proc. Int. Cong. Schizophrenia Research.
269. Bissette G, Levant B, Banks B and **Nemeroff CB**: 1991. Seasonal alterations in hypothalamic neurotensin concentrations. Soc. Neurosci Abst. 17:1193.
270. Cain ST, Griff D, Joyner CM, Ellinwood EH and **Nemeroff CB**: 1991. Cocaine effects on CNS neurotensin concentrations. Soc. Neurosci Abst. 17:891
271. Clapacs JT, Cain ST, Knight DL, Smith WE and **Nemeroff CB**: 1991. Changes in neurotensin receptor density in rats chronically treated with haloperidol and sigma antagonist BMY 14802. Soc. Neurosci Abst. 17:806.
272. Dole KC, Owens MJ, Bissette G, Vargas MA and **Nemeroff CB**: 1991. Acute administration of the putative antidepressant nefazodone does not alter regional rat brain CRF concentrations. Soc. Neurosci Abst. 17:1435
273. Franks JA, Knight DL, Krishnan KRR, Slotkin TA and **Nemeroff CB**: 1991. [³H]-imipramine binding in platelets of never-medicated depressed patients. Soc. Neurosci Abst. 17:1456.

274. Knight DL, Krishnan KRR and **Nemeroff CB**: 1991. Lack of significant monthly variation in platelet [³H]-imipramine binding kinetics in controls or patients with major depression. Soc. Neurosci Abst. 17:1457.
275. Koegler SM, Kilts CD, Owens MJ, Ervin GN, Bissette G and **Nemeroff CB**: 1991. The effect of bilateral electrolytic lesions of the central amygdaloid nucleus on the concentration of corticotropin-releasing factor (CRF) in microdissected brain regions. Soc. Neurosci Abst. 17:963.
276. Myers B, Levant B, Bissette G and **Nemeroff CB**: 1991. Specificity of the increase in neurotensin concentrations after chronic antipsychotic drug treatment. Soc. Neurosci Abst. 17:986.
277. Owens MJ, Ritchie JC and **Nemeroff CB**: 1991. THDOC decreases plasma corticosterone concentrations via a non-glucocorticoid mechanism. Soc. Neurosci Abst. 17:1343.
278. **Nemeroff CB**, Knight DL and Krishnan KRR: 1991. Reduced platelet [³H]-paroxetine and [³H]-imipramine binding in major depression. Soc. Neurosci Abst. 17:1472.
279. Ritchie JC, Owens MJ and **Nemeroff CB**: 1991. Corticotropin-releasing factor metabolism in the rat hypothalamus. Soc. Neurosci Abst. 17:404
280. Vargas MA, Owens MJ, Ehlers CL and **Nemeroff CB**: 1991. Effects of chronic administration and abrupt withdrawal of ethanol on corticotropin-releasing factor (CRF) concentrations in discrete rat brain regions. Soc. Neurosci Abst. 17:1418.
281. Knight DL, McDonald W, Krishnan KRR and **Nemeroff CB**. 1991. Platelet imipramine binding and clinical symptoms. Proc. 144th Ann. Meeting Amer. Psychiat. Ass'n., NR 629, 199.
282. Escalona PR, McDonald WM, Doraiswamy PM, Hussain MM, **Nemeroff CB** and Krishnan KRR. 1991. MRI study of caudate nucleus in major depression. Proc. 144th Ann. Meeting Amer. Psychiat. Ass'n., NR 27, 55.
283. Fossey MD, Lydiard RB, Laraia MT, Bissette G, **Nemeroff CB** and Ballenger JC. 1991. Sex differences in CSF levels of CRF and TRH. Proc. 144th Ann. Meeting Amer. Psychiat. Ass'n., NR 326, 126.
284. **Nemeroff CB**. 1991. Problems of clinical practice in bipolar disorder. Proc. 144th Ann. Meeting Amer. Psychiat. Assn., 26.
285. **Nemeroff CB**. 1991. The thyroid axis in depression: pathophysiological and clinical implications. Proc. 144th Ann. Meeting Amer. Psychiat. Ass'n., 46.
286. Hussain MM, McDonald WM, Doraiswamy PM, Escalona PR, Figiel GS, Boyko OB, Ellinwood EH, Krishnan KRR and **Nemeroff CB**. 1991. MRI evidence of basal ganglia atrophy in depression. Proc. 144th Ann. Meeting Amer. Psychiat. Ass'n., 94-95.
287. **Nemeroff CB**, Owens MJ and Weiss JM. 1991. The role of corticotropin-releasing factor in the pathophysiology of anxiety. Proc. 144th Ann. Meeting Amer. Psychiat. Ass'n., 212.

288. Davidson JT, **Nemeroff CB**, Smith MA and Kudler HS. 1991. ACTH response to corticotropin-releasing hormone in PTSD. Proc. 144th Ann. Meeting Amer. Psychiat. Ass'n., 227.
289. **Nemeroff CB**, Owens MJ and Bissette G. 1991. The role of corticotropin-releasing factor (CRF) in the pathophysiology of depression. Biol. Psychiat. 29, 11 Suppl., 47-48S.
290. Bissette G and **Nemeroff CB**. 1991. The role of thyrotropin-releasing hormone (TRH) in depression. Biol. Psychiat. 29, 11 Suppl., 48S.
291. **Nemeroff CB**. 1991. Depression, aging and psychoimmunology: focus on the pituitary-thyroid axis. Biol. Psychiat. 29, 11 Suppl., 80S.
292. Krishnan KRR, Doraiswamy PM, Lurie SN, Figiel G, Husain M, Boyko O, Ellinwood EH and **Nemeroff CB**. 1991. Morphological changes of the pituitary adrenocortical system as depicted by NMRI imaging in depressives. Biol. Psychiat. 29, 11 Suppl., 152S.
293. Freeman A, **Nemeroff CB**, Bradley R, Chou WC and Libb W. 1991. Tritiated platelet imipramine binding and treatment response in depressed outpatients. Biol. Psychiat. 29, 11 Suppl., 259-260S.
294. Fossey MD, Lydiard RB, Larain MT, Bissette G, and **Nemeroff CB**. 1991. Sex differences in CSF levels of CRF and TRH. Biol. Psychiat. 29, 11 Suppl., 542S.
295. Bissette G, Owens MJ and **Nemeroff CB**. 1991. Neuropeptides and mental illness: focus on affective disorder. Biol. Psychiat. 29, 11 Suppl., 706S.
296. Krishnan KRR, Blazer DG, Knight DL, Benjamin D, Meyerson LR and **Nemeroff CB**. 1991. Putative endogenous inhibitor of the tritiated imipramine binding site in depressed patients. Biol. Psychiat. 29, 11 Suppl., 708S.
297. **Nemeroff CB**. 1991. Dysregulation in affective disorders: the role of corticotropin-releasing hormone. Neuroendocrinology Lett. 13:168.
298. Griff D, Cain ST, Joyner CM, Ellinwood EH and **Nemeroff CB**. 1991. Cocaine effects on CNS neurotensin concentrations. Proc. 2nd Int. Conf. Neurotensin, pp 18.
299. **Nemeroff CB**, Weiss JM, Bissette G and Owens MJ. 1990. Evidence for a role for corticotropin-releasing factor in the pathogenesis of anxiety disorders and in the actions of triazolo-benzodiazepines. J. Psychiat. Res. 24, suppl 1:90-91.
300. **Nemeroff CB**, Bissette G, Levant B, Dorsa D, and Merchant K. 1991. The effects of antipsychotic drugs on regional CNS concentrations of neurotensin and neurotensin mRNA levels. Proc. Amer. Coll. Neuropsychopharmacology 30th Annual Meeting, 10.
301. **Nemeroff CB**, and Bissette G. 1991. CSF TRH, autoimmune thyroiditis and the TSH response to TRH in depression, Proc. Amer. Coll. of Neuropsychopharmacology, 30th Annual Meeting, 86.
302. Bissette G, Owens MJ, and **Nemeroff CB**. 1991. Hypothalamic-pituitary-adrenal axis alterations in stress and anxiety. Proc. Amer. Coll. of Neuropsychopharmacology, 30th Annual Meeting, 88.

303. **Nemeroff CB**, Weiss JM, Bissette G and Owens MJ. 1990. Evidence for a role for corticotropin-releasing factor in the pathogenesis of anxiety disorders and in the action of triazolobenzodiazepines. *J. Psychiat. Res.* 24, Suppl. 1, 90-91.
304. **Nemeroff CB** and Craighead WE. 1992. Multimodal treatment of patients with bipolar disorder and PTSD. *Proc. Amer. Psychiat. Assn.* 145th Ann. meeting, 5.
305. **Nemeroff CB**. 1992. Neurochemical hypothesis for subtyping of schizophrenia. *Proc. Amer. Psychiat. Assn.* 145th Ann. meeting, 20.
306. **Nemeroff CB**. 1992. The biology of bipolar disorder. *Proc. Amer. Psychiat. Assn.* 145th Ann. Meeting, 34.
307. **Nemeroff CB**. 1992. The serotonin uptake site. *Proc. Amer. Psychiat. Assn.* 145th Ann. meeting, 44.
308. Bissette G and **Nemeroff CB**. 1992. The neurochemistry of Alzheimer's disease. *Proc. Amer. Psychiat. Assn.* 145th Ann. meeting, 217.
309. Veith RC, Lewis N, Linares OA, Ashleigh EA, Kohen R, Barnes RF, Murburg, Peskind ER, Pascualy M, Bissette G, **Nemeroff CB**, Halter JB and Raskind, MR. 1992. Effects of acute and chronic desipramine administration on sympathetic nervous system activity in major depression. *Proc. 7th Intl. Catecholamine Symposium*, 38.
310. Clement R, Griff D, Banks B, **Nemeroff CB**, Kitabgi P and Bissette G. 1992. Haloperidol increases neuromedian N as well as neurotensin concentrations in specific brain regions. *Soc. Neurosci. Abstr.* 18:916.
311. **Nemeroff CB**. 1992. CRF and depression. *J. Psychopharmacol. Suppl.* A87.
312. **Nemeroff CB**. 1992. The role of CRF in depression. *Proc. XXIII Int. Soc. Psychoneuroendocrinology Annual Meeting*, 39.
313. Owens MJ and **Nemeroff CB** 1992. Effects of stress and benzodiazepines on corticotropin-releasing factor neurons. *Int Soc Psychoneuroendocrinology, satellite meeting on CRF*, pp10.
314. **Nemeroff CB**, Owens MJ and Knight DL. 1992. Effects of chronic antidepressant treatment on corticotropin-releasing factor neurons in the rat. *Soc. Neurosci. Abstr.* 18:202.
315. Myers B, Levey A and **Nemeroff CB**. 1992. Quantitation of neurotensin receptor mRNA using polymerase chain reaction. *Soc. Neurosci. Abstr.* 18:454.
316. Owens MJ, Knight DL and **Nemeroff CB**. 1992. Effects of para-chloramphetamine lesions on platelet [³H]-paroxetine binding in rats. *Soc. Neurosci. Abstr.* 18:928.
317. Hayden-Hixson DM, White N, Ritchie JC and **Nemeroff CB**. 1992. Neonatal handling: effects on spatial memory, basal corticosterone levels and hippocampal function. *Soc. Neurosci. Abstr.* 18:1426.
318. Kilts CD and **Nemeroff CB**, 1993. The role of neurotensin in schizophrenia and antipsychotic drug action: preclinical and clinical findings. *9th World Congress of Psychiatry*.

319. Figiel GS and **Nemeroff CB**, 1992. Structural brain changes in bipolar disorder. Proc 31st Ann Meeting, American College of Neuropsychopharmacol, 8.
320. **Nemeroff CB**, Krishnan KRR, Knight DL and Freeman H. 1992. [³H]-Imipramine binding as a predictor of treatment response. Proc. 31st Ann meeting of the Amer. College of Neuropsychopharmacology, 66.
321. Figiel GS and **Nemeroff CB**, 1992. Clinical correlates of structural brain changes in the depressed elderly. Proc. 31st Ann meeting of the Amer. College of Neuropsychopharmacology, 67.
322. Adinoff B, Linnoila M, Bissette G, Guidotti A, Mefford I and **Nemeroff CB**. 1992. Cerebrospinal fluid concentrations of CRH, DBI and catecholamine metabolites during alcohol withdrawal and abstinence. Proc. 31st Ann meeting of the Amer. College of Neuropsychopharmacology, 129.
323. Owens MJ, Knight DL and **Nemeroff CB**. 1992. Effects of para-chloroamphetamine and fenfluramine lesions on platelet [³H]-paroxetine binding in rats. Proc. 31st Ann meeting of the Amer. College of Neuropsychopharmacology, 191.
324. Bissette G, **Nemeroff CB**, Naidu S, Moser H and. 1993. Neuropeptide alterations in Rett's syndrome. Soc. Biol. Psychiat.
325. **Nemeroff CB**, Owens MJ, Plott SJ and Levine S. 1993. Increased density of regional brain CRF binding sites after maternal deprivation. Soc. Neurosci. Abst. 19:1.
326. Ballenger CA, Owens MJ, Plott SJ, Morgan WN, Oxford GS and **Nemeroff CB**. 1993. Do prolonged changes in CNS 5-HT neurons or hypercorticotesteronemia alter platelet serotonin transporter binding? Soc. Neurosci. Abst. 19:498.
327. Knight DL, Owens MJ, Morgan WN and **Nemeroff CB**. 1993. Regional differences in ³H-citalopram binding in response to saline injections or fenfluramine-induced lesions Soc. Neurosci. Abst. 19:498.
328. Owens MJ and **Nemeroff CB**. 1993. Acute effects of benzodiazepines on regional brain CRF concentrations: comparison of alprazolam, diazepam, and lorazepam. Soc. Neurosci. Abst. 19:1866.
329. Kinkead B, Owens MJ and **Nemeroff CB**. 1993. The effects of sertindole on regional CNS neurotensin concentrations in the rat brain. Soc. Neurosci. Abst. 19:856.
330. Ritchie JC and **Nemeroff CB**. 1993. Corticotropin-releasing factor degradation by purified peptidases. Soc. Neurosci. Abst. 19:1363.
331. Stowe ZN, Landry JC and **Nemeroff CB**. 1993. The effects of systemically administered SR48692, a non-peptide neurotensin receptor antagonist, on the firing rates of individual dopamine neurons in the ventral tegmental area. Soc. Neurosci. Abst. 19:728.
332. Heuser I, Bissette G, Gotthardt U, Schnider J, Lammers C-H, Dettling M, Deuschle M, Schweiger U, **Nemeroff CB** and Holsboer F. 1993. Effects of amitriptyline upon HPA system regulation. Biol. Psychiatry 33:72a.

333. **Nemeroff CB.** 1993. Biological markers of depression: an update. Proc. 146th Ann. meeting, Amer. Psychiat. Assn; 18-19.
334. **Nemeroff CB.** 1993. How can we diagnose the 75% of bipolar patients who currently go unrecognized? Proc. 146th Ann. meeting, Amer. Psychiat. Assn; 42.
335. **Nemeroff CB.** 1993. The role of CRF in depression. Proc. 146th Ann. meeting, Amer. Psychiat. Assn; 122.
336. Krishnan DRR, Doraiswamy PM, McDonald WM, Axelson DA, Boyko OB, **Nemeroff CB** and Dunnick NR. 1993. Pituitary size in depression. Proc. 146th Ann. meeting, Amer. Psychiat. Assn; 122.
337. Escalona PR, Early B, McDonald WM, **Nemeroff CB** and Krishnan KRR. 1993. Reduction of cerebellar volume in depression. Proc. 146th Ann. meeting, Amer. Psychiat. Assn. NR187, 106.
338. **Nemeroff CB.** 1993. The role of CRF in depression. Proc. Canadian College of Neuropsychopharmacology, 16th Ann. meeting; S 2.1.
339. McDaniel JS, Reed D, Marsteller F, Seelig B, Musselman D and **Nemeroff CB.** 1993. Affective disorders in breast and gastrointestinal cancers. Ann. Meeting of the Acad. Psychosomatic Medicine.
340. **Nemeroff CB.** 1993. The role of CRF in the pathophysiology of depression. Proc. Soc. Drug Research, Cambridge, England, 12.
341. **Nemeroff CB,** McDaniel JS, Reed D, Wingard J, Seelig B and Musselman D. 1993. Cancer and depression: diagnostic and biological measures. Neuropsychopharmacol. 9; Suppl 2:40-41S.
342. **Nemeroff CB.** The role of CRF in the pathophysiology of depression: preclinical and clinical studies. Neuropsychopharmacol. 9; Suppl 2:3S.
343. **Nemeroff CB.** 1993. Depression: an age-related disease. Neuroendocrinology Lett. 15:283
344. Kasckow JW, Owens MJ, Han J, Stipetic MD and **Nemeroff CB.** 1994. The BE(2)-C cell secretes corticotropin-releasing factor and responds to forskolin. Soc. Biol. Psychiat.
345. **Nemeroff CB.** 1993. Affective Disease and Peptides. J. Neurol. Sci. 120:4-5.
346. **Nemeroff CB,** Owens MJ and Weiss JM. 1993. Regulation of CRF in the locus coeruleus: behavioral and pharmacological manipulations. Proc. 32nd Annual Meeting of the American College of Neuropsychopharmacology, 9.
347. Stowe ZN, Landry JC and **Nemeroff CB.** 1993. The effects of a non-peptide neurotensin receptor antagonist, SR 48692 on the firing rates of ventral/tegmental area dopamine neurons. Proc. 32nd Annual Meeting of the American College of Neuropsychopharmacology, 96.
348. Musselman DL, **Nemeroff CB,** McDaniel JS, Reed D, Wingard J and Seeling B. 1993. Cancer and depression: diagnostic considerations and biological markers. Proc 32nd Annual Meeting of the American College of Neuropsychopharmacology, 123.

349. Tollefson GD, Heligenstein JH, **Nemeroff CB** and Birkett MA. 1993. Do [³H]-imi platelet studies reflect treatment outcome of major depression: agitated subtype? Proc. 32nd Annual Meeting of the American College of Neuropsychopharmacology, 164.
350. Owens MJ, Ballenger CA, Morgan WN, Knight DL and **Nemeroff CB**. 1993. Platelet 5HT transporter and 5HT₂ receptor binding following chronic hypercorticosteranemia, 5HT depletion or DOI administrations in the rat. Proc. 32nd Annual Meeting of the American College of Neuropsychopharmacology, 166.
351. Kasckow JW, Parkes DG, Owens MJ, Han J, Stipetic MD, Vale WW and **Nemeroff CB**. 1994. The BE (2)-M17 human neuroblastoma cell line synthesizes and secretes corticotropin-releasing factor. Proc Endocrine Soc 76th Ann Meeting, 642.
352. Kasckow JW, Mulcahey JJ, Han J, Owens MJ, Stipetic MD, Breitman D and **Nemeroff CB**. 1994. Interleukin-1 α induces corticotropin-releasing factor secretion and synthesis from NPLC-KC cells through various second messenger pathways. Soc Neurosci Abst 20:956.
353. Owens MJ, Mulcahey JJ, Kasckow JH, Plotsky PM and **Nemeroff CB**. 1994. Exposure to a CRF receptor antisense oligonucleotide decreases CRF receptor binding in vitro. Soc Neurosci Abst 20:16.
354. Kinkead B, Owens MJ and **Nemeroff CB**. 1994. Ontogeny of the effect of antipsychotic drug treatment on regional CNS neurotensin concentrations in the rat brain. Soc Neurosci Abst 20:225.
355. Stout SC, Owens MJ, Mulcahey JJ and **Nemeroff CB**. 1994. CRF receptor binding following chronic antidepressant treatment in the rat. Soc Neurosci Abst 20:383.
356. Ritchie JC, Sundar KS and **Nemeroff CB**. 1994. Effect of specific peptidase inhibitors on CRF-induced ACTH release in cultured rat pituitary cells. Soc Neurosci Abst 20:447.
357. Stowe ZN, Landry JC, Tang ZL and **Nemeroff CB**. 1994. Dopamine-induced inhibition is attenuated by iontophoretically applied neurotensin in the nucleus accumbens of rats. Soc Neurosci Abst 20:1348.
358. Landry JC, Stowe ZN, Owens MJ, Plotsky PM and **Nemeroff CB**. 1994. CRF-induced excitation of neuronal firing rates in locus coeruleus neurons is attenuated by systemic administration of alprazolam. Soc Neurosci Abst 20:1347.
359. Darnell A, Bremner JD, Liahio J, Krystal J, **Nemeroff CB**, Owens M, Erdos I and Charney DS. 1994. CSF levels of corticotropin-releasing factor in chronic post-traumatic stress disorder. Soc Neurosci Abst 20:17.
360. Kasckow JW, Owens MJ, Han J, Stipetic MD and **Nemeroff CB**. 1994. The BE(2)-C cell secretes corticotropin-releasing factor and responds to forskolin. Biol Psychiat 35:663.
361. Small GW, Schneider LS, Holman S, Bystritsky A, Myers BS and **Nemeroff CB**. 1994. Site variability in geriatric depression trial. Proc Amer Psychiat Assn, 150th Ann Meeting, New Research 182.

362. Small GW, Schneider LS, Holman S, Brysritsky A, Meyers BS and **Nemeroff CB**. 1994. Estrogen plus fluoxetine for geriatric depression. Proc Amer Psychiat Assn, 150th Ann Meeting, New Research 203.
363. Stowe ZN, Owens MJ and **Nemeroff CB**. 1994. Pilot study of platelet serotonin transporter binding sites in women with post-partum depression. Proc Amer Psychiat Assn, 150th Ann Meeting, New Research 166.
364. **Nemeroff CB**. 1994. Treatment of depression in bipolar patients. Proc Amer Psychiat Assn, 150th Ann Meeting, 301-302.
365. **Nemeroff CB**. 1994. Neuropeptides and schizophrenia. Proc Amer Psychiat Assn, 150th Ann Meeting, 148-149.
366. Coplan JD, Rosenblum LA, Owens MJ, Andrews MW, Gorman JM and **Nemeroff CB**. 1994. Increased cerebrospinal fluid CRF concentrations in adult non-human primates previously exposed to adverse experiences as adults. Soc Neurosci Abst 20:17.
367. Heuser I, Bissette G, Dettling M, Lammers C-H, Gotthardt U, Schweiger U, **Nemeroff CB** and Holsboer F. 1994. Neuroendocrine regulation in elderly depressed patients--CSF and plasma studies. Neuropsychopharmacology 10, 3S, Part 1:605.
368. **Nemeroff CB**, Owens MJ and Weiss JM. 1994. The role of corticotropin-releasing factor (CRF) in the pathophysiology of depression and anxiety disorders. Neuropsychopharmacology 10, 3S, Part 1:375S.
369. **Nemeroff CB**, Owens MJ and Weiss JM. 1994. Stress, CRF and monoamine activity in lower animals and man. Neuropsychopharmacology 10, 3S, Part 1:927S.
370. Stowe ZN, Casarella J, Landry J and **Nemeroff CB**. 1994. Open-labelled prospective trial of sertraline for women with moderate to severe post-partum depression. Neuropsychopharmacology 10, 3S, Part 2:106S.
371. Doraiswamy M, Krishnan K, Ritchie J, Tupler L, McDonald W, Marcovina S, Knight D and **Nemeroff CB**. 1994. Apolipoprotein E4 in late onset depression. Neuropsychopharmacology 10, 3S, Part 3:22.
372. **Nemeroff CB**. 1994. Corticotropin-releasing factor and the genesis of depression. Proc. Royal College of Psychiatrists Annual Meeting, 27.
373. Stowe ZN, Kilts CD, Ely T and **Nemeroff CB**. 1995. Excretion of sertraline in human breast milk. Proc Amer Soc Psychosomat Obstet Gynecol.
374. **Nemeroff CB**, Musselman DL, Reed D, Porter MF, Wingard J and McDaniel JS. 1994. Neurobiology of cancer and depression. Proc 25 Ann Meeting, Int Soc Psycho-neuroendocrinology, 37.
375. Stowe ZN and **Nemeroff CB**. 1995. Depression during pregnancy and the postpartum. Proc Amer Psychiatric Assn, 151st Ann Meeting.

376. Risby E, Morgan WN, Stipetic M, Owens MJ and **Nemeroff CB**. 1994. Increased platelet 5HT₂ binding in bipolar patients requiring anticonvulsants. Soc Neurosci Abst 20:1161.
377. Owens CA, Owens MJ, Thrivikramen KV and **Nemeroff CB**. 1994. The effects of early maternal deprivation on neurochemical and endocrine responses to stress in adult rats. Soc Neurosci Abstr 20:372.
378. Knight DL, Owens MJ, Morgan WN and **Nemeroff CB**. 1994. [³H]-citalopram binding to brain and platelet 5HT transporters: developmental increases in binding density in prefrontal cortex of young adult rats. Soc Neurosci Abstr 20:293.
379. **Nemeroff CB**. 1994. Neurohormones, stress and psychiatric illness. Proc First World Congress on Stress, 66.
380. **Nemeroff CB**, Owens MJ, Owens CA, Ehlers C, Robbins T and Levine S. 1994. The neurobiological consequences of early traumatic experiences: focus on corticotropin-releasing factor. Eur Neuropsychopharmacol 4:255-256.
381. Lieberman JA, Safferman AZ, Szymanski S, Kronig M, Cooper T, Iodarola M, Bissette G and **Nemeroff CB**. 1994. Biochemical effects of clozapine in treatment-resistant schizophrenia. Soc Neurosci Abst 20:226.
382. Han J, Kasckow JW, Parkes DB, Owens MJ, Stipetic M, Breitman D, Kazanjian HL and **Nemeroff CB**. 1995. Regulation of CRF in BE(2)-M17 and BE(2)-C neuroblastoma cell lines. Soc Biol Psychiat Ann Meeting.
383. **Nemeroff CB** and Owens MJ. 1994. Evidence for a preeminent role for corticotropin-releasing factor in the pathophysiology of post-traumatic stress disorder: preclinical and clinical studies. Proc Amer College Neuropsychopharmacol. 33rd Ann Meeting, 74.
384. Owens MJ, Mulcahey JJ, Kasckow JW, Plotsky PM and **Nemeroff CB**. 1994. Antisense knockdown of CRF receptors in rat pituitary cultures. Proc Amer College Neuropsychopharmacol. 33rd Ann Meeting, 85.
385. Coplan JD, Andrews MW, Rosenblum LA, Owens MJ, Cooper T, Gorman JM and **Nemeroff CB**. 1994. Persistent elevations of CSF concentrations of CRF somatostatin, HVA and 5HIAA in grown nonhuman primates exposed to early life stressors. Proc Amer College Neuropsychopharmacol. 33rd Ann Meeting, 147.
386. Stowe ZN, Landry JC, Tang ZL and **Nemeroff CB**. 1994. Iontophoretic application of neurotensin attenuates DA-induced inhibitions in both the core and shell subregions of the nucleus accumbens in rats. Proc Amer College Neuropsychopharmacol. 33rd Ann Meeting, 173.
387. Musselman DL, Knight B, Kilts CD, Bonsall R, Tomer A, Harker LA and **Nemeroff CB**. 1994. Platelet function, serotonergic and sympathoadrenal activity in major depression. Proc Amer College Neuropsychopharmacol. 33rd Ann Meeting, 215.
388. Winn SS, Stowe ZN, Landry JC, Kilts CD, Ely T and **Nemeroff CB**. 1995. Sertraline in breast milk and nursing infants. Proc Amer Psychiat Assn 148th Ann Meeting, 73.

389. Stowe ZN, Landry JC, Porter MF and **Nemeroff CB**. 1995. The use of rating scales in postpartum depression. Proc Amer Psychiat Assn 148th Ann Meeting, 138.
390. Musselman DL, Knight BT, Porter MR, Marzec U, Kilts CD, Bonsall R, Tomer A, Harker LA and **Nemeroff CB**. 1995. Exaggerated platelet reactivity in depression. Proc Amer Psychiat Assn 148th Ann Meeting, 68.
391. Musselman DL and **Nemeroff CB**. 1994. Depression and endocrine disorders: focus on the thyroid and adrenal. In: Critical Issues in the Treatment of Affective Disorders. SZ Langer, N Brunello, G Racagni and J Mendelwicz, Eds, Int Acad Biomed Drug Res, Basel, Karger 9:189-191.
392. Kinkead B, Owens MJ and **Nemeroff CB**. 1995. Ontogeny of the effect of antipsychotic drug treatment on neurotensin/neuromedin N mRNA expression in the rat brain. Soc Neurosci Abstr 21:767.
393. Morgan WN, Owens MJ, Daley JT, Knight DL, Stowe ZN and **Nemeroff CB**. 1995. The effects of reduced pH during serial dilutions in radioligand competition binding studies. Soc Neurosci Abstr 21:767.
394. Kasckow JW, Mulchahey JJ, Parkes DG, Kilts CD, Lambert P, Owens MJ, Risby ED, Stipetic, MD and **Nemeroff CB**. 1995. Dexamethasone does not alter basal corticotropin-releasing factor (CRF) produced by rat amygdaloid neurons in culture. Soc Neurosci Abstr 21:1394.
395. Radke JM, Young LY, Owens MJ and **Nemeroff CB**. 1995. Effect of haloperidol on neurotensin release in the rat basal ganglia: a microdialysis study. Soc Neurosci Abstr 21:1596.
396. Ritchie JC and **Nemeroff CB**. 1995. Effect of three ectopeptidases on corticotropin-releasing factor: metabolism and functional aspects. Soc Neurosci Abstr 21:761.
397. Wolf SS, Bachus SE, Kinkead BL, Owens MJ, **Nemeroff CB**, Kleinman JE and Hyde TM. 1995. Neurotensin receptor mRNA localization in human midbrain, basal ganglia, cingulate cortex and hippocampus: formation by in situ hybridization. Soc Neurosci Abstr 21:2049.
398. **Nemeroff CB**, Ninan, PT, Ballenger JC, Feighner JP, Greist JH and Patterson W. 1995. Safety and tolerance of fluvoxamine versus sertraline in depressed outpatients. Proc Amer Psychiat Assn 148th Ann Meeting, 177.
399. Han J, Kasckow JW, Parkes DG, Owens MJ, Stipetic MD, Breitman D, Kazanjian HL and **Nemeroff CB**. 1995. Regulation of CRF in BE(2)-M17 and BE(2)-C neuroblastoma cell lines. Biol Psychiat 37:647, 195.
400. Coplan JD, Rosenblum LA, Andrews M, **Nemeroff CB**, Owens MJ and Gorman JM. 1995. Biological effects of aversive rearing in primates. Proc Amer Psychiat Assn 148th Ann Meeting, 125.
401. Stowe ZN and **Nemeroff CB**. 1995. Depression during pregnancy and the postpartum. Proc Amer Psychiat Assn 148th Ann Meeting, 147.
402. **Nemeroff CB**. 1995. Pharmacological treatment of subsyndromal depression. Proc Amer Psychiat Assn 148th Ann Meeting, 164.

403. Owens MJ, Plotsky PM, Thiruvikraman KV and **Nemeroff CB**. 1995. The hypothalamus, corticotropin-releasing factor and affective disorders. Proc Amer Psychiat Assn 148th Ann Meeting, 168.
404. **Nemeroff CB**. 1995. Medical factors interrelated with bipolar disorder. Proc Amer Psychiat Assn 148th Ann Meeting, 241.
405. **Nemeroff CB**. 1995. Management of treatment-refractory depression. Proc Amer Psychiat Assn 148th Ann Meeting, 265.
406. Small GW, Bystritsky A, Meyers BS, **Nemeroff CB** and Birkett M. 1995. Co-morbid disease states in the elderly and the impact on quality of care. Int. Psychogeriatric Soc.
407. Stowe ZN and **Nemeroff CB**. 1996. Antidepressants in breast milk: focus on SSRIs. Proc Amer Psychiatric Assn 149th Ann Meeting, 145.
408. Stowe ZN and **Nemeroff CB**. 1996. Depression in pregnancy and the puerperium. Proc Amer Psychiatric Assn 149th Ann Meeting, 303.
409. **Nemeroff CB**, Krishnan KRR, Musselman DL, Landry J, Fernandez MP and Porter MR. 1995. Brain magnetic resonance imaging and adrenal CT imaging in affective disorders. Proc 2nd Int Conf on New Directions in Affective Disorders, 547.
410. **Nemeroff CB**, McDaniel JS, Musselman DL, Porter MR, Reed DR, Glover S, Fernandez MP and Landry J. 1995. Clinical and neurobiological characteristics of depression in cancer. Proc 2nd Int Conf on New Directions in Affective Disorders. S259.
411. Wall TL, **Nemeroff CB**, Garcia-Andrade C and Ehlers C. 1995. Cortisol responses following placebo and alcohol in populations at high and low genetic risk for alcoholism. Proc 26th Ann Meeting of the Int Soc Psychoneuroendocrinology, 111.
412. Owens MJ, Morgan WN, Plott SE, Ieni J and **Nemeroff CB**. 1995. In vitro inhibition of the rat and human serotonin and norepinephrine transporters by the antidepressant nefazadone and its metabolites. Soc Neurosci Abstr 21:766.
413. Knight DL, Owens MJ, Winders KJ, Ieni J and **Nemeroff CB**. 1995. In vivo inhibition of the serotonin transporter by the antidepressant nefazadone in the rat. Soc Neurosci Abstr 21:866.
414. Musselman DL, Porter MF, Ninan PT, Knight BT, Bonsall RW, Emery MS, Stowe ZA, Hauenstein EJ, Krishnan KRR, Davidson JT and **Nemeroff CB**. 1995. Thyroid autoantibodies in patients with mood and anxiety disorders. Soc Neurosci Abstr 21:1737.
415. Ely TD, Lambert PD, Gross R, **Nemeroff CB** and Kilts CD. 1995. Effect of central neurotensin administration on fos expression in the rat brain-relating function to anatomy. Soc Neurosci Abstr 21:2053.
416. **Nemeroff CB**, Stout, SC and Owens, MJ. 1995. Stress peptides and HPA axis reactivity in depression. Proc VIIIth Congress Eur Col of Neuropsychopharmacol, 5:242.

417. **Nemeroff CB**, Ninan PT, Ballenger JC, Feighner J, Greist JH and Patterson WM. Comparison of the safety and tolerance of fluvoxamine and sertraline in depressed outpatients. 1995. Proc VIIIth Congress Eur Col of Neuropsychopharmacol, 5:304.
418. Coplan JD, Andrews MW, Rosenblum LA, Owens MJ, Cooper T, Gorman JM and **Nemeroff CB**. 1995. Behavioral, monoaminergic, neuroendocrine and neuropeptidergic alterations in grown nonhuman primates exposed to unpredictable early rearing: relevance to human anxiety. Proc VIIIth Congress Eur Col of Neuropsychopharmacol, 5:353.
419. Owens MJ, Mulcahey JJ, Thrivikramen KV, Plotsky PM, Plott SJ and **Nemeroff CB**. 1995. Antisense targeting of CRF receptors. Proc 34th Ann meeting of the Amer College of Neuropsychopharmacol, 27.
420. **Nemeroff CB** and Owens MJ. 1995. CRF and depression: preclinical and clinical update. Proc 34th Ann meeting of the Amer College of Neuropsychopharmacol, 29.
421. Stowe ZN, Landry JC, Owens MJ, Plotsky PM and **Nemeroff CB**. 1995. The effects of directly applied CRF on the firing rates of individual locus coeruleus neurons. Proc 34th Ann meeting of the Amer College of Neuropsychopharmacol, 152.
422. Figiel GS, McDonald WM and **Nemeroff CB**. 1995. A study of continuation ECT (C-ECT) versus continuation pharmacotherapy (c-pharmacotherapy) on relapse rates in the depressed elderly following a therapeutic trial of ECT. Proc 34th Ann meeting of the Amer College of Neuropsychopharmacol, 281.
423. Pomara N, Deptula D, Nolan K, Tun H, Singh R, Leviste F, Ritchie JC, Greenblatt DJ and **Nemeroff CB**. 1996. Differential effects of alprazolam and lorazepam on plasma cortisol in normal elderly. Biol Psychiat 39:624.
424. Tupler LA, Krishnan KRR, Ritchie JC, McDonald WM, Knight DL, **Nemeroff CB** and Carroll BJ. 1996. Cognitive impairment in elderly depressed individuals with Apo E4. Bio Psychiat 39:659.
425. Kinkead B, Lorch S, Owens MJ and **Nemeroff CB**. 1996. Gender based differences in the effects of antipsychotic drug treatment on neurotensin concentrations in the rat brain. Soc Neurosci Abstr 22:1926.
426. Mulchahey JJ, Plotsky PM, **Nemeroff CB**, Angerer E, Stalla GK and Newton CJ. 1996. Ligand independent activity of human estrogen receptors is tyrosine kinase dependent. Soc Neurosci Abstr 22:262.
427. McDaniel JS, Musselman DL, Porter MR, Reed DA and **Nemeroff CB**. 1996. Depression in patients with cancer. Proc Amer Psychiat Assn 149th Ann Meeting, 133.
428. Stowe ZN and **Nemeroff CB**. 1996. Breastfeeding and psychotropic drug use. Proc Amer Psychiat Assn 149th Ann Meeting, 289.
429. **Nemeroff CB**. 1996. Treatment of refractory depression: problems and promises. Proc Amer Psychiat Assn 149th Ann Meeting, 293.

430. **Nemeroff CB.** 1996. Antidepressant metabolism and the cytochrome P450 system. Proc Amer Psychiat Assn 149th Ann Meeting, 295.
431. Binder E, Kinkead B, Owens, MJ and **Nemeroff CB.** 1996. Effects of acute clozapine or haloperidol treatment on neurotensin/neurokinin B and neurotensin receptor mRNA expression in distinct regions of the rat brain. Soc Neurosci Abstr 22:1765.
432. Radke JM, Owens MJ and **Nemeroff CB.** 1996. Comparison of acute and chronic administration of haloperidol on neurotensin release in the rat brain. Soc Neurosci Abstr 22:1926.
433. **Nemeroff CB,** Plotsky PM and Owens MJ. 1996. The role of CRF in the pathophysiology of mood and anxiety disorders: preclinical and clinical studies. Proc 10th Intl Cong Endocrinol, Vol II: 703.
434. **Nemeroff CB.** 1996. New vistas in the hypothalamic-pituitary-thyroid axis and mood disorders. Proc 27th Ann meeting of the Int Soc of Psychoneuroendocrinology, 3.
435. **Nemeroff CB.** 1996. Co-morbid depression and anxiety: epidemiology and diagnosis. Proc 27th Ann meeting of the Int Soc of Psychoneuroendocrinology, 19.
436. Owens MJ, Plotsky PM and **Nemeroff CB.** 1996. CRF, the HPA axis and depression: role of early life events. Proc 27th Ann meeting of the Int Soc of Psychoneuroendocrinology, 26.
437. **Nemeroff CB.** 1996. Psychopharmacology and psychoneuroendocrinology in the 21st century. Proc 27th Ann meeting of the Int Soc of Psychoneuroendocrinology, 52.
438. **Nemeroff CB.** 1996. Depression: a model for integrated pathophysiology and treatment approaches. Proc X World Congress of Psychiatry, Vol I: 4.
439. **Nemeroff CB.** 1996. Hormonal responses in normals and in patients with mental disorders. Proc X World Congress of Psychiatry, Vol I: 8.
440. McDaniel JS, Musselman DL, Porter MR, Reed DA and **Nemeroff CB.** 1996. Depression in patients with cancer. Proc X World Congress of Psychiatry, Vol I: 14.
441. **Nemeroff CB.** 1996. Quality of life and new antipsychotics. Proc X World Congress of Psychiatry, Vol I:39.
442. **Nemeroff CB,** Owens MJ, Kinkead B. 1996. Preclinical and clinical investigations of the role of neurotensin in the pathophysiology of schizophrenia and in the mechanisms of action of antipsychotic drugs. Proc X World Congress of Psychiatry, Vol I:72.
443. **Nemeroff CB,** Owens MJ, Radke J and Kinkead B. 1996. The role of non-monoaminergic systems in atypical antipsychotic drug action: focus on neurotensin. Proc X World Congress of Psychiatry, Vol I:122.
444. Hartline KM, Owens MJ, Plott SJ, Ritchie JC and **Nemeroff CB.** 1996. Effects of acute administration of benzodiazepine agonists and partial inverse agonists on HPA axis function. Soc Neurosci Abstr 22:2014.

445. Stout SC, Owens MJ and **Nemeroff CB**. 1996. CRF receptor binding, mRNA expression and signal transduction after chronic antidepressant treatment in rats. Soc Neurosci Abstr 22:1545.
446. Owens MJ, Morgan WN and **Nemeroff CB**. 1996. α_1 acid glycoprotein does not modify [3 H]-5-HT uptake by the human serotonin transporter in vitro. Soc Neurosci Abstr 22:731.
447. Knight DL, Morgan WN, Owens MJ and **Nemeroff CB**. 1996. In vitro binding profile of modern antidepressants and their metabolites: correlations between affinities at various receptors. Soc Neurosci Abstr 22:179.
448. Bissette B, Smith W, Crain B and **Nemeroff CB**. 1996. Neuropeptides, phosphorylated TAU and neuropathology in Alzheimer's disease. Soc Neurosci Abstr 22:204.
449. Musselman DL, Porter MR, Ninan PT, Knight BT, Bonsall RW, Emery MS, Stowe ZN, Hauenstein EJ, Krishnan KRR, Davidson JT and **Nemeroff CB**. 1996. Prevalence of thyroid autoantibodies in psychiatric disorders. Proc 35th Ann meeting of the Amer College of Neuropsychopharmacol; 236.
450. Ninan PI, Musselman DL, Knight DL, Kane CP, Bonsall RW and **Nemeroff CB**. 1996. Hypothalamic-pituitary-thyroid axis and antidepressant response in major depression. Proc 35th Ann meeting of the Amer College of Neuropsychopharmacol; 235.
451. Musselman DL, Pisell TL, Miller AH, Porter MR, Pearce BD, Knight BT, Ninan PT Landry JL, Bonsall R, Emery M, Glover S, McDaniel JS, Seelig B and **Nemeroff CB**. 1997. Cytokine plasma concentrations in cancer patients with depression. Soc Biol Psychiatry Abstr 41:7(S);97.
452. **Nemeroff CB**, Kinkead B, Radke J and Owens MJ. 1996. The effects of atypical antipsychotic drugs on regional brain neurotensin concentrations, NT and mRNA expression and extracellular fluid NT concentrations. Proc 35th Ann meeting of the Amer College of Neuropsychopharmacol; 10.
453. **Nemeroff CB**, Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR and Harker LA. 1996. Exaggerated platelet reactivity in depressed patients: a risk factor for ischemic heart disease. Proc 35th Ann meeting of the Amer College of Neuropsychopharmacol; 52.
454. Owens MJ, Morgan WN and **Nemeroff CB**. 1996. α_1 acid glycoprotein does not modify [3 H]-citalopram binding or [3 H]-5-HT uptake by the human serotonin transporter in vitro. Proc 35th Ann meeting of the Amer College of Neuropsychopharmacol; 157.
455. **Nemeroff CB** and Owens MJ. 1997. Serotonin transporter binding: pathophysiology and neuropsychopharmacology. Soc Biol Psychiatry Abstr 41:7(S);206.
456. Rush AJ, Keller MB, Zajecka J, Trivedi M, Ninan P and **Nemeroff CB**. 1997. National collaborative study of nefazodone and CBT-CD in chronically depressed patients. Soc Biol Psychiatry Abstr 41:7 (S);317.
457. Stout SC, Owens MJ, Heim C and **Nemeroff CB**. 1997. Attenuation by venlafaxine of stress effects of CRF systems and the HPA axis of rats. Soc Neurosci Abstr 23:1077.

458. Kinkead B, Owens, MJ and **Nemeroff CB**. 1997. The effects of subchronic antipsychotic drug administration on neurotensin concentrations in the rat brain. Soc Neurosci Abstr 23:1673.
459. Ehlers CL, Kaneko W, Kupfer DJ, Owens MJ, Frank E and **Nemeroff CB**. 1997. Gender differences in sleep and hormonal response: vulnerability or protection against depression? Int Soc Psychoneuroendocrinol Abstr, S139.
460. Stowe ZN, Llewellyn AM, Owens MJ, Ritchie JC, Kilts CD and **Nemeroff CB**. 1997. Antidepressants in pregnancy and lactation. Proc Amer Psychiat Assn Ann Meeting, 103.
461. **Nemeroff CB**. 1997. Treating depression in the bipolar patient. Proc Amer Psychiat Assn Ann Meeting, 272.
462. **Nemeroff CB**, Musselman DL. 1997. Depression and comorbid cardiovascular disease. Proc Amer Psychiat Assn Ann Meeting, 282.
463. Strader JR, Llewellyn AM, Stowe ZN and **Nemeroff CB**. 1997. Predictors of treatment response in pregnancy and postpartum disorders. Proc Amer Psychiat Assn Ann Meeting, 93.
464. Stowe ZN, Llewellyn AM, Strader JR, Kilts CB, Ritchie JC and **Nemeroff CB**. 1997. Placental passage of antidepressants. Proc Amer Psychiat Assn Ann Meeting, 119.
465. Llewellyn AM, Stowe ZN and **Nemeroff CB**. 1997. Infant outcome after sertraline exposure. Proc Amer Psychiat Assn Ann Meeting, 176.
466. Plotsky PM, Ladd CO, Huot RL, Thiruvikraman KV and **Nemeroff CB**. 1997. Long-term consequences of maternal separation in Long Evans rats and their reversal by antidepressants. Int Soc Psychoneuroendocrinol Abstr., S174.
467. Coskun V, **Nemeroff CB** Plotsky PM and Anand KJS. 1997. Repetitive neonatal pain causes behavioral changes and reduced cortical Fos activation following pain in adult rats. Soc Neurosci 23:94.7.
468. Knight DL, Owens MJ, Morgan WN and **Nemeroff CB**. 1997. Effect of chronic paroxetine administration on norepinephrine transporter kinetics in rat brain. Soc Neurosci 23:275.5
469. Musselman DL, Pisell TL, Lewison B, Pearce BD, Knight BT, Ninan PT, **Nemeroff CB** and Miller AH. 1997. Interleukin-6 plasma concentrations in cancer patients with depression. Soc Neurosci 23:393.29.
470. Binder E, Owens MJ and **Nemeroff CB**. 1997. Importance of neurotensin in behavioral effects of antipsychotic drugs examined via in vitro and in vivo antisense knockdown of the neurotensin receptor. Soc Neurosci 23:1361.
471. Hartline KM, Morgan WN, Ritchie JC, **Nemeroff CB** and Owens MJ. 1997. Effects of chronic administration of benzodiazepine agonists and partial inverse agonists on hypothalamic and extrahypothalamic CRF neuronal systems. Soc Neurosci 23:2149.
472. Radke JM, Owens MJ and **Nemeroff CB**. 1997. Glutamate-neurotensin interactions in the rat brain. Soc Neurosci 23:2331.

473. **Nemeroff CB.** 1997. Overview of CRF in psychiatric diseases. Xth Congress of the European College of Neuropsychopharmacology, 7:S86.
474. **Nemeroff CB,** Owens MJ and Plotsky P. 1997. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Xth Congress of the European College of Neuropsychopharmacology, 7:S109.
475. Stowe ZN, Llewellyn AM, Strader JR, Landry JC, Owens MJ, Ritchie J, Kilts CD and Nemeroff CV. 1997. Identification and treatment of postpartum depression. Xth Congress of the European College of Neuropsychopharmacology, 7:S108.
476. Ninan PT, Knight BT, Kirk L and **Nemeroff CB.** 1998. Trichotillomania: A controlled trial of venlafaxine. Soc Biol Psychiat.
477. **Nemeroff CB,** Owens MJ, Plotsky PM and Stout ST. 1997. The role of corticotropin-releasing factor (CRF) in depression: therapeutic implications. 36th Annual Meeting, American College of Neuropsychopharmacology, 18.
478. Coplan JD, Smith ELP, Trost RC, Scharff BA, Bjornsen L, Owens MJ, **Nemeroff CB,** Gorman JM and Rosenblum LA. 1997. Growth hormone response to clonidine in adversely-reared primates & inhibitory role of corticotropin-releasing factor. 36th Annual Meeting, American College of Neuropsychopharmacology, 129.
479. Ninan PT, Knight BT, Musselman DL, Kane CP and **Nemeroff CB.** 1997. Hypothalamic pituitary thyroid axis and antidepressant response in major depression. 36th Annual Meeting, American College of Neuropsychopharmacology, 139.
480. Kinkead B, Owens MJ and **Nemeroff CB.** 1997. Estrous cycle-related differences in the effects of acute haloperidol administration on the neurotensin system of the rat brain. 36th Annual Meeting, American College of Neuropsychopharmacology, 193.
481. Owens MJ, Knight DL, Morgan WN and **Nemeroff CB.** 1997. Chronic paroxetine administration at clinically relevant concentrations may alter norepinephrine transporter kinetics in rat brain. 1997. 36th Annual Meeting, American College of Neuropsychopharmacology, 268.
482. Musselman DL, Lewison BJ, Porter MR, Pearce BD, McDaniel JS, Miller AH and **Nemeroff CB.** 1997. HPA axis hyperactivity and interleukin-6 plasma concentrations in cancer patients with depression. 36th Annual Meeting, American College of Neuropsychopharmacology, 316.
483. Malison RT, Price LH, Berman R, Pelton GH, Carpenter L, Sanacora G, Owens MJ, **Nemeroff CB,** Rajeevan N, Baldwin RM, Seibyl JP, Innis RB and Charney DS. 1997. Reduced midbrain serotonin transporter binding in major depression as measured by [¹²³I]β-CIT SPECT. Society of Nuclear Medicine, 45th Annual Meeting.
484. Martarello L, Kilts CD, Ely T, Owens, MJ, **Nemeroff CB** and Goodman MM. 1998. Design, synthesis and characterization of fluorinated pyrrolopyrimidines as candidate high affinity selective PET ligands for the CRF1 receptor. International Society of Psychoneuro-endocrinology, XXIX Congress, 24.

485. Newport DJ, Stowe ZN, Strader JR, Ritchie JC, Llewellyn AM and **Nemeroff CB**. 1998. Neuroendocrinology of depression during pregnancy. American Psychiatric Association Annual Meeting, NR100:94.
486. Knight BT, Ninan PT, **Nemeroff CB**, Musselman DL and Kelsey JE. 1998. Thyroid axis and treatment response in depression. American Psychiatric Association Annual Meeting, NR246:134.
487. Stowe ZN, Llewellyn AM, De A and **Nemeroff CB**. 1998. Maternal depression: impact on infant health. American Psychiatric Association Annual Meeting, Symposium 12:64.
488. **Nemeroff CB**. 1998. Are platelets the link between depression and ischemic heart disease? American Psychiatric Association Annual Meeting, Symposium2:272.
489. **Nemeroff CB** and Musselman DL. 1998. Depression and cardiovascular disease: epidemiology, pathophysiology and treatment. International Society of Psychoneuroendocrinology XXIX Congress, 21.
490. Heim C, Graham Y, Heit S, Bonsall R, Miller AH and **Nemeroff CB**. 1998. Increased sensitivity of the hypothalamic-pituitary-adrenal (HPA) axis to psychosocial stress in adult survivors of childhood abuse. International Society of Psychoneuroendocrinology XXIX Congress, 23.
491. **Nemeroff CB**, Owens MJ, Heim C, Stout S, Graham Y, Miller AH and Plotsky PM. 1998. Early life stress and the vulnerability to depression: preclinical and clinical studies. XX1st CINP Congress, 42.
492. Owens MJ, Hostetter AL, Knight DL, Ritchie JC, Lleyellyn A, **Nemeroff CB** and Stowe ZN. 1998. Fetal exposure to sert antagonist antidepressants in rats. Soc Neurosci 24:1489.
493. Skelton KH, Owens MJ, Knight DL, Ritchie JL and **Nemeroff CB**. 1998. The effects of chronic administration of the benzodiazepines alprazolam and lorazepam on hypothalamic and extrahypothalamic CRF neuronal systems. Soc Neurosci 24:1489.
494. Kinkead B, Binder E, Owens MJ and **Nemeroff CB**. 1998. Interaction between the neurotensin receptor antagonist SR142948A and dopamine agonists in prepulse inhibition of the acoustic startle response. Soc Neurosci 24:1926.
495. Binder E, Owens MJ, Gross RE, Kilts CD and **Nemeroff CB**. 1998. Involvement of neurotensin in latent inhibition. Soc Neurosci 23:202.
496. Tang ZL, Stowe ZN, Plotsky PM, **Nemeroff CB** and Ely T. 1998. Effects of cocaine on the activity of DA neurons in the ventral tegmental area. Soc Neurosci 23:354.
497. Stowe ZN, Tang ZL, Plotsky PM and **Nemeroff CB**. 1998. The effects of maternal separation on the neuronal activity in locus coeruleus and nucleus accumbens. Soc Neurosci 23:355.
498. Heim C, Graham YP, Heit S, bonsall R, Miller AH and **Nemeroff CB**. 1998. Increased reactivity of the hypothalamic-pituitary-adrenal (HPA) axis to psychosocial stress in adult survivors of childhood abuse. Soc Neurosci 23:505.

499. Knight DL, Lindsey K, Owens MJ and **Nemeroff CB**. 1998. Serum valproic acid concentrations in the rat. *Soc Neurosci* 23:996.
500. **Nemeroff CB**. 1998. What can we learn from CSF studies: the CRF database. XIth Congress of the European College of Neuropsychopharmacology. S86.
501. **Nemeroff CB** and Amchin J. 1998. Placebo-controlled trial of the efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. XIth Congress of the European College of Neuropsychopharmacology. S157.
502. Bowden CL, Calabrese JR, **Nemeroff CB**, Lydiard RB, and McElroy SL. 1998. Effects on suicidality of divalproex, lithium and placebo in randomized one-year maintenance treatment of bipolar disorder. 37th Annual Meeting, American College of Neuropsychopharmacology, 120.
503. Owens MJ, Borthayre AB, Lindsey K, Knight DL and **Nemeroff CB**. 1998. Acute and subchronic effects of sodium valproate on CRF systems in the rat. 37th Annual Meeting, American College of Neuropsychopharmacology, 128.
504. **Nemeroff CB**. 1998. Advances in neuropeptide neurobiology: focus on Substance P. 37th Annual Meeting, American College of Neuropsychopharmacology, 8.
505. Ehlers CL, Somes C, Li T-K, Lumeng L, Kinkead B, Owens MJ and **Nemeroff CB**. 1998. Neurotensin (NT) studies in alcohol naive, preferring, and non-preferring rats. 37th Annual Meeting, American College of Neuropsychopharmacology, 242.
506. **Nemeroff CB** and Amchin J. 1998. Placebo-controlled trial of the efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. 37th Annual Meeting, American College of Neuropsychopharmacology, 210.
507. Skelton KH, Knight DL, Ritchie JC, **Nemeroff CB** and Owens MJ. 1998. Opposite effects of chronic alprazolam treatment versus stress and anxiety models on hypothalamic and extrahypothalamic CRF neuronal systems in the rat. 37th Annual Meeting, American College of Neuropsychopharmacology, 199.
508. Musselman DL, Knight BT, Baron A, Penna S and **Nemeroff CB**. 1998. Effects of paroxetine treatment on platelet reactivity in patients with major depression. 37th Annual Meeting, American College of Neuropsychopharmacology, 219.
509. Stowe ZN, Owens MJ, Hosteter A, Ritchie J and **Nemeroff CB**. 1998. Placental passage of antidepressants: defining exposure. 37th Annual Meeting, American College of Neuropsychopharmacology, 319.
510. Juncos J, Yeung P, Sweitzer D, Arvanitis L and **Nemeroff CB**. 1998. Quetiapine improves psychotic symptoms associated with Parkinson's Disease. 37th Annual Meeting, American College of Neuropsychopharmacology, 341.
511. Kinkead B, Binder E, Owens MJ and **Nemeroff CB**. 1999. The effects of haloperidol on prepulse inhibition in isolation reared rats are blocked by the neurotensin receptor antagonist SR142948A. *Society for Neuroscience abstr*, 1:65.

512. Stout SC, Owens MJ and **Nemeroff CB**. 1999. Preprotachykinin-A and neurokinin 2 receptor mRNA expression are unchanged in rat forebrain after chronic antidepressant administration. Society for Neuroscience abstr, 1:1066.
513. Miller AH, Musselman DL, Pearce BD, Penna S and **Nemeroff CB**. 1999. Pretreatment with the antidepressant paroxetine blocks the development of behavioral alterations in humans during high dose interferon alpha therapy. Society for Neuroscience abstr, 1:698.
514. Miller AH, Musselman DL, Pearce BD, Penna S and **Nemeroff CB**. 1999. Pretreatment with the antidepressant paroxetine attenuates development of sickness behavior during high dose interferon alpha therapy. International Society for Psychoneuroendocrinology Annual Meeting, 35.
515. Musselman DL, Lawson DH, Penna S, Pearce BD, Su C **Nemeroff CB** and Miller AH. 1999. Paroxetine pretreatment reduces interferon-alpha-induced depression. Society of Biological Psychiatry, 54th Annual Meeting, 110S.
516. Rausch JL, Coccaro EF, **Nemeroff CB**, Charney DS, Brewerton TD and Lahti AC. 1999. What have we learned from challenge studies? Society of Biological Psychiatry, 54th Annual Meeting, 46S.
517. Plotsky PM, Sanchez MM, Huot BL, Ladd CO, Hawks BW, Stowe ZN and **Nemeroff CB**. 1999. The role of CRF and noradrenaline in depression: new data from mice, rats, and primates. 7th Catecholamine and Other Neurotransmitters in Stress, Smolenice, Slovakia, June 28 - July3.
518. Graham YP, Goodman SH, Stowe ZN, Plotsky PM, Robbins M and **Nemeroff CB**. 1999. Maternal postpartum depression: effects on infants' neuroendocrine stress reactions. American Psychiatric Association Annual Meeting, 78.
519. Juncos JL, Yeung PP, Sweitzer D, Arvanitis LA and **Nemeroff CB**. 1999. Quetiapine improves psychotic symptoms associated with Parkinson's disease. American Psychiatric Association Annual Meeting, 253.
520. **Nemeroff CB**. 1999. Depression and cardiovascular disease. American Psychiatric Association Annual Meeting, 142.
521. **Nemeroff CB**. 1999. The role of early adverse life experience in the development of mood disorders. American Psychiatric Association Annual Meeting, 228.
522. **Nemeroff CB**. 1999. Problems with currently available antidepressants. American Psychiatric Association Annual Meeting, 273.
523. **Nemeroff CB**. 1999. The persistent neurobiological consequences of early untoward life events: treatment implications. American Psychiatric Association Annual Meeting, 279.
524. **Nemeroff CB**. 1999. The HPA axis and the pathophysiology of depression: the role of early adverse experience. International Society of Psychoneuroendocrinology Annual Meeting, 32.
525. Skelton KH, **Nemeroff CB** and Owens MJ. 1999. Urocortin, the CRF₂ receptor and effects of anxiolytic drugs. International Society of Psychoneuroendocrinology Annual Meeting, 33.

526. **Nemeroff CB.** 1999. Treatment of severe depression. International Society of Psychoneuroendocrinology Annual Meeting, 19.
527. **Nemeroff CB.** 1999. Early-life stress and depression. XI World Congress of Psychiatry, 156.
528. Plotsky PM and **Nemeroff CB.** 1999. Maternal separation as a vulnerability factor for disorders of emotional regulation. American College of Neuropsychopharmacology Annual Meeting, 18.
529. **Nemeroff CB,** Heim C, Newport DJ and Miller AM. 1999. Persistent effects of early untoward life events in humans: implications for pathophysiology and treatment. American College of Neuropsychopharmacology Annual Meeting, 19.
530. Skelton KH, Knight DL, Ritchie JL, **Nemeroff CB** and Owens MJ. 1999. Alterations in CNS CRF and urocortin neuronal systems following spontaneous and precipitated alprazolam withdrawal in the rat. Society for Neuroscience abstr, 1:1319.
531. Heim C, Newport DJ, Heit S, Graham YP, Bonsall R, Miller AH and **Nemeroff CB.** 1999. Pituitary-adrenal responses to CRF stimulation in adult survivors of childhood abuse with and without depression. Society for Neuroscience abstr, 2:1454.
532. Binder E, Owens MJ and **Nemeroff CB.** 1999. Involvement of neurotensin receptor activation in antipsychotic drug induced Fos expression. Society for Neuroscience abstr, 2:1569.
533. Skelton KH, Knight DL, Ritchie JC, **Nemeroff CB** and Owens MJ. 1999. Activation of corticotropin-releasing factor and urocortin neuronal systems following spontaneous alprazolam withdrawal in the rat. American College of Neuropsychopharmacology Annual Meeting, 122.
534. Ninan PT and **Nemeroff CB.** 2000. Symptomatic anxiety in the treatment of chronic depression with nefazodone, CBASP and their combination. Anxiety Disorders Assoc. of America National Conference.
535. Musselman DL, Marzec UM, Davidoff MN, Reemsnyder AJ, Goodkin RS, Hanson SR, Harker LA, Taylor WR and **Nemeroff CB.** 2000. Platelet activation of depressed patients in comparison to patients with aortic atherosclerosis. Society of Biol Psychiat Annual Meeting, 76S.
536. Musselman DL, Marzec UM, Owens MJ, Reemsnyder AJ, Goodkin RS, Hanson SR and **Nemeroff CB.** 2000. Platelet activation in treatment responders vs. nonresponders in patients with major depression. Society of Biol Psychiat Annual Meeting, 77S.
537. **Nemeroff CB,** Owens MJ, Skelton K, Guttman d, Winslow JT and Plotsky PM. 2000. CRF₁ receptor antagonists as novel putative antidepressants and anxiolytics. Society of Biol Psychiat Annual Meeting, 64S.
538. Miller MH and **Nemeroff CB.** 2000. A chair's life: Ethiopia, Taiwan, Geneva, Atlanta, and Los Angeles. Am Psychiatric Assn Annual Meeting, 213.
539. **Nemeroff CB.** 2000. Corticotropin-releasing factor antagonists: promising therapy for depression. Am Psychiatric Assn Annual Meeting, 260.

540. **Nemeroff CB.** 2000. Novel actions of antidepressants. Am Psychiatric Assn Annual Meeting, 270.
541. **Nemeroff CB.** 2000. Interactions of noradrenergic and CRF-containing neural systems: implications for the pathophysiology and treatment of depression. XXIInd CINP Congress, S36.
542. **Nemeroff CB.** 2000. The role of neuropeptides in the pathophysiology of depression and the mechanism of actions of antidepressant drugs. XXIInd CINP Congress, S58.
543. Malison RT, Staley J, Price LH, Berman R, Pelton GH, Carpenter L, Sanacora G, Owens MG, **Nemeroff CB**, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB and Charney SD. SPECT imaging of serotonin transporters in major depression with [¹²³I]-CIT. XXIInd CINP Congress, S74.
544. **Nemeroff CB** and Cantillon M. 2000. Venlafaxine demonstrates excellent response frequency in trial with fluoxetine and placebo in depressed patients. XXIInd CINP Congress, S191.
545. Kilts C, Gross R, Newport J, Knight B, Ely T, **Nemeroff CB** and Kelsey J. 2000. A functional neuroimaging study of social anxiety and its treatment. XXIInd CINP Congress, S290.
546. **Nemeroff CB.** 2000. The HPA axis and the pathophysiology of depression: the role of early adverse experience. J Psychopharmacol14:4.
547. **Nemeroff CB.** 2000. Clinical studies on the role of CRF in mood and anxiety disorders. Neuropsychopharmacology 23(S2):5.
548. Gutman DA, Owens MJ, Skelton KH, Knight DL, Thirivikraman KV, Plotsky PM and **Nemeroff CB.** 2000. Behavioral, neuroendocrine and pharmacokinetic observations on CRF₁-selective antagonist, R121919 in the rat. Neuropsychopharmacology 23(S2):119.
549. Musselman DL, Lawson DH, Gumnick J, Goodkin R, Pearce BD, Su C, **Nemeroff CB** and Miller AH. 2000. Prevention of interferon-alpha-associated depression and anxiety by paroxetine in a randomized, placebo-controlled trial. Neuropsychopharmacology 23(S2):133.
550. Skelton KH, Owens MJ, Gutman DA, O'Brien D, Oren D, Thirivikraman KV, Easterling KW, Holtzman G, Knight DL and **Nemeroff CB.** 2000. The corticotropin-releasing factor (CRF)₁, receptor antagonist, R121919, attenuates the behavioral and neuroendocrine response to precipitated morphine or lorazepam withdrawal in the rat. Neuropsychopharmacology 23(S2):149.
551. Kinkead B, Binder EB, Owens MJ and **Nemeroff CB.** 2000. The role of neurotensin neurotransmission in the effects of antipsychotic drugs on prepulse inhibition in isolation reared rats. Soc Neurosci Abstr 26:1002.
552. Binder EB, Kinkead B, Owens MJ and **Nemeroff CB.** 2000. Prepulse inhibition deficits in isolation reared rats and their antipsychotic drug-induced restoration are dependent on neurotensin neurotransmission. Soc Neurosci Abstr 26:1772.
553. Gutman DA, Owens MJ, Skelton KH, Knight DL, Thirivikraman KV, Plotsky PM and **Nemeroff CB.** 2000. Behavioral, neuroendocrine, and pharmacokinetic observations on the CRF₁-selective antagonist, R121919 in the rat. Soc Neurosci Abstr 26:2149.

554. Owens MJ, Skelton KH, Gutman DA, O'Brien D, Oren D, Thrivikraman, KV, Easterline KW, Holtzman SG, Knight DL and **Nemeroff CB**. 2000. The CRF₁ antagonist, R121919, attenuates the behavioral and neuroendocrine response to precipitated morphine or lorazepam withdrawal. Soc Neurosci Abstr 26:2149.
555. Skelton KH, **Nemeroff CB** and Owens MJ. 2000. Spontaneous withdrawal from the triazolobenzodiazepine, alprazolam, dramatically increases corticotropin-releasing factor mRNA expression in the rat cerebral cortex. Soc Neurosci Abstr 26:2266.
556. Ely TD, Kelsey J, Gross RE, Knight B, Selvig A, Newport DJ, **Nemeroff CB** and Kilts CD. 2000. Reciprocal paralimbic-prefrontal activity in social anxiety disorder. Soc Neurosci Abstr 26:2310.
557. Arborelius L, Plotsky PM, **Nemeroff CB** and Owens MJ. Increased 5-HT cell firing responsiveness to citalopram in adult rats previously subjected to maternal deprivation. Soc Neurosci Abstr 26:2314.
558. Newport DJ and **Nemeroff CB**. 2000. Stress and depression: From vulnerability to treatment. Eur Neuropsychopharmacol 10(Suppl 3):164-165.
559. Kinkead B, Owens MJ and **Nemeroff CB**. 2000. The effects of typical and atypical antipsychotic drugs on isolation rearing-induced deficits in prepulse inhibition: the role of the neurotensin system. American College of Neuropsychopharmacology Annual Meeting, 210.
560. **Nemeroff CB**, Kinkead B, Binder EB and Owens MJ. 2000. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs. Seroquel Roundtable meeting.
561. Owens MJ, Skelton KH, Gutman DA, O'Brien D, Oren D, Thrivikraman KV, Easterling KW, Holtzman SG, Knight DL and **Nemeroff CB**. 2000. The CRF₁ antagonist, R121919, attenuates the behavioral and neuroendocrine response to precipitated morphine or lorazepam withdrawal. American College of Neuropsychopharmacology Annual Meeting, 112.
562. Hirschfeld RMA, Dunner DL, Keitner G, Klien D, Koran LM, Kornstein SG, Markowitz J, Miller I, **Nemeroff CB**, Ninan PT, Ruah AJ, Schatzberg AF, Thase ME, Trivedi MH and Keller MB. 2000. Psychosocial functioning in chronic major depression: treatment with nefazodone, CBASP, and their combination. American College of Neuropsychopharmacology Annual Meeting, 147.
563. Ninan PT, Rush AJ, Kornstein SG, Rothbaum BO, Manber R, Thase ME, Trivedi M, Zajecka J, Borian FE and **Nemeroff CB**. 2000. Symptomatic anxiety in the treatment of chronic major depression with nefazodone, CBAS-psychotherapy (CBASP), and their combination. American College of Neuropsychopharmacology Annual Meeting, 173.
564. Miller AH, Musselman DL, Gumnick JF, Lawson DH, Duggirala S, Reemsnyder AJ, Goodkin RS and **Nemeroff CB**. 2000. Antidepressant prophylaxis for medically ill patients at high risk for affective disorders. American College of Neuropsychopharmacology Annual Meeting, 259.
565. **Nemeroff CB**. 2001. Gonadal steroids and CRH-serotonergic interactions: vulnerability factors in the development of mood disorders. 1st World Congress on Women's Mental Health, 9.

566. Coplan JD, Smith ELP, Batuman O, **Nemeroff CB**, Gorman JM and Rosenblum LA. 2001. Long-term consequences of early life stress in non-human primates. 1st World Congress on Women's Mental Health, 16.
567. **Nemeroff CB**, Heim C, Newport DJ and Miller AH. 2001. The relationship of early trauma to neuroendocrine and cardiovascular alterations in women with and without adult depression. 1st World Congress on Women's Mental Health, 23.
568. Heim C, Newport DJ, Miller AH and **Nemeroff CB**. 2001. The role of early adverse experiences in the pathophysiology of mood and anxiety disorders: neuroendocrinological studies in adult women with a history of childhood abuse. 1st World Congress on Women's Mental Health, 55.
569. Carpenter L, Kirwin PDS, Anderson G, Pelton GH, McDougale CJ, Malison RT, Owens MJ, **Nemeroff CB** and Price LH. 2001. Standard tryptophan depletion protocol increases CSF corticotropin-releasing factor in health adult humans. Soc Neurosci Abstr.
570. Martarello L, Kilts CD, Ely T, Owens MJ, **Nemeroff CB** and Goodman MM. 1999. Design, synthesis and characterization of fluorinated- and iodinated- pyrrolo [2,3-d]pyrimidines as candidates for CRF1 receptor PET/SPECT ligands. J. Labeled Compounds & Radiopharmaceuticals 42(S1):S312-S314.
571. Bachus SE, Kleinman JE, Kindead B, Hyde TM, Owens MJ, **Nemeroff CB** and Egan ME. 2001. Nigral neurotensin receptor mRNA following chronic haloperidol. Soc Neurosci Abstr 446.10.
572. Gilmor ML, Owens MJ and **Nemeroff CB**. 2001. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Soc Neurosci Abstr 916.11.
573. Gilmor ML, Owens MJ and **Nemeroff CB**. 2001. Paroxetine inhibits norepinephrine uptake in depression. World Federation of Societies of Biological Psychiatry.
574. Marzec UM, Maldonado DDC, Reemsnyder AJ, Manatunga A, Musselman DL, **Nemeroff CB** and Hanson SR. 2001. In vitro effects of paroxetine upon platelet activation. Soc Biol Psychiat, 56th Annual Meeting, 49(8S):37S.
575. Thrivikraman KV, Kindead B, Owens MJ, **Nemeroff CB** and Plotsky PM. 2001. Diurnal plasticity induced gene expression profile with special reference to GABAA receptor subunits in rat brain regions. Soc Neurosci Abstr 735.11.
576. **Nemeroff CB**. 2001. Psychopharmacology in the 21st century: focus on depression. The Royal Australian and New Zealand College of Psychiatrists 36th Congress, 36.
577. **Nemeroff CB**, Heim C, Newport DJ and Miller AH. 2001. The long-term effects of early life trauma on the CNS: implications for the pathophysiology of depression and PTSD. Annual meeting, American College of Neuropsychopharmacology, 70.
578. Carpenter LL, Kirwin PD, Pelton GH, McDougale CJ, Malison RT, Owens MJ, **Nemeroff CB** and Price LH. 2001. Tryptophan depletion increases DSF corticotropin releasing factor in healthy adult humans. Annual meeting, American College of Neuropsychopharmacology, 137.
579. Carpenter LL, Pelton GH, Heninger GR, McDougale CJ, Malison RT, Owens MJ, **Nemeroff CB** and Price LH. 2001. Relationship between CSF corticotropin releasing factor and perceived early

life stress in depressed patients and healthy controls. Annual meeting, American College of Neuropsychopharmacology, 137.

- 580. Owens MJ, Gilmor M and **Nemeroff CB**. 2001. Evidence for inhibition of norepinephrine reuptake in patients with major depression treatment with paroxetine. Annual meeting, American College of Neuropsychopharmacology, 141.
- 581. Vythilingam M, Heim C, Newport DJ, Miller AH, Anderson E, Charney DS, **Nemeroff CB** and Bremner JD. 2001. Reduced hippocampal volume in adult major depression: role of childhood trauma. Annual meeting, American College of Neuropsychopharmacology, 241.
- 582. Kalin NH, **Nemeroff CB**, Wan GJ, Panish JM and Cantillon M. 2001. Improved general life functioning with venlafaxine versus fluoxetine in outpatients with major depression. Annual meeting, American College of Neuropsychopharmacology, 344.
- 583. Evans DL, **Nemeroff CB**, Thase ME, Wan GJ, Panish JM and Cantillon M. 2001. Improved social activity level, general life and cognitive functioning with venlafaxine versus fluoxetine in inpatients with melancholic depression. Annual meeting, American College of Neuropsychopharmacology, 345.
- 584. **Nemeroff CB**, Entsuah R and Kunz NR. 2001. Remission rates during long-term treatment of depression. Annual meeting, American College of Neuropsychopharmacology, 370.
- 585. Ely T, Gross R, Temple L, Jarboe K, Schweitzer J, Lewine R, **Nemeroff CB** and Kilts C. 2001. Neural correlates of the effects of newer generation antipsychotics on cognitive impairments associated with schizophrenia. Annual meeting, American College of Neuropsychopharmacology, 383.
- 586. Gutman DA, Skelton KS, Knight DL, Owens, MJ and **Nemeroff CB**. 2001. Effects of chronic treatment with the small molecule CRF1 antagonist R121919 in rats. Soc Neurosci Annual Meeting, 665.5
- 587. Hartline-Skelton K, Gilmor ML, **Nemeroff CB** and Owens MJ. 2001. Chronic valproic acid and lithium administration alter corticotropin-releasing factor gene expression. Soc Neurosci Annual Meeting, 732.10.
- 588. McConathy J, Knight DL, Owens MJ, **Nemeroff CB** and Goodman MM. 2001. Candidate PET ligands for the norepinephrine transporter. Soc Neurosci Annual Meeting, 975.17.
- 589. Owens MJ, Kinkead B, Egnatashvili V, Cassel T and **Nemeroff CB**. 2001. The role of neurotensin neurotransmission in the effects of clozapine and risperidone on prepulse inhibition in isolation reared rats. Soc Neurosci Annual Meeting, 90.12.
- 590. Kinkead B, Cassell T, Owens MJ, Dobner PR, Deitemeyer N and **Nemeroff CB**. 2001. Prepulse inhibition of the acoustic startle response in neurotensin knockout mice. Soc Neurosci Annual Meeting, 90.13.
- 591. Gumnick JF, Capuron L, Musselman DL, Lawson DH, Reemsnyder A, **Nemeroff CB** and Miller AH. 2001. Paroxetine effects on the neuropsychiatric and neurovegetative/somatic symptoms induced by interferon-alpha. Soc Neurosci Annual Meeting, 217.9.

592. Heim C, Newport DJ, Pearce BD, Wilcox MM, **Nemeroff CB** and Miller AH. 2001. Neuroendocrine and immune alterations in adult women after childhood abuse: implications for the pathophysiology of physical complaints. Soc Neurosci Annual Meeting, 412.15.
593. Serebruany V, Glassman A, Malinin A, Krishnan KRR, Finkel M, **Nemeroff CB**, Gurbel P, Clary C, Harrison W and O'Connor C. 2002. Effects of Zoloft on platelet/endothelial biomarkers in depressed patients after acute coronary events: sertraline antidepressant heart attack randomized trial (SADHART platelet substudy). Amer Coll Cardiology Annual Meeting.
594. **Nemeroff CB**. 2002. New treatments for atypical depression. Annual meeting, American Psychiatric Association, 268.
595. **Nemeroff CB**. 2002. Childhood trauma and the neurobiology of mood disorders. Annual meeting, American Psychiatric Association, 285.
596. Carpenter LL, Pelton GH, Malison RT, Owens MJ, **Nemeroff CB** and Price LH. 2002. Relationship between CSF corticotropin releasing factor and perceived early life stress in depressed patients and healthy controls. Biol Psychiat 51:136S (401).
597. **Nemeroff CB**. 2002. Remission after long-term treatment with venlafaxine. XII World Congress of Psychiatry, 110.
598. Banig AA, Kinkead B, **Nemeroff CB**, Sheridan RE and Bachus SE. 2002. Nigral neurotensin receptor mRNA following long-term chronic haloperidol in rats. Soc Neurosci Annual Meeting, 895.7.
599. Caceda R, Cassell T, Egnatashvili V, Kinkead B and **Nemeroff CB**. 2002. The role of neurotensin neurotransmission in antipsychotic drug-induced facilitation of latent inhibition in rats. Soc Neurosci Annual Meeting, 89.13
600. Miller AH, Capuron L, Raison CL, Lawson DH, Musselman DL, Su Y, Owens MJ and **Nemeroff CB**. 2002. Interferon-alpha-induced depression is associated with an exaggerated HPA axis response to the initial injection of interferon-alpha. Soc Neurosci Annual Meeting, 103.9.
601. Kinkead B, Cassell T, Maeno H and **Nemeroff CB**. 2002. Prepulse inhibition of the acoustic startle response in neurotensin1 receptor knockout mice. Soc Neurosci Annual Meeting, 89.12.
602. Thiruvikraman KV, Kinkead B, Jia T, Garlow SJ, Plotsky PM and **Nemeroff CB**. 2002. Diurnal pattern of CRF-related gene expression in rat brain. Soc Neurosci Annual Meeting, 223.3
603. Capuron L, Pagnoni G, Lawson DH, Demetrashvili M, Woolwine BJ, Kilts CD, Bremner JD, **Nemeroff CB** and Miller AH. 2002. Altered fronto-pallidal activity during high-dose interferon-alpha treatment as determined by positron emission tomography. Soc Neurosci Annual Meeting, 498.5.
604. Winslow JT, Noble PL, Lyon CK, Ritchie JC, **Nemeroff CB**, Plotsky PM and Sanchez MM. 2002. Reduced HPA axis function in juvenile rhesus monkeys with early adverse experience. Soc Neurosci Annual Meeting, 668.12.

605. **Nemeroff CB.** 2003. Early abuse and HPA axis dysregulation in major depression. World Psychiatric Association International Conference, 14.
606. **Nemeroff CB.** 2003. The neurobiology of depression: the role of serotonin and norepinephrine. World Psychiatric Association International Conference, 62
607. Sharma T, Lieberman JA, McEvoy JP, Perkins DO, Hamer RM, Zipursky RB, Kahn RS, Gur RE, Centorrino F, Glick I, Green AI, **Nemeroff CB**, Rothschild AJ, Strakowski SM, Tohen M and Tollefson GD. 2003. Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia. 16th Congress of the European College of Neuropsychopharmacology, S134.
608. **Nemeroff CB**, Entsuah AR, Willard L, Demitrack M and Thase M. 2003. Venlafaxine and SSRIs: pooled remission analysis. 16th Congress of the European College of Neuropsychopharmacology, S255.
609. Watkins L, Davidson JRT, Connor KM, Beebe KL, Krulewicz S, Abraham K, Zhang W, Owens M and **Nemeroff CB.** 2003. Effects of paroxetine and venlafaxine-XR on heart rate variability in depression. 16th Congress of the European College of Neuropsychopharmacology, S274.
610. Kahn RS, Lieberman JA, Charles C, Sharma T, Zipursky RB, Gur R, Tohen M, Green AI, McEvoy JP, Perkins DO, Hamer RM, **Nemeroff CB**, Rothschild AJ, Kuldau J, Strakowski SM and Tollefson GD. 2003. Antipsychotic treatment effects of progression of brain pathomorphology in first episode schizophrenia. 16th Congress of the European College of Neuropsychopharmacology, S337.
611. Geraciotti TD, Owens MJ, Baker DG, Kinkead B, Ekhtor NN and **Nemeroff CB.** 2003. Elevated basal and stress-provoked cerebrospinal fluid substance P concentrations in post-traumatic stress disorder. Annual meeting, International Society of Psychoneuroendocrinology.
612. Caceda R, Kinkead B, Owens MJ and **Nemeroff CB.** 2003. Lentiviral mediated expression of neurotensin receptor 1 in the rat brain. Annual meeting, Society for Neuroscience, 313.13.
613. Gutman DA, Boss-Williams K, Coyer M, Owens MJ, **Nemeroff CB** and Weiss JM. 2003. The CRF antagonist R121919 increases dominant behaviors of swim - high and swim - low rats. Annual meeting, Society for Neuroscience, 538.10.
614. Thiruvikraman K, Moore LA, Silverman MN, Welberg LAM, **Nemeroff CB** and Plotsky PM. 2003. Evaluation of corticotropin-releasing factor (CRF) receptor binding pattern in normal and CRF deficient mouse brain regions. Annual meeting, Society for Neuroscience, 709.5.
615. Yan F, Kinkead B and **Nemeroff CB.** 2003. The effects of Intra-nucleus accumbens neurotensin on prepulse inhibition of acoustic startle in female rats. Annual meeting, Society for Neuroscience, 858.15.
616. Pomara N, Willoughby LM, Ritchie JC, Sidtis JJ, Greenblatt DJ, and **Nemeroff CB.** 2003. Interdose elevation in plasma cortisol during chronic treatment with alprazolam but not lorazepam: a pilot study in health elderly. Annual meeting, American College of Neuropsychopharmacology, 128.

617. Kranzler JD, Gendreau R, Clauw DJ, Rao SG and **Nemeroff CB**. 2003. Treatment of pain in fibromyalgia is distinct from treatment of mood. Annual meeting, American College of Neuropsychopharmacology, 207.
618. Entsuah R and **Nemeroff CB**. 2003. Venlafaxine vs SSRIs: comparison of somatic symptom resolution. Annual meeting, American College of Neuropsychopharmacology, 208.
619. Raison CL, Borisov AS, Broadwell SD, Manatunga AK, Woolwine BJ, Jacobson IM, **Nemeroff CB** and Miller AH. 2003. Depression during IFN-alpha plus ribavirin therapy: prevalence and prediction. Annual meeting, American College of Neuropsychopharmacology, 208.
620. Capuron L, Pagnoni G, Berns GS, Kilts CD, **Nemeroff CB** and Miller AH. 2003. IFN-alpha-induced pallidal activation: relevance to depression in the medically ill. Annual meeting, American College of Neuropsychopharmacology, 79.
621. **Nemeroff CB**. 2003. The interface of academic departments and the pharmaceutical industry: focus on the Emory-GSK-NIMH Center for Antidepressant Drug Discovery. Annual meeting, American College of Neuropsychopharmacology, 60.
622. Gaynes BN, Ekstrom RD, Hamer RM, Jacobsen FM, **Nemeroff CB**, Suppes P and Golden RN. 2003. Phototherapy in mood disorders: a systematic evidence-based review of the literature. Annual meeting, American College of Neuropsychopharmacology, 150.
623. Carpenter LL, Price LH, Kinkead BK, Cassell T, Sanacora G, Owens MJ and **Nemeroff CB**. 2003. Elevated cerebrospinal fluid concentration of Substance P in major depression. Annual meeting, American College of Neuropsychopharmacology, 215.
624. Davidson JR, Watkins L, Owens M, Dube E, Krulewicz S, Connor K, Zhang W, Abraham K, Krishnan R and **Nemeroff CB**. 2003. Effects of paroxetine and venlafaxine-XR on heart rate variability in depression and the role of norepinephrine transport inhibition. Annual meeting, American College of Neuropsychopharmacology, 93.
625. Kling MA, Carpenter LL, Moreno F, Price LH, Owens MJ, Kinkead BK and **Nemeroff CB**. 2003. Decreased cerebrospinal fluid (CSF) concentrations of Substance P (SP) in medicated patients with treatment-resistant depression (TRD). Annual meeting, American College of Neuropsychopharmacology, 161.
626. Kinkead B, Egnatashvili V, Cassell T, Dobner PR, Deitemeyer N, and **Nemeroff CB**. 2003. The effect of antipsychotic drugs on prepulse inhibition of the acoustic startle response in neurotensin knockout mice. Annual meeting, American College of Neuropsychopharmacology, 233.
627. Feifel D, Kinkead B, Cassell T, **Nemeroff CB**, Shilling P and Melendez G. 2003. Dopamine system and sensorimotor gating abnormalities in a genetic animal model with relevance to schizophrenia. Annual meeting, American College of Neuropsychopharmacology, 112.
628. **Nemeroff CB**. 2003. Behavioral and neurochemical predictors of antipsychotic drug action. American Psychiatric Association 156th Annual Meeting, 20D.
629. **Nemeroff CB**. 2003. Approaches to optimizing therapies across psychiatric diagnoses: remission is the goal. American Psychiatric Association 156th Annual Meeting, 34A.

630. **Nemeroff CB.** 2003. Biological perspectives. American Psychiatric Association 156th Annual Meeting, 37D.
631. Capuron L, Pagnoni G, Kilts CD, **Nemeroff CB**, Berman GS and Miller AH. 2003. Interferon alpha-induced fronto-striatal dysfunction: from symptoms to neural correlates. American Psychiatric Association 156th Annual Meeting, 22C.
632. Raison C, Capuron L, Musselman DL, Lawson D, **Nemeroff CB** and Miller AH. 2003. Prediction and prevention of interferon alpha-induced depressive symptoms. American Psychiatric Association 156th Annual Meeting, 22B.
633. **Nemeroff CB.** 2003. New treatments for atypical depression. American Psychiatric Association 156th Annual Meeting, 20E.
634. **Nemeroff CB.** 2003. Use of atypical antipsychotics in mood disorders. American Psychiatric Association 156th Annual Meeting, 35B.
635. **Nemeroff CB.** 2003. Childhood trauma and the neurobiology of mood disorders. American Psychiatric Association 156th Annual Meeting, 32B.
636. **Nemeroff CB.** 2003. The pathophysiology and psychopharmacology of comorbid cardiovascular disease and depression. American Psychiatric Association 156th Annual Meeting, 24A.
637. **Nemeroff CB.** 2004. SSRIs dual reuptake inhibitors, and isomers: myths, facts, and clinical reality. WFSBP International Congress of Biological Psychiatry, 5:5108.
638. **Nemeroff CB.** 2004. The shared neurobiology of depression: the role of serotonin and norepinephrine. WFSBP International Congress of Biological Psychiatry, 5:6117
639. **Nemeroff CB**, Entsuah R, Willard L, Demitrack M and Thase M. 2004. Comprehensive pooled analysis of remission data: venlafaxine vs SSRIs (COMPARE). WFSBP International Congress of Biological Psychiatry, 5:6238.
640. **Nemeroff CB**, Plotsky PP, Heim C, Newport J, Penza K and Miller AH. 2004. Early life abuse and the pathophysiology of depression. WFSBP International Congress of Biological Psychiatry, 5:7065.
641. **Nemeroff CB.** 2004. Further evidence for alterations in CRF and substance P systems in depression. J Affective Dis 78:S47.
642. **Nemeroff CB.** 2004. The role of early traumatic life experiences on the activity of the HPA axis in depression. J Affective Dis 78:S52.
643. **Nemeroff CB.** 2004. SSRIs, SNRIs, and isomers: neuromythology versus evidence-based medicine. XXIV CINP Congress, S95.
644. Kinkead B, Cassell T, Egnatashvili V, Maeno H and **Nemeroff CB.** 2004. The effects of haloperidol and clozapine on prepulse inhibition of the acoustic startle response in neurotensin₁ receptor knockout mice. Biol Psychiat 55:66S.

645. **Nemeroff CB.** 2004. Identification of risk factors for development of depression: focus on early life trauma. American Psychiatric Association 157th Annual Meeting, 4.
646. **Nemeroff CB.** 2004. Heartache and heartbreak: depression and cardiovascular disease. American Psychiatric Association 157th Annual Meeting, 16.
647. **Nemeroff CB.** 2004. Introduction to treatment-resistant depression. American Psychiatric Association 157th Annual Meeting, 192.
648. Bremner JD, Fani N, Ashraf N, Votaw J, Brummer M, Vaccarino V, Goodman M, Reed L, and **Nemeroff CB.** 2004. Functional brain imaging alterations in acne patients treated with isotretinoin. Society for Neuroscience, 34th Annual Meeting, 114.2.
649. Felger JC, Martin EI, Mook D, Freeman AA, Crawford JL, Lyon CK, Sanchez MM, Rye DB, **Nemeroff CB** and Miller AH. 2004. Neuroendocrine and neurobiological effects of interferon (IFN) alpha in rhesus monkeys. Society for Neuroscience, 34th Annual Meeting, 315.11.
650. Capuron L, Pagnoni G, Demetrashvili M, Woolwine B, **Nemeroff CB**, Berns GS and Miller AH. 2004. Effect of IFN-alpha on regional brain activity during a task of visuo-spatial attention. Society for Neuroscience, 34th Annual Meeting, 431.3.
651. Sanchez M, Lyon CK, Noble PL, McCormack KM, Boudreau M, Crawford J, **Nemeroff CB**, Plotsky PM, Davis M, Newman TK and Winslow JT. 2004. Altered HPA axis function and startle response in non-human primates with adverse rearing: effects of sex and 5HTt genotype. Society for Neuroscience, 34th Annual Meeting, 571.14.
652. Thiruvikraman K, Skelton KH, Owens MJ, **Nemeroff CB** and Plotsky PM. 2004. Corticosterone-independent diurnal plasticity of CRF-receptor subtype binding in the rat lateral septum. Society for Neuroscience, 34th Annual Meeting, 760.18.
653. Feifel D, Shilling PD, Kinkead B, Murray T, Melendez G and **Nemeroff CB.** 2004. D2 receptor binding in the brattleboro rat: evidence of construct validity for schizophrenia. Society for Neuroscience, 34th Annual Meeting, 911.5.
654. Caceda R, Kinkead B, Owens MJ and **Nemeroff CB.** 2004. Virally mediated increased expression of neurotensin receptor 1 in the rat caudate brain. Society for Neuroscience, 34th Annual Meeting, 911.6.
655. Kinkead B, Murray T, Egnatashvili V, Maeno H and **Nemeroff CB.** 2004. The effects of olanzapine and quetiapine on prepulse inhibition of the acoustic startle response in neurotensin 1 receptor knockout mice. Society for Neuroscience, 34th Annual Meeting, 911.7.
656. Capuron L, Pagnoni G, Demetrashvili M, **Nemeroff CB**, Berns GS and Miller AH. 2004. Fronto-parietal recruitment enables interferon-alpha treated patients to maintain normal performance on a task of visuo-spatial attention. XXIV CINP Congress, S474.
657. **Nemeroff CB.** 2004. The role of early traumatic life experiences on the activity of the HPA axis in depression. Japanese Society of Biological Psychiatry and Japanese Society of Neuropsychopharmacology joint meeting, 81.

658. Kilts C, Ely TD, Newport DJ, Gross RE, Hamann S and **Nemeroff CB**. 2004. Dissociation of the effects of childhood trauma and major depression on the neural correlates of emotional memory. American College of Neuropsychopharmacology, 43rd Annual Meeting. Neuropsychopharmacol 29(12):S84.
659. Bremner JD, Mletzko T, Welter S, Reed L, Williams C, Heim C and **Nemeroff CB**. 2004. Treatment of post-traumatic stress disorder with phenytoin: an open label pilot study. American College of Neuropsychopharmacology, 43rd Annual Meeting. Neuropsychopharmacol 29(12):S91.
660. Bremner JD, Mletzko T, Welter S, Williams C, Quinn S, Reed L, Brummer M and **Nemeroff CB**. 2004. Effects of phenytoin on memory, cognition and brain structure in posttraumatic stress disorder: a pilot study. American College of Neuropsychopharmacology, 43rd Annual Meeting. Neuropsychopharmacol 29(12):S92.
661. Coplan JD, Altemus M, Mathew SJ, Smith EL, Scharf B, Coplan PM, Kral JS, Perera T, Dwork A, Gorman JM, Owens MJ, **Nemeroff CB**, Rosenblum LA. Synchronized maternal-infant elevations of primate CSF CRF in response to variable foraging demand. American College of Neuropsychopharmacology, 43rd Annual Meeting. Neuropsychopharmacol 29(12):S96.
662. Boone E, Owens MJ, **Nemeroff CB** and Garlow SJ. 2004. Genetic analysis of hypothalamic corticotropin releasing factor (CRF) system. American College of Neuropsychopharmacology, 43rd Annual Meeting. Neuropsychopharmacol 29(12):S140.
663. **Nemeroff CB**, Gharabawi GM, Canuso CM, Mahmoud R, Loescher A, Turkoz I, Rapaport MH. 2004. Augmentation with risperidone in chronic resistant depression: a double-blind placebo-controlled maintenance trial. American College of Neuropsychopharmacology, 43rd Annual Meeting. Neuropsychopharmacol 29(12):S159.
664. **Nemeroff CB**, Owens MJ, Heim C and Newport DJ. 2004. The expanding potential clinical utility of CRF₁ receptor antagonists: from mood and anxiety disorders to drug withdrawal. American College of Neuropsychopharmacology, 43rd Annual Meeting. Neuropsychopharmacol 29(12):S44.
665. Sanchez MM, Lyon CK, Noble PL, McCormack KM, Crawford JL, Boudreau M, Higley JD, **Nemeroff CB**, Plotsky PM, Davis M, Newman TK, Winslow JT. 2004. Adverse rearing alters hypothalamic-pituitary-adrenal axis function and startle response in developing non-human primates: effects of sex and serotonin-transporter genotype. American College of Neuropsychopharmacology, 43rd Annual Meeting. Neuropsychopharmacol 29(12):S205.
666. **Nemeroff CB**, Simon JS, Forbes A, Carson WH and McQuade R. 2004. Aripiprazole augmentation of SSRIs and SNRIs for the treatment of partial and non-responding patients with major depressive disorder. American College of Neuropsychopharmacology, 43rd Annual Meeting. Neuropsychopharmacol 29(12):S209.
667. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, **Nemeroff CB** and Miller AH. 2004. Syndrome of chronic fatigue in patients receiving interferon-alpha for chronic hepatitis C. American College of Neuropsychopharmacology, 43rd Annual Meeting. Neuropsychopharmacol 29(12):S234.

668. Thase ME, Ahmed S, Entsuaeh R, Sloan DM and **Nemeroff CB**. 2004. Meta-analysis and funnel plot analysis of studies comparing venlafaxine and selective serotonin reuptake inhibitors: the evidence revisited. American College of Neuropsychopharmacology, 43rd Annual Meeting. Neuropsychopharmacol 29(12):S238.
669. **Nemeroff CB** and Plotsky PM. 2004. Persistent neurobiological consequences of early life trauma: reversal by antidepressant treatment. American College of Neuropsychopharmacology, 43rd Annual Meeting. Neuropsychopharmacol 29(12):S56.
670. Fitzgerald LZ, Owens MJ, Naliboff BD, **Nemeroff CB** and Mayer EA. 2005. Elevated levels of central stress mediators in irritable bowel syndrome. Center for Neurovisceral Sciences & Women's Health, 2nd annual Basic and Translational Science Symposium, 37.
671. **Nemeroff CB**. 2005. Novel therapeutic approaches in the treatment of affective disorders. Endocrine Society, 87th Annual Meeting, 65.
672. **Nemeroff CB**. 2005. The persistent neurobiological consequences of early life abuse or neglect: implications for the pathophysiology and treatment of mood disorders. Biol Psychiatry 57:1S.
673. Thiruvikraman KV, Kinkead B, Gernert KM, **Nemeroff CB**, Plotsky PM and Owens MJ. 2005. The effect of corticosterone on diurnal differences in rat dorsal raphe gene expression. Biol Psychiat 57:27S.
674. Caceda R, Kinkead B, Owens MJ and **Nemeroff CB**. 2005. Antipsychotic drug-like effects of virally mediated overexpression of the neurotensin 1 receptor in the rat nucleus accumbens. Biol Psychiat 57:42S.
675. Musselman DL, Guo Y, Manatunga A, Gilles N, Porter MR, McDaniel JS and **Nemeroff CB**. 2005. The diagnosis of major depression in patients with cancer: a comparative approach. Biol Psychiat 57:48S.
676. Mletzko T, Bruce EC, Fu PP, Le N, **Nemeroff CB**, Manatunga A, Heim CM and Musselman DL. 2005. Oxidative stress increases after mental stress. Biol Psychiat 57:49S.
677. Sanchez MM, Lyon CK, Noble PL, Crawford JL, Boudreau M, Higley JD, **Nemeroff CB**, Plotsky PM, Newman TK and Winslow JT. 2005. Maternal separation alters hypothalamic-pituitary-adrenal (HPA) axis function in rhesus macaques: effects of sex and serotonin transporter gene variation. Biol Psychiat 57:57S.
678. Kilts CD, Ely TD, Newport JD, Gross RE, Hamann S and **Nemeroff CB**. 2005. Childhood trauma is associated with altered neural processing related to emotion perception and memory. Biol Psychiat 57:62S.
679. Bruce EC, Guo Y, McDonald WM, Brown AR, Emery M, Porquez J, Manatunga A, Bonsall R, **Nemeroff CB** and Musselman DL. 2005. Platelet thromboxane A₂ secretion in patients with major depression undergoing electroconvulsive therapy. Biol Psychiat 57:99S.
680. Thase ME, Entsuaeh R, Ahmed S, Sloan D and **Nemeroff CB**. 2005. Meta-analysis of ECTs comparing venlafaxine and SSRIs; the evidence revisited. Biol Psychiat 57:104S.

681. Kinkead B, Murray T, McMichael J, Dobner PR, Deitemeyer N and **Nemeroff CB**. 2005. Amphetamine fails to disrupt prepulse inhibition of the acoustic startle response in neurotensin knockout mice. *Biol Psychiat* 57:119S.
682. Hanson ND, Jutras M, Plotsky PM, **Nemeroff CB** and Owens MJ. 2005. Short-term corticosterone administration does not change erythropoietin receptor expression in the rat hippocampus. *Biol Psychiat* 57:120S.
683. Bremner JD, Cheema FA, Ashraf A, Afzal N, Fani N, Reed L, Musselman DL, Ritchie JC, Faber T, Votaw JR, **Nemeroff CB** and Vaccarino V. 2005. Mechanisms mediating the effects of stress and depression on myocardial dysfunction. *Biol Psychiat* 57:150S.
684. **Nemeroff CB**. 2005. Depression and cardiovascular disease: pathophysiology and treatment. *Biol Psychiat* 57:159S.
685. **Nemeroff CB**. 2005. CRF and the pathogenesis of depression: treatment implications. *World J Biol Psychiat* 6:116.
686. Thase ME, Entsuaeh R, Ahmed S, Sloan D and **Nemeroff CB**. 2005. Venlafaxine vs SSRIs in depression: meta-analysis of all known RCTs. *World J Biol Psychiat* 6:285.
687. **Nemeroff CB**. 2005. Advances in the treatment of psychiatric disorders. *World J Biol Psychiat* 6:399.
688. Simon JS, Sheehan D, Thase M, Owens M, Krulewicz S, Carpenter D and **Nemeroff CB**. 2005. Comparison of efficacy and tolerability of paroxetine CR versus venlafaxine XR. American Psychiatric Association Annual Meeting, Abstr 5852.
689. Bremner JD, Fani N, Ashraf A, Votaw J, Reed L, Vaccarino V and **Nemeroff CB**. 2005. Effects of isotretinoin on brain function in acne patients. American Psychiatric Association Annual Meeting, Abstr 6168.
690. Ader M, Bergman RN, Garvey T, Phillips LS, **Nemeroff CB**, Weinberger DR, Gharabawi GM, Mahmoud RA, Greenspan A, Morein JD and Zhu Y. 2005. Glucoregulation and adiposity with antipsychotic therapy in schizophrenia. American Psychiatric Association Annual Meeting, Abstr 6302.
691. Thase ME, Entsuaeh AR, Ahmed S, Sloan D and **Nemeroff CB**. 2005. Meta-analysis of randomized clinical trials comparing venlafaxine and SSRIs: the evidence revisited. American Psychiatric Association Annual Meeting, Abstr 6305.
692. Tyrka AR, Carpenter LL, McDougale CJ, Kirwin PD, Owens MJ, **Nemeroff CB** and Price LH. 2004. CSF corticotropin-releasing factor increases during tryptophan depletion. American Psychiatric Association Annual Meeting, Abstr 1615.
693. Carpenter LL, Price LH, Kinkead B, Cassell T, Sanacora G, Owens MJ and **Nemeroff CB**. 2004. Elevated CSF concentration of Substance P in major depression. American Psychiatric Association Annual Meeting, Abstr 2260.
694. Christie J and **Nemeroff CB**. 2003. Improving somatic symptoms associated with depression using SSRI treatment. American Psychiatric Association Annual Meeting, Abstr 694.

695. Gaynes BN, Ekstrom D, Hamer RM, Jacobsen FM, **Nemeroff CB**, Suppes P and Golden RN. 2003. Phototherapy: systematic review of the evidence. American Psychiatric Association Annual Meeting, Abstr 3214.
696. **Nemeroff CB**, Entsuah AR, Willard LB, Demitrack MA, Thase ME. 2003. Venlafaxine and SSRIs: pooled remission analysis. American Psychiatric Association Annual Meeting, Abstr 3092.
697. **Nemeroff CB**. 2005. The long term neurobiological consequences of child abuse: endocrine and brain imaging studies. ISPNE 36th Annual Conference, 22.
698. **Nemeroff CB**. 2005. The neurobiological consequences of early life stress: treatment implications. International Society for Traumatic Stress Studies (ISTSS), 21st Annual Meeting, 44.
699. Martin EI, Chhatwal JP, Nair HP, Owens MJ, **Nemeroff CB** and Ressler KJ. 2005. Development of CRF and CRF neuron-specific lentiviral vectors for use in brain-behavior studies. Soc. Neurosci 35th Annual Meeting, 340.1 (online).
700. Caceda R, Kinkead B, Owens MJ and **Nemeroff CB**. 2005. Neurotensin differentially modulates dizocilpine effects on sensorimotor gating and locomotion. Soc. Neurosci. 35th Annual Meeting, 444.11 (online).
701. Thiruvikraman KV, Moore LA, Zejnelovic F, Silverman MN, **Nemeroff CB** and Plotsky PM. 2005. Attenuated Fos-protein expression after restraint stress in the locus ceruleus of CRF-deficient mice. Soc. Neurosci. 35th Annual Meeting, 638.4 (online).
702. Pace TWW, Mletzko T, Alagbe O, Vogt GJ, Hu F, Miller AH, Bruce EC, Musselman DL, **Nemeroff CB** and Heim CM. 2005. Indicators of innate immune system activity in humans increase with psychosocial stressor challenge: major depressives vs nondepressives. Soc. Neurosci. 35th Annual Meeting, 639.16 (online).
703. Capuron L, Pagnoni G, Fornwalt FB, Demetrashvili M, Woolwine BJ, Lawson DH, **Nemeroff CB** and Miller AH. 2005. Brain metabolic changes and neurovegetative symptoms in medically ill patients undergoing interferon- α therapy. Soc. Neurosci. 35th Annual Meeting, 660.23 (online).
704. Hanson ND, Gutman DA, Owens MJ and **Nemeroff CB**. 2005. Effects of chronic treatment with a CRF₁ receptor antagonist on brain-derived neurotrophic factor mRNA expression in the hippocampus. Soc. Neurosci. 35th Annual Meeting, 677.1 (online).
705. Felger JC, Alagbe O, Mook D, Sanchez MM, **Nemeroff CB** and Miller AH. 2005. Immune, neuroendocrine, and behavioral response to interferon (IFN) α in Rhesus monkeys: a potential role for CRF. Soc. Neurosci. 35th Annual Meeting, 889.15 (online).
706. **Nemeroff CB**, Plotsky PM, Gould E and Coplan J. 2005. The neurobiology of early life trauma: role in the pathophysiology of mood and anxiety disorders. Soc. Neurosci 35th Annual Meeting, 927 (online).
707. **Nemeroff CB**, Heim C, Musselman DL and Miller AH. 2005. Brain systems regulating the organism's response to stress: preclinical and clinical studies. Neuropsychopharmacol 30(suppl 1):S19.

708. **Nemeroff CB**, Caceda R, Owens MJ and Kinkead B. 2005. Viral vector-induced overexpression of the NT₁ receptor in the nucleus accumbens: further evidence for antipsychotic effects of increased Ntergic neurotransmission. *Neuropsychopharmacol* 30(suppl 1):S48.
709. Kinkead B and **Nemeroff CB**. 2005. The role of neurotensin in estrous cycle regulation of prepulse inhibition of acoustic startle. *Neuropsychopharmacol* 30(suppl 1):S49.
710. Binder EB, Tang Y, **Nemeroff CB**, Cubells JF. 2005. Neurotensin system genes and susceptibility to cocaine-induced psychosis. *Neuropsychopharmacol* 30(suppl 1):S87.
711. Coplan JD, Kaufman D, Shorman I, Smith EL, Owens MJ, **Nemeroff CB**, Rosenblum LA, Kral JG and Banerji M. 2005. Variable foraging demand (VFD) exposure of primate maternal-infant dyads and impaired insulin action in juvenile offspring. *Neuropsychopharmacol* 30(suppl 1):S154).
712. Heim C, Mletzko T, Purselle D, Musselman DL and **Nemeroff CB**. 2005. The dexamethasone/CRF test in men with major depression: role of childhood trauma. *Neuropsychopharmacol* 30(suppl 1):S173.
713. Keitner GI, Ninan PT, Ryan CE, Garlow S, Solomon DA, **Nemeroff CB** and Keller MB. 2005. A randomized placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, nonpsychotic major depression. *Neuropsychopharmacol* 30(suppl 1):S175.
714. Harvey PD, Bilder R, Gharabawi GM, Canuso CM, Pandina GJ, Turkoz I and **Nemeroff CB**. 2005. Cognitive function in patients with resistant depression: effects of antidepressant monotherapy and risperidone augmentation. *Neuropsychopharmacol* 30(suppl 1):S183.
715. Capuron L, Pagnoni G, Demitrashvili M, Lawson DH, Berns GS, **Nemeroff CB** and Miller AH. 2005. Increased basal ganglia activity during interferon-alpha therapy for malignant melanoma: relationship with neurovegetative symptoms. *Neuropsychopharmacol* 30(suppl 1):S222.
716. Alagbe O, Pace T, Mletzko T, Vogt J, Nemeroff C, Heim C and Miller A. 2005. Changes in natural killer cell function, inflammatory signaling and plasma IL-6 production during acute stress in patients with major depression. *Neuropsychopharmacol* 30(suppl 1):S26
717. Guo Y, Musselman DL, Manatunga A, Gilles N, Lawson K, Porter M, McDaniel JS and **Nemeroff CB**. 2005. A novel approach to diagnosing major depression in patients with cancer. *Winship 3rd Annual International Scientific Symposium*.
718. **Nemeroff CB**. 2006. The neurobiology of depression: bringing the latest in science to clinicians. *Amer Psych Assoc 159th Annual Meeting*, 34.
719. **Nemeroff CB**. 2006. Evolving concepts in treatment-resistant depression. *Amer Psych Assoc 159th Annual Meeting*, 20.
720. **Nemeroff CB**. 2006. The neurobiological consequences of early life stress: clinical studies. *Intl J Neuropsychopharmacol* 9(suppl 1):65.
721. **Nemeroff CB**. 2006. A mechanistic approach to treatment-resistant depression. *Intl J Neuropsychopharmacol* 9(suppl 1):90.

722. Keller M, Yan B, Dunner D, Ferguson J, Friedman E, Gelenberg A, Hirschfeld R, Kocsis J, Kornstein S, Nemeroff C, Ninan P, Rothschild A, Schatzberg A, Shelton R, Thase M, Trivedi M, Zajecka J, Ahmed S, Musgnung J and Pedersen R. 2006. An analysis of recurrence prevention with venlafaxine XR in patients with recurrent unipolar major depression: a two-year maintenance treatment study. *Intl J Neuropsychopharmacol* 9(suppl 1):184.
723. Keller M, Yan B, Dunner D, Ferguson J, Friedman E, Gelenberg A, Hirschfeld R, Kocsis J, Kornstein S, Nemeroff C, Ninan P, Rothschild A, Schatzberg A, Shelton R, Thase M, Trivedi M, Zajecka J, Ahmed S, Musgnung J, Parker-Zavod E and Pedersen R. 2006. A placebo-controlled trial of venlafaxine XR in patients with recurrent unipolar major depression to assess recurrence prevention. *Intl J Neuropsychopharmacol* 9(suppl 1):233.
724. **Nemeroff CB**, Heim C, Miller AH, Newport DJ, Young LJ and Kilts CD. 2006. The neurobiology of early life trauma: contributions to the neurobiology of depression. 37th annual ISPNE conference, S029.
725. Keller M, Yan B, Dunner D, Ferguson J, Friedman E, Gelenberg A, Hirschfeld RMA, Kocsis J, Kornstein S, Nemeroff C, Ninan P, Rothschild A, Schatzberg A, Shelton R, Thase ME, Trivedi MH, Zajecka J, Ahmed S, Musgnung J and Pedersen R. 2006. Two-year maintenance treatment study assessing recurrence prevention with venlafaxine XR in patients with recurrent unipolar major depression. *Eur Neuropsychopharmacol* 16(4):S322.
726. Zeng F, Jarkas N, Voll RJ, Williams L, Votaw J, Howell L, Kilts C, **Nemeroff CB**, Goodman M. 2006. Synthesis, characterization and in vivo PET imaging in non-human primates of [¹¹C] (S,S)-MSREBOX: a new norepinephrine transporter (NET) imaging agent. Southeastern Regional Meeting of the American Chemical Society (SERMACS).
727. Pandina G, Bossie C, Kujawa M, Kosik-Gonzalez C, Turkoz I, Mahmoud R, and Nemeroff C. 2006. Impact of juvenile abuse on treatment outcome in depression. *Amer Psych Assoc*, Washington DC.
728. Ryan DE, Garlow SJ, Keitner GI, Solomon DA, Ninan PT, **Nemeroff CB** and Keller MB. 2006. Psychosocial functioning in patients with difficult-to-treat unipolar, nonpsychotic, major depression. *Neuropsychopharmacol* 31 (Suppl 1) S156.
729. Nemeroff D, Pandina G, Bossie C, Mahmoud R, Canuso C, Kujawa M, Kosik-Gonzalez C, Turkoz I and Gharabawi G. 2006. Impact of childhood abuse on treatment outcome in depression: Results of a double-blind risperidone augmentation trial. *Neuropsychopharmacol* 31 (Suppl 1) S158.
730. Neigh GN, Binder EB, Plotsky PM, Owens MJ, Taylor WR and Nemeroff C. 2006. Stress results in region specific decreases in expression of angiogenic factors in the brain. *Neuropsychopharmacol* 31 (Suppl 1) S161.
731. Caceda R, Kinkead B, Owens MJ and Nemeroff C. 2006. Could neurotensin receptor antagonists also be antipsychotics? *Neuropsychopharmacol* 31 (Suppl 1) S244.
732. Vergne D and **Nemeroff CB**. 2006. The interaction of serotonin transporter gene polymorphisms and early adverse life events on vulnerability for major depression. *Current Psych. Reports* 8 (6) 452-457.

733. Oliver LD, Bruce EC, Karaffa RE, Musselman DL and **Nemeroff CB**. 2007. Flow Cytometric Analysis of Cytosolic Calcium Mobilization in Platelets in Whole Blood Using Calcium Green-1 AM Fluorescent Indicator, ISLH, Miami, Florida.
734. Zeng F, Karkas N, Stehouwer JS, Voll RJ, Williams L, Votaw JR, Kilts CD, **Nemeroff CB** and Goodman MM. 2007. 18F-Labeled analogs of reboxetine as PET imaging agents for norepinephrine transporters. Society of Nuclear Medicine Meeting, DC, Washington.
735. Ryan CE, Garlow SJ, Keitner GI, Solomon DA, **Nemeroff CB**, and Keller MB. 2007. Risperidone Augmentation and Psychosocial Variables in Patients with Difficult-to-Treat Depression. Amer Psych Assoc, San Diego, California.
736. Kornstein SG, Ferdousi T, Holland PJ, **Nemeroff CB**, Rothschild AJ, Thase ME, and Trivedi MH. 2007. Influence of Gender and Menopausal Status on Response and Remission in Patients With Recurrent Depressive Disorder Treated With Venlafaxine XR or Fluoxetine. Amer Psych Assoc, San Diego, California.
737. Pandina GJ, Bossie C, Kujawa M, Kosik-Gonzalez C, Turkoz, I, Mahmoud RA, and **Nemeroff CB**. 2007. Impact of Juvenile Abuse of Treatment Outcome in Depression. Amer Psych Assoc, San Diego, California.
738. Binder EB, Owens MJ, Liu W, Fava M, Rush AJ, Trivedi MH, Cubells JF, and **Nemeroff CB**. 2007. Genetic Variants in Genes Regulating Corticotropin Releasing Hormone (CRH) System and Response to Citalopram in the STAR*D Sample. Biol Psychiatry 61 (Suppl 1) S559.
739. Binder EB, Houston MJ, Caceda R, Tang YL, Kinkead B, Deveau TC, Gelernter J, Kranzler HR, **Nemeroff CB**, and Cubells JF. 2007. Novel Promoter Variant in the Neurotensin Gene is Protective Against Cocaine-Induced Psychosis in African American Subjects. Biol Psychiatry 61 (Suppl 1) S660.
740. Ressler KJ, Binder, EB, Bradley RG, Tang YL, Liu W, Gillespie CF, Heim CM, Schwartz A, **Nemeroff CB** and Cubells JF. 2007. CRHR1 Haplotypes Moderate Effects of Early Life Stress (ELS) on Adult Depression. Biol Psychiatry 61 (Suppl 1) S748.
741. Selz K, Guo Y, Brown AR, Bruce EC, Lawson K, Schoenbeck J, Rushing N, McDonald WM, Stowe ZN, **Nemeroff CB** and Musselman DL. 2007. Finite Moment and Entropic Descriptors of Heart Rate Vulnerability in Patients with Major Depression Undergoing Electroconvulsive Therapy. Biol Psychiatry 61 (Suppl 1) S754.
742. **Nemeroff CB**. 2007. Caring for our Most Challenging Patients with Depression: An Interactive Forum on Novel Treatments. Amer Psych Assoc, San Diego, California.
743. **Nemeroff CB**. 2007. Mechanism of Action of Vagus Nerve Stimulation (VNS). Amer Psych Assoc, San Diego, California.
744. Thirivikraman KV, Torner L, **Nemeroff CB**, Holsboer F, Landgraf R, Plotsky PM and Neumann ID. 2007. Corticosterone Modulates Oxytocin Release into Blood and in the PVN After Forced Swim in Male Rats. World Congress on Neurohypophysis, Regensburg, Germany.

745. Kornstein SG, Ferdousi T, Holland P, **Nemeroff CB**, Rothschild AJ, Thase ME, Trivedi MH, Ahmed S, Pedersen J, Musgnung J and Keller MD. 2007. Response and Remission in Patients with Recurrent Depressive Disorder Treated with Venlafaxine XR or Fluoxetine: Effects of Gender and Menopausal Status. Amer Psych Assoc, San Diego, California.
746. Binder EB, Bradley RG, Epstein MP, Liu W, Newport DJ, Stowe ZN, **Nemeroff CB**, Schwartz A, Cubells JF and Ressler KJ. 2007. Influence of Child Abuse and Trauma on Adult Depressive Symptomatology is Moderated by the Corticotropin Releasing Hormone Receptor Gene, ECNP, Vienna, Austria.
747. Ninan P, Dunlop B, Dunner DL, Holland P, Kornstein SG, **Nemeroff CB**, Rothschild AJ, Shelton R, DeMers W, Pedersen R and Thase ME. 2007. Anxiety in Patients with Recurrent Major Depressive Disorder: Prevalence and Impact on Treatment Outcomes. US Psychiatric & Mental Health Meeting (USPMH), Orlando, Florida.
748. Caceda R, Kinkead B and **Nemeroff CB**. 2007. Neuropeptide interaction in the regulation of sensorimotor gating. Society for Neuroscienc. Abst. 33:643.7.
749. Kinkead B and **Nemeroff CB**. 2007. The role of neurotensin in amphetamine-induced behavioral sensitization: studies in neurotensin knockout mice. Society for Neuroscience Abst. 33:811.3.
750. **Nemeroff CB**. 2007 The neurobiological consequences of child abuse and neglect: Increased vulnerability for depression in adulthood. World Congress on Stress, Vienna, Austria.
751. Cubells JF, Tang YL, Houston MJ, Caceda R, Kinkead B, Kranzler HR, Gelernter J, Farrer L, **Nemeroff CB** and Binder EB. 2007. Genetic Association Analysis of Cocaine-Induced Psychosis: Variation in Dopamine-Related Genes Modulates Vulnerability in African-American Subjects.
752. Heim CM, Young LJ, Newport DJ, Mletzko TC, Miller AH and **Nemeroff CB**. 2007. Persistent CSF Oxytocin Reduction after Childhood Abuse. 46th Annual Meeting of The American College of Neuropsychopharmacology, Boca Raton, Florida.
753. Binder EB, Heim CM, Deveau TC, Katz ER, Mletzko TC, Newport DJ, Cubells JF, Stowe ZN and **Nemeroff CB**. 2007. Child Abuse Alters the Expression of Glucocorticoid Receptor-Regulating Chaperone and Co-Chaperone Genes. 46th Annual Meeting of The American College of Neuropsychopharmacology, Boca Raton, Florida.
754. Kinkead B and **Nemeroff CB**. 2007. Cocaine- and Amphetamine-Induced Behavioral Sensitization Are Related to Genetic Difference in the Neurotensin System in 5 Inbred Strains of Mice. 46th Annual Meeting of The American College of Neuropsychopharmacology, Boca Raton, Florida.
755. Garlow SJ, Dunlop B, Ninan PT and **Nemeroff CB**. 2007. Addition of Tri-Iodothyronine (T3) to Sertraline Does Not Impact Treatment Response in Patients with Major Depressive Disorder. 46th Annual Meeting of The American College of Neuropsychopharmacology, Boca Raton, Florida.
756. Bremner JD, Fani N, Cheema FA, Ashraf A, Reed L, Dent M, Votaw JR, Goodman MM, Soufer R, **Nemeroff CB** and Vaccarino V. Effects of Stress on Brain Function in Coronary Heart Disease

Patients with and Without Depression and Stress Induced Myocardial Ischemia. 2007. 46th Annual Meeting of The American College of Neuropsychopharmacology, Boca Raton, Florida.

- 757. Neigh GN, Martin L and **Nemeroff CB**. 2007. Microembolism Infarcts: A Rodent Model of Vascular Depression. 46th Annual Meeting of The American College of Neuropsychopharmacology, Boca Raton, Florida.
- 758. Caceda R, Kinkead B, Binder EB, Hasenkamp W, Duncan EJ, Cubells JF and **Nemeroff CB**. 2007. Association of a Novel Promoter Variant in the Neurotensin/Neuromedin N (NTS) Gene with Low Levels of Prepulse Inhibition of Acoustic Startle in Schizophrenic Patients of African American Descent. 46th Annual Meeting of The American College of Neuropsychopharmacology, Boca Raton, Florida.
- 759. Sanchez MM, Lyon CK, Boudreau M, Graff A, Noble PL, Plotsky PM, **Nemeroff CB** and Winslow JT. 2008. Effects of Early Life Stress on Physical Growth, Sleep and Metabolism During Puberty and Adolescence: Studies in Nonhuman Primates. 63rd Annual Meeting of the Society of Biological Psychiatry. 63: 68S
- 760. **Nemeroff CB**. 2008. Non-peptide ligands acting at CRF receptors as novel anxiolytics or antidepressants. ISAD 4th Biennial Conference. Cape Town, South Africa. Vol. 107 (Suppl 1), S35-7.1
- 761. Gillespie CF, Bradley RG, LiuW, Epstein MP, Deveau TC, Tang Y, Heim CM, **Nemeroff CB**, Schwartz AC, Cubells JF, Ressler KJ and Binder EB. 2008. Risk for adult posttraumatic stress disorder is predicted by child abuse and FKBP5, a Gene Regulating Stress-Responsiveness. Biological Psychiatry. 63: 1S-301S
- 762. **Nemeroff CB**. 2008. Persistent CSF Oxytocin Reduction After Childhood Abuse. American Psychiatric Association, Annual Meeting, Washington, DC
- 763. **Nemeroff CB**. 2008. Neurobiological Validators Applied to MDD and GAD. American Psychiatric Association, Annual Meeting, Washington, DC.
- 764. Hanson, N., **Nemeroff CB**, and Owens, M. 2008 Effects of a CRF antagonist on cell proliferation in the dentate gyrus. Society for Neuroscience Abstract.
- 765. Martin, EL, Chatwal, JP, Ressler, KJ, Owens, MJ. **Nemeroff CB**. 2008. Lentivirus-mediated chronic overexpression of CRF in the central nucleus of the amygdala produces anxiety-like behavior and HPA-axis hyperactivity as measured by the Dex/CRF Test. 39th Annual ISPNE Conference, Dresden, Germany.
- 766. **Nemeroff CB**. 2008. CRF, the neurobiology of depression and early life trauma: Implications for diagnosis and treatment. CINP XXVI Congress, July 13, Munich, Germany. P-17.
- 767. **Nemeroff CB**. 2008. The interaction of serotonin transporter gene polymorphism and early life stress on vulnerability to depression: pathophysiology and therapeutic perspective. XXVI CINP Congress, Munich, Germany. Vol 11 (Suppl 1), S-34.02.
- 768. Neigh, G., **Nemeroff CB**. 2008. Microembolism infarcts increase anxiety-like and depressive-like behavior in the rat. XXVI CINP Congress, Munich, Germany. Vol 11 (Suppl 1), S-11.26.

769. Deveau, T., Heim, C., Mletzko, T., Cubells, JF, **Nemeroff CB**, Binder, EB. 2008. Childhood trauma alters the expression of the glucocorticoid receptor co-chaperone BAG1. XXVI CINP Congress, Munich, Germany. Vol 11 (Suppl 1), P-09.63.
770. Haroon, B., Dunlop, B., Kelley, Mary, McKenzie, M., Betancourt, Y., Holtzheimer, P., Craighead, E., **Nemeroff CB**, Mayberg, H. 2008. Do declining depression rating scores between screening and randomization influence treatment outcomes in major depressive disorder. American College of Neuropsychopharmacology, 2008-PS-1503.
771. Sanchez, M.M., Boudreau, M., Lyon, C.K., Graff, A., Mook, D., Noble, P.L., **Nemeroff CB**, Winslow, J.T. 2008. Early Life Stress in Nonhuman Primates: Alterations in Emotionality, Physical Growth, HPA axis, Sleep and Metabolism during Puberty and Adolescence. 47th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Dec. 7-11, Scottsdale, AZ.
772. **Nemeroff CB**. 2008. Severe depression – how to diagnose and treat? 21st ECNP Congress, European Neuropsychopharmacology, August 30-September 11, Barcelona, Spain.
773. Bruce, E., Marzec, U., Oliver, L., Schmotzer, B., Manatunga, A., Ritchie, J., **Nemeroff CB**, Musselman, D. 2008. In Vitro Antidepressant Effects on the Enhanced Platelet Activation of Patients with Major Depressive Disorder. Vol 63 (Suppl 7S), P-202S.633.
774. Smith, A., Katz, E., Newport, J., Brennan, P., Ritchie, J., Ashe, M., **Nemeroff CB**, Cubells, J., Stowe, Z. 2008. Predictors of Neonatal Hypothalamic-Pituitary-Adrenal Axis Activity at Delivery in Women with Psychiatric Illness. Vol 63 (Suppl7S), P-231S.725.
775. Kinkead, B., Wang, J., Guillory, L., Shilling, P., Feifel, D., **Nemeroff CB**. 2008. Overexpression of NT1 receptor alters sensorimotor gating: Role of the nucleus accumbens and ventral palladium.
776. Dunlop, B., Binder, E., Mletzko, T., Heim, C., Betancourt, Y., McKenzie, M., Pfister, H., Holsboer, F., Ising, M., **Nemeroff CB**, Craighead, W.E., and Mayberg, H. 2009. Safety of the Dexamethasone-Corticotropin Releasing Hormone Procedure in Major Depressive Disorder: A Pooled Analysis. June 2009 NCDEU meeting.
777. **Nemeroff CB**. 2009. Rational Neuropsychopharmacology of Treatment-Refractory Depression, WPA International Congress, Treatments in Psychiatry: A New Update. Vol 8 (Suppl1), P-95.96.
778. **Nemeroff CB**. 2009. Depression and Inflammation: Research Evidence and Clinical Implications, WPA International Congress, Treatments in Psychiatry: A New Update. Vol 8 (Suppl1), P-112.
779. Prakash, C., Smith, E.L., Owens, M.J., **Nemeroff CB**, Rosenblum, L.A., and Coplan, J.D. 2009. Security of Attachments as a Function of Maternal Social Rank; Hypothalamo-Pituitary-Adrenal Axis Correlates. Biological Psychiatry, Vol 65(Suppl8S), P-45S.
780. Kinkead, B., Wang, J., Guillory, L., Shilling, P.D., Feifel, D., and **Nemeroff CB**. 2009. Overexpression of NT1 Receptor Alters Sensorimotor Gating: Role of the Nucleus Accumbens and Ventral Palladium. Biological Psychiatry, Vol 65(Suppl8S), P-205S.

781. Ressler, K.J., Bradley, B., Gillespie, C.F., Cubells, J., **Nemeroff CB** and Binder, E. 2009 Polymorphisms in CRHR1 Moderate the Effects of 5-HTTLPR x Child Abuse Interactions on Adult Depression. *Biological Psychiatry*, Vol 65(Suppl8S), P-227S.
782. Guillory, L.C., Wang, J., Caceda, R., Kinkead, B., Shilling, P.D., Feifel, D. and **Nemeroff CB**. 2009. Behavioral effects of viral vector over-expression of the Neurotensin in 1 receptor in the nucleus accumbens and ventral palladium of Brown Norway rats. *Soc. Neurosci Abst.*
783. Pace, T., Heim, C., **Nemeroff CB**, and Miller, A.H. 2010. History of Childhood Trauma is Associated with Glucocorticoid Sensitivity in Adulthood. *American Psychosomatic Society*.
784. Dunlop, B.W., DeFife, J.A., Marx, L., Garlow, S.J., Ninan, P.T., **Nemeroff CB**, Lilienfeld, S.O. The Effect of Sertraline on Psychopathic Traits. *The America College of Neuropsychopharmacology*, Miami Beach, Florida, December 2010.
785. Garlow, S., Ninan, P., **Nemeroff CB** The First Time is Best: Highest Remission Rate to SSRI Antidepressant in First Episode of Treatment for Depression. *The America College of Neuropsychopharmacology*, Miami Beach, Florida, December 2010.
786. Gould, F., Clarke, J., Harvey, P.D., Heim, C., **Nemeroff CB** The effects of Child Abuse and Neglect on Cognitive Functioning in Adulthood. *The America College of Neuropsychopharmacology*, Miami Beach, Florida, December 2010.
787. Myers, A., Ressler, K., Bradley, B., Mercer, K., Deveau, T., Smith, A., Gillespie, C., Cubells, J., Binder, E., **Nemeroff CB** Fine-Mapping of the Corticotropin-Releasing Hormone Receptor Gene. *The America College of Neuropsychopharmacology*, Miami Beach, Florida, December 2010.
788. Binder, E., **Nemeroff CB**, Schatzberg, A., Schlaepfer, T., Bol, K., Haazen, L., De Chaffoy, D., Buntinx, E. Interaction of Pimpamperone Augmentation of Citalopram and Genetic Variables in the Prediction of Antidepressant Response. *The America College of Neuropsychopharmacology*, Miami Beach, Florida, December 2010.
789. **Nemeroff CB**. 2011. The Neurobiology of Child Abuse: Treatment Implications, *Asian Journal of Psychiatry*, Volume 4, Suppl 1, July 2011.
790. Schatzberg, A., Binder, E., **Nemeroff CB**, Schlaepfer, T., Bol, K., Haazen, L., De Chaffoy, D., and Bruntinx, E. Interaction of Pimpamperone Citalopram and Genetic Variables in the Prediction of Antidepressant Response. 24th *European College of Neuropsychopharmacology*. Paris, France, September 2011.
791. Coccaro E.F., Owens M.J., Kinkead, B., and **Nemeroff C.B.** 2011. Cerebrospinal Fluid Substance P-Like Immunoreactivity: Correlates with Aggression in Personality Disordered Subjects. *American College of Neuropsychopharmacology*, 50th Annual Meeting, Waikoloa, Hawaii, P-268.
792. Heim C., Mayberg H.S., Mletzko T., **Nemeroff C.B.**, and Pruessner J.C. 2011. Reorganization of Somatosensory Cortex in Adult Women with Histories of Childhood Abuse. *American College of Neuropsychopharmacology*, 50th Annual Meeting, Waikoloa, Hawaii, P-270.

793. Myers A.J., Williams L., Gatt J.M., McAuley-Clark E., Dobson-Stone C., Schofield P., and **Nemeroff C.B.** 2011. Variation in the Oxytocin Receptor Gene is Associated with Increased Anxiety in Individuals with a History of Exposure to Early Life Stress. American College of Neuropsychopharmacology, 50th Annual Meeting, Waikoloa, Hawaii, P-305.
794. **Nemeroff C.B.**, Ramirez-Restrepo M., Mercer K.B., Ressler K.J., and Myers A.J. 2011. Association of an Intronic Deletion in the Corticotropin-Releasing Hormone Receptor Gene with Depression in African Americans. American College of Neuropsychopharmacology, 50th Annual Meeting, Waikoloa, Hawaii, P-308.
795. **Nemeroff C.B.** 2011. Personalized medicine and the risk of suicide: problems and promises. World Psychiatric Association 15th World Congress of Psychiatry. Buenos Aires, Argentina, P-44.
796. **Nemeroff C.B.** 2011. Heartache and heartbreak: the curious relationship between depression and heart disease. World Psychiatric Association 15th World Congress of Psychiatry. Buenos Aires, Argentina, P-86.
797. **Nemeroff C.B.** 2011. Disease vulnerof early childhood trauma. World Psychiatric Association 15th World Congress of Psychiatry. Buenos Aires, Argentina, P-215.
798. **Nemeroff C.B.** 2011. The effect of early life trauma on the corticotrophin-releasing factor circuits: implications for the pathophysiology and treatment of mood and anxiety disorder. World Psychiatric Association 15th World Congress of Psychiatry. Buenos Aires, Argentina, P-121.
799. **Nemeroff C.B.** 2011. The neurobiology of child abuse and neglect: impact on the pathophysiology and treatment of mood disorders. World Psychiatric Association 15th World Congress of Psychiatry. Buenos Aires, Argentina, P-162.
800. Guillory L.C., Qu H., Wang J., Bourke C., **Nemeroff C.B.**, Kinkead, B. Altered dopamine receptor and dopamine transporter gene expression in the striatum and frontal cortex of neurotensin null mice , Washington, DC. November 2011 Society for Neuroscience Annual Meeting.
801. **Nemeroff C.B.** 2012. Prediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry. 5th Biennial Conference of the International Society for Bipolar Disorders. Istanbul, Turkey, P-27.

802. Bellon A., Valente M., Matricon J., Gabhou F., Bendjemaa N., Gardette R., Yang S.K., **Nemeroff C.B.**, Hare J.M., Jay T.M., Krebs M.O., Hosmalin A., Feuillet V. 2012. Transdifferentiation of Macrophages into Neuronal-Like-Cells as a potential model for treatment prediction in Schizophrenia. Phoenix, Arizona. June 2012 NCDEU meeting.
803. Klengel T., Mehta D., Anacker C., Pruessner J.C., Pariante C.M., Pace T.W.W., Mercer K.B., Bradley B., Mayberg H., **Nemeroff C.B.**, Holsboer F., Heim C.M., Ressler K.J., Rein T. and Binder E.B. Allele-specific DNA deMethylation in FKBP5: A Molecular Mediator of Gene x Environment Interactions with Childhood Trauma. American College of Neuropsychopharmacology, 51st Annual Meeting, Hollywood, Florida, December 2012, P-130-132.
804. **Nemeroff C.B.** The Role of Corticotropin-Releasing Factor (CRF) in the Pathophysiology of Mood and Anxiety Disorders: A Tribute to Wylie Vale. American College of Neuropsychopharmacology, 51st Annual Meeting, Hollywood, Florida, December 3, 2012, P-S13.
805. Caceda R., Harvey P.D., Durand D., Cortes E., Prendes S., Wojas J. and **Nemeroff C.B.** Decision Making and Psychological Pain in Acutely Suicidal Depressed Patients. American College of Neuropsychopharmacology, 51st Annual Meeting, Hollywood, Florida, December 5, 2012, P-S362-S363.
806. **Nemeroff C.B.** 2013. Heartache and Heartbreak: Depression and Cardiovascular Disease. 5th International Cardio Event: Cardiology towards the future System Medicine. Florence, Italy, P-69-71.
807. Klengel T., Mehta D., Anacker C., Rex-Haffner M., Pariante C.M., Pace T.W.W., Mercer K.B., Bradley B., **Nemeroff CB**, Holsboer F., Heim C.M., Ressler K.J., Rein T., and Binder E.B. Epigenetic Modification as Mediator of Gene-Childhood Trauma Interactions. 68th Annual Meeting of the Society of Biological Psychiatry. San Francisco, California. May 16, 2013. P-S15.
808. **Nemeroff C.B.** Personalized Medicine in Mood Disorders: Prediction of Disease Vulnerability and Treatment Response. 68th Annual Meeting of the Society of Biological Psychiatry. San Francisco, California. May 17, 2013. P-S122.
809. **Nemeroff C.B.** Neurobiological Consequences of Child Abuse. South African Journal of Psychiatry, SASOP Biological Psychiatry Congress 2013. Wild Coast Sun, Port Edward, South Africa. August 30, 2013. P-103.
810. **Nemeroff C.B.** Heartache and Heartbreak: Depression and Cardiovascular Disease. Qatar Clinical Neuroscience Conference, Doha, Qatar, March 16, 2014. P-31.
811. **Nemeroff C.B.** Working with the NIH. 69th Annual Meeting of the Society of Biological Psychiatry. New York, New York. May 10, 2014.
812. Reiner W., Panthangi V., Fulton S., Rozenboym A., Tang J., Perera T.D., Cooper T., Kral J.G., Owens M.S., **Nemeroff C.B.**, Mann J.J. and Coplan J.D. Influence of Maternal Glutamatergic Response on the Neurobiology of the Offspring. 69th Annual Meeting of the Society of Biological Psychiatry. New York, New York. May 10, 2014.

813. Karim A.A., Chandra P., St. Germain G., Perera T.D., Owens M.J., **Nemeroff C.B.**, Coplan J.D. CSF Oxytocin (OT) in Maternal Stress: Influence on HPA Axis. 69th Annual Meeting of the Society of Biological Psychiatry. New York, New York. May 10, 2014.
814. **Nemeroff C.B.** Working with the NIH. 70th Annual Meeting of the Society of Biological Psychiatry. Toronto, Canada. May 14, 2015.
815. Gould F., Asuzu K., Kimmel A.D., de Jesus M., Lubarsky S.R., Ressler K., and **Nemeroff C.B.** The Relationship Between ELS and PTSD Among ED Trauma Victims. 70th Annual Meeting of the Society of Biological Psychiatry. Toronto, Canada. May 14, 2015.
816. **Nemeroff C.B.** The Latest on Treatment-Resistant Depression. 168th Annual Meeting of the American Psychiatric Association. Toronto, Canada. Psychiatric Times. June 2, 2015.
817. Nishitani S., Michopoulos V., Javanovic T., Gould F., **Nemeroff C.B.**, Meyers A.J., Rothbaum B.O., Ressler K.J., and Smith A.K. Epigenome-wide Association Study to Focus on the Development of PTSD in Traumatized ED Patients. 71st Annual Scientific Convention and Meeting of the Society of Biological Psychiatry. Atlanta, Georgia. May 12, 2016.
818. Carillo-Roa T., Dunlop B.W., McGrath C.L., Czamara D., Zannas A.S., Kelley M.E., **Nemeroff C.B.**, Müller-Myhsok B., Craighead W.E., Mayberg H.S., and Binder E.B. Polygenic Scores Derived from Neuroimaging Endophenotypes Predict Outcomes to Psychotherapy and Medication Treatments for Major Depressive Disorder. 71st Annual Scientific Convention and Meeting of the Society of Biological Psychiatry. Atlanta, Georgia. May 13, 2016.
819. Lori A., Carillo-Roa T., Binder E.B., Mayberg H.S., McGrath C.L., Mletzko T., Laird J.L., Czamara D., Dunlop B.W., Craighead W.E., Keyyey M.E., Mulle J.G., **Nemeroff C.B.**, and Cubells J.F. Analysis of Rare Variants in ADRA1a with Response to Treatment for Major Depressive Disorder (MDD). 71st Annual Scientific Convention and Meeting of the Society of Biological Psychiatry. Atlanta, Georgia. May 13, 2016.
820. Michopoulos V., Nishitani S., Javanovic T., Gould F., **Nemeroff C.B.**, Meyers A.J., Rothbaum B.O., and Ressler K.J. Female-Specific Patterns of Methylation Associated with Risk of PTSD Development: A Prospective Study. 71st Annual Scientific Convention and Meeting of the Society of Biological Psychiatry. Atlanta, Georgia. May 14, 2016.
821. Smith A.K., Nishitani S., Michopoulos V., Javanovic T., **Nemeroff C.B.**, Meyers A.J., Rothbaum B., and Ressler K.J. Epigenome-wide association study to focus on the development of PTSD in traumatized ED patients. 46th Annual Conference of the International Society of Psychoneuroendocrinology. Miami, Florida. September 9, 2016.
822. Gonzalez Alfonso A., Gould F., Kimmel A., Ressler K., and **Nemeroff C.B.** Smoking (Tobacco), PTSD and Depression. 46th Annual Conference of the International Society of Psychoneuroendocrinology. Miami, Florida. September 10, 2016.
823. Kimmel A., Gould F., Kirmse R., Gomez N., Ressler K., and **Nemeroff C.B.** Non-sexual interpersonal trauma and PTSD. 46th Annual Conference of the International Society of Psychoneuroendocrinology. Miami, Florida. September 10, 2016.
824. **Nemeroff C.B.** Personalized Medicine in Psychiatry: The New Holy Grail. American Psychiatric Association 2017 Annual Meeting, San Diego, California, May 20, 2017.

825. **Nemeroff C.B.** Clinical Evidence for Alterations in CRF-Containing Circuits in Mood and Anxiety Disorders. American Psychiatric Association 2017 Annual Meeting, San Diego, California, May 20, 2017.
826. **Nemeroff C.B.** Targeting the HPA Axis and Novel Strategies to Treat Psychiatric Disorders. American Psychiatric Association 2017 Annual Meeting, San Diego, California, May 24, 2017.
827. Gould F., Dunlop B., Rosenthal J., Iosifescu D., Mathew S., Neylan T., Rothbaum B., **Nemeroff C.B.**, and Harvey P. 2017. The Temporal Stability of Cognitive Functioning and Functioning Capacity in Women with PTSD. *Biological Psychiatry*, Supplement 10:S213.
828. Pape J., Carrillo-Roa T., Iosifescu D., Mathew S., Neylan T., **Nemeroff C.B.**, Mayberg H., Dunlop B. and Binder E. 2017. DNA Methylation Biomarkers and Treatment Effects of a Corticotropin Releasing Hormone Type 1 Receptor Antagonist in a Biologically-Defined Subset of PTSD-Patients. *Biological Psychiatry*, Supplement 10:S222.
829. **Nemeroff C.B.** and Dunlop B. 2017. The CRH-1 Receptor Antagonist Saga in Mood and Anxiety Disorders: The Good, the Bad and the Ugly. *Biological Psychiatry*, Supplement 10:S279.
830. Bernanke J., Galfalvy H., Mortali M., Hoffman L., Haas A., Moutier C., **Nemeroff C.B.**, Stanley B., Clayton P., Harkavy-Friedman J., and Oquendo M. 2017. Suicidal Ideation and Behavior in Institutions of Higher Learning: Categorizing Levels of Risk. *Biological Psychiatry*, Supplement 10:S87-S88.
831. Vega ML, Newport GC, Bozhdaraj D, Saltz SB, **Nemeroff CB**, Newport DJ. Meta-analysis of prenatal antidepressant exposure as risk factor for autism: impact of comparison group definition. American Psychiatric Association 171st Annual Meeting, New York, 2018. Abstract 1724.
832. Vega ML, Newport GC, Bozhdaraj D, Saltz SB, **Nemeroff CB**, Newport DJ. Meta-analysis of prenatal antidepressant exposure as risk factor for autism: impact of comparison group definition. Steiner Young Investigator Award. North American Society for Psychosocial Obstetrics & Gynecology Biennial Meeting, Philadelphia, PA, 2018.

INVITED PRESENTATIONS

1. Central nervous system effects of peptides. Division of Neurology, Montreal General Hospital, McGill University, November 14, 1976.
2. Discussant, Round Table on Behavioral Neurochemistry of Peptides. American Society for Neurochemistry, Eighth Annual Meeting, Denver, Colorado, March 13 - 18, 1976.
3. Participant, Symposium on Central Effects of Polypeptides. International Society of Psychoneuroendocrinology, Eighth Annual Meeting, Atlanta, Georgia, May 8 - 12, 1977.
4. Brain effects of endogenous peptides. McLean Hospital Research Laboratory, Harvard Medical School, Belmont, Massachusetts, March 2, 1977.
5. Co-chairman, Symposium on Central Nervous System Effects of Endogenous Peptides. Eleventh Annual Winter Conference on Brain Research, Keystone, Colorado, January 21 - 28, 1978.
6. Central effects of peptides: Basic and clinical studies. Grand Rounds, Department of Psychiatry, Cedars of Sinai Hospital, University of California-Los Angeles, November 7, 1977.
7. Role of tubero-infundibular systems in neuroendocrine homeostasis. Laboratories of Neuroendocrinology, The Salk Institute for Biological Studies, La Jolla, California, November 11, 1977.
8. Tuberoinfundibular systems and neuroendocrine homeostasis. Department of Neuroscience, School of Medicine, University of Florida, Gainesville, Florida, November 22, 1977.
9. Peptides and neuroendocrinology. The Institute for Behavioral Genetics, University of Colorado, Boulder, Colorado, January 23, 1978.
10. Short course in Neuroendocrinology. Department of Physiology, School of Medicine, The Catholic University, Santiago, Chile, July 15 - August 15, 1978.
11. Behavioral effects of hypothalamic peptides; and experimental studies on neural control of the anterior pituitary. Institute of Physiology, University Austral de Chile, Valdivia, Chile, July 28, 1978.
12. Behavioral and pharmacological effects of endogenous peptides. Department of Pharmacology, School of Medicine, Washington University, St. Louis, Missouri, November 9, 1978.
13. Hypothalamic circuits and neuroendocrine homeostasis. Laboratory of Behavioral Neurotoxicology, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, February 28, 1979.
14. Chairman, Round Table Discussion on Special Problems in Peptide Research. American Society for Neurochemistry, Tenth Annual Meeting, Charleston, South Carolina, March 11 - 16, 1979.
15. Central nervous system effects of neurotensin. The Marine Biomedical Institute, University of Texas Medical Branch, Galveston, Texas, June 28, 1979.

16. Brain effects of neurotensin. Department of Anatomy, School of Medicine, University of South Florida, Tampa, Florida, July 2, 1979.
17. CNS effects of endogenous peptides. MRC Neurochemical Pharmacology Unit, Department of Pharmacology, Cambridge University Medical School, Cambridge, England, August 6, 1979.
18. Brain effects of neurotensin, an endogenous peptide. North Carolina Department of Mental Health Research, Dorothea Dix Hospital, Raleigh, North Carolina, November 27, 1979.
19. Chairman and Participant, Round Table Discussion on Do Peptides Fulfill the Criteria for Neurotransmitter Candidate? American Society for Neurochemistry, 11th Annual Meeting, Houston, Texas, March 2 - 7, 1980.
20. Participant, Symposium on Nutrition and Behavior, New Research Directions: Neurotoxic Amino Acids. Sponsored by the Franklin Research Center and the National Science Foundation, Williamsburg, Virginia, March 10 - 12, 1980.
21. Central nervous system effects of neurotensin. Rudolph Magnus Institute for Pharmacology, University of Utrecht, Utrecht, Netherlands, June 4, 1980.
22. Everything you ever wanted to know and need to know about neurotensin. Centre de Neurochimie, Centre National de la Recherche Scientifique, Strasbourg, France, June 23, 1980.
23. Participant, Symposium on Neurotensin and Neuroleptics: Similarities and Differences. Annual Meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December, 1980.
24. Central nervous system effects of neurotensin. Neurobiology Seminar Series, Columbia University College of Physicians and Surgeons, New York, March 17, 1981.
25. Behavioral and neurochemical effects of neurotensin. School of Medicine, University of Sherbrooke, Sherbrooke, Canada, May 29, 1981.
26. Neurochemical and pharmaco-behavioral effects of neurotensin. Department of Physiology, University of Texas Southwestern Medical School, Dallas, Texas, October 26, 1981.
27. Look what neurotensin does. Walter Reed Army Institute of Medical Research, Walter Reed Army Medical Center, Washington, DC, December 7, 1981.
28. Central nervous system effects of neurotensin. Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, Maryland, December 8, 1981.
29. Central nervous system effects of neurotensin, an endogenous peptide: implications for psychiatry. Grand Rounds, Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, North Carolina, February 4, 1982.
30. Central nervous system effects of neurotensin. Glenolden Laboratory, E.I. DuPont De Nemours & Company, Glenolden, Pennsylvania, June 15, 1982.
31. Is neurotensin an endogenous neuroleptic? Astra Pharmaceuticals, Sodertalje, Sweden, August 17, 1982.

32. Interactions of neurotensin with brain dopamine systems. Department of Pharmacology, University of Gothenberg, Gothenberg, Sweden, August 19, 1982.
33. University of Lund, Department of Histology, "Effects of neurotensin on the central nervous system", Lund, Sweden, August 20, 1982.
34. Department of Psychiatry, Karolinska Institute, St. Goran's Hospital, "CNS effects of neurotensin", Stockholm, Sweden, August 25, 1982.
35. Wenner-Gren International Symposium on Excitotoxins, "Effects of neurotoxic amino acids on neuroendocrine regulation", Stockholm, Sweden, August 26 - 27, 1982.
36. Veterans Administration Hospital, Department of Psychiatry, "Interactions of neurotensin with CNS dopamine systems", Minneapolis, Minnesota, September 29, 1982.
37. American Pain Society, Third Annual Meeting, Chairman and participant in symposium "Analgesic effects of non-opioid peptides", Miami Beach, Florida, October 30, 1982.
38. Co-chairman and participant, Symposium on Neuropeptides and Schizophrenia - Spinal Fluid and Brain Studies. American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 16, 1982.
39. Modification of brain dopamine systems by neurotensin: Implications for psychiatry. Department of Psychiatry, University of Minnesota School of Medicine, Minneapolis, Minnesota, January 25, 1983.
40. Interactions of neurotensin with brain dopamine systems. Department of Psychiatry, University of California - Irvine, Irvine, California, February 8, 1983.
41. Clinical significance of brain neuropeptides. The Salk Institute for Biological Studies, La Jolla, California, February 9, 1983.
42. Brain effects of neurotensin. Department of Psychiatry, University of Utah College of Medicine, Salt Lake City, Utah, February 10, 1983.
43. Central nervous system effects of neurotensin: Implications for psychiatry. Department of Psychiatry, The Medical College of Pennsylvania, Philadelphia, Pennsylvania, February 14, 1983.
44. Neurotensin and brain dopamine systems. Department of Pharmacology, Duke University School of Medicine, Durham, North Carolina, February 22, 1983.
45. Interactions of neurotensin with CNS dopamine systems. Mental Health Research Institute, University of Michigan School of Medicine, Ann Arbor, Michigan, March 3, 1983.
46. Clinical use of the dexamethasone suppression test. Grand Rounds (with Dwight Evans), Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, North Carolina, March 24, 1983.
47. Peptide-catecholamine interactions: Focus on neurotensin. Department of Physiology and Pharmacology, University of Southampton, Southampton, England, April 14, 1983.

48. Non-opioid peptides and analgesia. Symposium on Peptides, Society for Drug Research, Bristol, England, April 18 - 20, 1983.
49. Neurotensin-dopamine interactions: basic and clinical studies. Department of Physiology and Pharmacology, University of Nottingham, Nottingham, England, June 9, 1983.
50. Interaction of neurotensin and dopamine in limbic structures. Fifth International Catecholamine Symposium, Goteborg, Sweden, June 14, 1983.
51. Use of the dexamethasone suppression test in psychiatry. Symposium on Neuroendocrine Testing in Psychiatry, Free University of Brussels, Hospital Erasme, Brussels, Belgium, September 17, 1983.
52. Neurotensin and related peptides: Basic and clinical studies. University of Louvain, Louvain, Belgium, September 19, 1983.
53. Interactions of neurotensin with the mesolimbic dopamine system: neurobiological and clinical implications. Chairman and participant, Panel on Mesolimbic and Mesocortical Systems: Basic and Clinical Studies, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 12, 1983.
54. Participant, Panel on Issues in Clinical Psychobiological - Psychopharmacologic Research Training. American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 14, 1983.
55. Participant, Workshop on Neurotensin. Winter Conference on Brain Research, Steamboat, Colorado, January 24, 1983.
56. Dexamethasone suppression test: clinical applications. Biological Markers for Psychiatry - Toward DSM IV, Atlanta, Georgia, February 24, 1984.
57. Clinical utility of the dexamethasone suppression test. Grand Rounds, Department of Psychiatry, Duke University Medical Center, March 1, 1984.
58. The dexamethasone suppression test. Grand Rounds, John Umstead Hospital, Butner, North Carolina, March 22, 1984.
59. Overview of neuropeptides (Graduate Course in Pharmacology) and Neurotensin-dopamine interactions: basic and clinical studies (research seminar), Department of Pharmacology, Emory University School of Medicine, April 24, 1984.
60. Clinical utility of the dexamethasone suppression test. Department of Psychiatry, Manhattan Veterans Administration Hospital, New York University School of Medicine, New York, NY, April 30, 1984.
61. Neurotensin: an overview. Neuropsychopharmacology Symposium, Albert Einstein College of Medicine, Bronx, New York, May 2, 1984.
62. The dexamethasone suppression test. Biological Markers in Psychiatry - Society of Biological Psychiatry, Los Angeles, California, May 6, 1984.

63. Chairman and Participant, Non-Opioid Peptide Symposium, First International Symposium on Endocoids, Fort Worth Texas, May 23 - 26, 1984.
64. Panel on Scientific Reviewers, North Carolina Alcoholism Research Authority, Raleigh, North Carolina, June 1, 1984.
65. Co-Chairman and participant, Symposium on Hypothalamic Peptides, Fifteenth International Congress of the International Society of Psychoneuroendocrinology, Vienna, Austria, July 15 - 19, 1984.
66. Interaction of neuropeptides and dopamine systems - focus on neurotensin. Invited participant, Dopamine '84 Symposium, Southampton, England, August 5 - 8, 1984.
67. Non-opioid neuropeptides: focus on neurotensin and CRF. Hormone- Neurotransmitter Interactions - The First Annual Albert Einstein College of Medicine Psychiatric Symposium, New York, NY, October 29 - 30, 1984.
68. Neuropeptides in cerebrospinal fluid: problems and promises. Chairman and participant, American College of Neuropsychopharmacology Panel, San Juan, Puerto Rico, December, 1984.
69. Participant, Panel on Neuropeptides Modulating Dopaminergic Function: New Horizons for the Dopamine Hypothesis of Schizophrenia, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December, 1984.
70. Physiology and pathophysiology of corticotrophin-releasing hormone. Department of Physiology and Psychiatry, University of New Mexico School of Medicine, Albuquerque, New Mexico, January 22, 1985.
71. Participant, Panel on Central and Peripheral Peptides, Winter Neuropeptide Conference, Breckenridge, Colorado, January 24, 1985.
72. Neurotensin-dopamine interactions. Institute of Animal Behavior, Rutgers University, Newark, New Jersey, March 19, 1985.
73. Dopamine Hypothesis of Schizophrenia, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December, 1984.
74. The interaction of neurotensin with dopaminergic pathways in the central nervous system: basic neurobiology and implications for the pathogenesis and treatment of schizophrenia. The Curt P. Richter Award Lecture, Sixteenth Congress of the International Society of Psychoneuroendocrinology, Kyoto, Japan, April 15, 1985.
75. Discussant, Symposium on Cholecystokinin in Schizophrenia, Twenty-fifth meeting of the New Clinical Drug Evaluation Unit Program, Key Biscayne, Florida, May 2, 1985.
76. Neuropeptides in schizophrenia: preclinical and clinical studies. Participant, Symposium on Biology of Schizophrenia: New Concepts, Society of Biological Psychiatry, Dallas, Texas, May 19, 1985.

77. The neurobiology of neurotensin. Co-Chairman and participant, Symposium on Anatomy and Behavioral Effects of Brain Peptides, Fifth International Washington Spring Symposium, Neural and Endocrine Peptides and Receptors '85, Washington, DC, May 28-31, 1985.
78. Analysis of the integrity of neuropeptide-containing neural systems in senile dementia of the Alzheimer's type: evidence for degeneration of somatostatinergic and corticotropin-releasing factor-containing neurons. New Investigator Award, 42nd Annual Meeting, American Geriatrics Society, New York, NY, July 12, 1985.
79. Recent research in behaviorally active peptides. Grand Rounds, Long Island Jewish Hillside Hospital, Long Island, New York, July 11, 1985.
80. Chairman and participant, Symposium on Neuropeptides and Neurotransmitters in Senile Dementia of the Alzheimer's Type, 13th International Congress of Gerontology, New York, NY, July 14, 1985.
81. Neurotensin-dopamine interactions - preclinical and clinical studies. American Hoechst-Roussel Pharmaceuticals, Somerville, New Jersey, August 2, 1985.
82. Neurotensin, dopamine and antipsychotic drugs. Department of Psychiatry, University of Cincinnati School of Medicine, Cincinnati, Ohio, August 20, 1985.
83. Studies on the hypothalamic-pituitary-adrenal axis in depression. Mt. Sinai Medical Center, University of Wisconsin, Milwaukee, Wisconsin, September 5, 1985.
84. Corticotropin-releasing hormone: preclinical and clinical studies. Grand Rounds, Department of Psychiatry, University of Wisconsin, Madison, Wisconsin, September 6, 1985.
85. Chairman and Participant, Symposium on Preclinical and Clinical Aspects of Neuropeptides in Psychiatric Disorders, IVth World Congress of Biological Psychiatry, Philadelphia, PA., September 9, 1985.
86. Participants, Symposium on Biological Markers and Possible Clinical Implications, IVth World Congress of Biological Psychiatry, Philadelphia, PA., September 11, 1985.
87. Panic attacks and agoraphobia; and Sleep disorders. Clinical up-date, North Carolina Division of Mental Health, Southern Pines, North Carolina, September 17, 1985.
88. Preclinical and clinical studies with corticotropin-releasing factor: implications for the etiology and pathogenesis of neuropsychiatric disorders. Visiting Professor, Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, September 27, 1985.
89. Neurotensin-dopamine interactions. Department of Biochemistry, University of Nice, Nice, France, October 8, 1985.
90. Peptidergic-catecholaminergic interactions in the amygdala, nucleus accumbens and other basal ganglia structures. Invited participant, Neurotransmitter Interactions in the Basal Ganglia, Grenoble, France, October 9 - 11, 1985.

91. Chairman and participant, Symposium on Recent Advances in the Hypothalamic Pituitary-Adrenal Axis in Affective Disorders, World Psychiatric Association Regional Symposium on Affective Disorders, Athens, Greece, October 13 - 17, 1985.
92. Corticotropin-releasing factor: basic and clinical studies. St. Elizabeth's Hospital, National Institute of Mental Health, Washington, DC, November 13, 1985.
93. Update on depression and panic disorders. Inn, Goldsboro, North Carolina, November 18, 1985.
94. Invited participant, International Workshop on Rett Syndrome, Johns Hopkins University and The Kennedy Institute for Handicapped Children, Baltimore, Maryland, November 20 - 21, 1985.
95. Corticotropin-releasing factor: preclinical and clinical investigations. Institute for Psychiatric Research, Indiana University Medical Center, Indianapolis, Indiana, November 26, 1985.
96. Co-chairman and participant, Panel on Problems and Promises of Post-Mortem Brain Tissue Analysis, American College of Neuropsychopharmacology, 24th Annual Meeting, Maui, Hawaii, December 11, 1985.
97. Co-chairman and participant, Panel on Recent Advances in Hypothalamic- Pituitary-Adrenal Physiology and Pathophysiology, American College of Neuropsychopharmacology, 24th Annual Meeting, Maui, Hawaii, December 13, 1985.
98. Preclinical and clinical studies with corticotropin-releasing factor (CRF): implications for the pathogenesis of psychiatric disorders. Rockefeller University Behavioral Biology Seminar, New York, NY, January 30, 1986.
99. Elevated corticotropin-releasing factor-like immunoreactivity in depressed patients. Biological Psychiatry Seminar, Department of Psychiatry, Cleveland Metropolitan General Hospital, Case Western Reserve University, Cleveland, Ohio, February 13, 1986.
100. Antidepressants. Clinical Update for Physicians, Duke University Medical Center, Durham, North Carolina, February 19, 1986.
101. Preclinical and clinical studies with corticotropin-releasing factor: implications for psychiatric disorders. Academic Conference, McLean Hospital, Belmont, Massachusetts, February 21, 1986.
102. Participant, Symposium on Recent Developments in Neuropeptide Research: Implications for Psychosomatic Medicine, American Psychosomatic Society, Baltimore, Maryland, March 20, 1986.
103. Preclinical and clinical studies with corticotropin-releasing factor: implications for the pathogenesis of psychiatric disorders. Department of Physiology, University of Texas Health Sciences Center, Dallas, Texas, May 2, 1986.
104. Somatostatin and behavior: preclinical and clinical studies. International Congress on Somatostatin, Serono Symposium, Washington, DC, May 7, 1986.

105. Peptide-monoamine interaction: basic and clinical studies. Participant, Symposium on Neurotransmitter-Neuroendocrine Relationships, American Psychiatric Association, Washington, DC, May 12, 1986.
106. Neuropeptides in Alzheimer's disease, Abbott Laboratories, Abbott Park, Illinois, May 21, 1986.
107. Dementia update: practical research applications to clinical practice, The Charlotte Area Health Education Center, Charlotte, North Carolina, May 27, 1986.
108. Interactions of neurotensin with brain dopamine systems, Loyola University Medical Center, Department of Pharmacology, Maywood, Illinois, June 17, 1986.
109. The role of corticotropin-releasing factor in psychiatric disorders: preclinical and clinical studies, University of Chicago Pritzker School of Medicine, Department of Pharmacology and Physiology, Chicago, Illinois, June 18, 1986.
110. Chairman and participant, symposium on Modulation of behavior by peptides/hormones, XXX International Congress of Physiological Sciences, Vancouver, B.C., Canada, July 14, 1986.
111. Preclinical and clinical studies with CRF: Implications in the pathogenesis of depressive disorders, Invited participant, Peptidergic Aminergic Actions and Their Interactions, Satellite Symposium of the XXX International Congress of Physiological Sciences, Pullman, Washington, July 22, 1986.
112. Anxiety and depression and Sleep Disorders, Eleventh Annual Conference of North Carolina Academy of Physician Assistants, Wrightsville Beach, North Carolina, August 23, 1986.
113. Corticotropin-releasing factor: evaluation of its role in affective disorders, Grand Rounds, Emory University School of Medicine, Department of Psychiatry, Atlanta, Georgia, September 3, 1986.
114. Recent advances in the diagnosis and pathophysiology of Alzheimer's disease, Symposium on Practical Approaches to the Geriatric Patient, San Antonio, Texas, October 18, 1986.
115. Psychiatric management of the patient with acute myocardial infarction, First Annual Charlotte Symposium on Cardiovascular Diseases - The Brain and the Heart: Clinical Interrelationships, Charlotte, North Carolina, October 29, 1986.
116. CRH: Evidence for its involvement in psychiatric disorders - from preclinical and clinical studies, NIH Conference on the Mechanisms of Physical and Emotional Stress, Bethesda, Maryland, November 6 - 8, 1986.
117. Interactions of neurotensin with CNS dopamine systems: implications for the pharmacotherapy of schizophrenia, In Society for Neuroscience Symposium on Mechanisms of Neuropeptide Actions on Behavior, Washington, DC, November 13, 1986.
118. The involvement of CRF in the pathophysiology of affective disorders. Grand Rounds, State University of New York - Stony Brook, Department of Psychiatry, Stony Brook, New York, November 25, 1986.

119. Neuroleptic drugs, neurotensin and the mesolimbic dopamine system. In: American College of Neuropsychopharmacology 25th Annual Meeting, Co-chairman and participant in panel on "Recent developments in the regulation of the mesolimbic and mesocortical dopamine systems: basic and clinical implications", Washington, D.C., December 9, 1986.
120. Peptides in schizophrenia. In: American College of Neuropsychopharmacology 25th Annual Meeting Panel on "Biology of schizophrenia", Washington, D.C., December 11, 1986.
121. Chairman and participant, Panel on Recent advances in the neurobiology of corticotropin-releasing factor, Eighth Annual Winter Neuropeptide Conference, Breckenridge, Colorado, January 20, 1987.
122. Banquet address, Neuropeptides in psychiatry: Problems and promises, Eighth Annual Winter Neuropeptide Conference, Breckenridge, Colorado, January 21, 1987.
123. Recent developments in the neurochemistry of Alzheimer's disease: focus on cholinergic and peptidergic systems. First Joseph and Kathleen Bryan Alzheimer's Disease Research Center Conference, Duke University Medical Center, Durham, NC, February 10, 1987.
124. Management of depression. First Joseph and Kathleen Bryan Alzheimer's Disease Research Center Conference, Duke University Medical Center, Durham, NC, February 11, 1987.
125. Anxiety and depression associated with serious illness and disease. North Carolina Academy of Family Physicians Annual Meeting, Research Triangle Park, NC, February 21, 1987.
126. Evidence for hypersecretion of corticotropin-releasing factor (CRF) in depressive disorder. Grand Rounds, Columbia University College of Physicians and Surgeons, Department of Psychiatry, New York, New York, February 27, 1987.
127. Neuropeptide involvement in Alzheimer's disease. Grand Rounds, Cornell Medical Center - New York Hospital, Westchester Division, Department of Psychiatry, White Plains, New York, March 6, 1987.
128. Does hypersecretion of corticotropin-releasing factor produce many of the signs and symptoms of depression? University of California-San Diego, Department of Psychiatry, La Jolla, California, March 9, 1987.
129. Does corticotropin-releasing factor have a role in the pathogenesis of major depression? University of California-San Diego, Department of Neuroscience, La Jolla, California, March 10, 1987.
130. The role of corticotropin-releasing hormone in major depression. Visiting Professor, University of South Florida College of Medicine, Department of Psychiatry, Tampa, Florida, March 20, 1987.
131. Corticotropin-releasing factor and depression. Grand Rounds, Ohio State University, Department of Psychiatry, Columbus, Ohio, April 1, 1987.
132. Preclinical and clinical investigations of corticotropin-releasing factor: assessment of its role in depressive disorders. Symposium on Neuropeptides and Affective Disorders, International Conference on New Directions in Affective Disorders, Jerusalem, Israel, April 7, 1987.

133. Neuropeptides in postmortem human tissue and cerebrospinal fluid: relationship to monoamine systems. New York Academy of Sciences Conference on the Mesocorticolimbic Dopamine System, Miami, Florida, May 5, 1987.
134. Chairman and participant of Symposium, Intelligent Biological Testing in Psychiatry, American Psychiatric Association, 14th Annual Meeting, Chicago, Illinois, May 13, 1987.
135. Abnormal thyroid function in psychiatric patients. Symposium on Psychiatric Uses of Medical Treatments, American Psychiatric Assn., 14th Ann. Meeting, May 13, 1987.
136. Corticotropin-releasing factor and depression. National Institute of Drug Abuse, Baltimore, Maryland, May 21, 1987.
137. The role of corticotropin-releasing factor in depression: preclinical and clinical studies. Grand Rounds, Medical University of South Carolina, Department of Psychiatry, Charleston, South Carolina, May 24, 1987.
138. Behavioral effects of corticotropin-releasing factor. Colloquium on Peptides and Behavior, International Society of Neurochemistry 11th Biennial Meeting / American Society for Neurochemistry 18th Annual Meeting, Caracas, Venezuela, June 5, 1987.
139. The clinical neurobiology of corticotropin-releasing factor. Second World Congress of Neuroscience Satellite Symposium on Peptidergic and Purinergic Neurons, Pecs, Hungary, August 15, 1987.
140. Chairman and participant, Roundtable: Clinical perspectives of neuropeptide research, Second World Congress of Neuroscience, Budapest, Hungary, August 17, 1987.
141. Psychiatric management of the acute myocardial infarction patient. AHEC Conference on the Brain and the Heart, Greensboro, North Carolina, September 9, 1987.
142. Neuroendocrine correlates of mind/body relationships: The role of corticotropin-releasing factor in psychiatric disorders. Grand Rounds, Medical College of Georgia, Department of Psychiatry and Health Behavior, Augusta, Georgia, September 16, 1987.
143. Corticotropin-releasing factor and depression. Eisenhower Army Medical Center, Department of Psychiatry, Augusta, Georgia, September 16, 1987.
144. TRH: preclinical and clinical studies. New York Academy of Sciences Conference on Recent Advances in the Biomedical Significance of Thyrotropin- Releasing Hormone (TRH), Bethesda, Maryland, November 9-11, 1987.
145. Neuropeptides in psychiatric brain disorders. Diseases of the Nervous System Third International High Technology Conference, Columbus, Ohio, November 13, 1987.
146. Studies of neuropeptides in Alzheimer's disease and Huntington's disease. National Conference on Spectrum of Dementing Illnesses, Columbia, South Carolina, November 14, 1987.
147. Neuropeptides. Recent Advances in the Diagnosis and Treatment of Neurological Disorders, New Orleans, Louisiana, November 19, 1987.

148. Recent advances in the biology of Alzheimer's disease: Implications for diagnosis and treatment, Grand Rounds, Highland Hospital, Asheville, North Carolina, December 2, 1987.
149. Preclinical and clinical studies with corticotropin-releasing factor: implications for affective disorders. Chairman and participant, Symposium on Recent Advances in the Psychobiology of Stress, American College of Neuropsychopharmacology, 26th Annual Meeting, San Juan, Puerto Rico, December 9, 1987.
150. Neuropeptides and neuropeptide receptors in post-mortem tissue: fact or artifact? In: Symposium on Receptor Ligand Mismatches, American College of Neuropsychopharmacology, 26th Annual Meeting, San Juan Puerto Rico, December 9, 1987.
151. Sleep disorders. Grand Rounds, William S. Hall Institute, Department of Psychiatry, University of South Carolina School of Medicine, Columbia, South Carolina, January 15, 1988.
152. Chairman, Panel on The physiology and pathophysiology of growth hormone secretion, 21st Winter Conference on Brain Research, Steamboat Springs, Colorado, January 29, 1988.
153. The role of corticotropin-releasing factor in affective disorders. Grand Rounds, East Tennessee State University School of Medicine, Department of Psychiatry, Johnson City, Tennessee, February 6, 1988.
154. Platelet receptor binding studies in psychiatry. Grand Rounds, University of Minnesota School of Medicine, Department of Psychiatry, Minneapolis, Minnesota, February 9, 1988.
155. Preclinical and clinical studies with corticotropin-releasing factor: implications for the pathogenesis of affective disorders. Grand Rounds, University of Arizona School of Medicine, Department of Pharmacology, Tucson, Arizona, February, 18, 1988.
156. Neuropeptides: relevance to psychiatry. University of Wisconsin, Department of Psychiatry, Mt. Sinai Hospital, Milwaukee, Wisconsin, February 25, 1988.
157. "Psychobiology of Adult Depression" and "Neurobiology of Alzheimer's Disease", Wisconsin Psychiatric Association, Annual Scientific Meeting, Madison, Wisconsin, February 26-28, 1988.
158. Recent advances in Alzheimer's disease research. Pinellas County Psychiatric Society, Clearwater, Florida, February 29, 1988.
159. Sleep disorders. Grand Rounds, Department of Medicine, University of South Carolina School of Medicine, Richland Hospital, Columbia, South Carolina, March 11, 1988.
160. The role of corticotropin-releasing factor (CRF) in affective disorders. Nathan Kline Institute, Rockland State Hospital, Orangeburg, New York, April 4, 1988.
161. Invited participant, Genetic Approaches to Schizophrenia, Cold Springs Harbor Laboratory-Banbury Center, Cold Springs Harbor, New York, April 17-20, 1988.
162. The role of corticotropin-releasing factor in depression and Alzheimer's disease. GREC center, UCLA, VA-Sepulveda, Los Angeles, California, May 3, 1988.

163. Stress and the neuropeptide cascade. Society of Biological Psychiatry, 43rd Annual Meeting, Montreal, Canada, May 6, 1988.
164. Chairman and participant, Symposium on Biomedical advances in Alzheimer's disease, 141st Ann. Meeting Amer. Psychiat. Assn., Montreal, Canada, May 8, 1988.
165. The Clinical Biology of CRF. Symposium on Stress, Cortisol, Symptoms and Course in Depression, 141st Ann. Meeting Amer. Psychiat. Assn., Montreal, Canada, May 9, 1988.
166. Chairman and participant, Symposium on Neuropeptides in Psychiatric Disorders, 141st Ann. Meeting Amer. Psychiat. Assn., Montreal, Canada, May 11, 1988.
167. CRF: A Role in the Pathophysiology of Anxiety. Symposium on Recent Clinical/Basic Research in Panic Disorders, 141st Ann. Meeting Amer. Psychiat. Assn., Montreal, Canada, May 12, 1988.
168. The role of corticotropin-releasing factor in depression. Grand Rounds, Department of Psychiatry, East Carolina University School of Medicine, Greenville, North Carolina, May 26, 1988.
169. Corticotropin-releasing factor and affective disorders. Colloquium on Biobehavioral Sciences, Department of Psychiatry, University of California-Los Angeles, Los Angeles, California, June 13, 1988.
170. Corticotropin-releasing factor and depression: preclinical and clinical studies. Grand Rounds, Department of Psychiatry, Harbor-UCLA Medical Center, Torrance, California, June 13, 1988.
171. Chairman and participant, Symposium on Neurochemistry in Psychiatry and Neurology, Present and Future Developments. Use of platelet receptor binding studies in neuropsychiatry. Amer. Assn. Clin. Chem. Ann. Meeting, July 26, 1988.
172. Antidepressant overdose: its epidemiology, pathogenesis and treatment. Grand Rounds, Department of Psychiatry and Behavioral Sciences, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, August 5, 1988.
173. The role of corticotropin-releasing factor (CRF) in the pathogenesis of depression. Symposium on Biological Markers of Affective Disorders -- Impact of Basic Neuroendocrine and Sleep Research. 16th Congress of Collegium Internationale Neuro-Psychopharmacologicum, August 18, 1988.
174. Co-chairman and participant, Symposium on Clinical Aspects of Neuropeptide Research. 16th Congress of Collegium Internationale Neuro-Psychopharmacologicum, August 18, 1988.
175. The role of corticotropin-releasing factor in depression. Grand Rounds, Department of Psychiatry, Mercer University School of Medicine, Macon, Georgia, August 24, 1988.
176. Basic and clinical studies with corticotropin-releasing factor. Department of Basic Science, Mercer University School of Medicine, Macon, Georgia, August 25, 1988.
177. The role of corticotropin-releasing factor in affective disorders. Maryland Psychiatric Research Institute, Baltimore, Maryland, August 29, 1988.

178. The role of corticotropin-releasing factor in mood disorders. Grand Rounds, Department of Psychiatry, New York University School of Medicine, New York, New York, September 8, 1988.
179. Age-related changes in neuroendocrine stress response: focus on the pituitary-adrenal axis. Seventh Ann. Symposium on Geriatrics and Gerontology: Endocrine Function and Aging, St. Louis, Missouri, September 15, 1988.
180. Platelet receptor binding studies in psychiatry. Research Seminar, Department of Psychiatry, University of Iowa College of Medicine, Iowa City, Iowa, September 26, 1988.
181. The role of corticotropin-releasing factor in depression. Grand Rounds, Department of Psychiatry, University of Iowa College of Medicine, Iowa City, Iowa, September 27, 1988.
182. The differential diagnosis and treatment of anxiety disorders. Grand Rounds, Department of Psychiatry, University of Illinois School of Medicine, Illinois State Psychiatric Institute, Chicago, Illinois, September 29, 1988.
183. Invited Discussant, McLean Hospital Symposium on Benzodiazepines, Boston, Massachusetts, September 29-October 1, 1988.
184. The role of corticotropin-releasing factor in depressive disorders. Grand Rounds, Department of Psychiatry, University of Rochester, College of Medicine and Dentistry, Rochester, New York, October 5, 1988.
185. Interactions of neurotensin with brain dopamine systems. Neuroscience Seminar, Department of Physiology, McGill University, Montreal, Quebec, Canada, October 6, 1988.
186. Recent advances in the psychopharmacologic treatment of affective disorders. Southeastern Symposium in Clinical Psychiatry, Atlanta, Georgia, October 15, 1988.
187. Recent advances in the biology of affective disorders: the role of corticotropin-releasing factor in depression. Grand Rounds, Department of Psychiatry, Albany Medical College, Albany, New York, October 19, 1988.
188. Clinical significance of psychoneuroendocrinology in psychiatry. Symposium on: Interrelationship between Depression, The Immune System and the Endocrine System. Charleston, South Carolina, October 22, 1988.
189. Recent advances in the biology and treatment of depression. Mental Health Association of Alabama Annual Scientific Symposium. Birmingham, Alabama, October 27, 1988.
190. Is corticotropin-releasing factor the elusive black bile that causes depression? Grand Rounds, Department of Psychiatry, University of Alabama School of Medicine, Birmingham, Alabama, October 28, 1988.
191. The role of corticotropin-releasing factor in the pathogenesis of depression. Grand Rounds, Department of Psychiatry, University of Washington School of Medicine, Seattle, Washington, November 3, 1988.

192. Corticotropin-releasing factor and the pathogenesis of depression. Grand Rounds, Department of Psychiatry, The Johns Hopkins University School of Medicine, Baltimore, Maryland, November 7, 1988.
193. Corticotropin-releasing factor and depression. Department of Pharmacology, University of Florida College of Medicine, Gainesville, Florida, November 9, 1988.
194. The synaptic chemistry of schizophrenia. Symposium on the Neurobiology of Schizophrenia. Society for Neuroscience, Toronto, Canada, November 13, 1988.
195. The role of neuropeptides in psychiatry. Grand Rounds, Shepperd and Enoch Pratt Hospital, Baltimore, Maryland, November 24, 1988.
196. An overview of basic neuroendocrinology. Fourth Annual Meeting on the Biology of Sleep, Palm Springs, California, November 30-December 1, 1988.
197. Stress, corticotropin-releasing factor (CRF) and the locus coeruleus. Panel on Neuroendocrine and Immune Relationships. 27th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 13, 1988.
198. Corticotropin-releasing factor and affective disorder. Grand Rounds, Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, January 10, 1989.
199. Neurotensin, an endogenous peptide and schizophrenia. Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, January 11, 1989.
200. Differential diagnosis and treatment of anxiety disorders. Grand Rounds, VA Medical Center, Columbia, South Carolina, January 12, 1989.
201. Recent advances in the treatment of affective disorders. Grand Rounds, Dorothea Dix Hospital, Raleigh, North Carolina, January 19, 1989.
202. Recent advances in the neurobiology of affective disorders. Grand Rounds, Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, North Carolina, January 19, 1989.
203. Neurotensin-dopamine interactions: an update. Research Seminar, Scripps Institute and Clinic, La Jolla, California, January 24, 1989.
204. Workshop participant, Pharmacologic Treatment of Personality Disorders, American College of Psychiatrists, Monterey, California, February 2, 1989.
205. Recent advances in the treatment of affective disorders. Grand Rounds, Department of Psychiatry, University of South Florida School of Medicine, Tampa, Florida, February 10, 1989.
206. Participant, McArthur Foundation Workshop on Stress and Depression, Scripps Clinic and Research Foundation, La Jolla, California, February 20-22, 1989.
207. Recent advances in the treatment of affective disorders. Richmond Psychiatric Society, Richmond, Virginia, March 2, 1989.

208. The role of corticotropin-releasing factor in the pathogenesis of depression. Grand Rounds, Department of Psychiatry, Medical College of Virginia, Richmond, Virginia, March 3, 1989.
209. Corticotropin-releasing factor and affective disorder. Grand Rounds, Department of Psychiatry, State University of New York at Buffalo, School of Medicine, Buffalo, New York, March 17, 1989.
210. The role of corticotropin-releasing factor in the pathogenesis of depression. Grand Rounds, Department of Psychiatry, New York Hospital - Cornell Medical Center, Westchester Division, White Plains, New York, March 24, 1989.
211. Neurotensin, dopamine and schizophrenia. Grand Rounds, Allen Memorial Hospital - Royal Victoria Hospital, Montreal, Quebec, Canada, March 30, 1989.
212. Corticotropin-releasing hormone: basic and clinical studies. Center for Behavioral Biology, Concordia University, Montreal, Quebec, Canada, March 30, 1989.
213. The role of corticotropin-releasing factor in the pathogenesis of depression. Grand Rounds, Montreal General Hospital, Montreal, Quebec, Canada, March 31, 1989.
214. Neuropeptides in schizophrenia. International Congress on Schizophrenia Research. San Diego, California, April 4, 1989.
215. Recent advances in the biological treatment of depression. Research Symposium, Alliance for the Mentally Ill of Illinois, Springfield, Illinois, April 7, 1989.
216. The role of corticotropin-releasing factor in the pathogenesis of depression. Grand Rounds, Department of Psychiatry, Baylor College of Medicine, Houston, Texas, April 12, 1989.
217. The role of corticotropin-releasing factor in depression. Visiting Professor, Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, April 13, 1989.
218. Laboratory assessment of depression: a 1990's perspective. Northern California Psychiatric Society, Asilomar, California, April 16, 1989.
219. Use of hypothalamic peptides in diagnosis and treatment of psychiatric disorders. Serono Laboratories, Norwell, Massachusetts, April 17, 1989.
220. Comorbidity of stress and depression: potential role of corticotropin-releasing factor as a mediator of both anxiety and depression. Seventh Annual Missouri Conference on Depression: Comorbidity, St. Louis, Missouri, April 19, 1989.
221. Impact of peptide research in psychiatry. Symposium on Peptides as Targets for Drug Research, Mid-Atlantic Pharmacology Society, Piscataway, New Jersey, April 20, 1989.
222. Chairman and participant, Symposium on Neurochemistry of Neurological and Psychiatric Disorders, International Society of Neurochemistry, Algarve, Portugal, April 27, 1989.
223. Differential diagnosis of anxiety: implications for drug treatment. Indiana Council of Mental Health, Evansville, Indiana, May 3, 1989.

224. Participant, Symposium on New Horizons in Psychiatric Research. New horizons for depression associated with medical illness. American Psychiatric Association 142nd Annual Meeting, San Francisco, California, May 9, 1989.
225. The role of corticotropin-releasing factor in the pathogenesis of depression. Department of Pharmacology, Medical College of Pennsylvania, Philadelphia, Pennsylvania, May 15, 1989.
226. Alteration of Neuropeptides in Psychiatric and Neurological Disorders. The Kennedy Institute, John Hopkins University, Baltimore, Maryland, May 19, 1989.
227. Basic studies relevant to the Neurobiology of Manic-Depressive Illness. Update on Manic-Depressive Illness, Duke University Medical Center, Durham North Carolina, May 19, 1989.
228. Clinical Advances in the Neurochemistry of Manic-Depressive Illness. Update on Manic-Depressive Illness, Duke University Medical Center, Durham, North Carolina, May 20, 1989.
229. Platelet receptor binding studies in psychiatry. Grand Rounds, University of Michigan, Department of Psychiatry, Ann Arbor, Michigan, May 24, 1989.
230. The role of corticotropin-releasing factor (CRF) in anxiety and affective disorders: preclinical and clinical studies. University of Michigan, Department of Psychiatry, Ann Arbor, Michigan, May 24, 1989.
231. Basic and clinical studies with corticotropin-releasing factor. University of Virginia, Biodynamics Institute, Charlottesville, Virginia, May 26, 1989.
232. Corticotropin-releasing factor: preclinical and clinical studies. Grass Foundation Traveling Scientist, Society for Neuroscience, Shreveport, Louisiana, May 30, 1989.
233. Neurotensin, dopamine, schizophrenia and sigma receptors. Sterling Drug Company, Rensselaer, New York, June 5, 1989.
234. Psychopharmacological management of treatment-resistant depression. Northbrooke Hospital, Brown Deer, Wisconsin, August 9, 1989.
235. Stress, corticotropin-releasing factor and the pathogenesis of psychiatric disorders. Department of Pharmacology, Washington State University, Pullman, Washington, August 16, 1989.
236. Psychopharmacologic treatment of depression. 19th Brazilian Congress of Psychiatry, Sao Paulo, Brazil, September 7, 1989.
237. Chronic stress and the psychopathology of affected disorders. Symposium on Stress, Biological Rhythms and Psychiatric Disorders. Amsterdam, The Netherlands, September 14, 1989.
238. Neurotensin, dopamine and schizophrenia: a ten year sojourn Grand Rounds, Duke University Medical Center, Department of Psychiatry, Durham, North Carolina, September 21, 1989.
239. Central nervous system effects of corticotropin-releasing factor. Department of Psychiatry, University of Mainz, Mainz, West Germany, September 28, 1989.

240. Neurochemical and behavioral effects of CRH administration in animals and humans. Third Freiburg Psychiatric Symposium on basic and clinical strategies in Neuroendocrine Research, Titisee, Federal Republic of Germany, September 29, 1989.
241. Corticotropin-releasing factor and depression. Symposium on the Neurobiology of Stress. British Association of Psychopharmacology. The Royal Society, London, England, October 20, 1989.
242. Current approaches to the biology and treatment of schizophrenia: focus on neuropeptides. Organon International, Oss, The Netherlands, October 24, 1989.
243. Biochemistry of depression. Fourth Annual Neurological Disorders Conference. Communitech Market Intelligence. Phoenix, Arizona, October 30, 1989.
244. Chairman and participant symposium: Recent advances in the biology of affective disorders. Society for Neuroscience 19th Annual Meeting, Phoenix, Arizona, November 2, 1989.
245. Biological Markers in depression. Symposium on Concepts in Depression for the 90's. Orlando, Florida November 4, 1989.
246. The neurobiology of normal aging and dementia. Dorothea Dix Hospital, Raleigh, North Carolina, November 8, 1989.
247. Recent advances in the neurobiology of Alzheimer's disease: implications for treatment. Sixth Annual Alzheimer's Disease Symposium, Knoxville, Tennessee, November 9, 1989.
248. The role of corticotropin-releasing factor in the pathogenesis of anxiety and depression. G.D. Searle and Co., Skokie, Illinois, November 28, 1989.
249. The role of corticotropin-releasing factor in anxiety and depressive disorders. Grand Rounds, Department of Mental Health Sciences, Hahnemann University, Philadelphia, Pennsylvania, November 30, 1989.
250. Invited participant, McArthur Foundation meeting on "Patterns of neuroendocrine response to challenge." Mt. Sinai School of Medicine, New York, New York, December 1, 1989.
251. Differential diagnosis and management of patients with dementia. North Carolina Academy of Family Physicians, Raleigh, North Carolina, December 2, 1989.
252. Chairman and participant, The adrenal gland in clinical psychiatry, 28th Annual Meeting of the American College of Neuropsychopharmacology, Maui, Hawaii, December 12, 1989.
253. Participant, panel on Afferent Regulation of Midbrain dopamine neurons, 28th Annual Meeting of the American College of Neuropsychopharmacology, Maui, Hawaii, December 13, 1989.
254. Corticotropin-releasing factor: a neuropeptide and its role in depression. Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, January 10, 1990.

255. The hypothalamic-pituitary-adrenal axis and its role in affective disorders. Grand Rounds, Department of Psychiatry, University of Kansas-Wichita, School of Medicine, Wichita, Kansas, February 1, 1990.
256. Chairman and participant, panel on Neuropeptides and Psychiatry 1990, Neuropeptides in schizophrenia, Eleventh Annual Winter Neuropeptide Conference, Breckenridge, Colorado, February 9, 1990.
257. Neurotransmitter regulation of CRF secretion, Eleventh Annual Winter Neuropeptide Conference, Breckenridge, Colorado, February 9, 1990.
258. The role of corticotropin-releasing factor in stress and depression. Massachusetts Institute of Technology, Cambridge, Massachusetts, February 12, 1990.
259. The adrenal and thyroid axes in psychiatric disorders: an overview. The American College of Psychiatrists, Palm Springs, California, February 17, 1990.
260. Corticotropin-releasing factor, stress and depression. Psychopharmacology lecture series, Massachusetts Mental Health Center, Harvard Medical School, Boston, Massachusetts, March 2, 1990.
261. Use and abuse of benzodiazepines: What are the facts? Sixteenth Annual Symposium on Psychopharmacology, University of Louisville, Louisville, Kentucky, March 15, 1990.
262. Neuropeptides in affective disorders. Grand Rounds. St. Johns Mercy Hospital, St. Louis, Missouri, March 29, 1990.
263. Corticotropin-releasing factor in depression. Academic Grand Rounds. Department of Psychiatry, Southern Illinois University School of Medicine, Springfield, Illinois, April 3, 1990.
264. Neuropeptides, antipsychotic drugs and schizophrenia. Visiting Professor of Neuroscience and Psychiatry, John Hopkins University School of Medicine, Baltimore, Maryland, April 5, 1990.
265. Pharmacological Management of treatment-resistant depression. Regional APA symposium, San Juan, Puerto Rico, April 7, 1990.
266. New neuroendocrine findings in affective disorders. Fourth Annual Mood Disorders Symposium. John Hopkins University School of Medicine, Baltimore, Maryland, April 11, 1990.
267. The diagnosis and treatment of anxiety. Missouri Institute of Psychiatry 22nd Annual Visiting Speaker Series, St. Louis, Missouri, April 20, 1990.
268. Neurobiology of affective disorders. Advances in Neurobiology and Diagnosis and Management of Psychiatric Disorders: An update. Sinai Hospital of Baltimore, Baltimore, Maryland, April 28, 1990.
269. Evidence for a role for corticotropin-releasing factor in the pathogenesis of anxiety disorders and in the actions of triazolobenzodiazepines. Panic and Anxiety: A Decade of Progress. Geneva, Switzerland, June 22, 1990.

270. Distinguished lecturer in Psychiatry, The Neurobiology of Anxiety, University of Tennessee Medical Center at Knoxville, Department of Medicine Grand Rounds, July 17, 1990.
271. Invited participant. Research in the 90's, National Alliance for the Mentally Ill, Tenth Annual Meeting, July 21, 1990.
272. Pituitary-adrenal hyperactivity in depression: implications for the development of novel treatments. Grand Rounds, Fair Oaks Hospital, Summit, New Jersey, July 25, 1990.
273. Controversies concerning the chronic use of benzodiazepines, Grand Rounds, Louisiana State University School of Medicine, Department of Psychiatry, New Orleans, Louisiana, July 26, 1990.
274. Co-chairman and participant, Symposium on Neuropeptides, Corticotropin- releasing hormone, mood and behavior: basic and clinical studies. XXI Int. Cong. Soc. Psychoneuroendocrinology, Buffalo, New York, August 23, 1990.
275. Depressive disease and neuroendocrine findings, Grand Rounds, University of Arkansas, Department of Psychiatry, Little Rock, Arkansas, September 21, 1990.
276. Anxiety disorders. American Suicide Foundation, Eastern Division, New York, New York, October 11, 1990.
277. Biological markers of mental disease: a special focus on CRF. Brain, Behavior and Biology: The Interface, Minnesota Psychiatric Society, October 12, 1990.
278. Recent advances in neurobiology and their application to diagnosis and treatment of affective disorders. North Carolina Psychiatric Ass'n Annual Meeting, Asheville, North Carolina, October, 26, 1990.
279. Augmentation regimens. The Changing Horizon in the Treatment of Depression and Related Disorders, Chantilly, Virginia, November 10, 1990.
280. The CRF theory of depression, Grand Rounds, University of West Virginia School of Medicine, Department of Psychiatry, Morgantown, West Virginia, November 14, 1990.
281. Interactions of neurotensin and brain dopamine systems. University of West Virginia, Department of Pharmacology, Morgantown, West Virginia, November 14, 1990.
282. Serotonergic mechanisms in mood disorders. The Challenge of Major Depression. Washington, D.C., November 17, 1990.
283. The Role of Corticotropin-releasing factor (CRF) in the pathophysiology of affective disorder: preclinical and clinical studies. Beverly lecture. Clarke Institute of Psychiatry, University of Toronto, Toronto, Canada. November 28, 1990.
284. The psychobiologic workup of the depressed older adult: Depression in later life: new diagnostic and treatment findings. Duke University Medical Center, December 1, 1990.
285. New findings on the biological basis of stress. Mind and Disease: an integrative approach. Fairfax Hospital, Fairfax, Virginia, December 4, 1990.

286. Neuropeptide alterations in major depression: state or trait markers? Panel on The Clinical Course of Depression: can State Versus Trait Variables be Untangled? 29th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 11, 1990.
287. Co-chairman and participant, Panel on Meeting the Future. New vistas in neuropeptide research in neuropsychiatry. 29th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 12, 1990.
288. Co-chairman and participant, Panel on Advances in Geriatric Depression: Platelet measures of serotonergic function in depressed patients. 29th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 13, 1990.
289. Platelet receptor binding in depression, Grand Rounds, Department of Psychiatry, East Carolina University School of Medicine, Greenville, North Carolina, January 3, 1991.
290. The hypothalamic-pituitary-adrenal axis and depression: clinical and preclinical studies. Grand Rounds, Department of Psychiatry, Emory University School of Medicine, Atlanta, Georgia, January 8, 1991.
291. Side effects of anti-manic medications. Summit Conference on the Treatment of Bipolar Disorder. Snowmass Village Colorado, January 26, 1991.
292. Participant, Specialized Panel on "The Neurobiology of Stress and Anxiety Disorders: New Evidence for an Interaction between Corticotropin-Releasing Factor and Norepinephrine in the Central Nervous System. 24th Annual Winter Conference on Brain Research, Vail, Colorado, January 28, 1991.
293. Invited participant, Sixth Meeting of the International Study Group on the Pharmacology of Memory Disorders Associated with Aging, Zurich, Switzerland, February 15-17, 1991.
294. The neurobiologic basis of anxiety disorders. Update on Anxiety Disorders for the Primary Care Physician. University of North Carolina School of Medicine, Chapel Hill, North Carolina, March 1, 1991.
295. Psychopharmacology for the elderly patient. Polypharmacy in the Elderly. VA Symposium, Durham, North Carolina, March 6, 1991.
296. How to prepare a research grant. Panel: Meet the Investigators. Association for Academic Psychiatry, Tampa, Florida, March 9, 1991.
297. Management of treatment-resistant depression. Alberta Psychiatric Associates, Banff, Alberta, Canada, March 16, 1991.
298. Corticotropin-releasing factor and depression. Howard Rome lecturer, Grand Rounds, Mayo Clinic, Department of Psychiatry, Rochester, Minnesota, March 26, 1991.
299. The role of corticotropin-releasing factor in depression. Grand Rounds, Department of Psychiatry, Chicago Medical School, North Chicago, Illinois, March 28, 1991.

300. CRF as a probe in psychiatry. Advances in Psychopharmacology and Behavioral Neurobiology, Massachusetts General Hospital, Boston, Massachusetts, March 29, 1991.
301. Use of anticonvulsants in the treatment of manic-depressive illness. Grand Rounds, St. Vincent's Hospital, Harrison, New York, April 4, 1991.
302. The role of corticotropin-releasing factor in depression. DuPont Merck Pharmaceuticals, Wilmington, Delaware, April 8, 1991.
303. Corticotropin-releasing factor and depression. Grand Rounds, Department of Psychiatry, University of California - San Francisco, San Francisco, California, April 10, 1991.
304. Keynote address, Southern Association for Research in Psychiatry, "How I came to do what I am doing," Tampa, Florida, April 26, 1991.
305. Managing the depressive component in bipolar disorder. Practical Clinical Guidelines for the Management of Bipolar Disorder, Scottsdale, Arizona, April 27, 1991.
306. Problems in clinical practice with bipolar disorder. A paradigm for the treatment of bipolar disorder. American Psychiatric Association, New Orleans, Louisiana, May 12, 1991.
307. The role of corticotropin-releasing factor in the pathophysiology of affective and anxiety disorders. Grand Rounds, Department of Psychiatry, Mt. Sinai School of Medicine, New York, New York, May 21, 1991.
308. Neuroendocrine alterations in depression. The Donald H. Nelson Lecture. University of Missouri-Columbia, Columbia, Missouri, May 22, 1991.
309. Is corticotropin-releasing factor (CRF) the black bile of melancholia? The 21st Roy R. Grinker, Sr. Visiting Professor Lecture. Department of Psychiatry, Michael Reese Hospital, Chicago, Illinois, May 28, 1991.
310. Recent advances in the treatment of bipolar disorders. Grand Rounds, Department of Psychiatry, Michigan State University, E. Lansing, Michigan, August 14, 1991.
311. Advances in the diagnosis and treatment of bipolar disorder. Grand Rounds, Department of Psychiatry, Tulane University School of Medicine, New Orleans, Louisiana, August 30, 1991.
312. The role for corticotropin-releasing factor in the pathogenesis of depression. Grand Rounds, Department of Psychiatry, Cornell University Medical College, Payne-Whitney Clinic, New York, New York, September 4, 1991.
313. Recent advances in the neurobiology of Alzheimer's disease. Grand Rounds, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, September 12, 1991.
314. Depression in medical illness vs primary depression: biological considerations. NIMH Research Workshop on Comorbidity of Medical and Mental Illnesses. Chevy Chase, Maryland, September 25, 1991.

315. Neuropeptide alterations in Alzheimer's disease: beyond neuroendocrinology. National Institute on Aging workshop on "Neuroendocrinology and Aging: Perspectives and prospectives". Airlie, Virginia, October 10, 1991.
316. Management of treatment-resistant depression. Symposium on management of depression. The North Carolina Psychiatric Association Annual Meeting, Atlantic Beach, North Carolina, October 19, 1991.
317. The role of corticotropin-releasing factor in the pathogenesis of depression: laboratory and clinical investigation. Neurobiology of Affective Disorders, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, October 26, 1991.
318. The biology of depression. New Vistas in the diagnosis and treatment of depression. Atlanta, Georgia, November 16, 1991.
319. Management of treatment-resistant depression. U.S. Psychiatric Congress. New York, New York, November 22, 1991.
320. Diagnosis of bipolar disorder. U.S. Psychiatric Congress, New York, New York, November 23, 1991.
321. The role of corticotropin-releasing factor in depression. Grand Rounds, Department of Psychiatry, Wright State University School of Medicine, Dayton, Ohio, November 26, 1991.
322. The effects of antipsychotic drugs on regional CNS concentrations of neurotensin and neurotensin mRNA levels. In: Role of neuropeptides and receptor-coupled signal transduction pathways in psychotropic drug action and stress. Proc. 30th Annual Meeting of the Amer. Coll. of Neuropsychopharmacology, San Juan, Puerto Rico, December 10, 1991.
323. Chairman and participant, The Thyroid Axis, The Brain and Psychiatric Disorders. American College of Neuropsychopharmacology. 30th Annual Meeting, San Juan Puerto Rico, December 13, 1991.
324. Brain imaging and neurochemical studies in Parkinson's disease and major depression: focus on magnetic resonance imaging and neuropeptide alterations. Psychobiology of Parkinson's Disease Satellite Meeting, American College of Neuropsychopharmacology 30th Annual Meeting, San Juan, Puerto Rico, December 14, 1991.
325. The role of corticotropin-releasing factor in the pathophysiology of depression: preclinical and clinical studies. Grand Rounds, Department of Psychiatry, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, December 18, 1991.
326. The psychoneuroendocrinology of depression. Grand Rounds, Department of Psychiatry, University of Texas School of Medicine at Houston, Houston, Texas, January 15, 1992.
327. Diagnosis and treatment of bipolar disorder. Western Pennsylvania Psychiatric Association, Pittsburgh, Pennsylvania, January 20, 1992.
328. Diagnosis and treatment of manic depressive illness. Grand Rounds, Department of Psychiatry, Henry Ford Hospital, Detroit, Michigan, January 23, 1992.

329. Management of treatment-resistant depression. Grand Rounds, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, January 24, 1992.
330. Chairman and participant, Symposium on serotonin and its relation to psychiatric diseases. San Francisco, California, February 11, 1992.
331. Co-Chairman and participant, Bipolar Disorder: current progress and future directions in diagnosis and management. Snowbird, Utah, February 17-19, 1992.
332. Neurotensin-dopamine interactions: neurochemical, neuropharmacological and behavioral studies. Department of Anatomy and Cell Biology, Emory University School of Medicine, Atlanta, Georgia, February 26, 1992.
333. The role of corticotropin-releasing factor in the pathophysiology of affective disorders: laboratory and clinical studies. CIBA Foundation Symposium on Corticotropin-releasing Factor. London, England, March 10-12, 1992.
334. Non-dopaminergic mechanisms of antipsychotic drug action. Symposium on Antipsychotic Drugs, International Academy of Biomedical Research, Monte Carlo, Monaco. March 16-18, 1992.
335. Chairman and participant, Symposium: Innovations in the treatment of depression: the biology of depression. Atlanta, Georgia, March 21, 1992.
336. The hypothalamic-pituitary-adrenal axis in depression: an update. Research Seminar, Department of Psychiatry, University of Iowa College of Medicine, Iowa City, Iowa, March 23, 1992.
337. Management of treatment-resistant depression. Grand Rounds, Department of Psychiatry, University of Iowa College of Medicine, Iowa City, Iowa, March 24, 1992.
338. Diagnosis and treatment of anxiety disorders. Grand Rounds, Department of Psychiatry, Baptist Hospital, Nashville, Tennessee, March 30, 1992.
339. Neuroendocrine and receptor mechanisms in anxiety and depression: clinical implications. Grand Rounds, Department of Psychiatry, Vanderbilt University, Nashville, Tennessee, March 31, 1992.
340. The role of corticotropin-releasing factor in the pathogenesis of major depression: preclinical and clinical studies. Visiting Scholar Program, Department of Psychiatry, University of Vermont, Burlington, VT, April 10, 1992.
341. Neurochemical hypotheses for subtyping of schizophrenia. In: Novel antipsychotic agents: the search for safe and effective first-line therapy. American Psychiatric Association 145th Annual Meeting, Washington, DC, May 2, 1992.
342. The biology of bipolar disorder. In: Bipolar Disorder: current progress and future directions in diagnosis and management. American Psychiatric Association 145th Annual meeting, Washington, DC, May 3, 1992.

343. Differentiating organic/medical factors in mood disorders. Symposium on research advances in psychiatry: an update for the clinician. American Psychiatric Association 145th Annual meeting, Washington, DC, May 4, 1992.
344. Chairman and participant, Symposium on Serotonin and psychiatric disorders: New Vistas. The Serotonin Uptake Site. American Psychiatric Association 145th Annual meeting, Washington, DC, May 5, 1992.
345. The role of corticotropin-releasing factor in the pathophysiology of major depression. Grand Rounds, Department of Psychiatry, University of Louisville, Louisville, Kentucky, April 22, 1992.
346. The role of neuropeptides in depression. Growth factors, peptides and receptors '92, XII Washington International Spring Symposium, Washington, DC, June 2, 1992.
347. The role of neuropeptides in the pathophysiology of affective disorders. Plenary lecture, XVIII Collegium Internationale Neuro-Psychopharmacologicum, Nice, France, July 2, 1992.
348. Chairman and participant, Symposium on Biology of Neuropeptides. Somatostatin: a neuropeptide system pathologically altered in Alzheimer's disease and depression. XVIII Collegium Internationale Neuro-Psychopharmacologicum, Nice, France, June 30, 1992.
349. Chairman and participant, Symposium on Neurobiology of Serotonin. The presynaptic serotonin uptake site in depression. XVIII Collegium Internationale Neuro-Psychopharmacologicum, Nice, France, July 1, 1992.
350. CRF and depression, Symposium on Neuropeptides in Stress, Anxiety and Depression: Basic and Clinical Aspects. Brit. Assn. Psychopharmacology/European Behavioral Pharmacol. Society Joint meeting, Cambridge, England, August 7, 1992.
351. CRF and depression. Symposium on neuropeptides in stress, anxiety and depression: basic and clinical aspects. Brit. Assn. Psychopharmacology/European Behavioral Pharmacol. Society Joint Meeting, Cambridge, England, August 7, 1992.
352. The role of CRF in depression. XXIII Annual Meeting of the Int. Soc. Psychoneuroendocrinology, Madison, Wisconsin, August 17, 1992.
353. The neurobiology of anxiety. Grand Rounds, Department of Psychiatry, Walter Reed Army Hospital, Washington, DC, September 3, 1992.
354. Invited participant, NIMH workshop, Candidate gene approaches to bipolar disorder. Peptide and neuroendocrine candidates. Rockville, Maryland, September 8, 1992.
355. Invited participant, NIMH Research Workshop, Assessment of Psychopathology in Physical Illness. Depression in pancreatic cancer. Chevy Chase, Maryland, September 22, 1992.
356. Co-chairman and participant, Bipolar Disorder: Current progress and future directions in diagnosis and management, "The Biology of Bipolar Illness". Amelia Island, Florida, September 27-30, 1992.

357. The role of serotonergic systems in the pathophysiology of depression. Grand Rounds, Department of Psychiatry, Medical College of Wisconsin, Milwaukee, Wisconsin, October 14, 1992.
358. Serotonergic antagonists as antipsychotics. European College of Neuropsychopharmacology, Marbella, Spain, October 18-21, 1992.
359. Diagnosis and treatment of bipolar disorder. Grand Rounds, Department of Psychiatry, Louisiana State University School of Medicine, Shreveport, Louisiana, November 6, 1992.
360. Recent advances in the treatment of bipolar disorder. Grand Rounds, Department of Psychiatry, Eastern Virginia Medical School, Norfolk, Virginia, November 12, 1992.
361. Co-chairman and participant, Panel on biological predictors of antidepressant drug response. 31st Annual meeting of the Amer. College of Neuropsychopharmacology. San Juan, Puerto Rico, December 18, 1992.
362. Clinical case conference co-chair, Panic disorder: pharmacologic and psychotherapeutic strategies. American College of Psychiatrists Annual Meeting, Naples, Florida, February 19, 1993.
363. Depression in the medically ill: diagnostic, biological and treatment considerations. UCLA Colloquium in Biobehavioral Sciences, Los Angeles, California, March 15, 1993.
364. Diagnosis and treatment of depression in the medically ill. Grand Rounds, Department of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, March 23, 1993.
365. Biology and treatment of bipolar disorder. Grand Rounds, Department of Psychiatry, University of Alabama School of Medicine, Birmingham, Alabama, April 6, 1993.
366. Diagnosis and treatment of bipolar disorder. Grand Rounds, Department of Psychiatry, University of Kentucky School of Medicine, Lexington, Kentucky, April 18, 1993.
367. Is corticotropin-releasing factor the black bile of melancholia? Further studies of hypothalamic-pituitary-adrenal axis dysregulation in depression. Ninth Annual Edward J. Sachar Award lecture, Columbia University College of Physicians and Surgeons, New York, New York, May 7, 1993.
368. Hypothalamic-pituitary-adrenal axis dysfunction in depression. Grand Rounds, Department of Psychiatry, Medical College of Georgia, Augusta, Georgia, May 13, 1993.
369. The role of CRF in depression. Canadian College of Neuropsychopharmacology, 16th Annual meeting, Montreal, Canada, May 31, 1993.
370. Corticotropin-releasing factor antagonists as potential anxiolytics and antidepressants. In: Symposium on Strategies for the Development of Neuropeptide-based Therapeutics. Summer Neuropeptide Conference 1993, Martha's Vineyard, Massachusetts, June 24, 1993.
371. The role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. In: The Decade of the Brain: Recent developments in the neurochemistry of

- depression, mania and other mood disorders. National Academy of Clinical Biochemistry 17th Annual Meeting, New York, NY, July 10, 1993.
372. The role of CRF in the pathophysiology of depression. Society for Drug Research, Cambridge, England, July 15, 1993.
 373. CRF and Depression. University of Cambridge, Department of Psychiatry, Addenbrooke's Hospital, Cambridge, England, July 15, 1993.
 374. Invited participant, Consensus Conference on Classic and Newer Antidepressants, Saint Tropez, France, September 4-5, 1993.
 375. The role of CRF in the pathophysiology of depression: preclinical and clinical studies. First Int. Congress on Hormones, Brain and Neuropsychopharmacology. Rhodes, Greece, September 14, 1993.
 376. Cancer and depression: diagnostic and biologic measures. First Int. Congress on Hormones, Brain and Neuropsychopharmacology. Rhodes, Greece, September 17, 1993.
 377. Depression: an age-related disease. Int Soc Psychoneuroendocrinology, 24th Annual Meeting, Taormina, Sicily, September 23, 1993.
 378. Biology and treatment of schizophrenia and other psychoses. Florida Psychiatric Society Annual Meeting. Orlando, Florida, October 16, 1993.
 379. Diagnosis and treatment of depression in the medically ill. Grand Rounds, Department of Psychiatry and Human Behavior, University of Mississippi School of Medicine, Jackson, Mississippi, November 30, 1993.
 380. Peptides and affective disorders. Association for Research in Nervous and Mental Disease, 73rd Annual Meeting, New York, New York, December 3, 1993.
 381. Co-chairman and participant, panel on molecular regulation of central corticotropin-releasing hormone. Regulation of CRF in the Locus Coeruleus: Behavioral and Pharmacological Manipulations. 32nd Annual Meeting of the American College of Neuropsychopharmacology, Honolulu, Hawaii, December 14, 1993.
 382. Is corticotropin-releasing factor the black bile of melancholia? Further studies of HPA axis dysregulation in depression. Grand Rounds, Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, North Carolina, January 20, 1994.
 383. New strategies for treatment resistant depression. Clinical psychopharmacology: an update. Stanford University School of Medicine, Stanford, California, January 22, 1994.
 384. Diagnosis and treatment of bipolar disorder. Grand Rounds, Department of Psychiatry, Beth Israel Hospital, New York, New York, February 3, 1994.
 385. The effect of typical and atypical antipsychotic drugs on neurotensin-containing neurons in the central nervous system. Second International Conference on Clozapine, Garden City, New York, February 25, 1994.

386. Depression and endocrine disorders: focus on the thyroid and adrenal. Second International Conference on Mood Disorders, Paris, France, March 12, 1994.
387. Diagnosis and treatment of bipolar disorder. Grand Rounds, Department of Psychiatry, University of Tennessee School of Medicine, Memphis, Tennessee, March 19, 1994.
388. Is corticotropin-releasing factor the black bile of melancholia? Further studies of the hypothalamic-pituitary-adrenal axis dysregulation in depression. Grand Rounds, Department of Psychiatry, University of Rochester School of Medicine, Rochester, New York, March 30, 1994.
389. Management of treatment-refractory depression. Grand Rounds, Department of Psychiatry, New York Medical College, Valhalla, New York, March 31, 1994.
390. Is CRF the black bile of melancholia: further studies of HPA axis dysregulation in depression. Grand Rounds, Department of Psychiatry, University of Oregon Health Sciences Center, Portland, Oregon, April 5, 1994.
391. Is CRF the black bile of melancholia: further studies of HPA axis dysregulation in depression. Grand Rounds, Department of Psychiatry, University of Manitoba School of Medicine, Winnipeg, Canada, April 7, 1994.
392. Further studies of HPA axis dysregulation in depression. Grand Rounds, Department of Psychiatry, University of Wisconsin School of Medicine, Madison, Wisconsin, May 6, 1994.
393. Hypothalamic-pituitary-adrenal axis: alterations after early trauma. Plenary address, Society of Biological Psychiatry, 49th Annual meeting, Philadelphia, Pennsylvania, May 19, 1994.
394. Treatment of depression in bipolar patients. American Psychiatric Assn 150th Annual Meeting, Philadelphia, Pennsylvania, May 23, 1994.
395. Corticotropin-releasing factor and the genesis of depression. Royal College of Psychiatrists Annual Meeting, Cork, Ireland, July 7, 1994.
396. Neurobiology of cancer and depression. 25th Ann Meeting, Int Soc Psycho-neuroendocrinology, Seattle, Washington, August 18, 1994.
397. Corticotropin-releasing factor, early adverse life experience and the pathophysiology of depression. Grand Rounds, Department of Psychiatry, University of California/San Diego, San Diego, California, September 8, 1994.
398. Management of treatment-refractory depression. Grand Rounds, Department of Psychiatry and Behavioral Sciences, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, September 16, 1994.
399. Managing the patient with depressive disorders: evolving treatment options. American Academy of Clinical Psychiatrists Annual Meeting, Washington DC, October 8, 1994.
400. Neurohormones, stress and psychiatric illness. First World Congress on Stress, Washington DC, October 8, 1994.

401. Recent advances in the biology of depression. Grand Rounds, Department of Psychiatry, Rush Presbyterian Medical Center, Chicago, Illinois, October 13, 1994.
402. Invited participant, Cayman Neuropeptide Conference, November 18-20, 1994.
403. Evidence for a preeminent role for corticotropin-releasing factor in the pathophysiology of post-traumatic stress disorder: preclinical and clinical studies. American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 14, 1994.
404. The role of HPA axis alterations in the pathophysiology of affective disorders. Grand Rounds, Massachusetts Mental Health Center, Harvard Medical School, Boston, Massachusetts, January 20, 1995.
405. The biology of mood disorders. Grand Rounds, Department of Psychiatry, Southern Illinois School of Medicine, Springfield, Illinois, February 24, 1995.
406. Hypothalamic-pituitary-adrenal axis alterations in mood disorders. Grand rounds, Department of Psychiatry, University of Kansas School of Medicine, Wichita, Kansas, February 28, 1995.
407. Diagnosis and treatment of bipolar disorder. 17th Annual Winter Menninger Psychiatry Conference, Park City, Utah, March 8, 1995.
408. Diagnosis and management of depression in the elderly. 17th Annual Winter Menninger Psychiatry Conference, Park City, Utah, March 9, 1995.
409. Management of treatment-refractory depression. Grand Rounds, Department of Psychiatry, Georgetown University School of Medicine, March 23, 1995.
410. Contemporary management of depression. Grand Rounds, The Menninger Clinic, Topeka, Kansas, April 19, 1995.
411. Co-chairman and participant, Brain and Adrenal Gland Imaging in Affective Disorders. Second International Conference on New Directions in Affective Disorders. Jerusalem, Israel, September 4, 1995.
412. Participant, Depression in the Medically Ill. Second International Conference on new Directions in Affective Disorders, Jerusalem, Israel, September 7, 1995.
413. Corticotropin-releasing Factor, Stress and the Pathogenesis of Mood and Anxiety Disorders. The Neurobiology of Stress, A satellite symposium to the meeting of European Neuroscientists, Groningen, The Netherlands, September 9, 1995.
414. The role of CRF in depression: the importance of early adverse experience. Grand Rounds, Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, September 26, 1995.
415. Management of treatment-refractory depression. Grand Rounds, Department of Psychiatry, University of Complutense School of Medicine, Madrid, Spain, October 8, 1995.

416. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch at Galveston, Galveston, Texas, October 31, 1995.
417. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry and Behavioral Sciences, University of Texas Southwestern Medical School at Dallas, Dallas, Texas, November 4, 1995.
418. The role of corticotropin-releasing factor (CRF) in the pathophysiology of depression: the role of early adverse experience. In: The Neurobiology of Early Trauma: Implications for the Pathophysiology of Mood and Anxiety Disorders. 25th Annual Meeting of the Society of Neuroscience, San Diego, California, November 13, 1995.
419. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, November 16, 1995.
420. Controversies in the treatment of depression. First Regional ACNP Update on Practical Clinical Psychopharmacology, New York, New York, December 2, 1995.
421. Management of Treatment-Refractory Depression. New York State Office of Mental Health Research Conference, Albany, New York, December 5, 1995.
422. Co-Chairman and participant, Corticotropin-releasing factors: from gene to therapy. Amer College Neuropsychopharmacol. San Juan, Puerto Rico, December 13, 1995.
423. The Role of Serotonin in the Pathophysiology of Depression. Grand Rounds, Department of Psychiatry, University of Missouri School of Medicine, Kansas City, Missouri, January 11, 1996.
424. The Role of Serotonin in the Pathophysiology of Depression. Grand Rounds, Department of Psychiatry, St. Louis University School of Medicine, St. Louis, Missouri, January 23, 1996.
425. The HPA Axis and the Pathophysiology of Depression: The Role of Early Adverse Experience. Grand Rounds, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, February 1, 1996.
426. The HPA Axis and the Pathophysiology of Depression: The Potential Role of Early Adverse Experience. NIH Directors Conference, Bethesda, Maryland, February 14, 1996.
427. The HPA Axis and the Pathophysiology of Depression: The Role of Early Adverse Experience. Grand Rounds, Department of Psychiatry, Cornell University School of Medicine, New York, New York, March 20, 1996.
428. The HPA Axis and the Pathophysiology of Depression: The Role of Early Adverse Experience. Grand Rounds, Department of Psychiatry, University of Florida School of Medicine, Gainesville, Florida, March 26, 1996.
429. The HPA Axis and the Pathophysiology of Depression: The Role of Early Adverse Experience. Grand Rounds, Department of Psychiatry, University of Hawaii School of Medicine, Honolulu, Hawaii, May 17, 1996.

430. The HPA Axis and the Pathophysiology of Depression: The Role of Early Adverse Experience. Grand Rounds, Department of Psychiatry, University of Arkansas School of Medicine, Little Rock, Arkansas, May 24, 1996.
431. Psychopharmacology in the 21st Century. Grand Rounds, Department of Psychiatry, Medical College of Wisconsin, Milwaukee, Wisconsin, July 10, 1996.
432. The HPA Axis and the Pathophysiology of Depression: The Role of Early Adverse Experience. Grand Rounds, Department of Psychiatry, The University of Michigan, Ann Arbor, Michigan, July 17, 1996.
433. The HPA Axis and the Pathophysiology of Depression: The Role of Early Adverse Experience. Grand Rounds, Department of Psychiatry, University of Colorado Health Sciences Center, Denver, Colorado, September 18, 1996.
434. Mixed Depression/Anxiety States. Grand Rounds, Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, Utah, October 8, 1996.
435. The HPA Axis and the Pathophysiology of Depression: The Role of Early Adverse Experience. Grand Rounds, Department of Psychiatry, Medical College of Georgia, Augusta, Georgia, October 31, 1996.
436. The HPA Axis and the Pathophysiology of Depression: The Role of Early Adverse Experience. Grand Rounds, Department of Psychiatry, University of Mississippi, Jackson, Mississippi, November 1, 1996.
437. Antidepressants and the Cytochrome P450 System. Grand Rounds, Department of Psychiatry, University of Maryland, Baltimore, Maryland, November 7, 1996.
438. Psychopharmacology in the 21st Century. Grand Rounds, Department of Psychiatry, Stanford University, Stanford, California, January 9, 1997.
439. The HPA Axis and the Pathophysiology of Depression: The Role of Early Adverse Experience. Grand Rounds, Department of Psychiatry, Jefferson Hospital, Philadelphia Pennsylvania, February 5, 1997.
440. Psychopharmacology in the 21st Century. Grand Rounds, Department of Psychiatry, Albert Einstein Medical Center, Philadelphia, Pennsylvania, March 7, 1997.
441. The HPA axis and the pathophysiology of depression: the role of early adverse experience. The Eighteenth Annual Alberto DiMascio Memorial Lecture, Tufts University School of Medicine, Boston, Massachusetts, April 7, 1997.
442. Psychopharmacology in the 21st Century. Plenary lecture, Stress and the Pituitary Adrenal Axis, Center for Psychobiological and Psychosomatic Research, University of Trier, Trier, Germany, June 21, 1997.
443. Psychopharmacology in the 21st century. Grand Rounds, Department of Psychiatry, Baylor University College of Medicine, Houston, Texas, September 3, 1997.

444. Overview of CRH in psychiatric diseases. Xth Congress of the European College of Neuropsychopharmacology, Vienna, Austria, September 14, 1997.
445. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Xth Congress of the European College of Neuropsychopharmacology, Vienna, Austria, September 15, 1997.
446. Treatment of Anxiety Disorders. Grand Rounds, Department of Psychiatry, University of Kansas, Kansas City, Kansas, October 3, 1997.
447. Depression and Cardiovascular Disease. Grand Rounds, Department of Psychiatry, University of Nebraska, Creighton University Medical Center, October 8, 1997.
448. Theoretical approaches to the pharmacotherapy of affective disorders in the 21st century. Serotonin Summit, Amsterdam, Netherlands, October 24, 1997.
449. Psychopharmacology in the 21st century: the elements of style and being mentored by a giant. The 14th Annual George C. Ham Symposium, Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, North Carolina, November 1, 1997.
450. Biological impact of early abuse on adult major depressive disorder. International Society for Traumatic Stress Studies, 13th Annual Meeting, Montreal, Canada. November 9, 1997.
451. Depression and Cardiovascular Disease. Grand Rounds, Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, November 11, 1997.
452. The Role of Corticotropin-Releasing Factor (CRF) in Depression: Therapeutic Implications. American College of Neuropsychopharmacology, 36th Annual Meeting, Waikoloa, Hawaii, December 10, 1997.
453. Depression and Cardiovascular Disease. Grand Rounds, Department of Internal Medicine, University of Texas, Houston, Texas, January 6, 1998.
454. Psychopharmacology in the 21st Century. Grand Rounds, Department of Psychiatry and Behavioral Sciences, University of Texas, Houston, Texas, January 7, 1998.
455. Depression and Cardiovascular Disease. Grand Rounds, Department of Psychiatry, Evanston Hospital, Evanston, Illinois, January 27, 1998.
456. Depression and Cardiovascular Disease. Grand Rounds, Department of Psychiatry, Reading Hospital, Reading, Pennsylvania, February 10, 1998.
457. Psychopharmacology in the 21st Century. Grand Rounds, Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, Georgia, February 26, 1998.
458. Reassessing the Role of Lithium in the Management of Bipolar Disorder. Grand Rounds, Case Western Reserve University, Cleveland, Ohio, April 10, 1998.
459. Depression and Cardiovascular Disease. Grand Rounds, Department of Cardiology, Emory University School of Medicine, Atlanta, Georgia, April 13, 1998.

460. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, McLean Hospital, Boston, Massachusetts, April 23, 1998.
461. The HPA axis and the pathophysiology of depression: the role of early adverse experience. The 26th Annual Herbert S. Ripley Lecture, Department of Psychiatry and Behavioral Sciences, The University of Washington, Seattle, Washington, May 6, 1998.
462. Neurochemical mechanisms underlying brain alteration in depression. XX1st CINP Congress, Glasgow, Scotland, July 12, 1998.
463. Early life stress and the vulnerability to depression: preclinical and clinical studies. XX1st CINP Congress, Glasgow, Scotland, July 14, 1998.
464. Depression and cardiovascular disease: epidemiology, pathophysiology and treatment. International Society of Psychoneuroendocrinology, 29th Annual Meeting, Trier, Germany, August 4, 1998.
465. Depression and heart disease: pathophysiology and treatment. Grand Rounds, Department of Psychiatry, University of Cincinnati, Cincinnati, Ohio, August 26, 1998.
466. Depression and cardiovascular disease. Grand Rounds, Department of Psychiatry and Behavioral Sciences, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, August 28, 1998.
467. The HPA axis and the pathophysiology of depression: the role of early adverse experience, Grand Rounds, Department of Psychiatry, Wayne State University, Detroit, Michigan, September 30, 1998.
468. The HPA axis and the pathophysiology of depression: the role of early adverse experience, Grand Rounds, Brigham and Women's Hospital, Boston, Massachusetts, October 1, 1998.
469. The HPA axis and the pathophysiology of depression: the role of early adverse experience, Grand Rounds, Department of Psychiatry, Oregon Health Sciences University, Portland, Oregon, October 13, 1998.
470. Depression and cardiovascular disease. Grand Rounds, Providence St. Vincent Medical Center, Portland, Oregon, October 14, 1998.
471. What can we learn from CSF studies: the CRF database. Plenary lecture, European College of Neuropsychopharmacology Annual Meeting, Paris, France, November 2, 1998.
472. The relationship of depression and coronary artery disease. Grand Rounds, Mt. Sinai Hospital, New York, New York, December 1, 1998.
473. Psychopharmacology in the 21st century. Joseph A. Stokes, Jr., Visiting Professor Lecture, Children's Hospital of Philadelphia, January 21, 1999, Philadelphia, Pennsylvania.
474. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Neurodevelopmental factors in psychopathology, Emory University, January 29, 1999, Atlanta, Georgia.

475. Depression and cardiovascular disease. Grand Rounds, Indiana University, Department of Psychiatry, Indianapolis, Indiana, February 26, 1999.
476. Neuropharmacology of the future. Masters of Psychiatry Psychopharmacology Update, University of Miami School of Medicine, Key West, Florida, February 27, 1999.
477. Neurosciences contribution to developing new treatments. American Psychopathological Association Annual Meeting, New York, New York, March 4, 1999.
478. Psychopharmacology in the 21st century. American Association for Geriatric Psychiatry, New Orleans, Louisiana, March 15, 1999.
479. Psychopharmacology in the 21st century. Grand Rounds, Department of Psychiatry, State University of New York Health Science Center at Brooklyn, March 17, 1999.
480. The impact of early life adverse experiences on brain systems involved in anxiety and affective disorders. Anxiety Disorders Association of America Annual Meeting, San Diego, California, March 25, 1999.
481. The relationship of depression to cardiovascular disease. Grand Rounds, Reading Hospital, Reading, Pennsylvania, March 31, 1999.
482. Depression and cardiovascular disease. Grand Rounds, Department of Psychiatry, Beth Israel Medical Center, New York, April 1, 1999.
483. The neurobiology of early trauma and the pathophysiology of depression. Myself Lecture, Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, April 14, 1999.
484. The role of neurotensin in the pathophysiology and pharmacotherapy of schizophrenia. Plenary Lecture, International Congress on Schizophrenia Research, Santa Fe, New Mexico, April 19, 1999.
485. The role of early adverse life experience in the development of mood disorders. American Psychiatric Association Annual Meeting, Washington DC, May 16, 1999.
486. The persistent neurobiological consequences of early untoward life events: treatment implications. American Psychiatric Association Annual Meeting, Washington DC, May 19, 1999.
487. Problems with currently available antidepressants. American Psychiatric Association Annual Meeting, Washington DC, May 19, 1999.
488. Depression and cardiovascular disease. American Psychiatric Association Annual Meeting, Washington DC, May 20, 1999.
489. Innovations in antidepressant treatment development. NCDEU 39th Annual Meeting, Boca Raton, Florida, June 2, 1999.
490. Depression and Heart Disease. Grand Rounds, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, June 3, 1999.

491. Neurobiology of early trauma: implications for the pathophysiology of depression. Fifth Annual Medicine in the 21st Century Symposium, UMDNJ New Jersey Medical School, Department of Psychiatry, Newark, NJ, June 11, 1999.
492. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Fleur Strand Research Award Keynote Lecture, Summer Neuropeptide Conference, Key West, Florida, June 29, 1999.
493. Early life stress and depression. XI World Congress of Psychiatry, Hamburg, Germany, August 7, 1999.
494. Managing depressive symptoms in bipolar disorders. Chair and participant, 12th ECNP Congress, London, England, September 25, 1999.
495. Depression and cardiovascular disease. Grand Rounds, Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI, September 29, 1999.
496. Psychotropic drug trials. USA-Cuba Neuroscience meeting, Havana, Cuba, October 21, 1999.
497. Neuroscience of psychiatry. Session moderator, USA-Cuba Neuroscience meeting, Havana, Cuba, October 22, 1999.
498. Alterations in the hypothalamic-pituitary-adrenal axis in depression: the role of early untoward experience. Grand Rounds, Department of Psychiatry, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL, November 10, 1999.
499. Mixed depression and anxiety. Grand Rounds, Department of Medicine, University of Mississippi, Jackson, Mississippi, November 16, 1999.
500. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, November 17, 1999.
501. Adverse effect of depression on cardiovascular disease: biology and treatment. Grand Rounds, Department of Medicine, University of Rochester Medical Center, Rochester, NY, December 2, 1999.
502. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry and Human Behavior, Jefferson Medical College, Philadelphia PA, January 19, 2000.
503. The psychiatrist as medical consultant. Session participant, The American College of Psychiatrists Annual Meeting, Naples, Florida, February 17, 2000.
504. The neurobiology of early trauma. Masters of Psychiatry: Advances for the 21st Century. University of Miami School of Medicine, Key West FL, February 26, 2000.
505. Pharmacotherapy of depression in dementia. American Association for Geriatric Psychiatry Annual Meeting, Miami, FL, March 14, 2000.
506. The persistent neurobiological consequences of early abuse. Plenary lecture, 43rd Congress of the Swiss Society of Child and Adolescent Psychiatry, Lausanne, Switzerland, April 7, 2000.

507. The HPA axis and the pathophysiology of depression: the role of early adverse experience. William C. Menninger Memorial Award Lecture, American College of Physicians, Philadelphia PA, April 14, 2000.
508. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry, Duke University Medical Center, April 20, 2000.
509. CRF₁ receptor antagonists as novel putative antidepressants and anxiolytics. Society of Biological Psychiatry Annual Meeting, Chicago, Illinois, May 12, 2000.
510. Corticotropin-releasing factor antagonists: promising therapy for depression. American Psychiatric Association Annual Meeting, Chicago, Illinois, May 14, 2000.
511. Novel actions of antidepressants. American Psychiatric Association Annual Meeting, Chicago, Illinois, May 14, 2000.
512. The adverse impact of depression on cardiovascular disease: pathophysiology and treatment considerations. American Psychiatric Association Annual Meeting, Chicago, Illinois, May 15, 2000.
513. A chair's life: Ethiopia, Taiwan, Geneva, Atlanta and Los Angeles. American Psychiatric Association Annual Meeting, Chicago, Illinois, May 16, 2000.
514. Noradrenaline and antidepressant response. Chair and participant, XXIInd CIMP Congress, Brussels, Belgium, July 11, 2000.
515. The role of noradrenaline in the pathophysiology of depression and its treatment. XXIInd CIMP Congress, Brussels, Belgium, July 11, 2000.
516. Interactions of noradrenergic and CRF-containing neural systems: implications for the pathophysiology and treatment of depression. XXIInd CIMP Congress, Brussels, Belgium, July 11, 2000.
517. The role of neuropeptides in the pathophysiology of depression and the mechanism of action of antidepressant drugs. Plenary lecture, XXIInd CIMP Congress, Brussels, Belgium, July 12, 2000.
518. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Guest Lecture, British Association for Psychopharmacology, Cambridge, England, July 17, 2000.
519. CRF antagonists. Chair and participant, Second International Congress on Hormones, Brain and Neuropsychopharmacology, Rhodes, Greece, July 18, 2000.
520. The role of norepinephrine in depression. Grand Rounds, The Institute of Living, Hartford, Connecticut, August 9, 2000.
521. The future of psychopharmacology: problems and promises. National Depressive and Manic-Depressive Association 2000 National Conference, Boston, Massachusetts, August 12, 2000.
522. Psychopharmacology in the 21st century. Guest lecture, Rudolf Magnus Institute, University of Utrecht, Utrecht, Netherlands, September 3, 2000.

523. The HPA axis and the pathophysiology of depression: the role of early adverse experience. The Second Organon Lecture, Institute of Psychiatry at the Maudsley, King's College London, London, England, September 4, 2000.
524. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, September 20, 2000.
525. Depression and heart disease: biology and treatment. Current Concepts in Neurosciences and Psychiatry, Hilton Head Island, South Carolina, September 30, 2000.
526. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. National Depressive and Manic-Depressive Association 2000 Consensus Conference, Washington DC, October 17, 2000.
527. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, October 20, 2000.
528. Depression and cardiovascular disease. Grand Rounds, Department of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, October 31, 2000.
529. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry, University of Cincinnati, Cincinnati, Ohio, November 1, 2000.
530. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand rounds, Department of Psychiatry, University of Kansas Medical Center, Kansas City, Kansas, November 10, 2000.
531. The role of CRF systems in the pathophysiology of depression and anxiety: do they mediate the effects of early trauma? The 17th Annual George C. Ham Symposium, University of North Carolina School of Medicine, Chapel Hill, North Carolina, November 18, 2000.
532. Neurosciences and the brain: the past, the present and the future. Psychiatry in the 21st Century: Mental Illness and Addiction, Department of Psychiatry, University of Toronto, Toronto, Canada, November 30, 2000.
533. Psychopharmacology of the future: problems and promises. Psychopharmacology State of the Art at the Dawn of the 21st Century, New York Academy of Medicine, Albert Einstein College of Medicine, New York, New York, December 1, 2000.
534. Long term effect of trauma early in life on the brain: implications for vulnerability to depression and anxiety. Emory University Great Teachers Lecture Series, Emory University, Atlanta, Georgia, January 25, 2001.
535. Depression and cardiovascular disease. Grand Rounds, Department of Psychiatry, University of Alabama, Birmingham, Alabama, January 30, 2001.
536. Novel drug development of mood and anxiety disorders. Invited lecture, American College of Psychiatrists Annual Meeting, Tucson, Arizona, February 21, 2001.

537. The role of norepinephrine in the pathophysiology of depression and anxiety disorders. Grand Rounds, Department of Psychiatry, California Pacific Medical Center, San Francisco, California, March 6, 2001.
538. The persistent neurobiological consequences of early life trauma: implications for the pathophysiology of mood and anxiety disorders. The Patricia R. Barchas Award lecture, American Psychosomatic Society Annual Meeting, Monterey, California, March 10, 2001.
539. How does trauma increase risk for mood and anxiety disorders? Invited lecture, Anxiety Disorders Association of America Annual Meeting, Atlanta, Georgia, March 23, 2001.
540. CRF-serotonergic interaction in the aetiology of depression and anxiety. 1st World Congress on Women's Mental Health, Berlin, Germany, March 28, 2001.
541. The relationship of early trauma to neuroendocrine and cardiovascular alterations in women with and without adult depression. 1st World Congress on Women's Mental Health, Berlin, Germany, March 29, 2001.
542. From laboratory bench to bedside: advances in the neurobiology and neuropharmacology in depression in women. 1st World Congress on Women's Mental Health, Berlin, Germany, March 29, 2001.
543. Neurobiology of early trauma and its treatment implications. Grand Rounds, Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, April 10, 2001.
544. The neurobiology of depression and the neurobiology of early trauma: implications for the neurobiology of suicide. Research Award Lecture, American Foundation for Suicide Prevention, New York, New York, April 30, 2001.
545. Behavioral and neurochemical predictors of antipsychotic drug action. American Psychiatric Association Annual Meeting, New Orleans, Louisiana, May 6, 2001.
546. Biopsychosocial model: biological perspectives. American Psychiatric Association Annual Meeting, New Orleans, Louisiana, May 8, 2001.
547. Approaches to optimizing therapies across psychiatric diagnoses: remission is the goal. American Psychiatric Association Annual Meeting, New Orleans, Louisiana, May 8, 2001.
548. Psychopharmacology in the 21st century: focus on depression. Keynote address, The Royal Australian and New Zealand College of Psychiatrists (RANZCP) 36th Congress, Canberra, Australia, May 22, 2001.
549. Anticonvulsants in the treatment of bipolar disorder. The Royal Australian and New Zealand College of Psychiatrists (RANZCP) 36th Congress, Canberra, Australia, May 22, 2001.
550. Treatment of depression. Grand Rounds, Department of Psychiatry, Alta Bates Summit Medical Center, Berkeley, CA, June 5, 2001.
551. Long-term neurobiological consequences of early life trauma. Keynote address, joint meeting of the American Academy of Psychoanalysis (AAP) and Organizzazione di Psicoanalisti Italiani-Federazione e Registro (OPIFER), Venice, Italy, June 18, 2001.

- 552. The clinical relevance of norepinephrine. Florida Psychiatric Society, Ft. Lauderdale, FL, June 26, 2001.
- 553. The role of norepinephrine in depression and its treatment. Grand Rounds, Department of Psychiatry, Four Winds Hospital, Saratoga Springs, NY, June 27, 2001.
- 554. From receptor pharmacology to clinical reality. 7th World Congress of Biological Psychiatry, Berlin, German July 3, 2001.
- 555. The role of CRF in the pathophysiology of mood and anxiety disorders. 7th World Congress of Biological Psychiatry, Berlin, Germany, July 4, 2001.
- 556. From mentee to mentor: the transition of the young investigator to the established investigator. Keynote speaker, NIMH Division of Neuroscience and Basic Behavioral Science, Mentored Clinical Neuroscience Research Career Development Workshop, Bethesda, Maryland, July 23, 2001.
- 557. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry, Harbor/UCLA Medical Center, Torrance, CA, July 25, 2001.
- 558. The future of clinical research. National Institute of Mental Health Workshop, Rockville, MD, August 13, 2001.
- 559. Depression and cardiovascular disease. Grand Rounds, St. Luke's Medical Center, Milwaukee WI, September 20, 2001.
- 560. Depression and cardiovascular disease. Grand Rounds, Department of Psychiatry, University of Oklahoma, Oklahoma City, OK, September 20, 2001.
- 561. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry, University of Oklahoma, Tulsa, OK, September 26, 2001.
- 562. Psychopharmacology in the 21st century. Guest lecture, Tulsa Psychiatric Society, Tulsa, OK, September 26, 2001.
- 563. The clinical relevance of norepinephrine. Grand Rounds, Department of Psychiatry, St. Vincent's Hospital Westchester, Harrison, New York, October 2, 2001.
- 564. Neurobiological basis of major psychiatric disorders and addictions: problems and promises. Keynote lecture, The II International Symposium on Mental Health and Addictions, Mexico City, Mexico, October 10, 2001.
- 565. The importance of remission in the treatment of depression. Grand Rounds, Department of Psychiatry, Ochsner Clinic, New Orleans, Louisiana, October 16, 2001.
- 566. Psychopharmacology in the new millennium. University of South Carolina School of Medicine, Current Concepts in Neurosciences and Psychiatry 26th Annual Hilton Head Symposium, Hilton Head, South Carolina, November 3, 2001.

- 567. The relationship of depression and cardiovascular disease. The 18th Annual George C. Ham Symposium, University of North Carolina School of Medicine, Chapel Hill, North Carolina, November 18, 2001.
- 568. The clinical relevance of norepinephrine. Grand Rounds, St. Elizabeth's Medical Center of Boston, Boston, Massachusetts, November 28, 2001.
- 569. Depression and cardiovascular disease. Grand Rounds, Cambridge Hospital, Boston, Massachusetts, November 28, 2001.
- 570. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry, University of Massachusetts Medical School, Boston, Massachusetts, November 29, 2001.
- 571. The long-term effects of early life trauma on the CNS: implications for the pathophysiology of depression and PTSD. American College of Neuropsychopharmacology Annual Meeting, Waikoloa, Hawaii, December 13, 2001.
- 572. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry, Beth Israel Hospital, New York, New York, December 19, 2001.
- 573. Psychopharmacology in the 21st century. Grand Rounds, Department of Psychiatry, Beth Israel Hospital, New York, New York, December 20, 2001.
- 574. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry, Medical College of Georgia, Augusta, Georgia, January 10, 2002.
- 575. The role of dopamine in depression and other psychiatric disorders. Grand Rounds, Department of Psychiatry & Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, Alabama, January 15, 2002.
- 576. Early abuse and neglect and the etiology of mood and anxiety disorders in adulthood. Invited lecture, 4th Annual Masters of Psychiatry meeting, Florida Psychiatric Association Annual Meeting, Miami, Florida, February 23, 2002.
- 577. Neurobiological findings in clinical depression and bipolar disorder. Plenary lecture, The International Society for Affective Disorders Conference, Taormina, Sicily, March 11, 2002.
- 578. The relationship between affective disorders and physical illness. Chair and participant, The International Society for Affective Disorders Conference, Taormina, Sicily, March 11, 2002.
- 579. The role of early trauma in the development of depression. East Tennessee State University College of Medicine, Women's Health Conference, Johnson City, Tennessee, March 19, 2002.
- 580. Co-chair and participant, meeting on Effects of Early Life Events on Mind Brain Body Interactions, Sedona, Arizona, April 7-11, 2002.
- 581. Stress and its impact on Brain Development, Usdin Award Lecture, West Coast College of Biological Psychiatry, Santa Monica, California, April 19, 2002.

582. The neurobiological consequences of early life trauma increases vulnerability for depression in adulthood: therapeutic implications. Hamilton Ford Lecture, Titus Harris Society 42nd. Annual Meeting, Galveston, Texas, April 26, 2002.
583. The HPA axis and the pathophysiology of depression: the role of early adverse experience. The Silvio Conte Research Center Neurobiology Seminar, California Institute of Technology, Pasadena, California, May 15, 2002.
584. Atypical depression: overview and new developments. American Psychiatric Association Annual Meeting, Philadelphia, Pennsylvania, May 19, 2002.
585. Childhood trauma and the neurobiology of mood disorders. American Psychiatric Association Annual Meeting, Philadelphia, Pennsylvania, May 21, 2002.
586. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry, MCP Hahnemann University, Philadelphia, Pennsylvania, May 23, 2002.
587. Remission is the goal of treatment of depression. Plenary lecture, National Depressive and Manic-Depressive Association Annual Meeting, Orlando, Florida, August 10, 2002.
588. Preclinical studies of novel antidepressants. XII World Congress of Psychiatry, Yokohama, Japan, August 28, 2002.
589. Unmet needs and the neurobiology of depression. XII World Congress of Psychiatry, Yokohama, Japan, August 28, 2002.
590. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry, University of South Florida, Tampa, Florida, September 6, 2002.
591. Depression and cardiovascular disease. Grand Rounds, Department of Psychiatry, State University of New York, Buffalo, New York, November 1, 2002.
592. Psychopharmacology in the new millennium: implications for the treatment of psychiatric disorders. Burlingame Award Lecture, The Institute of Living, Hartford, Connecticut, November 5, 2002.
593. The preeminent role of early life trauma in the neurobiology of depression. Grand Rounds, Department of Psychiatry, The Institute of Living, Hartford, Connecticut, November 6, 2002.
594. The role of early trauma in the pathophysiology of depression. The International Society for Traumatic Stress Studies 18th Annual Meeting, Baltimore, Maryland, November 8, 2002.
595. Psychopharmacology in the 21st century. The 19th Annual George C. Ham Symposium, Chapel Hill, North Carolina, November 23, 2002.
596. The role of dopamine in depression and other psychiatric disorders. Grand Rounds, Department of Psychiatry, California Pacific Medical Center, San Francisco, California, December 17, 2002.

597. Early life trauma and the pathophysiology of depression: preclinical and clinical studies. Institut Pasteur Euroconference on Depression, Paris, France, January 17, 2003.
598. The hypothalamic-pituitary-adrenal axis in depression. American Association for the Advancement of Science (AAAS) Annual Meeting, Denver, Colorado, February 14, 2003.
599. Depression and cardiovascular disease. Grand Rounds, Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, February 25, 2003.
600. The role of dopamine in depression and other psychiatric disorders. Department of Psychiatry, University of Texas Southwestern, Dallas, Texas, March 13, 2003.
601. Animal models and clinical evidence for the enduring effect of early stress. Anxiety Disorders Association of America Annual Meeting, Toronto, Canada, March 27, 2003.
602. Heartache and heartbreak: important interactions of depression and cardiovascular disease. University of Wisconsin/Madison, Wisconsin Symposium on Emotion and Related Events, Madison, Wisconsin, April 10, 2003.
603. Psychoneuroimmunology: relevance to psychiatry. College of Psychiatric and Neurologic Pharmacists (CPNP) Annual Meeting, Charleston, South Carolina, May 2, 2003.
604. The persistent neurobiological consequences of early life trauma: implications for the pathophysiology of mood and anxiety disorders. National Institutes of Health, Clinical Center Grand Rounds, Washington DC, May 14, 2003.
605. Heartache and heartbreak: the remarkable relationship between depression and heart disease. Grand Rounds, Department of Psychiatry, Cedars-Sinai Medical Center, Los Angeles, California, May 15, 2003.
606. The pathophysiology and psychopharmacology of comorbid cardiovascular disease and depression. American Psychiatric Association Annual Meeting, San Francisco, California, May 18, 2003.
607. The neurobiological consequences of child abuse. Distinguished Psychiatrist Lecture, American Psychiatric Association Annual Meeting, San Francisco, California, May 19, 2003.
608. Use of antipsychotics in mood disorders. American Psychiatric Association Annual Meeting, San Francisco, California, May 20, 2003.
609. Heartache and heartbreak: important interactions of depression and cardiovascular disease. Grand Rounds, Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, Utah, June 4, 2003.
610. Early abuse and HPA axis dysregulation in major depression. Symposium, World Psychiatric Association Conference, Vienna, Austria, June 20, 2003.
611. The neurobiology of depression: serotonin and norepinephrine. Symposium, World Psychiatric Association Conference, Vienna, Austria, June 21, 2003.
612. Management of bipolar depression. Georgia Psychiatric Physicians Association Annual Meeting, Panama City, Florida, August 1, 2003.

613. Heartache and heartbreak: the remarkable relationship between heart disease and depression. 34th Annual ISPNE meeting, New York, New York, September 8, 2003.
614. Depression and painful physical symptoms: the mind-body connection. American Association of Family Physicians Annual Meeting, New Orleans, Louisiana, September 30, 2003.
615. The neurobiology of mania: implications for treatment. American Psychiatric Nursing Association, Atlanta, Georgia, October 7, 2003.
616. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry, Oregon Health Sciences University, Portland, Oregon, November 6, 2003.
617. Metabolic effects of antipsychotics. Panel co-chair, American College of Neuropsychopharmacology Annual Meeting, San Juan, Puerto Rico, December 9, 2003.
618. Heartache and heartbreak: the remarkable relationship between depression and cardiovascular disease. Plenary lecture, International College of Geriatric Psychoneuropharmacology, San Juan, Puerto Rico, December 12, 2003.
619. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry, Stanford University School of Medicine, Stanford, California, January 8, 2004.
620. Stress and CRF: from basics to clinical applications. UCLA Center for Neurovisceral Sciences & Women's Health Symposium, Los Angeles, California, January 9, 2004.
621. Neurobiological consequences of early life trauma: indications for the pathophysiology of depression. Cuba-US Workshop on Biological Psychiatry, Havana, Cuba, January 17, 2004.
622. Early life abuse and the pathophysiology of major depression. Symposium co-chair and participant, International Congress of Biological Psychiatry, Sydney, Australia, February 12, 2004.
623. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry, University of Illinois/Chicago, Chicago, Illinois, February 18, 2004.
624. Neurotensin, antipsychotic drugs and the pathophysiology of schizophrenia. Dean Award lecture, American College of Psychiatrists Annual Meeting, Miami, Florida, February 28, 2004.
625. Further evidence for alterations in CRF and substance P systems. International Society for Affective Disorders 2nd Biennial Conference, Cancun, Mexico, March 8, 2004.
626. The role of early traumatic life experiences on the activity of the HPA axis in depression. International Society for Affective Disorders 2nd Biennial Conference, Cancun, Mexico, March 8, 2004.
627. Heartache and heartbreak: the remarkable relationship between depression and cardiovascular disease. Neuroscience Education Institute Lifetime Achievement Award

- lecture, NEI Global Psychopharmacology Congress Annual Meeting, San Diego, California, March 11, 2004.
628. The HPA axis and the pathophysiology of depression: the role of early adverse experience. NEI Global Psychopharmacology Congress Annual Meeting, San Diego, California, March 12, 2004.
 629. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry, McLean Hospital, Boston, Massachusetts, April 1, 2004.
 630. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry, University of New Mexico, Albuquerque, New Mexico, April 9, 2004.
 631. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Frank O. Shobe Lecture, Department of Psychiatry, Washington University, St. Louis, Missouri, April 13, 2004.
 632. Early life trauma and mood disorders: environment meets genes. 7th Annual Stanford Symposium on Developmental Approaches to Psychopathology, Stanford University Department of Psychiatry, Stanford, California, April 23, 2004.
 633. Identification of risk factors for development of depression: focus on early life trauma. Chairman and participant, American Psychiatric Association 157th Annual Meeting, New York, New York, May 1, 2004.
 634. Heartache and heartbreak: the remarkable relationship between depression and heart disease. American Psychiatric Association 157th Annual Meeting, New York, New York, May 1, 2004.
 635. The biopsychosocial model: contribution of research. American Psychiatric Association 157th Annual Meeting, New York, New York, May 3, 2004.
 636. Introduction to treatment-resistant depression. Chairman and participant, American Psychiatric Association 157th Annual Meeting, New York, New York, May 5, 2004.
 637. The HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry, University of Kansas, Wichita, Kansas, June 15, 2004.
 638. SSRIs, SNRIs and isomers: myths, facts, and clinical reality. Chairman and participant, 24th Collegium International Neuro-Psychopharmacologicum (CINP), Paris, France, June 20, 2004.
 639. The role of early trauma in the pathophysiology of depression. Plenary lecture, 26th Annual Meeting, Japanese Society of Biological Psychiatry & 34th Annual Meeting Japanese Society of Neuropsychopharmacology, Tokyo, Japan, July 22, 2004.
 640. Psychopharmacology in the 21st century. Grand Rounds, Department of Psychiatry, Michigan State University, Lansing, Michigan, September 9, 2004.

641. Psychopharmacology in the 21st century. Grand Rounds, Department of Psychiatry, Reading Hospital, Reading, Pennsylvania, September 14, 2004.
642. Heartache and heartbreak: the remarkable relationship between depression and heart disease. Grand Rounds, Department of Psychiatry, Wayne State University, Detroit, Michigan, September 15, 2004.
643. The role of early trauma in the pathophysiology of depression. Grand Rounds, Department of Psychiatry, Vanderbilt University, Nashville, Tennessee, September 21, 2004.
644. The role of early trauma in the pathophysiology of depression. Grand Rounds, Department of Child and Adolescent Psychiatry, Children's Memorial Hospital, Northwestern University, Chicago, Illinois, September 24, 2004.
645. Advances in clinical neuroscience and psychopharmacology: from the laboratory bench to the bedside. Plenary lecture, 56th Institute on Psychiatric Services, Atlanta, Georgia, October 6, 2004.
646. Psychopharmacology in the 21st century. Grand Rounds, Department of Psychiatry, St. Pauls Hospital, Vancouver, British Columbia, October 8, 2004.
647. The role of early trauma in the pathophysiology of depression. Grand Rounds, Department of Psychiatry, Vancouver General Hospital, Vancouver, British Columbia, October 8, 2004.
648. The role of early trauma in the pathophysiology of depression. Invited lecture, Victoria Mood Disorders Conference, Victoria, British Columbia, October 9, 2004.
649. Psychopharmacology in the 21st century. Grand Rounds, Department of Psychiatry, University of Alabama/Birmingham, Birmingham, Alabama, October 12, 2004.
650. Management of bipolar depression. Grand Rounds, Department of Psychiatry, St. Louis University, St. Louis, Missouri, November 16, 2004.
651. Heartache and heartbreak: the remarkable relationship between depression and heart disease. Grand Rounds, Department of Psychiatry, Hannibal Regional Hospital, Hannibal, Missouri, November 16, 2004.
652. The remarkable relationship of the thyroid axis and mood disorders: clinical implications. American Association of Clinical Endocrinologists Consensus Conference, Washington DC, January 9, 2005.
653. The role of early life trauma in the pathophysiology of mood and anxiety disorders: the Emory-NIMH Conte Center. Grand Rounds, Department of Psychiatry, Emory University School of Medicine, Atlanta, Georgia, January 12, 2005.
654. Neurobiological effects of childhood abuse: implications for the pathophysiology of depression and anxiety. Plenary lecture, The Foundation for Psychocultural Research Conference, Los Angeles, California, February 13, 2005.

- 655. Early trauma as a risk factor for psychopathology: neurobiological and therapeutic implications. American College of Psychiatrists Annual Meeting, La Jolla, California, February 23, 2005.
- 656. Neurobiology of child abuse: treatment implications. Grand Rounds, Department of Psychiatry, East Tennessee State University, Johnson City, Tennessee, March 11, 2005.
- 657. Neurobiology of child abuse: treatment implications. Grand Rounds, Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, March 15, 2005.
- 658. Neurobiology of child abuse: treatment implications. Grand Rounds, Department of Psychiatry, University of Colorado/Denver, Denver, Colorado, March 30, 2005.
- 659. Neurobiology of child abuse: treatment implications. Grand Rounds, Department of Psychiatry, University of Wisconsin/Madison, Madison, Wisconsin, April 5, 2005.
- 660. The neurobiology of trauma. Plenary lecture, Interdisciplinary Responses to Trauma symposium, Emory University Psychoanalytic Institute, Atlanta, Georgia, April 29, 2005.
- 661. Psychopharmacology in the 21st century. Grand Rounds, Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, Utah, May 17, 2005.
- 662. The persistent neurobiological consequences of early life abuse or neglect: implications for the pathophysiology and treatment of mood disorders. Plenary lecture, Society of Biological Psychiatry, 60th Annual Meeting, Atlanta, Georgia, May 19, 2005.
- 663. The persistent neurobiological consequences of child abuse and neglect: therapeutic implications. Keynote lecture, The American Academy of Psychoanalysis and Dynamic Psychiatry, 49th Annual Meeting, Atlanta, Georgia, May 20, 2005.
- 664. The neurobiology of early life trauma: implications for the pathophysiology of mood and anxiety disorders. 2005 Spring Symposium, Atlanta Chapter Society for Neuroscience, Atlanta, Georgia, May 21, 2005.
- 665. The biopsychosocial model: contribution of research. Plenary lecture, the American College of Psychoanalysts Annual Meeting, Atlanta, Georgia, May 21, 2005.
- 666. Depression and cardiovascular disease: pathophysiology and treatment. American Psychiatric Association Annual Meeting, Atlanta, Georgia, May 21, 2005.
- 667. HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, June 3, 2005.
- 668. CRF and the pathogenesis of depression: treatment implications. Eighth World Congress of Biological Psychiatry, Vienna, Austria, June 29, 2005.
- 669. Advances in the treatment of psychiatric disorders. Eighth World Congress of Biological Psychiatry, Vienna, Austria, July 1, 2005.
- 670. Mood disorders: epidemiology, nosology, biology and treatment. Summer Program, RIKEN Brain Science Institute, Tokyo, Japan, July 20, 2005.

671. The role of early life trauma in the pathophysiology of mood disorders. Summer Program, RIKEN Brain Science Institute, Tokyo, Japan, July 20, 2005.
672. What's wrong in the depressed brain. The Picower Center Open Mind Series on Depression, Massachusetts Institute of Technology, Cambridge, Massachusetts, September 19, 2005.
673. Long term neurobiological consequences of child abuse: endocrine and brain imaging studies. Plenary lecture, International Society for Psychoneuroendocrinology, Annual Meeting, Montreal, Canada, September 25, 2005.
674. The neurobiology of child abuse: treatment implications. 1st Annual Update on Psychiatry, Mt. Sinai School of Medicine, New York, New York, October 1, 2005.
675. The neurobiological consequences of early life stress: treatment implications. Plenary lecture, International Society for Traumatic Stress Studies (ISTSS), 21st Annual Meeting, Toronto, Canada, November 3, 2005.
676. Persistent neurobiological consequences of child abuse in adult women: implications for the treatment of mood and anxiety disorders. Society for Neuroscience, 35th Annual Meeting, Washington DC, November 16, 2005.
677. The biology of childhood trauma. Institute of Psychiatry, King's College London, London, England, November 28, 2005.
678. Post MI depression and treatment implications. Neuroscience symposium, Department of Neuropsychiatry & Behavioral Science, University of South Carolina School of Medicine, Hilton Head, South Carolina, December 3, 2005.
679. Are there predictors of antidepressant treatment response? Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, December 17, 2005.
680. HPA axis and the pathophysiology of depression: the role of early adverse experience. Grand Rounds, Department of Psychiatry, Baylor College of Medicine, Houston, Texas, January 4, 2006.
681. Diagnosis and treatment of bipolar disorder. Grand Rounds, Department of Psychiatry, Cedars Sinai Hospital, Los Angeles, California, January 19, 2006.
682. Heartache and heartbreak: the relationship of depression and cardiovascular disease. Plenary lecture, American College of Psychiatrists Annual Meeting, San Juan, Puerto Rico, February 24, 2006.
683. Psychopharmacology in the 21st century. Alabama Psychiatric Society, Annual Meeting, Destin, Florida, April 8, 2006.
684. Future shock. Demons of the Mind, Library of Congress conference, Washington DC, April 20, 2006.
685. Evolving concepts in treatment-resistant depression. American Psychiatric Association, 159th Annual Meeting, Toronto, Canada, May 21, 2006.

- 686. The neurobiology of depression: bringing the latest in science to clinicians. American Psychiatric Association, 159th Annual Meeting, Toronto, Canada, May 21, 2006.
- 687. Treatment of bipolar disorder. American Psychiatric Association, 159th Annual Meeting, Toronto, Canada, May 22, 2006.
- 688. VNS therapy in treatment-resistant depression: putative mechanism of action. XXV CINP Congress, Chicago, Illinois, July 9, 2006.
- 689. The neurobiological consequences of early life stress: clinical studies. XXV CINP Congress, Chicago, Illinois, July 12, 2006.
- 690. Heartache and heartbreak: the remarkable relationship between depression and heart disease. 2nd Annual Comprehensive Review of Psychiatry, Niagara Falls, New York, July 22, 2006.
- 691. Neurobiology of early life trauma: contributions to the neurobiology of depression. 37th Annual Conference of the International Society of Psychoneuroendocrinology, Leiden, The Netherlands, August 25, 2006.
- 692. Persistent neurobiological consequences of early life trauma: implication for the pathophysiology and treatment of mood disorders. Rudolf Magnus Institute of Neuroscience, Utrecht, The Netherlands, August 28, 2006.
- 693. Stress and the biological basis of depression: Implications for treatment. 8th Annual Psychiatric Symposium, Wright State University, Boonshoft School of Medicine, Department of Psychiatry: The Dayton Psychiatric Society and the Wallace Kettering Neuroscience Institute, Dayton, Ohio, November 7, 2006.
- 694. Psychopharmacology in the 21st century. Grand Rounds, Mission Hospitals Department of Internal Medicine, Asheville, NC, November 16, 2006.
- 695. Psychopharmacology in the 21st century. Grand Rounds, Broughton Hospital, Morganton, NC.
- 696. Neurobiology of childhood trauma: Consequences for later mental health. Annual Conference of The Psychiatric Educational Foundation of Norway, Schizophrenia Days 2006. Stavanger, Norway, November 23, 2006.
- 697. Trauma and PTSD: A paradigm shift?. Annual Conference of The Psychiatric Educational Foundation of Norway, Schizophrenia Days 2006. Stavanger, Norway, November 24 and 25, 2006.
- 698. The neurobiology of child abuse: Implications for the pathophysiology of depression. Teaching Conference, The University of Oklahoma Health Sciences Center, Department of Psychiatry and Behavioral Sciences. January 11, 2007.
- 699. Persistent neurobiological consequences of early life trauma: implication for the pathophysiology and treatment of mood disorders. Grand Rounds, Butler Hospital (Brown University), Providence, RI. February 7, 2007.

700. Overlap in the neurobiology, genetics, clinical presentation and treatment of bipolar disorder and schizophrenia. Grand Rounds, Portneuf Medical Center, Pocatello, ID. Feb. 15, 2007.
701. The burden of severe depression: A review of diagnostic challenges and treatment alternatives. Continuing Education Depression Conference, Turin, Italy. March 30, 2007.
702. Is depression a disorder of the whole body? The curiously strong association of depression and heart disease. Conference on Depression: Brain Causes - Body Consequences, Institute of Psychiatry, Kings College, London. April 2-3, 2007.
703. Is depression a disorder of the whole body? Neuroscience Colloquium, London, England. April 4, 2007.
704. The neurobiology of child abuse: Implications for the pathophysiology of depression. Department of Psychiatry Grand Rounds, University of Massachusetts, Worcester, MA. April 19, 2007.
705. It's not all in your head: The physical effects of antipsychotics. Neuroscience Education Institute Psychopharmacology Academy Symposium. San Francisco, CA. April 29, 2007.
706. Heartache and Heartbreak: The remarkable relationship between depression and heart disease and Mood Disorders: The biopsychosocial model. Colorado Mental Health Institute at Pueblo. Pueblo, CO. May 10, 2007.
707. Mechanism of action of vagus nerve stimulation (VNS). American Psychiatric Association Symposium: Caring for Our Most Challenging Patients with Depression: An Interactive Forum on Novel Treatments. San Diego, CA. May 20, 2007.
708. The role of CRF in the pathophysiology of depression. Cancun, Mexico. June 4, 2007.
709. Does one size fit all? Customizing antipsychotic selection and dose to patient profile. Neuroscience Education Institute Psychopharmacology Academy Symposium. Tyson's Corner, VA. June 9, 2007.
710. The neurobiology of child abuse: treatment implications. Grand Rounds. Department of Psychiatry. Dartmouth University School of Medicine. Hanover, N.H. June 12, 2007.
711. Current and future management strategies for bipolar disorder. Grand Rounds. 2007 Neuroscience Grand Rounds Series: Enhancing Therapeutic Outcomes in Patients with Severe Mental Illness. Napa State Hospital, Napa, CA. July 23, 2007.
712. Managing chronic depression: treating to remission. Grand Rounds. 2007 Neuroscience Grand Rounds Series: Enhancing Therapeutic Outcomes in Patients with Severe Mental Illness. Santa Clara Valley Medical Center, San Jose, CA. August 9, 2007.
713. The neurobiology and psychopharmacology of depression and suicidality in children and adolescents. Conference on Youth Suicide: New Knowledge for a New Generation. American Foundation for Suicide Prevention, Dublin, Ireland. August 25-27, 2007.

- 714. The neurobiology of child abuse: implications for pathophysiology and treatment of depression. Grand Rounds, Department of Psychiatry, Ohio State University School of Medicine, Columbus, OH. September 5, 2007.
- 715. Psychopharmacology in the 21st Century. United Behavioral Health CME program. Columbus, Ohio. September 5, 2007.
- 716. The neurobiology of child abuse: Implications for pathophysiology and treatment of depression. Keynote speaker, 100th Anniversary Meeting of the Norwegian Psychiatric Association, Oslo, Norway. September 14, 2007.
- 717. The neurobiology of child abuse: Implications for pathophysiology and treatment of depression. The Inaugural Symposium, Untangling the Mind: Research on Depression, Anxiety and Schizophrenia. University of Ottawa Institute of Mental Health Research, Ottawa, Canada. September 26, 2007.
- 718. The neurobiological consequences of child abuse and neglect: Increased vulnerability for depression in adulthood. World Congress on Stress. Vienna, Austria. October 12, 2007.
- 719. Antipsychotic dosing and side-effect management: Improving patient outcomes. Grand Rounds, Department of Psychiatry, VA Medical Center, Tucson, AZ. October 24, 2007.
- 720. Antipsychotic dosing and side-effect management: Improving patient outcomes. Grand Rounds, Department of Psychiatry, University of Arizona, College of Medicine, Tucson, AZ. October 24, 2007.
- 721. Antipsychotic dosing and side-effect management: Improving patient outcomes. Grand Rounds, Department of Psychiatry, University Physicians Hospital at Kino, Tucson, AZ. October 25, 2007.
- 722. Does one size fit all? Customizing antipsychotic selection and dose to patient profile. Neuroscience Education Institute Academy. Chicago, IL. October 27, 2007.
- 723. Managing chronic depression: Treating to remission. Grand Rounds. Henry Ford Health System, Detroit, MI. November 1, 2007.
- 724. What's up and coming in psychopharmacology? Baylor College of Medicine 2007 Psychopharmacology Update. Houston, TX. November 2, 2007.
- 725. The neurobiology of child abuse: treatment implications. Grand Rounds. Department of Psychiatry, Cornell University Medical College, Payne Whitney Manhattan Campus, New York, NY. November 14, 2007.
- 726. The biological impact of early trauma. XI International Symposium, Chilean College of Neuropsychopharmacology. Santiago, Chile. November 23, 2007.
- 727. Neurobiological basis of major depression. XI International Symposium, Chilean College of Neuropsychopharmacology. Santiago, Chile. November 23, 2007.

- 728. Early Life Trauma, the Pathophysiology of Depression and Risk for Cardiovascular Disease. American College of Neuropsychopharmacology, 46th Annual Meeting. Boca Raton, Florida. December 12, 2007.
- 729. Antipsychotic dosing and side-effect management: Improving patient outcomes. Grand Rounds, Department of Psychiatry, Walter Reed Army Medical Center, Washington, D.C., December 19, 2007.
- 730. Neurobiology of depression: bringing the latest in science to clinicians. Puerto Rican College of Neuropsychopharmacology. San Juan, Puerto Rico. January 31, 2008.
- 731. The neurobiology of child abuse: pathophysiology and treatment implications. Grand Rounds, Department of Psychiatry, Stanford University School of Medicine, Stanford, CA. February 7, 2008.
- 732. Neuropharmacological basis for novel strategies in the treatment of refractory depression. Nevada Psychiatric Association 13th Annual Psychopharmacology Update. Las Vegas, NV. February 21, 2008
- 733. Non-peptide ligands acting at CRF receptors as novel anxiolytics or antidepressants. International Society for Affective Disorders (ISAD) 4th Biennial Conference. March 16, 2008. Cape Town, South Africa.
- 734. Neurobiology. PTSD Consensus Conference. March 19, 2008. Cape Town, South Africa.
- 735. Heartache and Heartbreak: The Remarkable Relationship Between Depression and Cardiovascular Disease. Grand Rounds, Department of Psychiatry. Dartmouth University School of Medicine. Hanover, NH. April 8, 2008.
- 736. The Neurobiology of Child Abuse and Neglect: Implications for the Treatment of Mood and Anxiety Disorders. 2008 George Ham Symposium for Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC. April 12, 2008.
- 737. The Neurobiology of Child Abuse: Implications for Pathophysiology and Treatment of Depression. 18th Annual Neuroscience Day, Louisville Chapter, Society for Neuroscience. Grass Lecture Speaker. Louisville, KY. April 17, 2008.
- 738. Psychopharmacology in the 21st Century. 18th Annual Neuroscience Day, Louisville Chapter, Society for Neuroscience. Grass Lecture Speaker, Louisville, KY. April 17, 2008.
- 739. The Neurobiology of Child Abuse and Neglect – Implications for the Prevention and Treatment of Depression and Anxiety Disorders. 2008 Research Day and Van Liere Convocation. West Virginia University Health Sciences Center. Morgantown, WV. April 23, 2008.
- 740. The Neurobiology of Child Abuse: Treatment Implications. Harold J. Lawn Endowed Lecture. Department of Psychiatry, University of Minnesota Medical School. April 30, 2008.
- 741. Addressing Unmet Needs in Severe Depression. 2008 Annual Meeting American Psychiatric Association, Washington, DC, May 3, 2008.

742. Persistent CSF Oxytocin Reduction After Childhood Abuse. 2008 Annual Meeting American Psychiatric Association, Washington, DC, May 3, 2008.
743. Depression and Generalized Anxiety: Research Planning For The DSM-V. 2008 Annual Meeting American Psychiatric Association, Washington, DC, May 3, 2008.
744. Review of Advances in Depression. FOCUS. 2008 Annual Meeting American Psychiatric Association, Washington, DC, May 3, 2008.
745. The Myth of the Med Check in Psychopharmacology. 2008 Annual Meeting American Psychiatric Association, Washington, DC, May 3, 2008.
746. The role of Corticotropin-Releasing Factor (CRF) and the HPA Axis in the pathophysiology of depression. CINP 50th Annual Meeting, Munich, Germany, July 14, 2008.
747. CRF, the neurobiology of depression and early life trauma: Implications for diagnosis and treatment. CINP 50th Annual Meeting, Munich, Germany, July 14, 2008.
748. The interaction of serotonin transporter gene polymorphism and early life stress on vulnerability to depression: pathophysiology and therapeutic perspective. CINP 50th Annual Meeting, Munich, Germany, July 16, 2008.
749. Chairman and participant, The role of Corticotropin-Releasing Factor (CRF) and the HPA Axis in the pathophysiology of depression. CINP 50th Annual Meeting, Munich, Germany, July 14, 2008.
750. Co-chairman and participant, Stress sensitization in spontaneous recurrence of methamphetamine psychosis, schizophrenia and depression. CINP 50th Annual Meeting, Munich, Germany, July 15, 2008.
751. Pharmacology of antipsychotics: Implications for the therapeutic mechanism of action and clinical effects. CINP 50th Annual Meeting, Munich, Germany, July 14, 2008.
752. Damned If You Do....Damned If You Don't. The Chair's challenge in achieving balance in managing conflict of interest. American Association of Chairs of Departments of Psychiatry (AACDP) Summer Retreat, Lake Oconee, Georgia, July 26, 2008.
751. Chairman: Severe Depression: How to Diagnose and Treat? Lundbeck Satellite Symposium, Barcelona, Spain, August 31, 2008. S599, C.11.02.
753. The Neurobiology of child abuse: Treatment Implications. Grand Rounds, Department of Psychiatry, Baylor College of Medicine, Houston, Texas, January 28, 2009.
754. Towards Recovery Goal: Future Horizons in Depression Treatment. Colburn School for Performing Arts, Los Angeles, California, February 7, 2009.
755. Debate: Should Psychiatry and Neurology be Integrated into the Single Specialty of Neuropsychiatry? ACP Annual Meeting, Tucson, Arizona, February 25, 2009.
756. The Neurobiology of Child Abuse: Treatment Implications. Grand Rounds, Department of Psychiatry, Medical University of South Carolina, Charleston, SC, March 13, 2009.

- 757. Psychopharmacology in the 21st Century. Carter XII Symposium, Bogota, Columbia, March 20, 2009.
- 758. The Neurobiology of Child Abuse: Implications for the Treatment of Mood and Anxiety Disorders, Carter XII Symposium, Bogota, Columbia, March 20, 2009.
- 759. Treatment of refractory depression, Carter XII Symposium, Bogota, Columbia, March 21, 2009.
- 760. Bipolar disorder and schizophrenia: a critical view of their differences, Carter XII Symposium, Bogota, Columbia, March 21, 2009.
- 761. The relationship between cardiovascular disease and depression, Carter XII Symposium, Bogota, Columbia, March 21, 2009.
- 762. Invited participant, Early life trauma in major depression: A distinct endophenotype, Cold Springs Harbor Laboratory-Banbury Center, Cold Springs Harbor, New York, March 23, 2009.
- 763. Rational Neuropsychopharmacology of treatment-refractory depression, WPA International Congress Treatments in Psychiatry: a new update, Florence, Italy, April 1, 2009.
- 764. Depression and inflammation: research evidence and clinical implications, WPA International Congress Treatments in Psychiatry: a new update, Florence, Italy, April 1, 2009.
- 765. Heartache and Heartbreak, American Academy of Psychoanalysis & Dynamic Psychiatry, San Francisco, CA, May 14, 2009.
- 766. Psychopharmacology in the 21st Century: Towards Personalized Medicine in Psychiatry. Hellenic American Psychiatric Association, San Francisco, CA, May 19, 2009.
- 767. Matters of the Heart: Depression and Cardiovascular Disease, American Psychiatric Association Presidential Symposium, San Francisco, CA, May 21, 1009.
- 768. Recent developments in the aetiopathogenesis of depression. 7th National Congress of the Turkish Society of Biological Psychiatry, Edirne, Turkey, June 4, 2009.
- 769. Recent developments in the management of treatment-resistant major depression and anxiety. 7th National Congress of the Turkish Society of Biological Psychiatry, Edirne, Turkey, June 4, 2009.
- 770. The Neurobiological Consequences of Early Life Stress and Trauma, Argentina Trauma Society, Buenos Aires, Argentina, June 24, 2009.
- 771. The Neurobiology and Psychopharmacological Treatment of Anxiety Disorders, Argentina Trauma Society, Buenos Aires, Argentina, June 25, 2009.
- 772. The Neurobiology of Mood Disorders and Mixed Depression/Anxiety, Argentina Trauma Society, Buenos Aires, Argentina, June 26, 2009.
- 773. The Neurobiology of GAD compared to Depression: Similarities and Differences. Argentina Trauma Society, Buenos Aires, Argentina, June 26, 2009.

774. Psychopharmacology in the 21st Century, Argentina Trauma Society, Buenos Aires, Argentina, June 26, 2009.
775. Heartache & Heartbreak, Masters Program in Affective Neuroscience, Florence, Italy, July 6, 2009.
776. Chairman, Session on Affective Disorders, Persistent Neurobiological Consequences of Child Abuse and Neglect: Implications for Pathogenesis and Treatment of Mood and Anxiety Disorders, Early Life Programming & Neurodevelopmental Disorders, University of Pennsylvania, Philadelphia, PA, July 28, 2009.
777. Indo-US Bilateral Conference on Translational Neuroscience: New Trends in Mental and Neurodegenerative Disorders Research, Chicago, IL, October 15, 2009.
778. The Role of corticotrophin-releasing factor circuits in the pathology of depression: Implications for CRF receptor antagonists as novel antidepressants. Neuropeptides Conference, Chicago, IL, October 16, 2009.
779. Early Life Stress, Genetic Polymorphisms and Vulnerability to Depression, First International Meeting on Personalized Medicine in Psychiatry, Mayflower Action Group, Washington, DC, October 24, 2009.
780. High Impact Outcomes from BRAINnet. First International Meeting on Personalized Medicine in Psychiatry, Mayflower Action Group, Washington, DC, October 25, 2009.
781. Depression and Inflammation: Implications for Depression as a Risk Factor for Medical Comorbidity. Third Annual International Brain Conference, Orlando, FL, December 5, 2009.
782. Depression and Inflammation: Implications for Depression as a Risk Factor for Medical Comorbidity. Grand Rounds, Department of Psychiatry, Ohio State University, Columbus, OH, January 20, 2010.
783. The Neurobiology of Child Abuse: Treatment Implications. Grand Rounds, Department of Psychiatry, University of Illinois/Chicago, Chicago, Illinois, February 17, 2010.
784. Complex Clinical Psychopharmacology: A Case-Based Approach. American College of Psychiatrists Annual Meeting, Fort Lauderdale, Florida, February 23, 2010.
785. The Neurobiology of Child Abuse: Treatment Implications. Grand Rounds, Department of Psychiatry, Tufts University, Boston, Massachusetts, March 22, 2010.
786. HPA Axis in Mood Disorders. 2010 Master Class Institute of Mental Health, University of British Columbia, Vancouver, Canada, April 15, 2010.
787. Neurobiology of Depression. Psychopharmacology 2010: A Master Class, Massachusetts Mental Health Center, Harvard Medical School, Boston, Massachusetts, April 23, 2010.
788. Neurobiology of Child Abuse and Neglect: Implications for Treatment of Mood and Anxiety Disorders. Florida Psychiatric Society Spring CME Meeting, Tampa, Florida, May 1, 2010.
789. Mental Health Transformation in Action Conference Awards Ceremony and Luncheon for Consumers, Law Enforcement and Community Partners. Keynote Speaker, University of

- Miami Behavioral Health, a program of the Department of Psychiatry and Behavioral Sciences, Miami, Florida, May 13, 2010.
790. The Neurobiology of Child Abuse: Treatment Implications. Grand Rounds, Department of Psychiatry and Behavioral Sciences, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, May 19, 2010.
 791. Neurobiological Predictors of Treatment Response in Major Depression. Advances in the Management of Treatment-Resistant Depression, American Psychiatric Association Annual Meeting, New Orleans, Louisiana, May 22, 2010.
 792. The Rage to Know. Making it in Research through Good and Bad Funding Times, Research Colloquium for Junior Investigators, American Psychiatric Association Annual Meeting, New Orleans, Louisiana, May 23, 2010.
 793. Management of Bipolar Disorder: Problems and Promises, Georgia Psychiatric Physicians Association Summer CME Meeting, Ponte Vedra Beach, Florida, August 6, 2010.
 794. Neurobiological Predictors of Treatment Response in Major Depression: Moving Toward Personalized Medicine in Psychiatry, Georgia Psychiatric Physicians Association Summer CME Meeting, Ponte Vedra Beach, Florida, August 7, 2010.
 795. Discussant, Bipolar Disorder Across the Life Span: A Case of Bipolar Disorder in Later Life, Georgia Psychiatric Physicians Association Summer CME Meeting, Ponte Vedra Beach, Florida, August 7, 2010.
 796. Clinical Case Challenge: A Medical Student's Suicide Attempt, 3rd Annual Chair Summit, Master Class for Neuroscience Professional Development, Chicago, Illinois, August 26, 2010.
 797. Heartache and Heartbreak: The Relationship Between Depression and Heart Disease, 3rd Annual Chair Summit, Master Class for Neuroscience Professional Development, Chicago, Illinois, August 27, 2010.
 798. Long-Term Consequences of Child Abuse, 3rd Annual Chair Summit, Master Class for Neuroscience Professional Development, Chicago, Illinois, August 27, 2010.
 799. Treatment-Resistant Depression, 3rd Annual Chair Summit, Master Class for Neuroscience Professional Development, Chicago, Illinois, August 28, 2010.
 800. Clinical Case Challenge: 22-Year-Old, Hispanic, Female Patient Returning from Afghanistan, 3rd Annual Chair Summit, Master Class for Neuroscience Professional Development, Chicago, Illinois, August 28, 2010.
 801. Neurobiology of Child Abuse: Treatment Implications. Grand Rounds, Department of Psychiatry, University of Florida School of Medicine, Gainesville, Florida, September 24, 2010.
 802. Neurobiology of Child Abuse: Treatment Implications. First International Conference of Psychiatry, Mental Health in a Socio-cultural Perspective, Al-Khobar, Kingdom of Saudi Arabia, October 5, 2010.

803. Progress in Suicide Prevention: State of Science. Grand Rounds, Ohio State University, Department of Psychiatry, Columbus, Ohio, October 27, 2010.
804. The Neurobiology of Child Abuse. Grand Rounds, Department of Psychiatry, University of Wisconsin, Madison, Wisconsin, November 12, 2010.
805. Has Drug Development in Psychiatry Hit a Road Block? An RFP Pro Con Panel. American College of Neuropsychopharmacology, 49th Annual Meeting. Miami Beach, Florida, December 6, 2010.
806. Heartache and Heartbreak: The Remarkable Relationship between Depression and Heart Disease. Grand Rounds, Department of Psychiatry and Behavioral Sciences, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, February 2, 2011.
807. The Neurobiology of Child Abuse: Treatment Implications. Grand Rounds, Department of Psychiatry and Neurosciences, University of South Florida, Tampa, Florida, February 3, 2011.
808. Progress in Suicide Prevention: State of the Science. Jewish Ethics in Medicine and Sciences Program, Jewish Chabad Center, Fort Lauderdale, Florida, February 10, 2011.
809. Heartache and Heartbreak. Advances in Psychosomatic Medicine VI. Cardiovascular Diseases and Diabetes: Socio-Emotional Perspective, San Juan, Puerto Rico, February 12, 2011.
810. Depresión and Inflamación. XIII Simposio Internacional de Actualizaciones en Psiquiatría, Bogotá, Colombia, March 8, 2011.
811. Neurobiological Predictors of Treatment Response in MDD. XIII Simposio Internacional de Actualizaciones en Psiquiatría, Bogotá, Colombia, March 8, 2011.
812. Management of Treatment Resistant Depression. American Physician Institute for Advanced Professional Studies. The 2nd Annual 2011 Master Psychopharmacology Course. Las Vegas, Nevada, March 12, 2011.
813. The Relationship of Depression and Heart Disease. American Physician Institute for Advanced Professional Studies. The 2nd Annual 2011 Master Psychopharmacology Course. Las Vegas, Nevada, March 12, 2011.
814. Biological Predictors of Posttraumatic Stress Disorder (PTSD) Vulnerability and Response to Treatment: Problems and Promises. 31st Annual Conference Anxiety Disorders Association of America, Anxiety and Related Disorders: Efficacy, Effectiveness, and Dissemination. New Orleans, Louisiana, March 25, 2011.
815. Early childhood adverse experiences have the potential to cause cognitive deficits. 13th International Congress on Schizophrenia Research, Colorado Springs, Colorado, April 2, 2011.
816. Was Kraepelin misguided about the absolute distinction between Schizophrenia and Bipolar Disorder? Overview, epidemiology, clinical course and response to treatment. 13th International Congress on Schizophrenia Research, Colorado Springs, Colorado, April 3, 2011.
817. Neurobiology of Depression: Therapeutic Implications. Harvard Medical School, Psychopharmacology 2011: A Master Class, Boston Massachusetts, April 29, 2011.

818. The Neurobiology of Child Abuse: Treatment Implications. The Florida Psychoanalytic Society, Scientific Meetings 2010-2011, Coral Gables, Florida, April 30, 2011.
819. Psychopharmacology: Treatment Resistant Disorders. FOCUS Live. American Psychiatric Association, 164th Annual Meeting, Honolulu, Hawaii. May 16, 2011.
820. The Myth of the Med Check: Psychodynamics and Psychopharmacology. Innovative uses of Psychodynamic Psychiatry across the Life Cycle Symposium. American Psychiatric Association, 164th Annual Meeting, Honolulu, Hawaii. May 17, 2011.
821. Neurobiology of Depression: Therapeutic Implications. Predictors of Disease Vulnerability and Treatment Response: Personalized Medicine in Psychiatry Symposium. American Psychiatric Association, 164th Annual Meeting, Honolulu, Hawaii. May 18, 2011.
822. Neurobiological Predictors of Treatment Response in Major Depression. APREBA - 8th Anual Asociación de Psiquiatras de Bayamón Scientific Meeting Psychopharmacology 2011. Isla Verde, Puerto Rico, June 4, 2011.
823. Depression and Inflammation, 4th Annual Chair Summit, Master Class for Neuroscience Professional Development, Annapolis, Maryland, June 24, 2011.
824. Early Childhood Trauma, 4th Annual Chair Summit, Master Class for Neuroscience Professional Development, Annapolis, Maryland, June 25, 2011.
825. The Neurobiology of Child Abuse: Treatment Implications. Grand Rounds, Department of Psychiatry and Behavioral Sciences, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, June 29, 2011.
826. The Neurobiology of Child Abuse: Treatment Implications. 3rd World Congress of Asian Psychiatry, Melbourne, Australia, August 3, 2011.
827. Deficits in Motivation in Mood and Anxiety Disorders: Pathophysiological Subtypes, Personalized Medicine and Opportunities for Drug Development. Human motivation and its disorders – A target for psychopharmacology? Paris, France, August 31, 2011.
828. Personalized medicine and the risk of suicide: problems and promises. World Psychiatric Association 15th World Congress of Psychiatry. Buenos Aires, Argentina, September 19, 2011.
829. Heartache and heartbreak: the curious relationship between depression and heart disease. World Psychiatric Association 15th World Congress of Psychiatry. Buenos Aires, Argentina, September 20, 2011.
830. Consequences of early childhood trauma. World Psychiatric Association 15th World Congress of Psychiatry. Buenos Aires, Argentina, September 20, 2011.
831. The effect of early life trauma on the corticotrophin-releasing factor circuits: implications for the pathophysiology and treatment of mood and anxiety disorder. World Psychiatric Association 15th World Congress of Psychiatry. Buenos Aires, Argentina, September 21, 2011.

832. The neurobiology of child abuse and neglect: impact on the pathophysiology and treatment of mood disorders. World Psychiatric Association 15th World Congress of Psychiatry. Buenos Aires, Argentina, September 22, 2011.
833. Clinical Depression and Bipolar Disorder: State-of-the-Art. The National Alliance on Mental Illness (NAMI) - What's New in Mental Health Research and Treatment. Miami, Florida, October 1, 2011.
834. Treatment of Bipolar Depression. American Physician Institute for Advanced Professional Studies, 2011 Adult Master Psychopharmacology Course. San Diego, California, October 14, 2011.
835. Treating Depression in Patients with Cardiovascular Disease. American Physician Institute for Advanced Professional Studies, 2011 Adult Master Psychopharmacology Course. San Diego, California, October 14, 2011.
836. Depression and Inflammation. 41st Institute of Medicine Annual Meeting. Arlington, Virginia, October 16, 2011.
837. Quantifying the Impact of MDD and TRD on Patient Outcomes. Academy of Managed Care Pharmacy (AMCP), 2011 Educational Conference, Atlanta, Georgia, October 20, 2011.
838. Benefits and Limitations of Available Antidepressant Pharmacotherapy and the Factors involved in Second- and Third-Line Decision-Making. Academy of Managed Care Pharmacy (AMCP), 2011 Educational Conference, Atlanta, Georgia, October 20, 2011.
839. Progress in Suicide Prevention: State of the Science. 13th Annual International Conference American Foundation for Suicide Prevention Survivors of Suicide Day, Boca Raton, Florida, November 19, 2011.
840. Psychopharmacology in the 21st century. New Horizons in the Treatment of Major Depressive Disorder. Dammam, Saudi Arabia, November 23, 2011.
841. Neurobiological predictors of treatment response in major depression. New Horizons in the Treatment of Major Depressive Disorder. Dammam, Saudi Arabia, November 23, 2011.
842. Psychopharmacology in the 21st century. New Horizons in the Treatment of Major Depressive Disorder. Riyadh, Saudi Arabia, November 24, 2011.
843. Neurobiological predictors of treatment response in major depression. New Horizons in the Treatment of Major Depressive Disorder. Riyadh, Saudi Arabia, November 24, 2011.
844. Psychopharmacology in the 21st century. New Horizons in the Treatment of Major Depressive Disorder. Jeddah, Saudi Arabia, November 25, 2011.
845. Neurobiological predictors of treatment response in major depression. New Horizons in the Treatment of Major Depressive Disorder. Jeddah, Saudi Arabia, November 25, 2011.
846. PTSD Biomarkers Study Group. American College of Neuropsychopharmacology, 50th Annual Meeting, Waikoloa, Hawaii, December 5, 2011.

847. Neurobiology of Gene-Environment Interactions in Medicating Child Abuse Associated Risk for Mood and Anxiety Disorders. American College of Neuropsychopharmacology, 50th Annual Meeting, Waikoloa, Hawaii, December 7, 2011.
848. The Neurobiology of Child Abuse: Treatment Implications. Grand Rounds, Department of Psychiatry and Behavioral Sciences, New York University, New York. January 12, 2012.
849. Current Trends in the Treatment of Depression. Miami CME Winter Series. Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida. January 27, 2012.
850. The Neurobiology of Child Abuse: Treatment Implications. Discovery of Science Grand Rounds, University of Miami Miller School of Medicine, Miami, Florida. February 9, 2012.
851. Depression is a Brain Disease. Mental Health and Addictions Disorders Science Summit. Tallahassee, Florida. February 15, 2012.
852. Recent Advances in the Management of Treatment Resistant Depression. 40th Anniversary Psychopharmacology Update, Las Vegas Psychiatric Society. Las Vegas, Nevada. February 17, 2012.
853. Neurobiological Consequences of Child Abuse and Neglect. College of Mathematics, Natural Sciences and Technology (CMNST), Guest Speaker – Dean’s Distinguished Lecturer Series, Delaware State University, Dover, Delaware. February 28, 2012.
854. Recognition and Treatment of Depression: Reducing Suicide and Misery in Difficult Times. College of Mathematics, Natural Sciences and Technology (CMNST), Guest Speaker – Dean’s Distinguished Lecturer Series, Delaware State University, Dover, Delaware. February 28, 2012.
855. Cancer and Depression: Mechanisms of Disease Progression and Susceptibility. The Metastatic Novel Opportunities for Breast Cancer Therapy. Expedition Inspiration 16th Annual Laura Evans Memorial Breast Cancer Symposium. Sun Valley, Idaho. March 8, 2012.
856. Prediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry. 5th Biennial Conference of the International Society for Bipolar Disorders. Istanbul, Turkey. March 16, 2012.
857. Implications of Child Abuse and Neglect for the Pathophysiology of PTSD and Related Disorders. 32nd ADAA Annual Conference, Arlington, Virginia. April 13, 2012.
858. The Relationship of Mood and Anxiety Disorders to Cardiovascular Disease. 32nd ADAA Annual Conference, Arlington, Virginia. April 13, 2012.
859. The Interface of Anxiety Disorders and Medical Disorders: Pathophysiology and Treatment Implications. 32nd ADAA Annual Conference, Arlington, Virginia. April 13, 2012.
860. A Difficult Depression Case. Florida Psychiatric Society 2012 Meeting, Clinical Neuroscience and Clinical Practice. Orlando, Florida. April 15, 2012.

861. The Neurobiology of Child Abuse and Neglect: Impact on the Pathophysiology and Treatment of Mood Disorders. American Psychiatric Association, 165th Annual Meeting, Philadelphia, Pennsylvania. May 6, 2012.
862. Identification of Genetic Polymorphisms that Mediate the Increased Vulnerability to Mood Disorders after Exposure to Child Abuse and Neglect. American Psychiatric Association, 165th Annual Meeting, Philadelphia, Pennsylvania. May 9, 2012.
863. Neurobiology of Bipolar Disorders. World Psychiatric Association Educational Seminar on Bipolar Disorders, Lima Peru. May 17, 2012.
864. Pharmacological Treatments of Bipolar Disorders. World Psychiatric Association Educational Seminar on Bipolar Disorders, Lima Peru. May 17, 2012.
865. The Neurobiology of Child Abuse: Treatment Implications. Medical University of South Carolina (MUSC), Charleston, South Carolina. May 24, 2012.
866. Invited participant, CINP workshop, There is a Future in Psychotherapeutic Drug Development: Perspectives from Industry and Academia, Stockholm, Sweden. June 3, 2012.
867. Personalized Medicine and the Management of Treatment Resistant Depression. 28th CINP World Congress of Neuropsychopharmacology, Stockholm, Sweden. June 4, 2012.
868. Recognition and Treatment of Depression: Reducing Suicide and Misery in Difficult Times. Florida Partners in Crisis Justice Institute Annual Conference. Orlando, Florida, July 11, 2012.
869. Mental Illness: A Treatable Brain Disease. Florida Partners in Crisis Justice Institute Annual Conference. Orlando, Florida, July 12, 2012.
870. The Neurobiology of Child Abuse: Treatment Implications. International Society of Psychoneuroendocrinology 42nd Annual Conference. New York, New York, September 13, 2012.
871. The Roadblock in Drug Development in Clinical Neuroscience. 2nd CNS Diseases World Summit. San Francisco, California, September 14, 2012.
872. Neurobiología de los Trastornos Afectivos: Implicaciones para la Medicina Personalizada. (Prediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry). 1^{er} Congreso del Capítulo Venezolano de la Sociedad Internacional de Trastornos Bipolares (ISBD). Caracas, Venezuela, September 22, 2012.
873. Personalized Medicine in Psychiatry. Dorothy Chapman Fuqua Lecture Series at Skyland Trail. Atlanta, Georgia, October 5, 2012.
874. Prediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry. Psychoneuroendocrinology in the 21st Century. Milano, Italy, October 10, 2012.
875. Alzheimer's Disease: A Maintenance of Certification Session. 5th Annual Chair Summit, Master Class for Neuroscience Professional Development, Orlando, Florida, October 12, 2012.

876. Personalized Medicine in Psychiatry: A Look to the Future. 5th Annual Chair Summit, Master Class for Neuroscience Professional Development, Orlando, Florida, October 12, 2012.
877. Depression and Inflammation: The Interplay with Autoimmune Diseases. 5th Annual Chair Summit, Master Class for Neuroscience Professional Development, Orlando, Florida, October 12, 2012.
878. Treatment Resistant Depression with Comorbid Anxiety Disorder. 5th Annual Chair Summit, Master Class for Neuroscience Professional Development, Orlando, Florida, October 12, 2012.
879. Neurobiological Consequences of Child Abuse and Neglect: Implications for the Pathophysiology and Treatment of Mood and Anxiety Disorders. World Psychiatric Association International Congress 2012. Prague, Czech Republic, October 18, 2012.
880. Women's Mental Health: How to Avoid Becoming a Cranky Old Person? National Association of Women Judges' 34th Annual Conference. Miami Florida, November 9, 2012.
881. Prediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry. Advances in Psychiatry. Riyadh, Saudi Arabia, November 15, 2012.
882. Management of Bipolar Disorder: Problems and Promises. Advances in Psychiatry. Riyadh, Saudi Arabia, November 15, 2012.
883. Prediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry. Advances in Psychiatry. Jeddah, Saudi Arabia, November 16, 2012.
884. Management of Bipolar Disorder: Problems and Promises. Jeddah, Saudi Arabia, November 16, 2012.
885. Management of Bipolar Disorder: Problems and Promises. Advances in Psychiatry. Cairo, Egypt, November 17, 2012.
886. The Role of Corticotropin-Releasing Factor (CRF) in the Pathophysiology of Mood and Anxiety Disorders: A Tribute to Wylie Vale. American College of Neuropsychopharmacology, 51st Annual Meeting, Hollywood, Florida, December 3, 2012.
887. Depression, personality and cardiovascular disease. 5th International Cardio Event: Cardiology towards the future System Medicine. Florence, Italy, January 18, 2013.
888. Biology of Depression – Recent Advances in the Neurobiology of Major Depressive Disorder. Miami CME Winter Series: Neurology Update and Stroke Intensive 2013. Miami, Florida, January 25, 2013.
889. The Relationship of Bipolar Disorder and Schizophrenia: Are the Same Disorders on a Continuum? Nevada Psychiatric Association 18th Annual Psychopharmacology Update, Las Vegas, Nevada, February 14, 2013.
890. Neurobiology and Treatment of Post-Traumatic Stress Disorder. Nevada Psychiatric Association 18th Annual Psychopharmacology Update, Las Vegas, Nevada, February 15, 2013.

891. Psychopharmacology: Current Capability and Future Promise. The American College of Psychiatrists 2013 Annual Meeting. Kauai, Hawaii, February 22, 2013.
892. Long-term Course of Bipolar I and Bipolar II: Findings from the NIMH Collaborative Depression Study and Implications for Treatment. The American College of Psychiatrists 2013 Annual Meeting. Kauai, Hawaii, February 23, 2013.
893. Neurobiological Consequences of Child Abuse. 2nd. Herrenhausen Conference on Mental Health. Hanover, Germany, April 4, 2013.
894. Heartache and Heartbreak: The Curious Relationship Between Depression and Cardiovascular Disorders. WPA 2013 Bucharest Congress. Bucharest, Romania, April 11, 2013.
895. Depression and Cardiovascular Disorders in Primary Care. WPA 2013 Bucharest Congress. Bucharest, Romania, April 11, 2013.
896. The Neurobiology and Treatment of Mood Disorders: Moving Towards Personalized Medicine in Psychiatry. Harvard Medical School, Psychopharmacology, 2013: A Master Class. Boston, Massachusetts, April 19, 2013.
897. Neurobiology of Bipolar Disorders. 2^{da}s Jornadas Educativas de la WPA, Panama City, Panama. May 2, 2013.
898. Management of Bipolar Disorders. 2^{da}s Jornadas Educativas de la WPA, Panama City, Panama. May 2, 2013.
899. The Neurobiology of Child Abuse: Treatment Implications. Grand Rounds, Boonshoft School of Medicine (BSOM), Wright State University Department of Psychiatry. Dayton, Ohio, May 28, 2013.
900. Grantsmanship 101. The Lieber Institute for Brain Development. Baltimore, Maryland, June 7, 2013.
901. Are Schizophrenia and Bipolar Disorder Separate Disorders or on a Continuum: Insights from Personalized Medicine. 10th. International Conference on Bipolar Disorders. Miami Beach, Florida, June 14, 2013.
902. The Neurobiology of Child Abuse: Treatment Implications. Inaugural Lecture Center for Affective Disorders Institute of Psychiatry, King's College, London. June 17, 2013.
903. Management of Bipolar Disorder: Problems and Promises. Primer Seminario Educativo de WPA, "Las Necesidades de Salud Mental en Centroamérica". Managua, Nicaragua. July 20, 2013.
904. Neurobiological Consequences of Child Abuse. XX Congreso Nacional de Prevención y Atención del Maltrato Infantil (unicef) Bogotá, Colombia. August 14, 2013.
905. Neurobiological Consequences of Child Abuse. SASOP Biological Psychiatry Congress 2013. Wild Coast Sun, Port Edward, South Africa. August 30, 2013.
906. Stress and Mental Illness: From Genomics to Imaging. Neuroscience School of Advanced Studies. Cortona, Italy. September 1, 2013.

907. The Neurobiology of Child Abuse. Grand Rounds, The University of New Mexico, Health Sciences Center, School of Medicine. Albuquerque, New Mexico. September 17, 2013.
908. Prediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry. North Carolina Psychiatric Association 2013 Annual Meeting and Scientific Session. Ashville, North Carolina. September 22, 2013.
909. Prediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry. 6th Annual Chair Summit, Master Class for Neuroscience Professional Development, Tampa, Florida, September 26, 2013.
910. Depression and Inflammation. 6th Annual Chair Summit, Master Class for Neuroscience Professional Development, Tampa, Florida, September 27, 2013.
911. Point-Counterpoint: Clinical Conundrums in Depression Management. 6th Annual Chair Summit, Master Class for Neuroscience Professional Development, Tampa, Florida, September 27, 2013.
912. El Tratamiento Farmacológico de la Depresión Bipolar. LII Congreso Colombiano de Psiquiatría. Cartagena de Indias, Colombia, October 12, 2013.
913. Personalized Medicine in Psychiatry: Problems and Promises. LII Congreso Colombiano de Psiquiatría. Cartagena de Indias, Colombia, October 12, 2013.
914. La Inflamación y los Trastornos del Estado de Animo: Citoquinas Proinflamatorias y la Patogenia de la Depresión. LII Congreso Colombiano de Psiquiatría. Cartagena de Indias, Colombia, October 12, 2013.
915. The Role of Early Life Trauma in Depression Vulnerability and Treatment Response. World Psychiatric Association International Congress 2013. Vienna, Austria, October 29, 2013.
916. Prediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry. World Psychiatric Association International Congress 2013. Vienna, Austria, October 29, 2013.
917. When the Immune System Subjugates as a Common Pathway for Depression, Anxiety, Pain and Sleep Disorder. Puerto Rico Academy of Psychiatry Annual Meeting: Brain, Body and Mind. Isla Verde, Puerto Rico, November 2, 2013.
918. Treating the Whole Patient with Schizophrenia and Bipolar Disorders: What are the Implications? Puerto Rico Academy of Psychiatry Annual Meeting: Brain, Body and Mind. Isla Verde, Puerto Rico, November 2, 2013.
919. The Neurobiology of Child Abuse and Neglect: Implications for the Pathogenesis and Treatment of Mood and Anxiety Disorders. Grand Rounds, Georgia Regents University School of Medicine Department of Psychiatry and Health Behavior. Augusta, Georgia, November 14, 2013.
920. The Role of Inflammation in the Pathophysiology of Mood, Aggressive and Medical Disorders: a Deadly Combination. American College of Neuropsychopharmacology, 52nd Annual Meeting, Hollywood, Florida, December 9, 2013.

921. The Pervasive and Persistent Neurobiological Consequences of Child Abuse and Neglect; Clinical Implications . American College of Neuropsychopharmacology, 52nd Annual Meeting, Hollywood, Florida, December 12, 2013.
922. The Neurobiology of Child Abuse and Neglect: Implications for the Pathogenesis and Treatment of Mood and Anxiety Disorders. Wayne State University Grand Rounds, Detroit, Michigan, January 15, 2014.
923. The Neurobiology of Child Abuse and Neglect: Implications for the Pathogenesis and Treatment of Mood and Anxiety Disorders. University of Texas Southwestern Medical Center Grand Rounds, Dallas, Texas, February 12, 2014.
924. Suicide discussion. American College of Psychiatrists Interest Group, San Antonio, Texas, February 20, 2014.
925. Treatment Resistant Depression: Role of Inflammation, Current Strategies and Potential New Treatments. University of North Carolina Grand Rounds, Chapel Hill, North Carolina, February 26, 2014.
926. Neurobiology of Child Abuse. University of North Carolina Grand Rounds. Chapel Hill, North Carolina, February 26, 2014.
927. The Neurobiology of Child Abuse and Neglect: Implications for the Pathogenesis and Treatment of Mood and Anxiety Disorders. McGill University Grand Rounds, Montreal, Quebec, March 13, 2014.
928. Heartache and Heartbreak: Depression and Cardiovascular Disease. Qatar Clinical Neuroscience Conference, Doha, Qatar, March 16, 2014.
929. The Rage to Know, the Rage to Teach, the Rage to Treat. Anxiety and Depression Association of America, Chicago, Illinois, March 26, 2014.
930. Neurobiology Mediating Effects of Early Life Trauma on Depression Treatment. Anxiety and Depression Association of America, Chicago, Illinois, March 28, 2014.
931. Management of Treatment Refractory Depression. Anxiety and Depression Association of America, Chicago, Illinois, March 28, 2014.
932. Neurobiology and Treatment of Post-Traumatic Stress Disorder. Florida Psychiatric Society 2014 Spring Meeting, Orlando, Florida, March 30, 2014.
933. Neurobiology of Child Abuse and Neglect: Implications for the Pathogenesis and Treatment of Mood and Anxiety Disorders. University of Arkansas Grand Rounds, Little Rock, Arkansas. April 3, 2014.
934. Treatment Resistant Depression: Role of Inflammation, Current Strategies and Potential New Treatment. Psychopharmacology 2014: A Master Class, Harvard Medical School, Boston, Massachusetts. April 25, 2014.
935. Suicide Lecture. Master Course 5, Psychopharmacology, 167th APA Annual Meeting, New York, New York, May 6, 2014.

936. Working with the NIH. 69th Annual Meeting Society of Biological Psychiatry. New York, New York, May 9, 2014.
937. Influence of Maternal Glutamatergic Response on the Neurobiology of the Offspring. 69th Annual Meeting of the Society of Biological Psychiatry. New York, New York. May 10, 2014.
938. CSF Oxytocin (OT) in Maternal Stress: Influence on HPA Axis. 69th Annual Meeting of the Society of Biological Psychiatry. New York, New York. May 10, 2014.
939. Prediction of Disease Vulnerability and Treatment Response in Mood Disorders; Personalized Medicine in Psychiatry. WPA Conference, Santiago, Chile. May 16, 2014.
940. Management of Bipolar Disorders: Problems and Promises. WPA Conference, Santiago, Chile. May 16, 2014.
941. Neurobiology of Child Abuse. Grand Rounds, University of Massachusetts Medical School, Boston, Massachusetts, June 12, 2014.
942. Prediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry. Case Western Reserve University School of Medicine, Cleveland, Ohio, June 20, 2014.
943. Treatment Resistant Depression. 29th CINP World Congress of Neuropsychopharmacology, Vancouver, Canada. June 23, 2014.
944. Personalized Medicine in Mood and Anxiety Disorders. 29th CINP World Congress of Neuropsychopharmacology, Vancouver, Canada. June 24, 2014.
945. Neurobiological Consequences of Child Abuse. 29th CINP World Congress of Neuropsychopharmacology, Vancouver, Canada. June 24, 2014.
946. Personalized Medicine in Mood and Anxiety Disorders. Grand Rounds, University of California, Davis, Sacramento, California. June 25, 2014.
947. Depression and Bipolar Disorder are Brain Diseases. Mental Health and Faith Community Partnership Steering Committee Meeting, Washington, DC, July 11, 2014.
948. Prediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry. Grand Rounds, University of Minnesota, Minneapolis, Minnesota. September 3, 2014.
949. Addressing Depression: Current and Emerging Treatment Options for Getting Our Patients to Remission. 7th Annual Chair Summit, Master Class for Neuroscience Professional Development, Tampa, Florida. September 11, 2014.
950. Clinical Conundrums in Depression Management. Chair Summit, Master Class for Neuroscience Professional Development, Tampa, Florida. September 12, 2014.
951. Welcome to the Ring: Bipolar Depression Faculty Debate. Chair Summit, Master Class for Neuroscience Professional Development, Tampa, Florida. September 12, 2014.

952. Wake up to Personalized Medicine. Chair Summit, Master Class for Neuroscience Professional Development , Tampa, Florida. September 13, 2014.
953. The Persistent and Pervasive Neurobiological Consequences of Child Abuse and Neglect: Treatment Implication. XVI World Congress of Psychiatry, World Psychiatric Association, Madrid, Spain. September 16, 2014.
954. Prediction of Disease, Vulnerability and Treatment Response in Mood Disorders, Personalized Medicine in Psychiatry. XVI World Congress of Psychiatry, World Psychiatric Association, Madrid, Spain. September 17, 2014.
955. Prediction of Disease Vulnerability. Neuroscience School of Advanced Studies. Cortona, Italy. October 5, 2014.
956. Obstacles in CNS Drug Development: Focus on Psychiatry. Neuroscience School of Advanced Studies. Cortona, Italy. October 5, 2014.
957. Neurobiology of Child Abuse and Neglect. Grand Rounds at Geisel School of Medicine at Dartmouth, Dartmouth College. Hanover, New Hampshire. October 21, 2014.
958. Neurobiology of Child Abuse and Neglect. German Association for Psychiatry, Psychotherapy and Psychosomatics. City Cube Berlin, Germany. November 26, 2014.
959. Heartache and Heartbreak. University of Miami Department of Cardiology Grand Rounds. Miami, Florida. December 12, 2014.
960. Post-traumatic Stress Disorder. Neurology Update and Stroke Intensive. University of Miami Miller School of Medicine Department of Neurology, Miami, Florida. January 22, 2015.
961. Human Trafficking: An Emerging Epidemic. University of Miami Miller School of Medicine Ethics Program, Miami, Florida. January 23, 2015.
962. Neurobiology of Child Abuse and Neglect. Grand Rounds at Stanford School of Medicine, Stanford, California. January 30, 2015.
963. Neurobiology of Child Abuse and Neglect. William K. Lecture Series, Laureate Institute for Brain Research, Tulsa, Oklahoma. February 3, 2015.
964. Neurobiology of Child Abuse and Neglect. Grand Rounds, University of Colorado Denver, Denver, Colorado. February 11, 2015.
965. Neurobiology and Treatment of Post-Traumatic Stress Disorder. Nevada Psychiatric Association, Las Vegas, Nevada. February 13, 2015.
966. The Rage to Know, the Rage to Teach, the Rage to Heal or Why we are all not on Wall Street. Keynote Awards Banquet Address, 41st Eastern-Atlantic Student Research Forum, February 28, 2015.
967. Prediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry. Doctorate Honoris Causa in Health Sciences Ceremony, Maimonides University, Northern Patagonia, Argentina. March 6, 2015.

968. The Rage to Know, the Rage to Heal, and the Rage to Teach: Progress in Science and Progress in Suicide Prevention. Argentinean Scientific Society, Buenos Aires, Argentina. March 7, 2015.
969. Improving Outcomes/Best Practices (Focus on Veterans and Trauma Victims). Prosecutors against Gun Violence, Miami, Florida. March 24, 2015.
970. The Rage to Know, the Rage to Heal, and the Rage to Teach: Success in Academia. ADAA Annual Conference, Miami, Florida. April 9, 2015.
971. Management of Treatment-Refractory Depression: The Art and the Science. ADAA Annual Conference, Miami, Florida. April 9, 2015.
972. Funding 101. ADAA Annual Conference, Miami, Florida. April 9, 2015.
973. Understanding Suicide Risk: What We Have Learned So Far. ADAA Annual Conference, Miami, Florida. April 10, 2015.
974. PTSD: Predicting its Development from Prospective Studies and Creating Early Interventions for its Prevention. ADAA Annual Conference, Miami, Florida. April 11, 2015.
975. Neurobiology of Child Abuse. Peruvian Psychiatric Association, National Institute of Mental Health, Lima, Peru. April 17, 2015.
976. Treatment Resistant Depression. Peruvian Psychiatric Association, National Institute of Mental Health, Lima, Peru. April 17, 2015.
977. Neurobiology and Treatment of PTSD. Psychopharmacology 2015: A Master Class. Boston, Massachusetts. April 24, 2015.
978. Diagnosis, Intervention and Pharmacological Advances. Stop the Stigma Conference – Nami of Miami: A Mental Health Summit. Miami, Florida. May 2, 2015.
979. Working with the NIH. 70th Annual Meeting of the Society of Biological Psychiatry. Toronto, Canada. May 14, 2015.
980. The Relationship Between ELS and PTSD Among ED Trauma Victims. 70th Annual Meeting of the Society of Biological Psychiatry. Toronto, Canada. May 14, 2015.
981. Child Abuse and Neglect Predict Disease Vulnerability and Treatment Response: Neurobiological Mechanisms. American Psychiatric Association 168th Annual Meeting, Toronto, Canada. May 16, 2015.
982. Why we all aren't on Wall Street – The Rage to Know... American Psychiatric Association 168th Annual Meeting, Toronto, Canada. May 17, 2015.
983. Paradise Lost: The Persistent Biological and Psychiatric Consequences of Child Abuse Neglect. American Psychiatric Association 168th Annual Meeting, Toronto, Canada. May 18, 2015.
984. Master Courses, Psychopharmacology. American Psychiatric Association 168th Annual Meeting, Toronto, Canada. May 19, 2015.

985. Management of Treatment-Resistant Depression: The Art and the Science. American Psychiatric Association 168th Annual Meeting, Toronto, Canada. May 19, 2015.
986. Neurobiology and Treatment of PTSD. American Psychiatric Association 168th Annual Meeting, Toronto, Canada. May 19, 2015.
987. The Neurobiology of Child Abuse and Neglect: Implications for the Pathophysiology and Treatment of Mood and Anxiety Disorders. Grand Rounds at University of Wisconsin. Madison, Wisconsin. May 29, 2015.
988. The Neurobiology of Child Abuse and Neglect. Laureate Institute for Brain Research – Frontiers in Neuroscience Conference. Tulsa, Oklahoma. June 2, 2015.
989. Toward a Personalized Treatment of Mental Disorders. Expo 2015 – Il Futuro della Salute Mentale. Milan, Italy. June 20, 2015.
990. Depression and Inflammation. American Society of Clinical Psychopharmacology Annual Meeting. Miami Beach, Florida. June 22, 2015.
991. Neurobiology of Child Abuse. Euro Global Summit and Medicare Expo on Psychiatry. Barcelona, Spain. July 21, 2015.
992. Prediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry. Euro Global Summit and Medicare Expo on Psychiatry. Barcelona, Spain. July 22, 2015.
993. Prediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry. ISPNE 2015 Conference. 2015 Lifetime Achievement Award. Edinburgh, Scotland. September 10, 2015.
994. Prediction of Disease Vulnerability and Treatment Response in Mood and Anxiety Disorders: Personalized Medicine in Psychiatry. Grand Rounds, University of Arkansas. Little Rock, Arkansas. September 17, 2015.
995. Meta-Analysis of Ketamine and Related Compounds in Depression. The Banbury Center, Cold Spring Harbor, New York. September 21, 2015.
996. Where are we with Suicide Prevention? 8th Annual Chair Summit, Master Class for Neuroscience Professional Development, Miami, Florida. September 24, 2015.
997. The Psychobiology of Abuse. IV World Congress of Medical Sexology. Miami, Florida. October 10, 2015.
998. Paradise Lost: The Persistent Biological and Psychiatry Consequences of Child Abuse and Neglect. 4th German Health Research Meeting on Behavioural Disorders Related to Violence, Neglect, Maltreatment, and Abuse in Childhood and Adolescence. Berlin, Germany. October 22, 2015.
999. Molecular Neuroscience: From Genes to Mental Health. 2015 Psychopharmacology Congress. Orlando, Florida. November 12, 2015.

1000. The Neurobiology of Child Abuse and Neglect: Implications for the Pathophysiology and Treatment of Mood and Anxiety Disorders. 2015 Psychopharmacology Congress. Orlando, Florida. November 12, 2015.
1001. Where Are We with Suicide Prevention? 2016 Neurology Update & Stroke Intensive. Miami Beach, Florida. January 28, 2016.
1002. Progress in Suicide Prevention. Temple Beth Am Honest Talk About Suicide: The Silent Epidemic. Pinecrest, Florida. January 31, 2016.
1003. What Can We Do to Avoid Becoming Cranky Old Men? Pri-Med South Annual Conference. Fort Lauderdale, Florida, February 6, 2016.
1004. Prediction of Disease Vulnerability & Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry. Georgia Psychiatric Physicians Association 2016 Winter CME Meeting. Atlanta, Georgia, February 13, 2016.
1005. Neurobiology of Child Abuse and Neglect. Traumatic Stress – New Mechanisms and Effective Treatment Conference. St Louis, Missouri, March 10, 2016.
1006. Rage to Know, the Rage to Heal, and the Rage to each: Success in Academia”. ADAA Annual Conference, Philadelphia, Pennsylvania, March 31, 2016.
1007. The Curious Relationship between Depression and Medical Disorders: Implications for Treatment. Harvard Psychopharmacology Course, Boston, Massachusetts, April 1, 2016.
1008. Preclinical and Clinical Evidence for Alterations in CRF-Containing Circuits in Mood and Anxiety Disorders. Harvard Psychopharmacology Course Symposium, Boston, Massachusetts, April 2, 2016.
1009. The Long Term Neurobiological Consequences of Early Life Stress and its Implications for Treatment of Mood and Anxiety Disorders (Neurobiology of Child Abuse), Harvard Psychopharmacology Course Symposium, Boston, Massachusetts, April 2, 2016.
1010. The Role of Inflammations in the Pathophysiology of Depression and its Treatment. Harvard Psychopharmacology Course Symposium, Boston, Massachusetts, April 2, 2016.
1011. Progress in Suicide Prevention: Focus of Early Life Stress. Harvard Psychopharmacology Course Symposium, Boston, Massachusetts, April 2, 2016.
1012. Neurobiology of Child Abuse and Neglect: Implications for the Pathophysiology and Treatment of Mood and Anxiety Disorders. Grand Rounds, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, April 8, 2016.
1013. Management of Treatment Resistant Depression: The Art and the Science. Oklahoma Psychiatric Association, Tulsa Oklahoma, April 9, 2016.
1014. Personalized Medicine in Mood and Anxiety Disorders. Oklahoma Psychiatric Association, PTulsa Oklahoma, April 9, 2016.
1015. The Neurobiology of Child Abuse. Institute of Living, Harford, Connecticut, April 14, 2016.

1016. The Neurobiology of Child Abuse. University of Connecticut, Farmington, Connecticut, April 15, 2016.
1017. Relationships, Humility, Science and Medicine/The Rage to Know. University of North Carolina Class Reunion, Pearls of Wisdom Presentation, Chapel Hill, North Carolina, April 16, 2016.
1018. The Neurobiology of Child Abuse. McGill University, Montreal, Canada, April 18, 2016.
1019. Prediction of Disease Vulnerability. Tufts University Grand Rounds, Boston, Massachusetts, May 10, 2016
1020. Personalized Medicine: Depression. American Psychiatric Association 169th Annual Meeting, Atlanta, Georgia, May 15, 2016.
1021. Personalized Medicine. Association des medecins psychiatres du Quebec (AMPQ) 2016 Annual Congress, Tremblant, Quebec, June 2, 2016.
1022. The Neurobiology of Child Abuse and Neglect: Implications for the Pathophysiology and Treatment of Mood and Anxiety Disorders. University of Wisconsin-Madison Grand Rounds, Madison, Wisconsin, June 17, 2016.
1023. Risk of Mood and Anxiety Disorders. National Academies of Science. Washington, DC, July 26, 2017.
1024. Basic Neuroscience: From Molecules to Symptoms. Harvard Summer Seminars, Martha's Vineyard, Massachusetts, August 22, 2016.
1025. The Neurobiology of Child Abuse and Neglect: Paradise Lost. Harvard Summer Seminars, Martha's Vineyard, Massachusetts, August 22, 2016.
1026. Psychopharmacological Management of Schizophrenia. Harvard Summer Seminars, Martha's Vineyard, Massachusetts, August 23, 2016.
1027. Management of Bipolar Disorder: Problems and Promises. Harvard Summer Seminars, Martha's Vineyard, Massachusetts, August 23, 2016.
1028. Treatment of Major Depression: Focus on Treatment-Resistant Depression (including case studies). Harvard Summer Seminars, Martha's Vineyard, Massachusetts, August 24, 2016.
1029. Treatment of Alcohol and Substance Abuse with the Burden of Addiction. Harvard Summer Seminars, Martha's Vineyard, Massachusetts, August 24, 2016.
1030. Prediction of Disease Vulnerability and Treatment of Mood and Anxiety Disorders: Personalized Medicine in Psychiatry. Harvard Summer Seminars, Martha's Vineyard, Massachusetts, August 25, 2016.
1031. Neurobiology and Treatment of Post-Traumatic Stress Disorder. Harvard Summer Seminars, Martha's Vineyard, Massachusetts, August 25, 2016.
1032. Mood Disorders in Women: From Menarche to Menopause. Harvard Summer Seminars, Martha's Vineyard, Massachusetts, August 26, 2016.

1033. Treatment of Anxiety Disorders. Harvard Summer Seminars, Martha's Vineyard, Massachusetts, August 26, 2016.
1034. Epigenome-wide Association Study to Focus on the Development of PTSD in traumatized ED Patients. 46th Annual Conference of the International Society of Psychoneuroendocrinology. Miami, Florida, September 9, 2016.
1035. Smoking (Tobacco), PTSD and Depression. 46th Annual Conference of the International Society of Psychoneuroendocrinology. Miami, Florida, September 10, 2016.
1036. Non-sexual Interpersonal Trauma and PTSD Development. 46th Annual Conference of the International Society of Psychoneuroendocrinology. Miami, Florida, September 10, 2016.
1037. Paradise Lost: The Neurobiology of Child Abuse and Neglect. 9th Annual Chair Summit, Coral Gables, Florida, September 15, 2016.
1038. Cognitive Dysfunction in MDD: Must Patients Just Accept it as Part of the Disease? 9th Annual Chair Summit, Coral Gables, Florida, September 16, 2016.
1039. Bipolar Depression: The Dating Game. 9th Annual Chair Summit, Coral Gables, Florida, September 16, 2016.
1040. Major Depression Disorder. 9th Annual Chair Summit, Coral Gables, Florida, September 16, 2016.
1041. Prediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry. Florida Psychiatric Society Fall Meeting, Saint Petersburg, Florida, September 24, 2016.
1042. Personalized Medicine. 12th Comprehensive Review of Psychiatry, Buffalo, New York, September 29, 2016.
1043. Paradise Lost: The Neurobiology of Child Abuse and Neglect. Mayo Clinic Grand Rounds, Rochester, Minnesota, October 5, 2016.
1044. Management of Bipolar Disorder. American Physician Institute, 7th Annual MasterPsych Conference, La Jolla, California, October 7, 2016.
1045. Management of Treatment of Resistant Depression. American Physician Institute, 7th Annual MasterPsych Conference, La Jolla, California, October 7, 2016.
1046. Paradise Lost: The Neurobiology of Child Abuse and Neglect. University of Oklahoma Distinguished Lecture, Oklahoma City, Oklahoma, November 3, 2016.
1047. Biological Basis of Depression. Oklahoma Center for Neuroscience 25th Anniversary Symposium, Oklahoma City, Oklahoma, November 3, 2016.
1048. Prediction of Disease Vulnerability and Treatment Response in Mood Disorders: Personalized Medicine in Psychiatry. University of Texas Rio Grande Grand Rounds, Edinburg, Texas, November 4, 2016.

1049. The Future of Psychiatry. 8th Annual Behavioral Health Conference, Edinburg, Texas, November 4, 2016.
1050. Prediction of Disease Vulnerability. Medical College of Georgia Grand Rounds, Augusta, Georgia, November 10, 2016.
1051. The Role of Inflammation in Depression. LIBR Institute Roadmap Workshop, Tulsa, Oklahoma, November 16, 2016.
1052. Paradise Lost: The Neurobiology of Child Abuse and Neglect. Biochemistry Seminar Series University of Miami, Miami, Florida November 18, 2016.
1053. The Role of Inflammation in the Pathophysiology of Depression and Treatment. World Stem Cell Summit, West Palm Beach, Florida, December 9, 2016.
1054. Neurobiology of Child Abuse. Trauma Symposium: Transgenerational Transmission of Trauma and Resilience at University of Miami Miller School of Medicine, January 20, 2017.
1055. Human Trafficking Key Note Address. 6th Annual SAO Forum, Miami, Florida, January 26, 2017.
1056. Paradise Lost: Neurobiology of Child Abuse. International Conference on Psychoneuroendocrinology of Depression and Anxiety Disorders, Buenos Aires, Argentina, January 31, 2017.
1057. Management of Treatment Resistant Depression. International Conference on Psychoneuroendocrinology of Depression and Anxiety Disorders, Buenos Aires, Argentina, January 31, 2017.
1058. The Neurobiology and Treatment of Post-Traumatic Stress Disorder: Problems and Promises. Nevada Psychiatric Association 22nd National Psychopharmacology Update, Las Vegas, Nevada, February 17, 2017.
1059. Beating Back the Black Dog of Depression and Suicide. Nevada Psychiatric Association 22nd National Psychopharmacology Update, Las Vegas, Nevada, February 17, 2017.
1060. Personalized Medicine in Psychiatry: Focus on Mood and Anxiety Disorders. University of Miami Grand Rounds, Miami, Florida, February 22, 2017.
1061. Paradise Lost: Th Neurobiology of Child Abuse and Neglect. University of Miami Psychology Colloquium, Miami, Florida, March 2, 2017.
1062. Paradise Lost: The Neurobiology of Child Abuse and Neglect. Israeli Society for Biological Psychiatry, Tel-Aviv, Israel, March 21, 2017.
1063. The Rage to Know, The Rage to Heal, and the Rage to Teach: Success in Academia. ADAA Annual Conference, San Francisco, California, April 6, 2017.
1064. Grantsmanship101. ADAA Annual Conference, San Francisco, California, April 6, 2017.
1065. Neurobiology and Treatment of PTSD. Harvard Psychopharmacology Master Class, Boston, Massachusetts, April 8, 2017.

1066. Personalized Medicine in Psychiatry. University of Texas Medical Branch Grand Rounds. Galveston, Texas, April 18, 2017.
1067. CRH-1 Receptor Antagonists Saga in Mood and Anxiety Disorders: The Good, the Bad and the Ugly. Society of Biological Psychiatry Annual Meeting, San Diego, California, May 20, 2017.
1068. Personalized Medicine in Psychiatry: The New Holy Grail. American Psychiatric Association 2017 Annual Meeting, San Diego, California, May 20, 2017.
1069. Rage to Know, the Rage to Teach and the Rage to Practice. APA Research Colloquium for Young Investigators, San Diego, California, May 21, 2017.
1070. Granstmanship 101. APA Research Colloquium for Young Investigators, San Diego, California, May 21, 2017.
1071. Clinical Evidence for Alterations in CRF-Containing Circuits in Mood and Anxiety Disorders. American Psychiatric Association 2017 Annual Meeting, San Diego, California, May 23, 2017.
1072. Targeting the HPA Axis and Novel Strategies to Treat Psychiatric Disorders. American Psychiatric Association 2017 Annual Meeting, San Diego, California, May 24, 2017.
1073. Paradise Lost: The Neurobiology of Child Abuse and Neglect. Department of Psychiatry Grand Rounds. State University of New York – Stonybrook, Stony Brook, New York, June 6, 2017.
1074. Management of Treatment Resistant Depression: The Art and the Science. Curso Interamericano de Actualizacion en Psiquiatria (CIAP) – 2nd Annual Advances in Diagnosis, Neurobiology, and Treatment of Psychiatric Disorders. New York, New York, June 12, 2017.
1075. Challenges in Managing Treatment-Resistant Depression. Neuroseries Live, Philadelphia, Pennsylvania, June 23, 2017.
1076. Basic Neuroscience. 28th Annual Summer Seminars Series, Psychopharmacology: A Master Class, Cape Cod, Massachusetts, July 24, 2017.
1077. Paradise Lost. 28th Annual Summer Seminars Series, Psychopharmacology: A Master Class, Cape Cod, Massachusetts, July 24, 2017.
1078. Treatment Resistant Depression. 28th Annual Summer Seminars Series, Psychopharmacology: A Master Class, Cape Cod, Massachusetts, July 25, 2017.
1079. Prediction of Disease. 28th Annual Summer Seminars Series, Psychopharmacology: A Master Class, Cape Cod, Massachusetts, July 25, 2017.
1080. PTSD. 28th Annual Summer Seminars Series, Psychopharmacology: A Master Class, Cape Cod, Massachusetts, July 26, 2017.
1081. Bipolar Disorder. 28th Annual Summer Seminars Series, Psychopharmacology: A Master Class, Cape Cod, Massachusetts, July 26, 2017.
1082. Schizophrenia. 28th Annual Summer Seminars Series, Psychopharmacology: A Master Class, Cape Cod, Massachusetts, July 27, 2017.

1083. Addiction. 28th Annual Summer Seminars Series, Psychopharmacology: A Master Class, Cape Cod, Massachusetts, July 27, 2017.
1084. Mood Disorders in Women. 28th Annual Summer Seminars Series, Psychopharmacology: A Master Class, Cape Cod, Massachusetts, July 28, 2017.
1085. Interesting Cases. 28th Annual Summer Seminars Series, Psychopharmacology: A Master Class, Cape Cod, Massachusetts, July 28, 2017.
1086. Post-Traumatic Stress Disorder. Georgia Psychiatric Physicians Association, Southern Psychiatric Association Summer, Summer CME Meeting, Amelia Island, Florida, August 5, 2017.
1087. Neurobiology of Child Abuse. Georgia Psychiatric Physicians Association, Southern Psychiatric Association Summer, Summer CME Meeting, Amelia Island, Florida, August 5, 2017.
1088. Personalized Medicine. Frontiers of Psychiatry 3 – New Directions, Mumbai, India, September 16, 2017.
1089. Treatment-Resistant Depression. Frontiers of Psychiatry 3 – New Directions, Mumbai, India, September 17, 2017.
1090. Paradise Lost. Wake Forest University Grand Rounds. Winston-Salem, North Carolina, September 22, 2017.
1091. Prediction of Disease Vulnerability and Treatment Response in Mood Disorders and PTSD: Personalized Medicine in Psychiatry. University of Missouri – Kansas City Hoenstra Lectureship, Kansas City, Missouri, September 28, 2017.
1092. Paradise Lost: The Neurobiology of Child Abuse. 7th International Symposium INECO Foundation, Buenos Aires, Argentina, October 3, 2017.
1093. The Science of Treatment Resistant Depression. Navitor Meeting, Cambridge, Massachusetts, October 11, 2017.
1094. Paradise Lost: The Neurobiology of Child Abuse and Neglect. Advances in Clinical Psychiatry 2017: Suicide Prevention, Baylor College of Medicine, Houston, Texas. October 20, 2017.
1095. Management of Treatment Resistant Depression. Boston University School of Medicine Guest Lecture with Students, Boston Massachusetts, November 2, 2017.
1096. Prediction of Disease Vulnerability. Boston University School of Medicine Grand Rounds, Boston Massachusetts, November 2, 2017.
1097. Management of Treatment Refractory Depression: The Art and the Science. 9th Annual Behavioral Medicine Conference, McAllen, Texas, November 3, 2017.
1098. Paradise Lost: Pathophysiology of Depression and Resilience. La depression nel 2017, Bari, Italy, November 7, 2017.

1099. New and Emerging Novel Pharmacotherapies for Major Depressive Disorder, Depression Subtypes, and Treatment-Resistant Depression. Exploring New and Emerging Therapies for Depression, Miami, Florida, November 9, 2017.
1100. Prediction of Disease Vulnerability and Treatment Response in Mood Disorders and PTSD: Personalized Medicine in Psychiatry. 10th Annual Chair Summit, Master Class for Neuroscience Professional Development, New Orleans, Louisiana, November 16, 2017.
1101. The Impact of Residual Symptoms in Major Depressive Disorder. 10th Annual Chair Summit, Master Class for Neuroscience Professional Development, New Orleans, Louisiana, November 17, 2017.
1102. The Brain-Body Connection. 10th Annual Chair Summit, Master Class for Neuroscience Professional Development, New Orleans, Louisiana, November 17, 2017.
1103. Post-Traumatic Stress Disorder. Neurology Update & Stroke Intensive, InterContinental Miami, Miami, Florida, January 18, 2018.
1104. Progress in Suicide Prevention. Miami VA Mental Health Summit, Miami, Florida, January 19, 2018.
1105. Prediction of Disease Vulnerability and Treatment Response in Mood Disorders and PTSD: Personalized Medicine in Psychiatry. BD2K-LINCS DCIC Systems Biology & Data Science Symposium, Miami, Florida, February 1, 2018.
1106. Prediction of Disease Vulnerability. University of California, San Diego, La Jolla, California, February 28, 2018.
1107. The Role of Inflammation at the Interface of Depression and Medical Disorders. Psychopharmacology 2018: A Master Class. Boston, Massachusetts. April 20, 2018.
1108. The Rage to Know. Research Colloquium Day 2, American Psychiatric Association Annual Meeting, New York, New York. May 6, 2018.
1109. Contributions to Personalized Medicine in Psychiatry. American Psychiatric Association Annual Meeting, New York, New York. May 7, 2018.
1110. Management of Treatment Refractory PTSD. American Psychiatric Association Annual Meeting, New York, New York. May 8, 2018.
1111. Neurobiology and Treatment of PTSD. American Psychiatric Association Annual Meeting, New York, New York. May 8, 2018.
1112. Is inflammation a Biomarker in Major Depressive Disorder? American Psychiatric Association Annual Meeting, New York, New York. May 8, 2018.